US20080261947A1 - Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient - Google Patents
Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient Download PDFInfo
- Publication number
- US20080261947A1 US20080261947A1 US12/137,267 US13726708A US2008261947A1 US 20080261947 A1 US20080261947 A1 US 20080261947A1 US 13726708 A US13726708 A US 13726708A US 2008261947 A1 US2008261947 A1 US 2008261947A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- hydrogen atom
- alkylene
- partially
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=NNC(=O)c[y]1.CC Chemical compound *C1=NNC(=O)c[y]1.CC 0.000 description 110
- PAMIQIKDUOTOBW-UHFFFAOYSA-N CN1CCCCC1 Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 92
- AVFZOVWCLRSYKC-UHFFFAOYSA-N CN1CCCC1 Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 71
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 68
- ZKUKXSWKWGHYKJ-UHFFFAOYSA-N CN1CCCCCC1 Chemical compound CN1CCCCCC1 ZKUKXSWKWGHYKJ-UHFFFAOYSA-N 0.000 description 67
- WWYVZTLIFYLZFM-UHFFFAOYSA-N CN1CCC1 Chemical compound CN1CCC1 WWYVZTLIFYLZFM-UHFFFAOYSA-N 0.000 description 60
- WGYZZCUTSHNMET-UHFFFAOYSA-N CNC1CCOCC1 Chemical compound CNC1CCOCC1 WGYZZCUTSHNMET-UHFFFAOYSA-N 0.000 description 56
- OVRKATYHWPCGPZ-UHFFFAOYSA-N CC1CCOCC1 Chemical compound CC1CCOCC1 OVRKATYHWPCGPZ-UHFFFAOYSA-N 0.000 description 32
- ORNBZCUHAICALK-UHFFFAOYSA-N CC1CC[N-](CC2=CC=CC=C2)CC1 Chemical compound CC1CC[N-](CC2=CC=CC=C2)CC1 ORNBZCUHAICALK-UHFFFAOYSA-N 0.000 description 30
- OAPDPORYXWQVJE-UHFFFAOYSA-N CCCC1=CC=C(N)C=C1 Chemical compound CCCC1=CC=C(N)C=C1 OAPDPORYXWQVJE-UHFFFAOYSA-N 0.000 description 30
- KLSLBUSXWBJMEC-UHFFFAOYSA-N CCCC1=CC=C(O)C=C1 Chemical compound CCCC1=CC=C(O)C=C1 KLSLBUSXWBJMEC-UHFFFAOYSA-N 0.000 description 30
- KBHWKXNXTURZCD-UHFFFAOYSA-N CCCC1=CC=C(OC)C=C1 Chemical compound CCCC1=CC=C(OC)C=C1 KBHWKXNXTURZCD-UHFFFAOYSA-N 0.000 description 30
- ZJIBLKYJGDLVSX-UHFFFAOYSA-N CCCC1CC[N-](CC2=CC=CC=C2)CC1 Chemical compound CCCC1CC[N-](CC2=CC=CC=C2)CC1 ZJIBLKYJGDLVSX-UHFFFAOYSA-N 0.000 description 30
- NWRUFJHICAREBX-UHFFFAOYSA-N CCCCCN1CCCC1 Chemical compound CCCCCN1CCCC1 NWRUFJHICAREBX-UHFFFAOYSA-N 0.000 description 22
- USSSMOHSXZRREE-UHFFFAOYSA-N CCCCN1CCCC(OC)C1 Chemical compound CCCCN1CCCC(OC)C1 USSSMOHSXZRREE-UHFFFAOYSA-N 0.000 description 22
- YAGRFRBKJVHQCD-UHFFFAOYSA-N COC1CCN(CCC(C)(C)C)CC1 Chemical compound COC1CCN(CCC(C)(C)C)CC1 YAGRFRBKJVHQCD-UHFFFAOYSA-N 0.000 description 22
- MPVBSYNIOWJPBC-UHFFFAOYSA-N COC1CCN(CCCC(C)(C)C)C1 Chemical compound COC1CCN(CCCC(C)(C)C)C1 MPVBSYNIOWJPBC-UHFFFAOYSA-N 0.000 description 22
- VPEPAJCCYQJGNW-UHFFFAOYSA-N C#CCN(C)CCSCC Chemical compound C#CCN(C)CCSCC VPEPAJCCYQJGNW-UHFFFAOYSA-N 0.000 description 21
- FQYCRRKIKAJQJA-UHFFFAOYSA-N C=C(C)CNCCCC(C)(C)C Chemical compound C=C(C)CNCCCC(C)(C)C FQYCRRKIKAJQJA-UHFFFAOYSA-N 0.000 description 21
- UFZOXMIQJDBTCT-UHFFFAOYSA-N C=C(C)CNCCSCC Chemical compound C=C(C)CNCCSCC UFZOXMIQJDBTCT-UHFFFAOYSA-N 0.000 description 21
- VWGZOERTHICPMK-UHFFFAOYSA-N CCCCCN1CCCC(OC)C1 Chemical compound CCCCCN1CCCC(OC)C1 VWGZOERTHICPMK-UHFFFAOYSA-N 0.000 description 21
- NUTSKRXOKJEZHQ-UHFFFAOYSA-N CCCCN1CC=CCC1 Chemical compound CCCCN1CC=CCC1 NUTSKRXOKJEZHQ-UHFFFAOYSA-N 0.000 description 21
- RMVCVDBUEPOBQX-UHFFFAOYSA-N CCCCN1CCC(OC)C1 Chemical compound CCCCN1CCC(OC)C1 RMVCVDBUEPOBQX-UHFFFAOYSA-N 0.000 description 21
- HXLHUPIZECLJAP-UHFFFAOYSA-N CCOCCN1CCOCC1 Chemical compound CCOCCN1CCOCC1 HXLHUPIZECLJAP-UHFFFAOYSA-N 0.000 description 21
- WNFHEXBNTBEUCM-UHFFFAOYSA-N CCSCCN1CCC(OC)C1 Chemical compound CCSCCN1CCC(OC)C1 WNFHEXBNTBEUCM-UHFFFAOYSA-N 0.000 description 21
- BLTCZTHQFJUIIJ-UHFFFAOYSA-N C#CCN(C)CCC(C)(C)C Chemical compound C#CCN(C)CCC(C)(C)C BLTCZTHQFJUIIJ-UHFFFAOYSA-N 0.000 description 20
- NJBSAFGMLJQVNT-UHFFFAOYSA-N C#CCN(C)CCCC Chemical compound C#CCN(C)CCCC NJBSAFGMLJQVNT-UHFFFAOYSA-N 0.000 description 20
- ZLSSWZIIDZZNDQ-UHFFFAOYSA-N C#CCN(C)CCCCC Chemical compound C#CCN(C)CCCCC ZLSSWZIIDZZNDQ-UHFFFAOYSA-N 0.000 description 20
- GGYSERMFKYUDPS-UHFFFAOYSA-N C#CCN(C)CCOCC Chemical compound C#CCN(C)CCOCC GGYSERMFKYUDPS-UHFFFAOYSA-N 0.000 description 20
- JHYHIRODANDVJH-UHFFFAOYSA-N C=C(C)CNCCCC Chemical compound C=C(C)CNCCCC JHYHIRODANDVJH-UHFFFAOYSA-N 0.000 description 20
- HKINEAOVTWICNO-UHFFFAOYSA-N C=C(C)CNCCOCC Chemical compound C=C(C)CNCCOCC HKINEAOVTWICNO-UHFFFAOYSA-N 0.000 description 20
- VOACIFOIIMQSGD-UHFFFAOYSA-N CC(C)(C)CCCN1CC=CCC1 Chemical compound CC(C)(C)CCCN1CC=CCC1 VOACIFOIIMQSGD-UHFFFAOYSA-N 0.000 description 20
- XEMOVVGGJCBRCN-UHFFFAOYSA-N CC(C)(C)CCCN1CCOCC1 Chemical compound CC(C)(C)CCCN1CCOCC1 XEMOVVGGJCBRCN-UHFFFAOYSA-N 0.000 description 20
- WGEMKUHXJXIQGW-UHFFFAOYSA-N CC(C)(C)CCN1CC=CCC1 Chemical compound CC(C)(C)CCN1CC=CCC1 WGEMKUHXJXIQGW-UHFFFAOYSA-N 0.000 description 20
- RGXUCUWVGKLACF-UHFFFAOYSA-N CC1=CC=CC(CN)=C1 Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 20
- KLCFXPKQAICDSP-UHFFFAOYSA-N CCCCCN1CC=CCC1 Chemical compound CCCCCN1CC=CCC1 KLCFXPKQAICDSP-UHFFFAOYSA-N 0.000 description 20
- RSWLGQNYSLMCCB-UHFFFAOYSA-N CCCCCN1CCC(OC)CC1 Chemical compound CCCCCN1CCC(OC)CC1 RSWLGQNYSLMCCB-UHFFFAOYSA-N 0.000 description 20
- LQWJONARYDIOSE-UHFFFAOYSA-N CCCCCN1CCCCC1 Chemical compound CCCCCN1CCCCC1 LQWJONARYDIOSE-UHFFFAOYSA-N 0.000 description 20
- IERWMZNDJGYCIA-UHFFFAOYSA-N CCCCCN1CCOCC1 Chemical compound CCCCCN1CCOCC1 IERWMZNDJGYCIA-UHFFFAOYSA-N 0.000 description 20
- PYWSUKUGSUGIBB-UHFFFAOYSA-N CCCCN1CCC(OC)CC1 Chemical compound CCCCN1CCC(OC)CC1 PYWSUKUGSUGIBB-UHFFFAOYSA-N 0.000 description 20
- AXWLKJWVMMAXBD-UHFFFAOYSA-N CCCCN1CCCCC1 Chemical compound CCCCN1CCCCC1 AXWLKJWVMMAXBD-UHFFFAOYSA-N 0.000 description 20
- LMRKVKPRHROQRR-UHFFFAOYSA-N CCCCN1CCOCC1 Chemical compound CCCCN1CCOCC1 LMRKVKPRHROQRR-UHFFFAOYSA-N 0.000 description 20
- BBHCCPCIXMEZGI-UHFFFAOYSA-N CCCCNCC=C(C)C Chemical compound CCCCNCC=C(C)C BBHCCPCIXMEZGI-UHFFFAOYSA-N 0.000 description 20
- NMILGIZTAZXMTM-UHFFFAOYSA-N CCCN1CCOCC1 Chemical compound CCCN1CCOCC1 NMILGIZTAZXMTM-UHFFFAOYSA-N 0.000 description 20
- DDQQWHPMRXVLFK-UHFFFAOYSA-N CCOCCN1CCC(OC)C1 Chemical compound CCOCCN1CCC(OC)C1 DDQQWHPMRXVLFK-UHFFFAOYSA-N 0.000 description 20
- GBEWXDWPSHORBW-UHFFFAOYSA-N CCOCCN1CCCC(OC)C1 Chemical compound CCOCCN1CCCC(OC)C1 GBEWXDWPSHORBW-UHFFFAOYSA-N 0.000 description 20
- CMXVZKXLGXHBSQ-UHFFFAOYSA-N CCOCCN1CCCC1 Chemical compound CCOCCN1CCCC1 CMXVZKXLGXHBSQ-UHFFFAOYSA-N 0.000 description 20
- GPGHOIHDWPDBCW-UHFFFAOYSA-N CCOCCNCC=C(C)C Chemical compound CCOCCNCC=C(C)C GPGHOIHDWPDBCW-UHFFFAOYSA-N 0.000 description 20
- BRLYSVNFNPKGQU-UHFFFAOYSA-N CCSCCN1CC=CCC1 Chemical compound CCSCCN1CC=CCC1 BRLYSVNFNPKGQU-UHFFFAOYSA-N 0.000 description 20
- BIBMOHFGEWVGGE-UHFFFAOYSA-N CCSCCN1CCCC(OC)C1 Chemical compound CCSCCN1CCCC(OC)C1 BIBMOHFGEWVGGE-UHFFFAOYSA-N 0.000 description 20
- XHGVIJLZMADWOB-UHFFFAOYSA-N CCSCCN1CCOCC1 Chemical compound CCSCCN1CCOCC1 XHGVIJLZMADWOB-UHFFFAOYSA-N 0.000 description 20
- KYWYKOFVVSAKSH-UHFFFAOYSA-N COC1CCCN(CCC(C)(C)C)C1 Chemical compound COC1CCCN(CCC(C)(C)C)C1 KYWYKOFVVSAKSH-UHFFFAOYSA-N 0.000 description 20
- HUZGDIHCQPXZNU-UHFFFAOYSA-N C#CCN(C)CCCC(C)(C)C Chemical compound C#CCN(C)CCCC(C)(C)C HUZGDIHCQPXZNU-UHFFFAOYSA-N 0.000 description 19
- IONYZQJNJQZUMX-UHFFFAOYSA-N C#CCNCCCC Chemical compound C#CCNCCCC IONYZQJNJQZUMX-UHFFFAOYSA-N 0.000 description 19
- UDJUIYMSYSDTRV-UHFFFAOYSA-N C=C(C)CNCCC(C)(C)C Chemical compound C=C(C)CNCCC(C)(C)C UDJUIYMSYSDTRV-UHFFFAOYSA-N 0.000 description 19
- ZEVFNYYPFPHAPA-UHFFFAOYSA-N C=C(C)CNCCCCC Chemical compound C=C(C)CNCCCCC ZEVFNYYPFPHAPA-UHFFFAOYSA-N 0.000 description 19
- VTZGZJMDQIRCRL-UHFFFAOYSA-N CC(C)=CCNCCC(C)(C)C Chemical compound CC(C)=CCNCCC(C)(C)C VTZGZJMDQIRCRL-UHFFFAOYSA-N 0.000 description 19
- ZJFVQFIMCHIJGQ-UHFFFAOYSA-N CC(C)=CCNCCCC(C)(C)C Chemical compound CC(C)=CCNCCCC(C)(C)C ZJFVQFIMCHIJGQ-UHFFFAOYSA-N 0.000 description 19
- KSMVBYPXNKCPAJ-UHFFFAOYSA-N CC1CCC(N)CC1 Chemical compound CC1CCC(N)CC1 KSMVBYPXNKCPAJ-UHFFFAOYSA-N 0.000 description 19
- AMKPQMFZCBTTAT-UHFFFAOYSA-N CCC1=CC(N)=CC=C1 Chemical compound CCC1=CC(N)=CC=C1 AMKPQMFZCBTTAT-UHFFFAOYSA-N 0.000 description 19
- MLAXEZHEGARMPE-UHFFFAOYSA-N CCCC1=CC=CN=C1 Chemical compound CCCC1=CC=CN=C1 MLAXEZHEGARMPE-UHFFFAOYSA-N 0.000 description 19
- LPXCHPSTROLSJX-UHFFFAOYSA-N CCCCC(=N)N Chemical compound CCCCC(=N)N LPXCHPSTROLSJX-UHFFFAOYSA-N 0.000 description 19
- JSHASCFKOSDFHY-UHFFFAOYSA-N CCCCN1CCCC1 Chemical compound CCCCN1CCCC1 JSHASCFKOSDFHY-UHFFFAOYSA-N 0.000 description 19
- YVHPNECEZVEGNJ-UHFFFAOYSA-N CCOCCN1CC=CCC1 Chemical compound CCOCCN1CC=CCC1 YVHPNECEZVEGNJ-UHFFFAOYSA-N 0.000 description 19
- QCZAFZCURZEGJR-UHFFFAOYSA-N CCOCCN1CCC(OC)CC1 Chemical compound CCOCCN1CCC(OC)CC1 QCZAFZCURZEGJR-UHFFFAOYSA-N 0.000 description 19
- KOSQHXGHNBGHNU-UHFFFAOYSA-N CCOCCN1CCC1 Chemical compound CCOCCN1CCC1 KOSQHXGHNBGHNU-UHFFFAOYSA-N 0.000 description 19
- FMYGTNODXBDYRP-UHFFFAOYSA-N CCOCCN1CCCCC1 Chemical compound CCOCCN1CCCCC1 FMYGTNODXBDYRP-UHFFFAOYSA-N 0.000 description 19
- MNFLRBMZMRLMSF-UHFFFAOYSA-N CCSCCN1CCC(OC)CC1 Chemical compound CCSCCN1CCC(OC)CC1 MNFLRBMZMRLMSF-UHFFFAOYSA-N 0.000 description 19
- ZKNFTOZEEYAJOT-UHFFFAOYSA-N CCSCCNCC=C(C)C Chemical compound CCSCCNCC=C(C)C ZKNFTOZEEYAJOT-UHFFFAOYSA-N 0.000 description 19
- PZUMGPQSLCLZSP-UHFFFAOYSA-N COC1CCCN(CCCC(C)(C)C)C1 Chemical compound COC1CCCN(CCCC(C)(C)C)C1 PZUMGPQSLCLZSP-UHFFFAOYSA-N 0.000 description 19
- DRSRFXPHURGKCZ-UHFFFAOYSA-N COC1CCN(CCC(C)(C)C)C1 Chemical compound COC1CCN(CCC(C)(C)C)C1 DRSRFXPHURGKCZ-UHFFFAOYSA-N 0.000 description 19
- SCPWRRBYXZFVPV-UHFFFAOYSA-N COC1CCN(CCCC(C)(C)C)CC1 Chemical compound COC1CCN(CCCC(C)(C)C)CC1 SCPWRRBYXZFVPV-UHFFFAOYSA-N 0.000 description 19
- QLWUUDMYTAATJZ-UHFFFAOYSA-N C#CCNCC Chemical compound C#CCNCC QLWUUDMYTAATJZ-UHFFFAOYSA-N 0.000 description 18
- PZDKPUHSLZLJNI-UHFFFAOYSA-N C#CCNCCCCC Chemical compound C#CCNCCCCC PZDKPUHSLZLJNI-UHFFFAOYSA-N 0.000 description 18
- PYOXIJHTSXVKMZ-UHFFFAOYSA-N CC(C)(C)CCN1CCOCC1 Chemical compound CC(C)(C)CCN1CCOCC1 PYOXIJHTSXVKMZ-UHFFFAOYSA-N 0.000 description 18
- HTHMVKNHGOVITA-UHFFFAOYSA-N CC1CNC1 Chemical compound CC1CNC1 HTHMVKNHGOVITA-UHFFFAOYSA-N 0.000 description 18
- VJXRKZJMGVSXPX-UHFFFAOYSA-N CCC1=CC=NC=C1 Chemical compound CCC1=CC=NC=C1 VJXRKZJMGVSXPX-UHFFFAOYSA-N 0.000 description 18
- UGPMCPGJKPZAAA-UHFFFAOYSA-N CCCCCN1CCC(OC)C1 Chemical compound CCCCCN1CCC(OC)C1 UGPMCPGJKPZAAA-UHFFFAOYSA-N 0.000 description 18
- KHLSECKSASTJCW-UHFFFAOYSA-N CCCCCNCC=C(C)C Chemical compound CCCCCNCC=C(C)C KHLSECKSASTJCW-UHFFFAOYSA-N 0.000 description 18
- BWMDMTSNSXYYSP-UHFFFAOYSA-N CCCNC(=N)N Chemical compound CCCNC(=N)N BWMDMTSNSXYYSP-UHFFFAOYSA-N 0.000 description 18
- SCZVXVGZMZRGRU-UHFFFAOYSA-N CCNCCN Chemical compound CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 18
- BPGIOCZAQDIBPI-UHFFFAOYSA-N CCOCCN Chemical compound CCOCCN BPGIOCZAQDIBPI-UHFFFAOYSA-N 0.000 description 18
- HJCTVUWPHAZTLI-UHFFFAOYSA-N CCSCCN Chemical compound CCSCCN HJCTVUWPHAZTLI-UHFFFAOYSA-N 0.000 description 18
- WQDDXVGJRSTLED-UHFFFAOYSA-N CN1CCN(C2=CC=CC=C2)CC1 Chemical compound CN1CCN(C2=CC=CC=C2)CC1 WQDDXVGJRSTLED-UHFFFAOYSA-N 0.000 description 9
- TXIOGJHPPVXTOY-UHFFFAOYSA-N CCN1CCN(C)CC1 Chemical compound CCN1CCN(C)CC1 TXIOGJHPPVXTOY-UHFFFAOYSA-N 0.000 description 8
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 7
- NGHHVCGBOOCIBY-UHFFFAOYSA-N CN1CCN(C2=CC=NC=C2)CC1 Chemical compound CN1CCN(C2=CC=NC=C2)CC1 NGHHVCGBOOCIBY-UHFFFAOYSA-N 0.000 description 7
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
- UCXFBUMFTFEEQQ-UHFFFAOYSA-N CC(C)[N-]1CCN(C)CC1 Chemical compound CC(C)[N-]1CCN(C)CC1 UCXFBUMFTFEEQQ-UHFFFAOYSA-N 0.000 description 6
- RXVGQIBJNXFOOI-UHFFFAOYSA-N CCCN1CCN(C)CC1 Chemical compound CCCN1CCN(C)CC1 RXVGQIBJNXFOOI-UHFFFAOYSA-N 0.000 description 6
- GXEWAQQSKFJHTL-UHFFFAOYSA-N CN1CCN(C2CCCCCC2)CC1 Chemical compound CN1CCN(C2CCCCCC2)CC1 GXEWAQQSKFJHTL-UHFFFAOYSA-N 0.000 description 6
- FKPOQLRUYSBKGA-UHFFFAOYSA-N CN1CCN(C2CCOCC2)CC1 Chemical compound CN1CCN(C2CCOCC2)CC1 FKPOQLRUYSBKGA-UHFFFAOYSA-N 0.000 description 6
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N CN1CCN(CCO)CC1 Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 6
- BKANKXLLSZNGER-UHFFFAOYSA-N CN1CC[N-](CC2=CC=CC=C2)CC1 Chemical compound CN1CC[N-](CC2=CC=CC=C2)CC1 BKANKXLLSZNGER-UHFFFAOYSA-N 0.000 description 6
- POFVDMANNKXPRR-UHFFFAOYSA-N CC1CC1C.CC1CCC1C.CC1CCCC1C.CC1CCCCC1C Chemical compound CC1CC1C.CC1CCC1C.CC1CCCC1C.CC1CCCCC1C POFVDMANNKXPRR-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N CN Chemical compound CN BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- IICIEOQDHWIAMK-UHFFFAOYSA-N CC(=O)NC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1 Chemical compound CC(=O)NC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1 IICIEOQDHWIAMK-UHFFFAOYSA-N 0.000 description 3
- PLADJBYYNIZOTA-UHFFFAOYSA-N CC(=O)NC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1C(F)(F)F Chemical compound CC(=O)NC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1C(F)(F)F PLADJBYYNIZOTA-UHFFFAOYSA-N 0.000 description 3
- BDOBMXJITOGFAA-UHFFFAOYSA-N CC(=O)NC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1Cl Chemical compound CC(=O)NC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1Cl BDOBMXJITOGFAA-UHFFFAOYSA-N 0.000 description 3
- VQSFKZNOMWESPN-UHFFFAOYSA-N CC1=CC(C2=NN=C(=O)C3=C2CCCC3)=CC=C1C(F)(F)F.[HH] Chemical compound CC1=CC(C2=NN=C(=O)C3=C2CCCC3)=CC=C1C(F)(F)F.[HH] VQSFKZNOMWESPN-UHFFFAOYSA-N 0.000 description 3
- ZRPIBVSWPCPLHV-UHFFFAOYSA-N CC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1.[HH] Chemical compound CC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1.[HH] ZRPIBVSWPCPLHV-UHFFFAOYSA-N 0.000 description 3
- WCVLIWZQGRSEIZ-UHFFFAOYSA-N CC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1Cl.[HH] Chemical compound CC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1Cl.[HH] WCVLIWZQGRSEIZ-UHFFFAOYSA-N 0.000 description 3
- REJJGFXYHBXDCQ-UHFFFAOYSA-N CCC(=O)NC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1C(F)(F)F Chemical compound CCC(=O)NC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1C(F)(F)F REJJGFXYHBXDCQ-UHFFFAOYSA-N 0.000 description 3
- HVQFNYHZICWMSQ-UHFFFAOYSA-N CCC(=O)NC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1Cl Chemical compound CCC(=O)NC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1Cl HVQFNYHZICWMSQ-UHFFFAOYSA-N 0.000 description 3
- BJPGORCJAQFUAK-UHFFFAOYSA-N CCNC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1 Chemical compound CCNC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1 BJPGORCJAQFUAK-UHFFFAOYSA-N 0.000 description 3
- OALRPKIPBZOQBU-UHFFFAOYSA-N CCNC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1C(F)(F)F Chemical compound CCNC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1C(F)(F)F OALRPKIPBZOQBU-UHFFFAOYSA-N 0.000 description 3
- DJFPGINUKJINSL-UHFFFAOYSA-N CCNC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1Cl Chemical compound CCNC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1Cl DJFPGINUKJINSL-UHFFFAOYSA-N 0.000 description 3
- NPJWYOKPFZPVCT-UHFFFAOYSA-N CNCC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1 Chemical compound CNCC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1 NPJWYOKPFZPVCT-UHFFFAOYSA-N 0.000 description 3
- RUZCNUKBLDELLW-UHFFFAOYSA-N CNCC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1C(F)(F)F Chemical compound CNCC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1C(F)(F)F RUZCNUKBLDELLW-UHFFFAOYSA-N 0.000 description 3
- ZAQPHKVATPRPFQ-UHFFFAOYSA-N CNCC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1Cl Chemical compound CNCC1=CC(C2=NNC(=O)C3=C2CCCC3)=CC=C1Cl ZAQPHKVATPRPFQ-UHFFFAOYSA-N 0.000 description 3
- ITUOQSJOYDWXDU-UHFFFAOYSA-N CNCC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1 Chemical compound CNCC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1 ITUOQSJOYDWXDU-UHFFFAOYSA-N 0.000 description 3
- JSSIENKCURTWRK-UHFFFAOYSA-N CNCC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1C(F)(F)F Chemical compound CNCC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1C(F)(F)F JSSIENKCURTWRK-UHFFFAOYSA-N 0.000 description 3
- ICKFCOAQURKYAT-UHFFFAOYSA-N CNCC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1Cl Chemical compound CNCC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1Cl ICKFCOAQURKYAT-UHFFFAOYSA-N 0.000 description 3
- SZLTXSAKLFPFNZ-UHFFFAOYSA-N CC(=O)NC1=CC(C2=NN=C(=O)C3=C2NCCC3)=CC=C1 Chemical compound CC(=O)NC1=CC(C2=NN=C(=O)C3=C2NCCC3)=CC=C1 SZLTXSAKLFPFNZ-UHFFFAOYSA-N 0.000 description 2
- KAKOUNRRKSHVJO-UHFFFAOYSA-N CC.CC1=CC=CC=C1 Chemical compound CC.CC1=CC=CC=C1 KAKOUNRRKSHVJO-UHFFFAOYSA-N 0.000 description 2
- ZABWMAYZKSELNK-UHFFFAOYSA-N CC.CC1=CC=CC=C1.CCCC Chemical compound CC.CC1=CC=CC=C1.CCCC ZABWMAYZKSELNK-UHFFFAOYSA-N 0.000 description 2
- VQKHIHZUTGUYNP-UHFFFAOYSA-N CCC1=NNC(=O)C2=C1CCCC2.[HH] Chemical compound CCC1=NNC(=O)C2=C1CCCC2.[HH] VQKHIHZUTGUYNP-UHFFFAOYSA-N 0.000 description 2
- VKUQYUPKGMHQFL-UHFFFAOYSA-N CCC1=NNC(=O)C2=C1NCCC2.[HH] Chemical compound CCC1=NNC(=O)C2=C1NCCC2.[HH] VKUQYUPKGMHQFL-UHFFFAOYSA-N 0.000 description 2
- MTVQLNATQAANRV-UHFFFAOYSA-N CCCC1=NNC(=O)C2=C1CCCC2 Chemical compound CCCC1=NNC(=O)C2=C1CCCC2 MTVQLNATQAANRV-UHFFFAOYSA-N 0.000 description 2
- AOGCJRGICKFVRK-UHFFFAOYSA-N CCCC1=NNC(=O)C2=C1NCCC2 Chemical compound CCCC1=NNC(=O)C2=C1NCCC2 AOGCJRGICKFVRK-UHFFFAOYSA-N 0.000 description 2
- HLFRQVOFZSKQOJ-UHFFFAOYSA-N CN(C)C(=O)CC1=NNC(=O)C2=C1CCCC2 Chemical compound CN(C)C(=O)CC1=NNC(=O)C2=C1CCCC2 HLFRQVOFZSKQOJ-UHFFFAOYSA-N 0.000 description 2
- IFZVTNHVPMFTHC-UHFFFAOYSA-N CN(C)C(=O)CC1=NNC(=O)C2=C1NCCC2 Chemical compound CN(C)C(=O)CC1=NNC(=O)C2=C1NCCC2 IFZVTNHVPMFTHC-UHFFFAOYSA-N 0.000 description 2
- SVLTVPDKQCRTGM-UHFFFAOYSA-N CNC(=O)CC1=NNC(=O)C2=C1CCCC2 Chemical compound CNC(=O)CC1=NNC(=O)C2=C1CCCC2 SVLTVPDKQCRTGM-UHFFFAOYSA-N 0.000 description 2
- QAIJRFZVWCGRCI-UHFFFAOYSA-N CNC(=O)CC1=NNC(=O)C2=C1NCCC2 Chemical compound CNC(=O)CC1=NNC(=O)C2=C1NCCC2 QAIJRFZVWCGRCI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N [H]N Chemical compound [H]N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LXFKARSSFMIWSU-UHFFFAOYSA-N C.CC.CC Chemical compound C.CC.CC LXFKARSSFMIWSU-UHFFFAOYSA-N 0.000 description 1
- HIGBXHZYEQZFIM-UHFFFAOYSA-N C.CN Chemical compound C.CN HIGBXHZYEQZFIM-UHFFFAOYSA-N 0.000 description 1
- NSQGSPVXTCYAIM-UHFFFAOYSA-N CC(=O)NC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1 Chemical compound CC(=O)NC1=CC(C2=NNC(=O)C3=C2NCCC3)=CC=C1 NSQGSPVXTCYAIM-UHFFFAOYSA-N 0.000 description 1
- AQWIJZZEAFKBNT-UHFFFAOYSA-N CC(=O)NCC1=NNC(=O)C2=C1CCCC2 Chemical compound CC(=O)NCC1=NNC(=O)C2=C1CCCC2 AQWIJZZEAFKBNT-UHFFFAOYSA-N 0.000 description 1
- APHFBTWEXVBEHR-UHFFFAOYSA-N CC(=O)NCC1=NNC(=O)C2=C1NCCC2 Chemical compound CC(=O)NCC1=NNC(=O)C2=C1NCCC2 APHFBTWEXVBEHR-UHFFFAOYSA-N 0.000 description 1
- IVBVRNYKBKHDMN-UHFFFAOYSA-N CC(=O)NCCC1=NNC(=O)C2=C1CCCC2 Chemical compound CC(=O)NCCC1=NNC(=O)C2=C1CCCC2 IVBVRNYKBKHDMN-UHFFFAOYSA-N 0.000 description 1
- YCEWHMFKFMMMLL-UHFFFAOYSA-N CC(=O)NCCC1=NNC(=O)C2=C1NCCC2 Chemical compound CC(=O)NCCC1=NNC(=O)C2=C1NCCC2 YCEWHMFKFMMMLL-UHFFFAOYSA-N 0.000 description 1
- HLYYZFKMDIFGBB-UHFFFAOYSA-N CC(C)N(C)C(=O)CC1=NNC(=O)C2=C1CCCC2 Chemical compound CC(C)N(C)C(=O)CC1=NNC(=O)C2=C1CCCC2 HLYYZFKMDIFGBB-UHFFFAOYSA-N 0.000 description 1
- QTOWWJHETYSDOC-UHFFFAOYSA-N CC(C)N(C)C(=O)CC1=NNC(=O)C2=C1NCCC2 Chemical compound CC(C)N(C)C(=O)CC1=NNC(=O)C2=C1NCCC2 QTOWWJHETYSDOC-UHFFFAOYSA-N 0.000 description 1
- KOWXKIHEBFTVRU-UHFFFAOYSA-N CC.CC Chemical compound CC.CC KOWXKIHEBFTVRU-UHFFFAOYSA-N 0.000 description 1
- NMRYTGODAHPNSO-UHFFFAOYSA-N CC.CC(=O)[Y]N Chemical compound CC.CC(=O)[Y]N NMRYTGODAHPNSO-UHFFFAOYSA-N 0.000 description 1
- HFVNIIMUYQUQTR-UHFFFAOYSA-N CC.CC.CCC1=NNC(=O)C2=C1CCCC2 Chemical compound CC.CC.CCC1=NNC(=O)C2=C1CCCC2 HFVNIIMUYQUQTR-UHFFFAOYSA-N 0.000 description 1
- ZWLILSYSSUGNCA-UHFFFAOYSA-N CC.CC.CCC1=NNC(=O)C2=C1NCCC2 Chemical compound CC.CC.CCC1=NNC(=O)C2=C1NCCC2 ZWLILSYSSUGNCA-UHFFFAOYSA-N 0.000 description 1
- UPJUOIJFAHSHTL-UHFFFAOYSA-N CC.CC.CCCC.O=C1NN=C(C2=CC=CC=C2)C2=C1CCCC2 Chemical compound CC.CC.CCCC.O=C1NN=C(C2=CC=CC=C2)C2=C1CCCC2 UPJUOIJFAHSHTL-UHFFFAOYSA-N 0.000 description 1
- RBUQWAWXPRLTSM-UHFFFAOYSA-N CC.CC.CCCC.O=C1NN=C(C2=CC=CC=C2)C2=C1CCCN2 Chemical compound CC.CC.CCCC.O=C1NN=C(C2=CC=CC=C2)C2=C1CCCN2 RBUQWAWXPRLTSM-UHFFFAOYSA-N 0.000 description 1
- BYAVDSLRQRXUOL-OPIVVEOKSA-M CC.CC1=NNC(=O)N[Y]1 Chemical compound CC.CC1=NNC(=O)N[Y]1 BYAVDSLRQRXUOL-OPIVVEOKSA-M 0.000 description 1
- LWSYSCQGRROTHV-UHFFFAOYSA-N CC.CCC Chemical compound CC.CCC LWSYSCQGRROTHV-UHFFFAOYSA-N 0.000 description 1
- VUCRXTCYCBAAEG-UHFFFAOYSA-N CC.CCCCC1=NNC(=O)C2=C1CCCC2 Chemical compound CC.CCCCC1=NNC(=O)C2=C1CCCC2 VUCRXTCYCBAAEG-UHFFFAOYSA-N 0.000 description 1
- ZHEFFXVUVUZBSM-UHFFFAOYSA-N CC.CCCCC1=NNC(=O)C2=C1NCCC2 Chemical compound CC.CCCCC1=NNC(=O)C2=C1NCCC2 ZHEFFXVUVUZBSM-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N CC.[H]N Chemical compound CC.[H]N OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- MPBYIJASAXJPDE-UHFFFAOYSA-N CC1=C(C)CCC1.CC1=C(C)CCCC1.CC1=C(C)CCCCC1.CC1=C(C)CNCC1.CC1=C(C)CNCC1.CC1=C(C)NCCC1.CC1=C(C)NCCC1.CC1=CSCCN1C.CC1CC=CCC1C.CC1CSCCN1C Chemical compound CC1=C(C)CCC1.CC1=C(C)CCCC1.CC1=C(C)CCCCC1.CC1=C(C)CNCC1.CC1=C(C)CNCC1.CC1=C(C)NCCC1.CC1=C(C)NCCC1.CC1=CSCCN1C.CC1CC=CCC1C.CC1CSCCN1C MPBYIJASAXJPDE-UHFFFAOYSA-N 0.000 description 1
- GTOCKDJHUBBOQK-UHFFFAOYSA-N CC1=C(C)CCC1.CC1=C(C)CCCC1.CC1=C(C)CCCCC1.CC1CC=CCC1C Chemical compound CC1=C(C)CCC1.CC1=C(C)CCCC1.CC1=C(C)CCCCC1.CC1CC=CCC1C GTOCKDJHUBBOQK-UHFFFAOYSA-N 0.000 description 1
- FTHUJTQMPXZAQP-UHFFFAOYSA-N CC1=C(C)CNCC1.CC1=C(C)CNCC1.CC1=C(C)NCCC1.CC1=C(C)NCCC1.CC1=C(C)NCCN1.CC1=CCCCN1C.CC1=CSCCN1C.CC1CCCCN1C.CC1CCCCN1C.CC1CCCN1C.CC1CCSCN1C.CC1CCSCN1C.CC1CSCCCN1C.CC1CSCCN1C.CC1CSCN1C.CC1SCCN1C Chemical compound CC1=C(C)CNCC1.CC1=C(C)CNCC1.CC1=C(C)NCCC1.CC1=C(C)NCCC1.CC1=C(C)NCCN1.CC1=CCCCN1C.CC1=CSCCN1C.CC1CCCCN1C.CC1CCCCN1C.CC1CCCN1C.CC1CCSCN1C.CC1CCSCN1C.CC1CSCCCN1C.CC1CSCCN1C.CC1CSCN1C.CC1SCCN1C FTHUJTQMPXZAQP-UHFFFAOYSA-N 0.000 description 1
- PWZKIZAHIAGUMK-UHFFFAOYSA-N CC1CCN(Cc2ccccc2)CC1 Chemical compound CC1CCN(Cc2ccccc2)CC1 PWZKIZAHIAGUMK-UHFFFAOYSA-N 0.000 description 1
- MPAYEWNVIPXRDP-UHFFFAOYSA-N CC=N Chemical compound CC=N MPAYEWNVIPXRDP-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N CCCC Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- TUFDKDIQQGZYGH-UHFFFAOYSA-N CCCCC1=NNC(=O)C2=C1CCCC2 Chemical compound CCCCC1=NNC(=O)C2=C1CCCC2 TUFDKDIQQGZYGH-UHFFFAOYSA-N 0.000 description 1
- URPYUROXAXWVFJ-UHFFFAOYSA-N CCCCC1=NNC(=O)C2=C1CCCC2.[HH] Chemical compound CCCCC1=NNC(=O)C2=C1CCCC2.[HH] URPYUROXAXWVFJ-UHFFFAOYSA-N 0.000 description 1
- CGOULYMCGOSBKP-UHFFFAOYSA-N CCCCC1=NNC(=O)C2=C1NCCC2 Chemical compound CCCCC1=NNC(=O)C2=C1NCCC2 CGOULYMCGOSBKP-UHFFFAOYSA-N 0.000 description 1
- WGIJPBUVRMVBNH-UHFFFAOYSA-N CCCCC1=NNC(=O)C2=C1NCCC2.[HH] Chemical compound CCCCC1=NNC(=O)C2=C1NCCC2.[HH] WGIJPBUVRMVBNH-UHFFFAOYSA-N 0.000 description 1
- QQPDCNRJGKMHTD-UHFFFAOYSA-N CCCCCC1=NNC(=O)C2=C1CCCC2 Chemical compound CCCCCC1=NNC(=O)C2=C1CCCC2 QQPDCNRJGKMHTD-UHFFFAOYSA-N 0.000 description 1
- ALPXJYFQSQRSHV-UHFFFAOYSA-N CCCCCC1=NNC(=O)C2=C1NCCC2 Chemical compound CCCCCC1=NNC(=O)C2=C1NCCC2 ALPXJYFQSQRSHV-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N CCCCCCN Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- AIOIZXGSWMVILL-UHFFFAOYSA-N CCN(C)C(=O)CC1=NNC(=O)C2=C1CCCC2 Chemical compound CCN(C)C(=O)CC1=NNC(=O)C2=C1CCCC2 AIOIZXGSWMVILL-UHFFFAOYSA-N 0.000 description 1
- RLBWIKYYWWVVFX-UHFFFAOYSA-N CCN(C)C(=O)CC1=NNC(=O)C2=C1NCCC2 Chemical compound CCN(C)C(=O)CC1=NNC(=O)C2=C1NCCC2 RLBWIKYYWWVVFX-UHFFFAOYSA-N 0.000 description 1
- VNBSVVVPPSYYBQ-UHFFFAOYSA-N CN(CC1=CC=CC=C1)C(=O)CC1=NNC(=O)C2=C1CCCC2 Chemical compound CN(CC1=CC=CC=C1)C(=O)CC1=NNC(=O)C2=C1CCCC2 VNBSVVVPPSYYBQ-UHFFFAOYSA-N 0.000 description 1
- QSUNEHNUTRUDRM-UHFFFAOYSA-N CN(CC1=CC=CC=C1)C(=O)CC1=NNC(=O)C2=C1NCCC2 Chemical compound CN(CC1=CC=CC=C1)C(=O)CC1=NNC(=O)C2=C1NCCC2 QSUNEHNUTRUDRM-UHFFFAOYSA-N 0.000 description 1
- NGHGCHXGQHNROG-UHFFFAOYSA-N CNCCC1=NNC(=O)C2=C1CCCC2 Chemical compound CNCCC1=NNC(=O)C2=C1CCCC2 NGHGCHXGQHNROG-UHFFFAOYSA-N 0.000 description 1
- CRTIOEZAHFEFJM-UHFFFAOYSA-N CNCCC1=NNC(=O)C2=C1NCCC2 Chemical compound CNCCC1=NNC(=O)C2=C1NCCC2 CRTIOEZAHFEFJM-UHFFFAOYSA-N 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N CNN Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- HGXKVNRBKJMVLX-UHFFFAOYSA-N O=C(C1=C2CCCC1)NN=C2c1ccccc1 Chemical compound O=C(C1=C2CCCC1)NN=C2c1ccccc1 HGXKVNRBKJMVLX-UHFFFAOYSA-N 0.000 description 1
- BTNABQNODGZISF-UHFFFAOYSA-N O=C1NN=C(CCCC2=CC=CC=C2)C2=C1CCCC2 Chemical compound O=C1NN=C(CCCC2=CC=CC=C2)C2=C1CCCC2 BTNABQNODGZISF-UHFFFAOYSA-N 0.000 description 1
- HVZSOXMOPCPRRP-UHFFFAOYSA-N O=C1NN=C(CCCC2=CC=CC=C2)C2=C1CCCN2 Chemical compound O=C1NN=C(CCCC2=CC=CC=C2)C2=C1CCCN2 HVZSOXMOPCPRRP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention relates to fused pyridazine derivative compounds.
- the present invention relates to
- Poly(ADP-ribose)polymerase (abbreviated as PARP hereinafter), which is a nuclear enzyme activated by DNA strand breaks, plays a role in the transfer reaction of ADP-ribose moiety from nicotinamide adenine dinucleotide (abbreviated as NAD + hereinafter) to various proteins such as histones, DNA-polymerases and DNA-topoisomerases, etc.
- PARP nicotinamide adenine dinucleotide
- caspase-3 which is one of interleukin-1 ⁇ -converting enzyme family, specifically cleaves PARP as the substrate ( Cell., 81, 801 (1995)), it is suggested PARP is associated with apoptosis.
- 3-aminobenzamide and nicotinamide generally known as inhibitors of PARP are useful for inhibition of cell death and improvement of diseases on various models of ischemic diseases (cerebral, myocardial, intestinal, skeletal muscular or retinal ischemia etc.), inflammatory diseases (arthritis, inflammatory bowel disease or multiple sclerosis etc.), diabetes, shock, extrapyramidal disease ( TIPS., 19, 287 (1998); Eur J. Pharmacol., 350, 1 (1998)) and hyperalgesia ( Pain, 72, 355 (1997)) in vitro, in vivo and in PARP knockout mouse. And it is reported that PARP inhibitor is useful as an antiretroviral drug such as an anti HIV drug ( Biochem. Biophys. Res.
- PARP inhibitor is useful for prevention and/or treatment of various diseases, for example, ischemic diseases (cerebral infarction, myocardial infarction, reperfusion injury or postoperative injury etc.), inflammatory diseases (inflammatory bowel disease, multiple sclerosis, arthritis or lung injury etc.), neurodegenerative disorders (extrapyramidal disease, Parkinson's disease, Alzheimer's disease, muscular dystrophy or lumbar spinal canal stenosis etc.), glaucoma, diabetes, diabetic complication, shock, head trauma, spinal cord injury, renal failure, hyperalgesia or blood flow obstruction etc. And it is useful as an antiretroviral drug such as an anti HIV drug, a sensitizer of anticancer therapy or an immunosuppressant.
- ischemic diseases cerebral infarction, myocardial infarction, reperfusion injury or postoperative injury etc.
- inflammatory diseases inflammatory bowel disease, multiple sclerosis, arthritis or lung injury etc.
- neurodegenerative disorders extrapyramidal disease, Parkinson'
- R 1A is (i) C1-4 alkyl substituted by hydroxy or amino, or
- a 1A is —NR 3A C(O)— etc. wherein R 3A is hydrogen or C1-4 alkyl etc., A 2A is C1-8 alkylene etc., A 3A is (i) hydrogen, (ii) —NR 17A R 18A or (iii) Cyc 2A etc. wherein R 17A is (i) hydrogen, (ii) C1-8 alkyl etc., and R 18A is (i) hydrogen or (ii) C1-8 alkyl etc., Cyc 2A is 3-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen atoms, 1-2 of oxygen atoms and/or one sulfur atom, R 2A is hydrogen or halogen etc. Necessary parts were extracted from the description of groups.) have PARP inhibitory activity.
- R 1B is hydrogen or C1-3 alkyl
- R 2B is hydrogen, R 1B and R 2B , taken together, are C1-4 alkylene
- R 3B is hydrogen or methyl
- nB is 0-3
- R 4B is 1-pyrrolyl. Necessary parts were extracted from the description of groups.) have inhibitory activity of platelet aggregation.
- R 1C is C1-4 alkoxy etc.
- R 2C is C1-8 alkoxy etc.
- R 3C and R 4C is hydrogen or R 3C and R 4C , taken together, are bond
- R 5C is hydrogen etc.
- Necessary parts were extracted from the description of groups.) have phosphodiesterase inhibitory activity.
- the present invention relates to
- R 2 and R 3 are each independently
- X and Y are each independently
- A is (1) A 1 , (2) A 2 , (3) A 3 , (4) A 4 or (5) A 5 ,
- a 2 is -E 1 -E 2 -E 3 -E 4 ,
- a 4 is
- R 6 and R 7 are each independently
- R 9 and R 13 are each independently
- R 10 and R 14 are each independently
- R 11 and R 12 are each independently
- R 15 , R 16 , R 17 , R 18 , R 19 , R 20 and R 21 are each independently
- R 22 and R 23 are each independently
- E 1 is C1-4 alkylene
- G 1 is C1-8 alkylene
- R 41 and R 42 are each dependently
- R 5 is (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) nitro, (6) NR 29 R 30 , (7) C1-8 alkyl substituted by NR 29 R 30 , (8) NHSO 2 OH, (9) amidino, (10) cyano, (11) a halogen atom, (12) Cyc8 or (13) C1-8 alkyl substituted by Cyc8,
- R 29 and R 30 are each independently
- Cyc2, Cyc3, Cyc4, Cyc5, Cyc6 and Cyc8 are each independently
- Cyc2, Cyc3, Cyc4, Cyc5, Cyc6 and Cyc8 are optionally substituted by 1 to 3 substituent(s) selected from (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C1-8 alkoxy, (4) halogen atom, (5) trihalomethyl, (6) trihalomethoxy, (7) C1-8 alkoxycarbonyl, (8) oxo, (9) C1-8 alkyl substituted by C1-8 alkoxy or phenyl, (10) hydroxy and (11) NR 29 R 30 ;
- n are each independently 1 or 2
- R 5 is not hydroxy or C1-8 alkoxy
- C1-8 alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl or isomeric groups thereof.
- C2-8 alkenyl means ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl or isomeric groups thereof.
- C2-8 alkynyl means ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl or isomeric groups thereof.
- C1-8 alkoxy means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy or isomeric groups thereof.
- C2-8 alkenyloxy means ethenyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy, heptenyloxy, octenyloxy or isomeric groups thereof.
- C2-8 alkynyloxy means ethynyloxy, propynyloxy, butynyloxy, pentynyloxy, hexynyloxy, heptynyloxy, octynyloxy or isomeric groups thereof.
- C1-8 alkylthio means methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio or isomeric groups thereof.
- C1-4 alkylene means methylene, ethylene, trimethylene, tetramethylene or isomeric groups thereof.
- C1-8 alkylene means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene or isomeric groups thereof.
- C2-8 alkenylene means ethenylene, propenylene, butenylene, pentenylene, hexenylene, heptenylene, octenylene or isomeric groups thereof.
- C1-8 alkoxycarbonyl means methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, heptyloxycarbonyl, octyloxycarbonyl or isomeric groups thereof.
- trihalomethyl is methyl substituted by three halogen atoms.
- trihalomethoxy is methoxyl substituted by three halogen atoms.
- C2-8 acyl means ethanoyl (acethyl), propanoyl (propionyl), butanoyl (butyryl), pentanoyl (valeryl), hexanoyl, heptanoyl, octanoyl or isomeric groups thereof.
- C3-8 cycloalkyl means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.
- halogen means chlorine, bromine, fluorine or iodine.
- cyclopropane is cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclononene, cyclodecene, cyclohexadiene, cycloheptadiene, cyclooctadiene etc.
- 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atoms selected from oxygen, nitrogen or sulfur atom represented by Cyc1, Cyc2, Cyc3, Cyc4, Cyc5, Cyc6, Cyc7 and Cyc8, 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atoms selected from oxygen, nitrogen or sulfur atom means, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiaine, thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine
- partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1-4 hetero atoms selected from oxygen, nitrogen or sulfur atom means aziridine, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine,
- the above hetero ring includes N-oxide which is the compound where nitrogen is oxidized.
- C3-10 mono- or bi-carbocyclic aryl represented by Cyc1, Cyc2, Cyc3, Cyc4, Cyc5, Cyc6, Cyc7 and Cyc8 is cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclononene, cyclodecene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene, benzene, pentalene, azulene, perhydroazulene, perhydropentalene, indene, perhydroindene, indan, naphthalen
- alkyl, alkenyl, alkynyl, alkylene and alkoxy group includes straight or branched ones.
- isomers on double bond, ring, fused ring (E-, Z-, cis-, trans-isomer), isomers generated from asymmetric carbon atom(s) (R—, S—, ⁇ -, ⁇ -isomer, enantiomer, diastereomer), optically active isomers (D-, L-, d-, l-isomer), polar compounds generated by chromatographic separation (more polar compound, less polar compound), equilibrium compounds, mixtures thereof at voluntary ratios and racemic mixtures are also included in the present invention.
- symbol indicates that it is bound to the opposite side of the sheet (namely ⁇ -configuration)
- symbol indicates that it is bound to the front side of the sheet (namely ⁇ -configuration)
- symbol indicates that it is ⁇ -, ⁇ - or a mixture thereof
- symbol indicates that it is a mixture of ⁇ -configuration and ⁇ -configuration.
- the compound of the present invention can be converted into a pharmaceutically acceptable salt by known methods.
- the pharmaceutically acceptable salt is preferably water-soluble.
- the pharmaceutically acceptable salt means, for example, salts of alkali metals (potassium, sodium, lithium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts (tetramethylammonium, tetrabutylammonium, etc.), salts of organic amines (triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine, etc.), acid-addition salts (inorganic acid salts (hydrochloride, hydrobromate, hydroiodate, sulfate, phosphate, nitrate, etc.), organic acid salts (acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, me
- solvates or solvates of the above alkai (earth) metals, ammonium, organic amines and acid-addition salts of the compound of the present invention are included in the pharmaceutically acceptable salt of the present invention.
- the solvate is preferably nontoxic and water-soluble.
- Appropriate solvate means, for example, solvates such as water, an alcohol solvent (ethanol etc.), etc.
- C3-7 mono-carbocyclic aryl is preferably partially or fully saturated C3-7 mono-carbocyclic aryl, or partially or fully saturated 3-7 membered mono-hetero aryl containing 1 to 2 hetero atom(s) selected from oxygen, nitrogen and sulfur atom.
- partially or fully saturated C3-7 mono-carbocyclic aryl, or partially or fully saturated 3-7 membered mono-hetero aryl is preferably following compounds;
- Partially or fully saturated 3-7 membered mono-hetero aryl containing 1 to 2 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms is preferably following compounds;
- A is preferably A 1 , A 2 or A 3 .
- D 1 is preferably —NR 6 C(O)—, —NR 6 C(S)—, —NR 6 SO 2 — or —CH 2 —NR 6 —, and more preferably —NR 6 C(O)—.
- D 2 is preferably C1-8 alkylene, C2-8 alkenylene, —(C1-4 alkylene)-O—(C1-4 alkylene)-, —(C1-4 alkylene)-S—(C1-4 alkylene)-, —(C1-4 alkylene)-NR 8 —(C1-4 alkylene)- or —(C1-8 alkylene)-(Cyc2)-, and more preferably C1-8 alkylene.
- D 3 is preferably —NR 9 R 10 or Cyc3.
- E 1 is preferably C1-4 alkylene.
- E 2 is preferably —C(O)NR 24 —, —NR 24 C(O)—, —NR 24 — or —S—
- E 3 is preferably bond or C1-8 alkylene.
- E 4 is preferably Cyc5 or NR 25 R 26 .
- Cyc1 is preferably partially or fully saturated 3-10 membered mono-hetero aryl containing 1 to 2 hetero atom(s) selected from oxygen, nitrogen and sulfur atom.
- At least one of X and Y is preferably N.
- Concrete compounds of the present invention include compounds shown in Tables 1 to 90, compounds described in Examples, and pharmaceutically acceptable salts thereof.
- Me represents methyl group
- Et represents ethyl group
- Pr represents propyl group
- i-Pr represents isopropyl group
- Bu represents butyl group
- c-Pr represents cyclopropyl group
- c-Bu represents cyclobutyl group
- c-Pen represents cyclopentyl group
- c-Hex represents cyclohexyl group
- Ph represents phenyl group
- Bn represents benzyl group, and other symbols have the same meanings as described above.
- the compound represented by formula (I) can be prepared by the following method or the method described in Example.
- D 1-1 is —NR 6 C(O)— or —CH 2 —NR 6 C(O)—, and other symbols have the same meanings as described above.
- the compound represented by formula (IA-1) can be prepared by the amidation of the compounds of formula (II)
- R 31 is —NHR 6 or —CH 2 —NHR 6 , and R 1-1 , R 4-1 and
- D 2-1 and D 3-1 are D 2 and D 3 respectively.
- amino in the group represented by D 2-1 , and carboxy, hydroxy, amino, amidino or guanidino in D 3-1 may be protected, if necessary.), if necessary, followed by removal of the protective group from the resulting product.
- the method of amidation is known.
- it includes the method
- the method via an acyl halide may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., oxalyl chloride or thionyl chloride etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent at ⁇ 20° C. to reflux temperature.
- an acyl halide e.g., oxalyl chloride or thionyl chloride etc.
- organic solvent e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran
- the obtained acyl halide derivative may be reacted with amine in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0 to 40° C.
- an inert organic solvent e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran
- tertiary amine e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.
- the obtained acyl halide derivative may be reacted in an organic solvent (dioxane, tetrahydrofuran) using an alkaline aqueous solution (e.g., sodium bicarbonate, sodium hydroxide) at 0 to 40
- the method via a mixed acid anhydride may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., pivaloyl chloride, tosyl chloride or mesyl chloride) or an acid derivative (ethyl chloroformate or isobutyl chloroformate) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran) or without a solvent, in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) at 0 to 40° C. And then the obtained mixed acid anhydride derivative may be reacted with amine in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran), at 0 to 40° C.
- an organic solvent e.g., chloroform,
- the method using a condensing agent may be carried out, for example, by reacting carboxylic acid with amine in an organic solvent (e.g., chloroform, methylene chloride, dimethylformamide, diethyl ether or tetrahydrofuran) or without a solvent, in the presence or absence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), using a condensing agent (e.g., 1,3-dicyclohexyl carbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,1′-carbodiimidazole (CDI), 2-chloro-1-methylpyridinium iodide, or 1-propanephosphonic acid cyclic anhydride (PPA)), in the presence or absence of 1-hydroxybenzothiazole (HOBt), at 0
- reaction described in (1), (2) and (3) may be carried out under an inert gas (e.g., argon, nitrogen) to avoid water in order to obtain a preferable result.
- an inert gas e.g., argon, nitrogen
- the removal of the protective group may be carried out by following method.
- reaction for removing the protective group for carboxyl, hydroxyl, amino, amidino or guanidino is well known, including, for example, the following:
- the deprotection through alkali hydrolysis may be effected, for example, in an organic solvent (e.g., methanol, tetrahydrofuran, dioxane) by the use of an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide), an alkaline earth metal hydroxide (e.g., barium hydroxide, calcium hydroxide) or a carbonate (e.g., sodium carbonate, potassium carbonate), or an aqueous solution thereof or their mixture, at 0 to 40° C.
- an organic solvent e.g., methanol, tetrahydrofuran, dioxane
- an alkali metal hydroxide e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide
- an alkaline earth metal hydroxide e.g., barium hydroxide, calcium hydroxide
- a carbonate e.g., sodium carbonate, potassium carbonate
- the deprotection under acidic condition may be effected, for example, in an organic solvent (e.g., dichloromethane, chloroform, dioxane, ethyl acetate, anisole) with an organic solvent (e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid) or an inorganic acid (e.g., hydrochloric acid, sulfuric acid) or their mixture (hydrogen bromide/acetic acid), at 0 to 100° C.
- an organic solvent e.g., dichloromethane, chloroform, dioxane, ethyl acetate, anisole
- an organic solvent e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid
- an inorganic acid e.g., hydrochloric acid, sulfuric acid
- the deprotection through hydrogenolysis may be effected, for example, in a solvent (e.g., ether-type (e.g., tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether), alcohol-type (e.g., methanol, ethanol), benzene-type (e.g., benzene, toluene), ketone-type (e.g., acetone, methyl ethyl ketone), nitrile-type (e.g., acetonitrile), amide-type (e.g., dimethylformamide), water, ethyl acetate, acetic acid, or mixed solvent of two or more of these), in the presence of a catalyst (e.g., palladium-carbon, palladium-black, palladium hydroxide, platinum oxide, Raney nickel), in a normal-pressure or increased-pressure hydrogen atmosphere or in the presence of ammonium formate
- the silyl deprotection may be effected, for example, in a water-miscible organic solvent (e.g., tetrahydrofuran, acetonitrile) by the use of tetrabutylammonium fluoride, at 0 to 40° C.
- a water-miscible organic solvent e.g., tetrahydrofuran, acetonitrile
- the carboxyl-protective group includes, for example, methyl, ethyl, t-butyl and benzyl.
- the hydroxyl-protective group includes, for example, methoxymethyl, 2-tetrahydropyranyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, acetyl and benzyl.
- the amino, amidino and guanidino-protective group includes, for example, benzyloxycarbonyl, t-butoxycarbonyl, trifluoroacetyl, 9-fluorenylmethoxycarbonyl and trimethylsilyl.
- the carboxyl, hydroxyl, amino, amidino or guanidino-protective group may be any others than those mentioned above, capable of being readily and selectively removed, and are not specifically defined. For example, those described in T. W. Greene, Protective Groups in Organic Synthesis, 3rd edition, Wiley, New York, 1999 may be used.
- the compound represented by formula (IA-2) can be prepared by the sulfonamidation of the compounds of formula (II-1)
- R 32 is halogen atom and other symbols have the same meanings as defined above.
- This sulfonamidation is known. For example, it is carried out at 0 to 40° C. in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine).
- an inert organic solvent e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran
- tertiary amine e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine
- the removal of the protective group may be carried out by the above method.
- the compound represented by formula (IA-3) can be prepared by esterifying the compounds of formula (V)
- the method of esterification is known.
- it includes the method
- the method via an acyl halide may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., oxalyl chloride or thionyl chloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent at ⁇ 20° C. to reflux temperature.
- an acyl halide e.g., oxalyl chloride or thionyl chloride etc.
- an inert organic solvent e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran
- acyl halide derivative may be reacted with alcohol in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0 to 40° C.
- an inert organic solvent e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran
- tertiary amine e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.
- the method via a mixed acid anhydride may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., pivaloyl chloride, tosyl chloride or mesyl chloride) or an acid derivative (ethyl chloroformate or isobutyl chloroformate) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran) or without a solvent, in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) at 0 to 40° C.
- an acyl halide e.g., pivaloyl chloride, tosyl chloride or mesyl chloride
- an acid derivative ethyl chloroformate or isobutyl chloroformate
- an inert organic solvent e.g., chlor
- the obtained mixed acid anhydride derivative may be reacted with alcohol in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran), at 0 to 40° C.
- an inert organic solvent e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran
- the method using a condensing agent may be carried out, for example, by reacting carboxylic acid with alcohol in an organic solvent (e.g., chloroform, methylene chloride, dimethylformamide, diethyl ether or tetrahydrofuran) or without a solvent, in the presence or absence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), using a condensing agent (e.g., 1,3-dicyclohexyl carbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,1′-carbodiimidazole (CDI) or 2-chloro-1-methylpyridinium iodide), in the presence or absence of 1-hydroxybenzothiazole (HOBt), at 0 to 40° C.
- an organic solvent e.g., chloroform
- reaction described in (1), (2) and (3) may be carried out under an inert gas (e.g., argon, nitrogen) to avoid water in order to obtain a preferable result.
- an inert gas e.g., argon, nitrogen
- the removal of the protective group may be carried out by the above method.
- the compound represented by formula (IA-4) can be prepared by the etherification of the compounds of formula (VI-1)
- This etherification of the compound of formula (VI-1) and the compound of formula (VII-1), and the compound of formula (VI-2) and the compound of formula (VII-2) is known.
- it is carried out at 0 to 100° C. in an inert organic solvent (e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide), an alkaline earth metal hydroxide (e.g., barium hydroxide, calcium hydroxide) or a carbonate (e.g., sodium carbonate, potassium carbonate), or an aqueous solution thereof or their mixture.
- an alkali metal hydroxide e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide
- an alkaline earth metal hydroxide e.g., barium hydroxide, calcium
- This etherification of the compound of formula (VI-1) and the compound of formula (VII-2) is known. For example, it is carried out at 0 to 60° C. by reacting with a corresponding alcohol compound in an organic solvent (dichloromethane, diethyl ether, tetrahydrofuran, acetonitrile, benzene, toluene, etc.) in the presence of an azo compound (diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1′-(azodicarbonyl)dipiperidine, 1,1′-azobis(N,N-dimethylformamide), etc.) and a phosphine compound (triphenylphosphine, tributylphosphine, trimethylphosphine, etc.).
- an organic solvent dichloromethane, diethyl ether, tetrahydrofuran, acetonitrile, benzene, toluen
- the deprotection reaction of the protective group may be carried out by the methods described above.
- the compound represented by formula (IA-5) can be prepared by reacting the above compound of formula (II-1)
- This reaction of the compound of formula (II) and the compound of formula (VIII-1), and the compound of formula (IX) and the compound of formula (VIII-2) is known.
- it is carried out at 0 to 100° C. in an inert organic solvent (e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether, tetrahydrofuran or acetonitrile) in the presence or absence of a base (e.g., triethylamine, pyridine).
- an inert organic solvent e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether, tetrahydrofuran or acetonitrile
- a base e.g., triethylamine, pyridine
- the deprotection reaction of the protective group may be carried out by the methods described above.
- D 2′ is C1-8 alkylene, C2-8 alkenylene, —(C1-4 alkylene)-O—(C1-4 alkylene)-, —(C1-4 alkylene)-S—(C1-4 alkylene)-, —(C1-4 alkylene)-NR 8 —(C1-4 alkylene)-, —(C1-8 alkylene)-(Cyc2)- or —(C1-4 alkylene)-(Cyc2)-(C1-4 alkylene)- and other symbols have the same meanings as described above.) can be prepared by reductive amination of the above compound of formula (II-1)
- D 2′′ is C1-7 alkylene, C2-7 alkenylene, —(C1-3 alkylene)-O—(C1-4 alkylene)-, —(C1-3 alkylene)-S—(C1-4 alkylene)-, —(C1-3 alkylene)-NR 8 —(C1-4 alkylene)-, —(C1-7 alkylene)-(Cyc2)- or —(C1-3 alkylene)-(Cyc2)-(C1-4 alkylene)- and other symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- the reductive amination is well known. For example, it may be carried out in an organic solvent (e.g., methanol, ethanol) in the presence of reducing agent (e.g., sodium cyanoborohydride, sodium borohydride, sodium triacetoxyborohydride) and, if necessary, in the presence of an acid (e.g., acetic acid, hydrogen chloride) at ⁇ 20 to 60° C.
- organic solvent e.g., methanol, ethanol
- reducing agent e.g., sodium cyanoborohydride, sodium borohydride, sodium triacetoxyborohydride
- an acid e.g., acetic acid, hydrogen chloride
- the removal of the protective group may be carried out by the methods described above.
- the compound represented by formula (IA-6) can be prepared by reacting the compound of formula (X)
- reaction of the compound of formula (X) and the compound of formula (VIII-1) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- reaction of the compound of formula (XI) and the compound of formula (VIII-2) may be carried out by the same method as the above reaction of the compound of formula (II-1) and the compound of formula (VIII-3).
- the removal of the protective group may be carried out by the methods described above.
- the compound represented by formula (IA-7) can be prepared by reacting the above compound of formula (II-1)
- reaction is known. It may be carried out in organic solvent (e.g., tetrahydrofuran, methylene chloride, diethyl ether) at 0 to 100° C.
- organic solvent e.g., tetrahydrofuran, methylene chloride, diethyl ether
- the removal of the protective group may be carried out by the methods described above.
- the compound represented by formula (IA-8) can be prepared by reacting the above compound of formula (II-1)
- the reaction is known. It may be carried out in an organic solvent (tetrahydro furan, methylene chloride, diethyl ether) at 0 to 100° C.
- organic solvent tetrahydro furan, methylene chloride, diethyl ether
- the removal of the protective group may be carried out by the methods described above.
- the compound represented by formula (IA-9) can be prepared by reacting the above compound of formula (II-1)
- the reaction is known. It may be carried out in an organic solvent (e.g., tetrahydrofuran, methylene chloride, diethyl ether) at ⁇ 78 to 40° C.
- organic solvent e.g., tetrahydrofuran, methylene chloride, diethyl ether
- the removal of the protective group may be carried out by the methods described above.
- the compound represented by formula (IA-10) can be prepared by thiocarbonylation of the compound of formula (XV)
- the reaction is known. It may be carried out in an organic solvent (e.g., dioxane, benzene, toluene, xylene, tetrahydrofuran), using Lawesson reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) at 20 to 150° C.
- organic solvent e.g., dioxane, benzene, toluene, xylene, tetrahydrofuran
- the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IA-11) can be prepared by reacting the above compound of formula (II-1)
- R 34 is C1-4 alkyl and other symbols have the same meanings as described above.
- the reaction is known.
- it may be carried out in an organic solvent (e.g., methanol, ethanol) at 0 to 50° C.
- an organic solvent e.g., methanol, ethanol
- the removal of the protective group may be carried out by the methods described above.
- the hetero ring is a hetero ring having at least one nitrogen atom which binds to D 2 ), i.e., a compound of formula (IA-12)
- the hetero ring is a hetero ring having at least one nitrogen atom which binds to D 2 and other symbols have the same meanings as described above.
- the compound represented by formula (IA-12) can be prepared by reacting a compound of formula (XVII)
- reaction of the compound of formula (XVII) and the compound of formula (XVIII) or (XIX) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IB-1) can be prepared by amidation of a compound of formula (XX)
- E 4-1 is E 4 .
- hydroxyl, amino or carboxyl in the group represented by E 4-1 may be protected, if necessary.
- Other symbols have the same meanings as defined above.
- amidation and the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IB-2) can be prepared by amidation of a compound of formula (XXII)
- amidation and the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IB-3) can be prepared by reacting a compound of formula (XXIV)
- reaction of the compound of formula (XXIV) and the compound of formula (XXI) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound formula (VIII-2).
- the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IB-4) can be prepared by esterifying the compound of formula (XX)
- the esterifying and the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IB-5) can be prepared by reacting a compound of formula (XXVI)
- the reaction is known.
- it may be carried out in an inert organic solvent (e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether, tetrahydrofuran, acetonitrile) in the presence or absence of a base (e.g., triethylamine, pyridine) at 0 to 100° C.
- an inert organic solvent e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether, tetrahydrofuran, acetonitrile
- a base e.g., triethylamine, pyridine
- the removal of the protective group may be carried out by the methods described above.
- the hetero ring is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to E 3 .) in Cyc5.), i.e., a compound of formula (IB-6)
- the hetero ring is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to E 3 .) in Cyc5.) and other symbols have the same meanings as described above.) can be prepared by the following method.
- the compound of formula (IB-6) can be prepared by reacting a compound of formula (XXVIII)
- reaction of the compound of formula (XXVIII) and the compound of formula (XXIX) or (XXX) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- the removal of the protective group may be carried out by the methods described above.
- the compound of formula (IC-1) can be prepared by reacting a compound of formula (XXXI)
- G 1-1 is bond or C1-7 alkylene
- Cyc1′ and G 2-1 are Cyc1 and G 2 respectively.
- amino in the group represented by Cyc1 and hydroxy and amino in the group represented by G 2-1 may be protected, if necessary.
- Other symbols have the same meanings as described above.
- hydrazine or a salt thereof e.g., hydride, chloride
- the reaction is known.
- it may be carried out in an organic solvent (e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran) at 50° C. to reflux temperature.
- an organic solvent e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran
- the removal of the protective group may be carried out by the methods described above.
- the hetero ring is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to G 1 .) in Cyc1.), i.e., a compound of formula (IC-1-1)
- the compound of formula (IC-1-1) can be prepared by reacting a compound of formula (XXXII)
- reaction of the compound of formula (XXXII) and the compound of formula (XXXIII) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- the removal of the protective group may be carried out by the methods described above.
- the reaction is known.
- it may be carried out in an organic solvent (e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran) at 50° C. to reflux temperature.
- an organic solvent e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran
- the removal of the protective group may be carried out by the methods described above.
- the compound of formula (ID-1) can be prepared by reacting a compound of formula (XXXV)
- the reaction is known.
- it may be carried out in an organic solvent (e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran) at 50° C. to reflux temperature.
- an organic solvent e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran
- the removal of the protective group may be carried out by the methods described above.
- the compound of formula (ID-1-1) can be prepared by reacting a compound of formula (XXXVI)
- the reaction may be carried out, for example, in an organic solvent (e.g., toluene, tetrahydrofuran, chloroform, methylene chloride) in the presence or absence of catalyst (e.g., p-toluenesulfonic acid, pyridine) at 50° C. to reflux temperature.
- organic solvent e.g., toluene, tetrahydrofuran, chloroform, methylene chloride
- catalyst e.g., p-toluenesulfonic acid, pyridine
- the removal of the protective group may be carried out by the methods described above.
- R 36 is —NHR 6 , —CH 2 —NHR 6 , —OH, —CH 2 —OH, —CH 2 —R 33 or halogen atom. With proviso that hydroxy and amino in the group represented by R 36 may be protected, if necessary.
- R 37 is the protecting group of amino
- R 38 is —NHR 6 , —CH 2 —NHR 6 , —OH, —CH 2 —OH, —CH 2 —R 33 or halogen atom
- BOP is benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
- Me is methyl
- Et is ethyl
- E 1-1 is bond or C1-3 alkylene
- Ph is phenyl
- TBAF is tetrabutylammonium fluoride
- TMSN 3 is trimethylsilylazide
- R 39 is COOH, —NHR 24 , halogen atom or —SCOCH 3 .
- R 40 is COOH, —NHR 24 , halogen atom or —SCOCH 3 , and other symbols have the same meanings as described above.
- the compound represented by formulae (XXXIX) and (XXXXXV) with bromo instead of chloro may be used, which could be readily understood by anyone skilled in the art.
- the reaction product can be purified by general purification techniques such as distillation under ordinary pressure or a reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing and recrystallization. Purification may be carried out in each reaction or after completion of several reactions.
- the reaction mixture contained each 10 ⁇ L of 500 mM Tris/HCl (pH 8.0, WAKO), 100 mM MgCl 2 , 50 mM dithiothreitol (sigma), 1 mg/mL activated DNA and 1 mM NAD (containing 3 H-NAD).
- the 10 ⁇ L of test compound was added to the reaction mixture and the reaction was started by addition of 10 ⁇ L of 0.1 U/ ⁇ L PARP (TREVIGEN). The reaction was terminated at 10 minutes by addition of 100 ⁇ L of 20% trichloroacetic acid.
- Model of cerebral or coronary ischemia-reperfusion was prepared according to procedures described previously ( Jpn. J. Stroke, 8, 1 (1986), Stroke, 27, 1624-1628 (1996) and Eur. J. Pharmacol., 270, 45 (1994)).
- the compounds of the present invention were improvement effective of these diseases.
- the toxicity of the compounds of the present invention represented by formula (I) is very low (For example, as a result of administering the compounds of the present invention to rats, they did not affect circulatory parameters, such as blood pressure, an electrocardiogram, and heart rate.) and therefore the compounds may be considered safe for pharmaceutical use.
- the compound of the present invention represented by formula (I) has PARP inhibitory activity, it is useful for prevention and/or treatment of various diseases, for example, ischemic diseases (cerebral infarction, myocardial infarction, reperfusion injury or postoperative injury etc.), inflammatory diseases (inflammatory bowel disease, multiple sclerosis, arthritis or lung injury etc.), neurodegenerative disorders (extrapyramidal disease, Parkinson's disease, Alzheimer's disease, muscular dystrophy or lumbar spinal canal stenosis etc.), glaucoma, diabetes, diabetic complication, shock, head trauma, spinal cord injury, renal failure or hyperalgesia etc.
- an antiretroviral drug such as an anti HIV drug, a sensitizer of anticancer therapy or an immunosuppressant.
- the compound represented by formula (I) or pharmaceutically acceptable salt thereof may be administered in combination with other pharmaceutical preparations to accomplish the following purposes:
- the compound represented by formula (I) and other pharmaceutical preparations may be administered in the form of formulation having these components incorporated in one preparation or may be administered in separate preparations. In the case where these pharmaceutical preparations are administered in separate preparations, they may be administered simultaneously or at different times. In the latter case, the compound represented by formula (I) may be administered before the other pharmaceutical preparations. Alternatively, the other pharmaceutical preparations may be administered before the compound represented by formula (I). The method for the administration of these pharmaceutical preparations may be the same or different.
- the diseases on which the preventive and/or treatment effect of the aforementioned combined preparations works are not specifically limited but may be those for which the preventive and/or treatment effect of the compound represented by formula (I) is complemented and/or enhanced.
- Examples of the other pharmaceutical preparations for complementing and/or enhancing the preventive and/or treatment effect of the compound represented by formula (I) on ischemic diseases include radical scavenger, astrocyto modulator, N-methyl-D-aspartate (NMDA) antagonist, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) antagonist, antithrombotic agent, thrombolytic agent, immunosuppressive agent, cell adhesion molecules inhibitor, nitrogen oxide synthase (NOS) inhibitor, neurotrophic factor and interleukin-8 inhibitor etc.
- radical scavenger astrocyto modulator
- NMDA N-methyl-D-aspartate
- AMPA alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate
- NOS nitrogen oxide synthase
- neurotrophic factor and interleukin-8 inhibitor etc.
- Examples of the other pharmaceutical preparations for complementing and/or enhancing the preventive and/or treatment effect of the compound represented by formula (I) on lumbar spinal canal stenosis include nitrogen oxide synthase (NOS) inhibitor, aldose reductase (AR) inhibitor, radical scavenger, N-methyl-D-aspartate (NMDA) antagonist, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) antagonist, neurotrophic factor and interleukin-8 inhibitor etc.
- NOS nitrogen oxide synthase
- AR aldose reductase
- NMDA N-methyl-D-aspartate
- AMPA alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate
- neurotrophic factor and interleukin-8 inhibitor etc.
- radical scavenger examples include, for example, edaravone and ebselen (DR-3305) etc.
- Examples of the astrocyto modulator include, for example, ONO-2506 etc.
- antithrombotic agent examples include, for example, sodium ozagrel, argatroban and aspirin etc.
- thrombolytic agent examples include, for example, tissue plasminogen activator (t-PA), urokinase and heparin etc.
- immunosuppressive agent examples include, for example, cyclosporin A, cyclophosphamide and tacrolimus etc.
- NOS inhibitor examples include, for example, L-NMMA and ONO-1714 etc.
- AR inhibitor examples include, for example, epalrestat, zenarestat, fidarestat, zopolrestat and AS-3201 etc.
- the weight proportion of the compound represented by formula (I) and the other pharmaceutical preparations is not specifically limited.
- Examples of the other pharmaceutical preparations for complementing and/or enhancing the preventive and/or treatment effect of the compound represented by formula (I) include not only those which have so far been found but also those which will be found on the basis of the aforementioned mechanism.
- the doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment.
- the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.
- the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
- the compound represented by formula (I) or the pharmaceutically acceptable salt thereof, or the concomitant drug combined the compound represented by formula (I) with pharmaceutical preparations may be administered in the form of, for example, solid compositions, liquid compositions or other compositions each for oral administration, or injections, preparations for external use or suppositories, each for parenteral administration.
- Solid compositions for oral administration include compressed tablets, pills, capsules, powders, and granules.
- Capsules include hard capsules and soft capsules.
- one or more of the active substance(s) may be admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium aluminometasilicate.
- the compositions may comprise, in accordance with the conventional process, additives other than the inert diluent, for example, lubricants such as magnesium stearate, disintegrants such as cellulose calcium glycolate, stabilizer such as lactose, and solubilizing agent such as glutamic acid or aspartic acid.
- Tablets or pills may be coated with a film of a gastric soluble or enteric substance such as sucrose, gelatin, hydroxypropyl cellulose or hydroxypropyl methylcellulose phthalate, or with two or more layers, if necessary.
- a gastric soluble or enteric substance such as sucrose, gelatin, hydroxypropyl cellulose or hydroxypropyl methylcellulose phthalate, or with two or more layers, if necessary.
- capsules made of a substance which can be absorbed in the body, for example, gelatin are included.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups and elixirs etc.
- Such liquid compositions comprise one or more of the active substance(s) and an ordinarily employed inert diluent(s) (for example, purified water or ethanol) dissolving the substance(s) therein.
- the compositions may comprise, in addition to the inert diluent, an adjuvant such as humectants or suspending agents, sweetening agents, flavoring agents, aromatic agents and antiseptics.
- compositions for oral administration include sprays which comprise one or more active substance(s) and are formulated in a manner known per se in the art.
- the compositions may comprise, in addition to an inert diluent, a stabilizer such as sodium bisulfite and an isotonization buffer such as sodium chloride, sodium citrate or citric acid.
- a stabilizer such as sodium bisulfite
- an isotonization buffer such as sodium chloride, sodium citrate or citric acid.
- injections for parenteral administration include sterile aqueous and/or non-aqueous solutions, suspensions and emulsions.
- the aqueous solutions or suspensions include, for example, distilled water for injection and saline.
- the non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohol such as ethanol and Polysorbate 80 (trade mark).
- sterile aqueous and non-aqueous solutions, suspensions, and emulsions may be used in combination.
- compositions may additionally comprise adjuvants such as antisaptic, humectant, emulsfier, dispersant, stabilizer (such as lactose) and solubilizing agent (such as glutamic acid and aspartic acid). They are sterilized by filtration through a bacteria retaining filter, the addition of a sterilizer, or irradiation. Also, a sterile solid composition is prepared and then, for example, a freeze-dried product may be dissolved in sterilized or sterile distilled water for injection or another sterile solvent before use.
- adjuvants such as antisaptic, humectant, emulsfier, dispersant, stabilizer (such as lactose) and solubilizing agent (such as glutamic acid and aspartic acid).
- solubilizing agent such as glutamic acid and aspartic acid
- compositions for parenteral administration include liquids for external use, ointments, endermic liniments, suppositories for intrarectal administration and pessaries for vaginal administration which comprise one or more of the active substance(s) and may be prepared by methods known per se.
- the solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations or TLC.
- the solvents in the parentheses in NMR show the solvents for measurement.
- Example 4(28) The compound prepared in Example 4(28) (150 mg) and lithium chloride (59 mg) were dissolved in dimethylformamide (2.0 mL) and the mixture was refluxed for 16 hours. After cooling to room temperature, to the reaction mixture was added 1N hydrochloric acid. The precipitate was collected by filtration. It was dried to give the compound of the present invention (126 mg) having the following physical data.
- Example 6 By the same procedure as described in Example 6, if necessary, by converting to corresponding salts by conventional method, using the compounds prepared in Example 4, 4(2), 4(3), 4(6), 4(7), 4(10), 4(12), 4(14), 4(13), 4(18), 4(19), 4(21), 4(23)-4(26), 4(28), 4(30) or 5 instead of the compound prepared in Example 3, the following compounds of the present invention were obtained.
- the filtrate was concentrated.
- the residue was diluted with ethyl acetate.
- the diluted solution was washed with a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous sodium sulfate and concentrated.
- the residue was recrystallized from ethanol to give the compound of the present invention (42 mg) having the following physical data.
- the compound was converted to a corresponding salt thereof by conventional method.
- the diluted solution was washed water, 1N hydrochloric acid, water, a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous sodium sulfate and concentrated to give the title compound (2.59 g) having the following physical data.
- the compound prepared in Reference example (199 mg) was separated with ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution and the water layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The obtained powder was dissolved in toluene (10 mL). Thereto were added hydrazine carboxylic acid ethyl ester (184 mg) and p-toluenesulfonic acid monohydrate (8.4 mg) and the mixture was refluxed overnight. After cooling the reaction mixture to room temperature, it was diluted in ethyl acetate.
- the diluted solution was washed with 1N hydrochloric acid, water and brine sequentially, dried over anhydrous sodium sulfate and concentrated.
- the more polar fraction was recrystallized from ethyl acetate to give the compound a (16.3 mg) having the following physical data.
- the less polar fraction was recrystallized from a mixed solution of ethyl acetate and hexane (1:1) to give the compound b (13.6 mg) having the following physical data.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
Abstract
Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.).
Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc.), diabetes, shock, head trauma, renal failure, hyperalgesia, etc. Moreover, these compounds are useful as agents against retroviruses (HIV etc.), sensitizers in treating cancer and immunosuppressants.
Description
- This is a Divisional of U.S. application Ser. No. 10/505,012 filed Aug. 18, 2004, which is a 371 of PCT Application No. PCT/JP03/01694, Feb. 18, 2003, which claims priority from Japanese Application No. 2002-42259 filed on Feb. 19, 2002 and 2002-199673 filed on Jul. 9, 2002. The above-noted applications are incorporated herein by reference in their entirety.
- The present invention relates to fused pyridazine derivative compounds.
- More particularly, the present invention relates to
- (1) pyridazine derivative compounds represented by formula (I)
- (wherein all symbols have the same meanings as described below), or pharmaceutically acceptable salts thereof,
(2) a process for preparing thereof, and
(3) an agent comprising the same as an active ingredient. - Poly(ADP-ribose)polymerase (abbreviated as PARP hereinafter), which is a nuclear enzyme activated by DNA strand breaks, plays a role in the transfer reaction of ADP-ribose moiety from nicotinamide adenine dinucleotide (abbreviated as NAD+ hereinafter) to various proteins such as histones, DNA-polymerases and DNA-topoisomerases, etc.
- DNA strand breaks caused by Peroxynitrite (ONOO−) and oxygen radicals lead to overactivation of PARP (PARP is activated up to 100 times when Zn finger domain of PARP binds to DNA with nicks.). It is thought that overactivation of PARP causes depletion of NAD+, which is essential for electron transport system, and consequently depletion of ATP, leading to energy failure, ultimately resulting in cell death. (The suicide hypothesis of PARP activation: Free Radic. Biol Med., 21, 855 (1996); TIPS., 19, 287 (1998)). Therefore, it is considered that PARP inhibitor is useful as inhibitor of cell death.
- Since caspase-3, which is one of interleukin-1β-converting enzyme family, specifically cleaves PARP as the substrate (Cell., 81, 801 (1995)), it is suggested PARP is associated with apoptosis.
- It is reported that 3-aminobenzamide and nicotinamide generally known as inhibitors of PARP are useful for inhibition of cell death and improvement of diseases on various models of ischemic diseases (cerebral, myocardial, intestinal, skeletal muscular or retinal ischemia etc.), inflammatory diseases (arthritis, inflammatory bowel disease or multiple sclerosis etc.), diabetes, shock, extrapyramidal disease (TIPS., 19, 287 (1998); Eur J. Pharmacol., 350, 1 (1998)) and hyperalgesia (Pain, 72, 355 (1997)) in vitro, in vivo and in PARP knockout mouse. And it is reported that PARP inhibitor is useful as an antiretroviral drug such as an anti HIV drug (Biochem. Biophys. Res. Commum., 180, 504 (1991)), a sensitizer of anticancer therapy (Radiat. Res., 126, 367 (1991); Br. J. Cancer., 72, 849 (1995)) or an immunosuppressant (Int. J. Immunopharmac., 17, 265 (1995)).
- PARP inhibitor is useful for prevention and/or treatment of various diseases, for example, ischemic diseases (cerebral infarction, myocardial infarction, reperfusion injury or postoperative injury etc.), inflammatory diseases (inflammatory bowel disease, multiple sclerosis, arthritis or lung injury etc.), neurodegenerative disorders (extrapyramidal disease, Parkinson's disease, Alzheimer's disease, muscular dystrophy or lumbar spinal canal stenosis etc.), glaucoma, diabetes, diabetic complication, shock, head trauma, spinal cord injury, renal failure, hyperalgesia or blood flow obstruction etc. And it is useful as an antiretroviral drug such as an anti HIV drug, a sensitizer of anticancer therapy or an immunosuppressant.
- As PARP inhibitor, for example, in the specification of WO00/44726, it is described that 2H-phthalazin-1-one derivatives represented by formula (A)
- (wherein R1A is
(i) C1-4 alkyl substituted by hydroxy or amino, or - in which A1A is —NR3AC(O)— etc. wherein R3A is hydrogen or C1-4 alkyl etc., A2A is C1-8 alkylene etc., A3A is (i) hydrogen, (ii) —NR17AR18A or (iii) Cyc2A etc. wherein R17A is (i) hydrogen, (ii) C1-8 alkyl etc., and R18A is (i) hydrogen or (ii) C1-8 alkyl etc., Cyc2A is 3-10 membered mono- or bi-heterocyclic ring containing 1-4 of nitrogen atoms, 1-2 of oxygen atoms and/or one sulfur atom, R2A is hydrogen or halogen etc. Necessary parts were extracted from the description of groups.) have PARP inhibitory activity.
- In the specification of DE3302021, it is described that compounds represented by formula (B)
- (wherein R1B is hydrogen or C1-3 alkyl, R2B is hydrogen, R1B and R2B, taken together, are C1-4 alkylene, R3B is hydrogen or methyl, nB is 0-3, R4B is 1-pyrrolyl. Necessary parts were extracted from the description of groups.) have inhibitory activity of platelet aggregation.
- In the specification of WO98/31674, it is described that compounds represented by formula (C)
- (wherein R1C is C1-4 alkoxy etc., R2C is C1-8 alkoxy etc., R3C and R4C is hydrogen or R3C and R4C, taken together, are bond, R5C is hydrogen etc. Necessary parts were extracted from the description of groups.) have phosphodiesterase inhibitory activity.
- In Journal of Medicinal Chemistry., 44(16), 2511-2522 and 2523-2535 (2001), it is described that 4-(3-chloro-4-methoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 244077-36-9) and 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 358368-98-6) have phosphodiesterase inhibitory activity.
- In Tetrahedron., 39(20), 3419-27 (1983), 4-phenyl-6,7,8,8a-tetrahydropyrrolo[1,2-d][1,2,4]triazin-1(2H)-one (CAS Registry No. 89311-30-8) is described as synthetic intermediate.
- In Synthesis., 240-242 (1995), 4-phenyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 154810-22-7), 4-(4-methylphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 154810-23-8), 4-(4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 154810-24-9), 4-(4-chlorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 154810-25-0), and 4-(4-bromophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 154810-26-1) are described as synthetic intermediate.
- In Bioorganic and Medicinal Chemistry., 6, 349-454 (1998), 7-hydroxy-4-phenyl-6,7,8,8a-tetrahydropyrrolo[1,2-d][1,2,4]triazin-1(2H)-one (CAS Registry No. 206126-90-1) and 4-phenyl-8,8a-dihydro[1,3]thiazolo[3,4-d][1,2,4]triazin-1(2H)-one (CAS Registry No. 206126-96-7) are described as synthetic intermediate.
- In Journal of Medicinal Chemistry., 43(12), 2310-2323 (2000), 4-(pyridin-4-ylmethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 212142-89-7) is described as synthetic intermediate.
- In the specification of FR2647676, 4-t-butoxycarbonylmethyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 134972-12-6) and 4-ethoxycarbonylmethyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one (CAS Registry No. 134973-24-3) are described as synthetic intermediate.
- In order to find a compound having poly(ADP-ribose)polymerase activity, the present inventors have conducted intensive studies and found, as a result, that the objects can be accomplished by the pyridazine derivative represented by formula (I), and thus the present invention has been accomplished.
- The present invention relates to
- (1) a fused pyridazine derivative compound represented by formula (I)
- wherein R1 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) halogen atom, (6) nitro, (7) NR2R3, (8) C2-8 acyl, (9) C1-8 alkoxy substituted by phenyl or (10) C2-8 acyl substituted by NR2R3,
- R2 and R3 are each independently
- (1) a hydrogen atom or (2) C1-8 alkyl,
- X and Y are each independently
-
- (1) a single bond or (2) a double bond,
- (1) partially or fully saturated C3-10 mono-carbocyclic aryl or (2) partially or fully saturated 3-10 membered mono-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms,
- A is (1) A1, (2) A2, (3) A3, (4) A4 or (5) A5,
- A1 is
- A2 is -E1-E2-E3-E4,
- A3 is
- A4 is
- A5 is
- D1 is
- (1) —NR6C(O)—, (2) —NR6C(S)—, (3) —NR6SO2—, (4) —CH2—NR6—, (5) —CH2—O—, (6) —OC(O)—, (7) —CH2—NR6C(O)—, (8) —NR6C(O)NR7—, (9) —NR6C(O)O—, (10) —NR6C(S)NR7—, (11) —NR6— or (12) —NR6C(═NR7)—,
- R6 and R7 are each independently
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) phenyl or (4) C1-8 alkyl substituted by phenyl,
- D2 is
- (1) C1-8 alkylene, (2) C2-8 alkenylene, (3) Cyc2, (4) —(C1-4 alkylene)-O—(C1-4 alkylene)-, (5) —(C1-4 alkylene)-S—(C1-4 alkylene)-, (6) —(C1-4 alkylene)-NR8—(C1-4 alkylene)-, (7)-(Cyc2)-(C1-8 alkylene)-, (8) —(C1-8 alkylene)-(Cyc2)- or (9) —(C1-4 alkylene)-(Cyc2)-(C1-4 alkylene)-,
- R8 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) phenyl or (5) C1-8 alkyl substituted by phenyl,
- D3 is
- (1) a hydrogen atom, (2) —NR9R10, (3) Cyc3, (4) —OR11, (5) COOR, (6) CONR13R14, (7) cyano, (8) a halogen atom, (9) —C(═CR15)NR16R17 or (10) —NR18C(═NR19)NR20R21,
- R9 and R13 are each independently
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) Cyc3, (6) C1-8 alkoxy, (7) C2-8 alkenyloxy, (8) C2-8 alkynyloxy or (9) C1-8 alkyl substituted by Cyc3, C1-8 alkoxy, C1-8 alkylthio, cyano, hydroxy or 1 to 3 halogen atom(s),
- R10 and R14 are each independently
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) C1-8 alkoxycarbonyl, (6) C2-8 acyl, (7) C3-8 cycloalkyl, (8) C1-8 alkoxycarbonyl substituted by Cyc4 or 1 to 3 halogen atom(s), or (9) C1-8 alkyl substituted by C1-8 alkoxy,
- R11 and R12 are each independently
- (1) a hydrogen atom or (2) C1-8 alkyl,
- R15, R16, R17, R18, R19, R20 and R21 are each independently
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) phenyl or (5) C1-8 alkyl substituted by phenyl,
- R4 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) halogen atom, (6) nitro or (7) NR22R23,
- R22 and R23 are each independently
- (1) a hydrogen atom or (2) C1-8 alkyl,
- E1 is C1-4 alkylene,
- E2 is
- R24 is
- (1) a hydrogen atom, (2) C1-8 alkyl or (3) C1-8 alkyl substituted by phenyl,
- E3 is
- (1) a bond or (2) C1-8 alkylene,
- E4 is
- (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C2-8 alkynyl, (4) Cyc5, (5) NR25R26, (6) OR27, (7) SR27, (8) COOR27, (9) C1-8 alkyl substituted by two of OR25, (10) C1-8 alkyl substituted by 1 to 3 halogen atom(s), (11) cyano or (12) C2-8 acyl,
- R25 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) Cyc5 or (6) C1-8 alkyl substituted by Cyc5 or OR28,
- R26 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) phenyl or (5) C1-8 alkyl substituted by phenyl,
- R27 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) Cyc5 or (4) C1-8 alkyl substituted by Cyc5,
- R28 is
- (1) a hydrogen atom or (2) C1-8 alkyl,
- G1 is C1-8 alkylene,
- Cyc1 is
- (1) partially or fully saturated C3-10 mono- or bi-carbocyclic aryl, or (2) partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms,
- G2 is
- (1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) C2-8 acyl, (5) Cyc6, (6) C1-8 alkyl or C2-8 alkenyl substituted by 1 to 2 substituent(s) selected from Cyc6, hydroxy and C1-8 alkoxy, (7) C1-8 alkoxycarbonyl substituted by Cyc6, (8) —C(O)-Cyc6, (9) nitro, (10) NR41R42, (11) C1-8 alkoxy or (12) C1-8 alkyl substituted by NR41R42,
- R41 and R42 are each dependently
- (1) a hydrogen atom or (2) C1-8 alkyl, R5 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) nitro, (6) NR29R30, (7) C1-8 alkyl substituted by NR29R30, (8) NHSO2OH, (9) amidino, (10) cyano, (11) a halogen atom, (12) Cyc8 or (13) C1-8 alkyl substituted by Cyc8, - R29 and R30 are each independently
- (1) a hydrogen atom or (2) C1-8 alkyl,
- Cyc2, Cyc3, Cyc4, Cyc5, Cyc6 and Cyc8 are each independently
- (1) partially or fully saturated C3-10 mono- or bi-carbocyclic aryl, or (2) partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms,
- Cyc7 is
- (1) partially or fully saturated C3-10 mono- or bi-carbocyclic aryl, or (2) partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms, with proviso that Cyc7 is not benzene,
- Cyc2, Cyc3, Cyc4, Cyc5, Cyc6 and Cyc8 are optionally substituted by 1 to 3 substituent(s) selected from (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C1-8 alkoxy, (4) halogen atom, (5) trihalomethyl, (6) trihalomethoxy, (7) C1-8 alkoxycarbonyl, (8) oxo, (9) C1-8 alkyl substituted by C1-8 alkoxy or phenyl, (10) hydroxy and (11) NR29R30;
- m and n are each independently 1 or 2,
- wherein
- (i) when A is A1 or A2, then
- is not
- (ii) when A is A4 and
- then
- R5 is not hydroxy or C1-8 alkoxy,
- (iii) when A is A5, then
- is not
- and
- (iv) following compounds of (1) to (13) are excepted;
- (1) 4-(3-chloro-4-methoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one,
- (2) 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (3) 4-phenyl-6,7,8,8a-tetrahydropyrrolo[1,2-d][1,2,4]triazin-1(2H)-one,
- (4) 4-phenyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (5) 4-(4-methylphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (6) 4-(4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (7) 4-(4-chlorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (8) 4-(4-bromophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (9) 7-hydroxy-4-phenyl-6,7,8,8a-tetrahydropyrrolo[1,2-d][1,2,4]triazin-1(2H)-one,
- (10) 4-phenyl-8,8a-dihydro[1,3]thiazolo[3,4-d][1,2,4]triazin-1(2H)-one,
- (11) 4-(pyridin-4-ylmethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (12) 4-t-butoxycarbonylmethyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
- (13) 4-ethoxycarbonylmethyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one, or
- a pharmaceutically acceptable salt thereof,
- (2) a process for preparing thereof, and
(3) an agent comprising the same as an active ingredient. - In the specification, C1-8 alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl or isomeric groups thereof.
- In the specification, C2-8 alkenyl means ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl or isomeric groups thereof.
- In the specification, C2-8 alkynyl means ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl or isomeric groups thereof.
- In the specification, C1-8 alkoxy means methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy or isomeric groups thereof.
- In the specification, C2-8 alkenyloxy means ethenyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy, heptenyloxy, octenyloxy or isomeric groups thereof.
- In the specification, C2-8 alkynyloxy means ethynyloxy, propynyloxy, butynyloxy, pentynyloxy, hexynyloxy, heptynyloxy, octynyloxy or isomeric groups thereof.
- In the specification, C1-8 alkylthio means methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio or isomeric groups thereof.
- In the specification, C1-4 alkylene means methylene, ethylene, trimethylene, tetramethylene or isomeric groups thereof.
- In the specification, C1-8 alkylene means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene or isomeric groups thereof.
- In the specification, C2-8 alkenylene means ethenylene, propenylene, butenylene, pentenylene, hexenylene, heptenylene, octenylene or isomeric groups thereof.
- In the specification, C1-8 alkoxycarbonyl means methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, heptyloxycarbonyl, octyloxycarbonyl or isomeric groups thereof.
- In the specification, trihalomethyl is methyl substituted by three halogen atoms.
- In the specification, trihalomethoxy is methoxyl substituted by three halogen atoms.
- In the specification, C2-8 acyl means ethanoyl (acethyl), propanoyl (propionyl), butanoyl (butyryl), pentanoyl (valeryl), hexanoyl, heptanoyl, octanoyl or isomeric groups thereof.
- In the specification, C3-8 cycloalkyl means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.
- In the specification, halogen means chlorine, bromine, fluorine or iodine.
- In the specification, partially or fully saturated C3-10 mono-carbocyclic aryl represented by
- is cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclononene, cyclodecene, cyclohexadiene, cycloheptadiene, cyclooctadiene etc.
- In the specification, partially or fully saturated 3-10 membered mono-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms represented by
- means aziridine, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, oxirane, oxetane, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrooxepine, tetrahydrooxepine, perhydrooxepine, thiirane, thietane, dihydrothiophene, tetrahydrothiophene, dihydrothiaine (dihydrothiopyran), tetrahydrothiaine (tetrahydrothiopyran), dihydrothiepine, tetrahydrothiepine, perhydrothiepine, dihydrooxazole, tetrahydrooxazole (oxazolidine), dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, perhydrooxadiazepine, dihydrothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, oxathiane, dioxolane, dioxane, dithiolane, dithiane etc.
- In the specification, among partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atoms selected from oxygen, nitrogen or sulfur atom represented by Cyc1, Cyc2, Cyc3, Cyc4, Cyc5, Cyc6, Cyc7 and Cyc8, 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atoms selected from oxygen, nitrogen or sulfur atom means, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiaine, thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, indolizine, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, dithianaphthalene, indazole, quinoline, isoquinoline, quinolizine, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, chromene, benzofurazan, benzothiadiazole, benzotriazole etc.
- Also, partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1-4 hetero atoms selected from oxygen, nitrogen or sulfur atom, means aziridine, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, oxirane, oxetane, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrooxepine, tetrahydrooxepine, perhydrooxepine, thiirane, thietane, dihydrothiophene, tetrahydrothiophene, dihydrothiaine (dihydrothiopyran), tetrahydrothiaine (tetrahydrothiopyran), dihydrothiepine, tetrahydrothiepine, perhydrothiepine, dihydrooxazole, tetrahydrooxazole (oxazolidine), dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, perhydrooxadiazepine, dihydrothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, oxathiane, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydro quinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydro isoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydro cinnoline, perhydrocinnoline, benzoxathiane, dihydrobenzoxazine, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, dioxolane, dioxane, dithiolane, dithiane, dioxaindan, benzodioxane, chroman, benzodithiolane, benzodithiane etc.
- The above hetero ring includes N-oxide which is the compound where nitrogen is oxidized.
- In the specification, partially or fully saturated C3-10 mono- or bi-carbocyclic aryl represented by Cyc1, Cyc2, Cyc3, Cyc4, Cyc5, Cyc6, Cyc7 and Cyc8 is cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclononene, cyclodecene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene, benzene, pentalene, azulene, perhydroazulene, perhydropentalene, indene, perhydroindene, indan, naphthalene, teterahydronaphthalene or perhydronaphthalene etc.
- Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkenyl, alkynyl, alkylene and alkoxy group includes straight or branched ones. In addition, isomers on double bond, ring, fused ring (E-, Z-, cis-, trans-isomer), isomers generated from asymmetric carbon atom(s) (R—, S—, α-, β-isomer, enantiomer, diastereomer), optically active isomers (D-, L-, d-, l-isomer), polar compounds generated by chromatographic separation (more polar compound, less polar compound), equilibrium compounds, mixtures thereof at voluntary ratios and racemic mixtures are also included in the present invention.
- According to the present invention, unless otherwise indicated and as is apparent for those skilled in the art, symbol indicates that it is bound to the opposite side of the sheet (namely α-configuration), symbol indicates that it is bound to the front side of the sheet (namely β-configuration), symbol indicates that it is α-, β- or a mixture thereof, and symbol indicates that it is a mixture of α-configuration and β-configuration.
- The compound of the present invention can be converted into a pharmaceutically acceptable salt by known methods.
- The pharmaceutically acceptable salt is preferably water-soluble.
- The pharmaceutically acceptable salt means, for example, salts of alkali metals (potassium, sodium, lithium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts (tetramethylammonium, tetrabutylammonium, etc.), salts of organic amines (triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine, etc.), acid-addition salts (inorganic acid salts (hydrochloride, hydrobromate, hydroiodate, sulfate, phosphate, nitrate, etc.), organic acid salts (acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate, etc.), etc.
- Furthermore, solvates or solvates of the above alkai (earth) metals, ammonium, organic amines and acid-addition salts of the compound of the present invention are included in the pharmaceutically acceptable salt of the present invention.
- The solvate is preferably nontoxic and water-soluble. Appropriate solvate means, for example, solvates such as water, an alcohol solvent (ethanol etc.), etc.
- In the specification,
- is preferably partially or fully saturated C3-7 mono-carbocyclic aryl, or partially or fully saturated 3-7 membered mono-hetero aryl containing 1 to 2 hetero atom(s) selected from oxygen, nitrogen and sulfur atom. Moreover, partially or fully saturated C3-7 mono-carbocyclic aryl, or partially or fully saturated 3-7 membered mono-hetero aryl is preferably following compounds;
- Partially or fully saturated 3-7 membered mono-hetero aryl containing 1 to 2 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms is preferably following compounds;
- In the specification, A is preferably A1, A2 or A3.
- In the specification, D1 is preferably —NR6C(O)—, —NR6C(S)—, —NR6SO2— or —CH2—NR6—, and more preferably —NR6C(O)—.
- In the specification, D2 is preferably C1-8 alkylene, C2-8 alkenylene, —(C1-4 alkylene)-O—(C1-4 alkylene)-, —(C1-4 alkylene)-S—(C1-4 alkylene)-, —(C1-4 alkylene)-NR8—(C1-4 alkylene)- or —(C1-8 alkylene)-(Cyc2)-, and more preferably C1-8 alkylene.
- In the specification, D3 is preferably —NR9R10 or Cyc3.
- In the specification, E1 is preferably C1-4 alkylene.
- In the specification, E2 is preferably —C(O)NR24—, —NR24C(O)—, —NR24— or —S—
- In the specification, E3 is preferably bond or C1-8 alkylene.
- In the specification, E4 is preferably Cyc5 or NR25R26.
- In the specification, Cyc1 is preferably partially or fully saturated 3-10 membered mono-hetero aryl containing 1 to 2 hetero atom(s) selected from oxygen, nitrogen and sulfur atom.
- In the specification, when A is A3 or A4, at least one of X and Y is preferably N.
- In the specification, when A is A3 or A4,
- is preferably
- Among the compounds of the present invention represented by formula (I), preferred compounds are compounds represented by formula (I-A-1)
- (wherein all symbols have the same meanings as described above.), compounds represented by formula (I-A-2)
- (wherein all symbols have the same meanings as described above.), compounds represented by formula (I-B-1)
- (wherein all symbols have the same meanings as described above.), compounds represented by formula (I-B-2)
- (wherein all symbols have the same meanings as described above.), compounds represented by formula (I-C-1)
- (wherein all symbols have the same meanings as described above.), and compounds represented by formula (I-C-2)
- (wherein all symbols have the same meanings as described above.).
- Concrete compounds of the present invention include compounds shown in Tables 1 to 90, compounds described in Examples, and pharmaceutically acceptable salts thereof.
- In each Table, Me represents methyl group, Et represents ethyl group, Pr represents propyl group, i-Pr represents isopropyl group, Bu represents butyl group, c-Pr represents cyclopropyl group, c-Bu represents cyclobutyl group, c-Pen represents cyclopentyl group, c-Hex represents cyclohexyl group, Ph represents phenyl group, Bn represents benzyl group, and other symbols have the same meanings as described above.
-
TABLE 1 (I-A-1-1) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 4 (I-A-1-2) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 7 (I-A-1-3) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 10 (I-A-1-4) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 13 (I-A-1-5) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 16 (I-A-1-6) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 19 (I-A-1-7) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 22 (I-A-1-8) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 25 (I-A-1-9) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 28 (I-A-2-1) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 31 (I-A-2-2) No —D2—D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 34 (I-A-2-3) No —D2—D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 37 (I-A-2-4) No —D2—D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 40 (I-A-2-5) No —D2—D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 43 (I-A-2-6) No —D2—D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 46 (I-A-2-7) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 49 (I-A-2-8) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 52 (I-A-2-9) No -D2-D3 1 Me 2 Pr 3 Bu 4 —CH2—Cl 5 —(CH2)3—OH 6 —(CH2)4—OH 7 —(CH2)3—CO2H 8 —(CH2)3—CO2Me 9 10 11 —(CH2)3—NH2 12 —(CH2)4—NH2 13 —(CH2)5—NH2 14 —(CH2)3—NHMe 15 —(CH2)4—NHMe 16 —CH2—NMe2 17 —(CH2)3—NMe2 18 —(CH2)4—NMe2 19 —(CH2)4—NH-c-Pr 20 —CH2—NH-c-Bu 21 22 23 24 25 26 27 28 29 30 -
TABLE 55 (I-B-1-1) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 56 (I-B-1-2) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 57 (I-B-1-3) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 58 (I-B-1-4) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 59 (I-B-1-5) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 60 (I-B-1-6) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— -
TABLE 61 (I-B-1-7) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— -
TABLE 62 (I-B-1-8) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 63 (I-B-1-9) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— -
TABLE 64 (I-B-1-10) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 65 (I-B-1-11) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 66 (I-B-1-12) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 67 (I-B-1-13) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— 33 —(CH2)3— Me 34 —(CH2)3— Et 35 —(CH2)3— Pr 36 —(CH2)3— i-Pr 37 —(CH2)3— Ph 38 —(CH2)3— Bn 39 —(CH2)3— c-Pr 40 —(CH2)3— c-Bu 41 —(CH2)3— c-Pen 42 —(CH2)3— c-Hex 43 —(CH2)3— 44 —(CH2)3— 45 —(CH2)3— 46 —(CH2)3— 47 —(CH2)3— 48 —(CH2)3— -
TABLE 68 (I-B-1-14) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— 33 —(CH2)3— Me 34 —(CH2)3— Et 35 —(CH2)3— Pr 36 —(CH2)3— i-Pr 37 —(CH2)3— Ph 38 —(CH2)3— Bn 39 —(CH2)3— c-Pr 40 —(CH2)3— c-Bu 41 —(CH2)3— c-Pen 42 —(CH2)3— c-Hex 43 —(CH2)3— 44 —(CH2)3— 45 —(CH2)3— 46 —(CH2)3— 47 —(CH2)3— 48 —(CH2)3— -
TABLE 69 (I-B-1-15) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— 33 —(CH2)3— Me 34 —(CH2)3— Et 35 —(CH2)3— Pr 36 —(CH2)3— i-Pr 37 —(CH2)3— Ph 38 —(CH2)3— Bn 39 —(CH2)3— c-Pr 40 —(CH2)3— c-Bu 41 —(CH2)3— c-Pen 42 —(CH2)3— c-Hex 43 —(CH2)3— 44 —(CH2)3— 45 —(CH2)3— 46 —(CH2)3— 47 —(CH2)3— 48 —(CH2)3— -
TABLE 70 (I-B-2-1) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 71 (I-B-2-2) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 72 (I-B-2-3) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 73 (I-B-2-4) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 74 (I-B-2-5) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 75 (I-B-2-6) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— -
TABLE 76 (I-B-2-7) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— -
TABLE 77 (I-B-2-8) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 78 (I-B-2-9) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— -
TABLE 79 (I-B-2-10) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 80 (I-B-2-11) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 81 (I-B-2-12) No -E3- -E4 1 —(CH2)2— —OH 2 —(CH2)2— —OMe 3 —(CH2)2— —NH2 4 —(CH2)2— —NHMe 5 —(CH2)2— —NHEt 6 —(CH2)2— —NHPr 7 —(CH2)2— —NH-i-Pr 8 —(CH2)2— —NMe2 9 —(CH2)2— —NEt2 10 —(CH2)2— —NPr2 11 —(CH2)2— —N(i-Pr)2 12 —(CH2)2— —NHPh 13 —(CH2)2— —NHBn 14 —(CH2)2— —NH-c-Pr 15 —(CH2)2— —NH-c-Bu 16 —(CH2)2— —NH-c-Pen 17 —(CH2)2— —NH-c-Hex 18 —(CH2)2— —NH—(CH2)2—OH 19 —(CH2)2— —NHCH(Me)(OH) 20 —(CH2)2— —N(Me)(c-Pen) 21 —(CH2)2— —N(Me)(c-Hex) 22 —(CH2)2— —N(Me)(Ph) 23 —(CH2)2— 24 —(CH2)2— 25 —(CH2)2— 26 —(CH2)2— 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)3— —OH 30 —(CH2)3— —OMe 31 —(CH2)3— —NH2 32 —(CH2)3— —NHMe 33 —(CH2)3— —NHEt 34 —(CH2)3— —NHPr 35 —(CH2)3— —NH-i-Pr 36 —(CH2)3— —NMe2 37 —(CH2)3— —NEt2 38 —(CH2)3— —NPr2 39 —(CH2)3— —N(i-Pr)2 40 —(CH2)3— —NHPh 41 —(CH2)3— —NHBn 42 —(CH2)3— —NH-c-Pr 43 —(CH2)3— —NH-c-Bu 44 —(CH2)3— —NH-c-Pen 45 —(CH2)3— —NH-c-Hex 46 —(CH2)3— —NH—(CH2)2—OH 47 —(CH2)3— —NHCH(Me)(OH) 48 —(CH2)3— —N(Me)(c-Pen) 49 —(CH2)3— —N(Me)(c-Hex) 50 —(CH2)3— —N(Me)(Ph) 51 —(CH2)3— 52 —(CH2)3— 53 —(CH2)3— 54 —(CH2)3— 55 —(CH2)3— 56 —(CH2)3— 57 —(CH2)4— —OH 58 —(CH2)4— —OMe 59 —(CH2)4— —NH2 60 —(CH2)4— —NHMe 61 —(CH2)4— —NHEt 62 —(CH2)4— —NHPr 63 —(CH2)4— —NH-i-Pr 64 —(CH2)4— —NMe2 65 —(CH2)4— —NEt2 66 —(CH2)4— —NPr2 67 —(CH2)4— —N(i-Pr)2 68 —(CH2)4— —NHPh 69 —(CH2)4— —NHBn 70 —(CH2)4— —NH-c-Pr 71 —(CH2)4— —NH-c-Bu 72 —(CH2)4— —NH-c-Pen 73 —(CH2)4— —NH-c-Hex 74 —(CH2)4— —NH—(CH2)2—OH 75 —(CH2)4— —NHCH(Me)(OH) 76 —(CH2)4— —N(Me)(c-Pen) 77 —(CH2)4— —N(Me)(c-Hex) 78 —(CH2)4— —N(Me)(Ph) 79 —(CH2)4— 80 —(CH2)4— 81 —(CH2)4— 82 —(CH2)4— 83 —(CH2)4— 84 —(CH2)4— -
TABLE 82 (I-B-2-13) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— 33 —(CH2)3— Me 34 —(CH2)3— Et 35 —(CH2)3— Pr 36 —(CH2)3— i-Pr 37 —(CH2)3— Ph 38 —(CH2)3— Bn 39 —(CH2)3— c-Pr 40 —(CH2)3— c-Bu 41 —(CH2)3— c-Pen 42 —(CH2)3— c-Hex 43 —(CH2)3— 44 —(CH2)3— 45 —(CH2)3— 46 —(CH2)3— 47 —(CH2)3— 48 —(CH2)3— -
TABLE 83 (I-B-2-14) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— 33 —(CH2)3— Me 34 —(CH2)3— Et 35 —(CH2)3— Pr 36 —(CH2)3— i-Pr 37 —(CH2)3— Ph 38 —(CH2)3— Bn 39 —(CH2)3— c-Pr 40 —(CH2)3— c-Bu 41 —(CH2)3— c-Pen 42 —(CH2)3— c-Hex 43 —(CH2)3— 44 —(CH2)3— 45 —(CH2)3— 46 —(CH2)3— 47 —(CH2)3— 48 —(CH2)3— -
TABLE 84 (I-B-2-15) No -E1- -E3-E4 1 —CH2— Me 2 —CH2— Et 3 —CH2— Pr 4 —CH2— i-Pr 5 —CH2— Ph 6 —CH2— Bn 7 —CH2— c-Pr 8 —CH2— c-Bu 9 —CH2— c-Pen 10 —CH2— c-Hex 11 —CH2— 12 —CH2— 13 —CH2— 14 —CH2— 15 —CH2— 16 —CH2— 17 —(CH2)2— Me 18 —(CH2)2— Et 19 —(CH2)2— Pr 20 —(CH2)2— i-Pr 21 —(CH2)2— Ph 22 —(CH2)2— Bn 23 —(CH2)2— c-Pr 24 —(CH2)2— c-Bu 25 —(CH2)2— c-Pen 26 —(CH2)2— c-Hex 27 —(CH2)2— 28 —(CH2)2— 29 —(CH2)2— 30 —(CH2)2— 31 —(CH2)2— 32 —(CH2)2— 33 —(CH2)3— Me 34 —(CH2)3— Et 35 —(CH2)3— Pr 36 —(CH2)3— i-Pr 37 —(CH2)3— Ph 38 —(CH2)3— Bn 39 —(CH2)3— c-Pr 40 —(CH2)3— c-Bu 41 —(CH2)3— c-Pen 42 —(CH2)3— c-Hex 43 —(CH2)3— 44 —(CH2)3— 45 —(CH2)3— 46 —(CH2)3— 47 —(CH2)3— 48 —(CH2)3— - The compound represented by formula (I) can be prepared by the following method or the method described in Example.
- (1) Among the compounds of the present invention represented by formula (I), a compound in which A represents A1, and D1 represents —NR6C(O)— or —CH2—NR6C(O)—, i.e., a compound represented by formula (IA-1)
- (wherein D1-1 is —NR6C(O)— or —CH2—NR6C(O)—, and other symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-1) can be prepared by the amidation of the compounds of formula (II)
- (wherein R31 is —NHR6 or —CH2—NHR6, and R1-1, R4-1 and
-
- respectively. With proviso that, hydroxyl or amino in the group represented by R1-1, hydroxyl or amino represented by R4-1, and amino in the group represented by
- may be protected, if necessary. Other symbols have the same meanings as defined above.) and a compound represented by formula (III)
-
HOOC-D2-1-D3-1 (III) - (wherein D2-1 and D3-1 are D2 and D3 respectively. With proviso that, amino in the group represented by D2-1, and carboxy, hydroxy, amino, amidino or guanidino in D3-1 may be protected, if necessary.), if necessary, followed by removal of the protective group from the resulting product.
- The method of amidation is known. For example, it includes the method
- (1) an acyl halide,
- (2) via a mixed acid anhydride,
- (3) using a condensing agent.
- These methods are explained as follows.
- (1) The method via an acyl halide may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., oxalyl chloride or thionyl chloride etc.) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent at −20° C. to reflux temperature. And then the obtained acyl halide derivative may be reacted with amine in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0 to 40° C. As an alternative, the obtained acyl halide derivative may be reacted in an organic solvent (dioxane, tetrahydrofuran) using an alkaline aqueous solution (e.g., sodium bicarbonate, sodium hydroxide) at 0 to 40° C.
- (2) The method via a mixed acid anhydride may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., pivaloyl chloride, tosyl chloride or mesyl chloride) or an acid derivative (ethyl chloroformate or isobutyl chloroformate) in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran) or without a solvent, in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) at 0 to 40° C. And then the obtained mixed acid anhydride derivative may be reacted with amine in an organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran), at 0 to 40° C.
- (3) The method using a condensing agent may be carried out, for example, by reacting carboxylic acid with amine in an organic solvent (e.g., chloroform, methylene chloride, dimethylformamide, diethyl ether or tetrahydrofuran) or without a solvent, in the presence or absence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), using a condensing agent (e.g., 1,3-dicyclohexyl carbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,1′-carbodiimidazole (CDI), 2-chloro-1-methylpyridinium iodide, or 1-propanephosphonic acid cyclic anhydride (PPA)), in the presence or absence of 1-hydroxybenzothiazole (HOBt), at 0 to 40° C.
- The reaction described in (1), (2) and (3) may be carried out under an inert gas (e.g., argon, nitrogen) to avoid water in order to obtain a preferable result.
- The removal of the protective group may be carried out by following method.
- The reaction for removing the protective group for carboxyl, hydroxyl, amino, amidino or guanidino is well known, including, for example, the following:
- (1) alkali hydrolysis,
- (2) deprotection under acidic condition,
- (3) deprotection through hydrogenolysis,
- (4) silyl deprotection.
- These methods are explained as follows.
- (1) The deprotection through alkali hydrolysis may be effected, for example, in an organic solvent (e.g., methanol, tetrahydrofuran, dioxane) by the use of an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide), an alkaline earth metal hydroxide (e.g., barium hydroxide, calcium hydroxide) or a carbonate (e.g., sodium carbonate, potassium carbonate), or an aqueous solution thereof or their mixture, at 0 to 40° C.
- (2) The deprotection under acidic condition may be effected, for example, in an organic solvent (e.g., dichloromethane, chloroform, dioxane, ethyl acetate, anisole) with an organic solvent (e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid) or an inorganic acid (e.g., hydrochloric acid, sulfuric acid) or their mixture (hydrogen bromide/acetic acid), at 0 to 100° C.
- (3) The deprotection through hydrogenolysis may be effected, for example, in a solvent (e.g., ether-type (e.g., tetrahydrofuran, dioxane, dimethoxyethane, diethyl ether), alcohol-type (e.g., methanol, ethanol), benzene-type (e.g., benzene, toluene), ketone-type (e.g., acetone, methyl ethyl ketone), nitrile-type (e.g., acetonitrile), amide-type (e.g., dimethylformamide), water, ethyl acetate, acetic acid, or mixed solvent of two or more of these), in the presence of a catalyst (e.g., palladium-carbon, palladium-black, palladium hydroxide, platinum oxide, Raney nickel), in a normal-pressure or increased-pressure hydrogen atmosphere or in the presence of ammonium formate, at 0 to 200° C.
- (4) The silyl deprotection may be effected, for example, in a water-miscible organic solvent (e.g., tetrahydrofuran, acetonitrile) by the use of tetrabutylammonium fluoride, at 0 to 40° C.
- The carboxyl-protective group includes, for example, methyl, ethyl, t-butyl and benzyl.
- The hydroxyl-protective group includes, for example, methoxymethyl, 2-tetrahydropyranyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, acetyl and benzyl.
- The amino, amidino and guanidino-protective group includes, for example, benzyloxycarbonyl, t-butoxycarbonyl, trifluoroacetyl, 9-fluorenylmethoxycarbonyl and trimethylsilyl.
- The carboxyl, hydroxyl, amino, amidino or guanidino-protective group may be any others than those mentioned above, capable of being readily and selectively removed, and are not specifically defined. For example, those described in T. W. Greene, Protective Groups in Organic Synthesis, 3rd edition, Wiley, New York, 1999 may be used.
- The intended compounds of the invention may be readily produced through selective use of the deprotecting reaction, which could be readily understood by anyone skilled in the art.
- (2) Among the compounds of the present invention represented by formula (I), a compound in which A represents A1, and D1 represents —NR6SO2—, i.e., a compound represented by formula (IA-2)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-2) can be prepared by the sulfonamidation of the compounds of formula (II-1)
- (wherein all symbols have the same meanings as defined above.) and a compound represented by formula (IV)
- (wherein R32 is halogen atom and other symbols have the same meanings as defined above.), if necessary, followed by removal of the protective group from the resulting product.
- This sulfonamidation is known. For example, it is carried out at 0 to 40° C. in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine).
- The removal of the protective group may be carried out by the above method.
- (3) Among the compounds of the present invention represented by formula (I), a compound in which A represents A1, and D1 represents —OC(O)—, i.e., a compound represented by formula (IA-3)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-3) can be prepared by esterifying the compounds of formula (V)
- (wherein all symbols have the same meanings as defined above.) with the above compound represented by formula (III)
-
HOOC-D2-1-D3-1 (III) - (wherein all symbols have the same meanings as defined above.), if necessary, followed by removal of the protective group from the resulting product.
- The method of esterification is known. For example, it includes the method
- (1) via an acyl halide,
- (2) via a mixed acid anhydride,
- (3) using a condensing agent.
- These methods are explained as follows.
- (1) The method via an acyl halide may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., oxalyl chloride or thionyl chloride etc.) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) or without a solvent at −20° C. to reflux temperature. And then the obtained acyl halide derivative may be reacted with alcohol in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0 to 40° C.
- (2) The method via a mixed acid anhydride may be carried out, for example, by reacting carboxylic acid with an acyl halide (e.g., pivaloyl chloride, tosyl chloride or mesyl chloride) or an acid derivative (ethyl chloroformate or isobutyl chloroformate) in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether, tetrahydrofuran) or without a solvent, in the presence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine) at 0 to 40° C. And then the obtained mixed acid anhydride derivative may be reacted with alcohol in an inert organic solvent (e.g., chloroform, methylene chloride, diethyl ether or tetrahydrofuran), at 0 to 40° C.
- (3) The method using a condensing agent may be carried out, for example, by reacting carboxylic acid with alcohol in an organic solvent (e.g., chloroform, methylene chloride, dimethylformamide, diethyl ether or tetrahydrofuran) or without a solvent, in the presence or absence of tertiary amine (e.g., pyridine, triethylamine, dimethylaniline or dimethylaminopyridine), using a condensing agent (e.g., 1,3-dicyclohexyl carbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,1′-carbodiimidazole (CDI) or 2-chloro-1-methylpyridinium iodide), in the presence or absence of 1-hydroxybenzothiazole (HOBt), at 0 to 40° C.
- The reaction described in (1), (2) and (3) may be carried out under an inert gas (e.g., argon, nitrogen) to avoid water in order to obtain a preferable result.
- The removal of the protective group may be carried out by the above method.
- (4) Among the compounds of the present invention represented by formula (I), a compound in which A represents A1, and D1 represents —CH2—O—, i.e., a compound represented by formula (IA-4)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-4) can be prepared by the etherification of the compounds of formula (VI-1)
- (wherein all symbols have the same meanings as described above.) and the compound of formula (VII-1)
-
R33-D2-1-D3-1 (VII-1) - (wherein R33 is a leaving group (halogen atom, mesyloxy or tosyloxy, etc.) and other symbols have the same meanings as described above.), if necessary, followed by removal of the protective group, by the etherification of the compounds of formula (VI-2)
- (wherein all symbols have the same meanings as described above.) and the compound of formula (VII-2)
-
HO-D2-1-D3-1 (VII-2) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protective group, or by the etherification of the above compounds of formula (VI-1)
- (wherein all symbols have the same meanings as described above.) and the compound of formula (VII-2)
-
HO-D2-1-D3-1 (VII-2) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protective group.
- This etherification of the compound of formula (VI-1) and the compound of formula (VII-1), and the compound of formula (VI-2) and the compound of formula (VII-2) is known. For example, it is carried out at 0 to 100° C. in an inert organic solvent (e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether or tetrahydrofuran) in the presence of an alkali metal hydroxide (e.g., sodium hydroxide, potassium hydroxide, lithium hydroxide), an alkaline earth metal hydroxide (e.g., barium hydroxide, calcium hydroxide) or a carbonate (e.g., sodium carbonate, potassium carbonate), or an aqueous solution thereof or their mixture.
- This etherification of the compound of formula (VI-1) and the compound of formula (VII-2) is known. For example, it is carried out at 0 to 60° C. by reacting with a corresponding alcohol compound in an organic solvent (dichloromethane, diethyl ether, tetrahydrofuran, acetonitrile, benzene, toluene, etc.) in the presence of an azo compound (diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1,1′-(azodicarbonyl)dipiperidine, 1,1′-azobis(N,N-dimethylformamide), etc.) and a phosphine compound (triphenylphosphine, tributylphosphine, trimethylphosphine, etc.).
- The deprotection reaction of the protective group may be carried out by the methods described above.
- (5) Among the compounds of the present invention represented by formula (I), a compound in which A represents A1, and D1 represents —NR6—, i.e., a compound represented by formula (IA-5)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-5) can be prepared by reacting the above compound of formula (II-1)
- (wherein all symbols have the same meanings as described above.) with the compound of formula (VIII-1)
-
R32-D2-1-D3-1 (VIII-1) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group, or by reacting the compound of formula (IX)
- (wherein all symbols have the same meanings as described above.) with the compound of formula (VIII-2)
-
R6HN-D2-1-D3-1 (VIII-2) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- This reaction of the compound of formula (II) and the compound of formula (VIII-1), and the compound of formula (IX) and the compound of formula (VIII-2) is known. For example, it is carried out at 0 to 100° C. in an inert organic solvent (e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether, tetrahydrofuran or acetonitrile) in the presence or absence of a base (e.g., triethylamine, pyridine).
- The deprotection reaction of the protective group may be carried out by the methods described above.
- Among the compounds of the present invention represented by formula (IA-5), a compound in which D2 is C1-8 alkylene, C2-8 alkenylene, —(C1-4 alkylene)-O—(C1-4 alkylene)-, —(C1-4 alkylene)-S—(C1-4 alkylene)-, —(C1-4 alkylene)-NR8—(C1-4 alkylene)-, —(C1-8 alkylene)-(Cyc2)- or —(C1-4 alkylene)-(Cyc2)-(C1-4 alkylene)-, i.e., a compound represented by formula (IA-5-1)
- (wherein D2′ is C1-8 alkylene, C2-8 alkenylene, —(C1-4 alkylene)-O—(C1-4 alkylene)-, —(C1-4 alkylene)-S—(C1-4 alkylene)-, —(C1-4 alkylene)-NR8—(C1-4 alkylene)-, —(C1-8 alkylene)-(Cyc2)- or —(C1-4 alkylene)-(Cyc2)-(C1-4 alkylene)- and other symbols have the same meanings as described above.) can be prepared by reductive amination of the above compound of formula (II-1)
- (wherein all symbols have the same meanings as described above.) and the compound of formula (VIII-3)
-
OHC-D2″-D 3-1 (VIII-3) - (wherein D2″ is C1-7 alkylene, C2-7 alkenylene, —(C1-3 alkylene)-O—(C1-4 alkylene)-, —(C1-3 alkylene)-S—(C1-4 alkylene)-, —(C1-3 alkylene)-NR8—(C1-4 alkylene)-, —(C1-7 alkylene)-(Cyc2)- or —(C1-3 alkylene)-(Cyc2)-(C1-4 alkylene)- and other symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reductive amination is well known. For example, it may be carried out in an organic solvent (e.g., methanol, ethanol) in the presence of reducing agent (e.g., sodium cyanoborohydride, sodium borohydride, sodium triacetoxyborohydride) and, if necessary, in the presence of an acid (e.g., acetic acid, hydrogen chloride) at −20 to 60° C.
- The removal of the protective group may be carried out by the methods described above.
- (6) Among the compounds of the present invention represent by formula (I), a compound in which A is A1 and D1 is —CH2—NR6—, i.e., a compound of formula (IA-6)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-6) can be prepared by reacting the compound of formula (X)
- (wherein all symbols have the same meanings as described above.) with the above compound of formula (VIII-1)
-
R32-D2-1-D3-1 (VIII-1) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group, or by reductive amination of the compound of formula (XI)
- (wherein all symbols have the same meanings as described above.) with the above compound of formula (VIII-2)
-
R6HN-D2-1-D3-1 (VIII-2) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction of the compound of formula (X) and the compound of formula (VIII-1) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- The reaction of the compound of formula (XI) and the compound of formula (VIII-2) may be carried out by the same method as the above reaction of the compound of formula (II-1) and the compound of formula (VIII-3).
- The removal of the protective group may be carried out by the methods described above.
- (7) Among the compounds represented by formula (I), a compound in which A is A1 and D1 is —NR6C(O)NR7—, i.e., a compound (IA-7)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-7) can be prepared by reacting the above compound of formula (II-1)
- (wherein all symbols have the same meanings as described above.) with the compound of formula (XII)
-
O═C═N-D2-1-D3-1 (XII) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction is known. It may be carried out in organic solvent (e.g., tetrahydrofuran, methylene chloride, diethyl ether) at 0 to 100° C.
- The removal of the protective group may be carried out by the methods described above.
- (8) Among the compounds represented by formula (I), a compound in which A is A1 and D1 is —NR6C(S)NR7—, i.e., a compound of formula (IA-8)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-8) can be prepared by reacting the above compound of formula (II-1)
- (wherein all symbols have the same meanings as described above.) with the compound of formula (XIII)
-
S═C═N-D2-1-D3-1 (XIII) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction is known. It may be carried out in an organic solvent (tetrahydro furan, methylene chloride, diethyl ether) at 0 to 100° C.
- The removal of the protective group may be carried out by the methods described above.
- (9) Among the compound of the present invention represented by formula (I), a compound in which A is A1 and D1 is —NR6C(O)O—, i.e., a compound of formula (IA-9)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-9) can be prepared by reacting the above compound of formula (II-1)
- (wherein all symbols have the same meanings as described above.) with the compound of formula (XIV)
- (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction is known. It may be carried out in an organic solvent (e.g., tetrahydrofuran, methylene chloride, diethyl ether) at −78 to 40° C.
- The removal of the protective group may be carried out by the methods described above.
- (10) Among the compounds of the present invention represented by formula (I), a compound in which A is A1 and D1 is —NR6C(S)—, i.e., a compound of formula (IA-10)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-10) can be prepared by thiocarbonylation of the compound of formula (XV)
- (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction is known. It may be carried out in an organic solvent (e.g., dioxane, benzene, toluene, xylene, tetrahydrofuran), using Lawesson reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) at 20 to 150° C.
- The removal of the protective group may be carried out by the methods described above.
- (11) Among the compound of the present invention represented by formula (I), a compound in which A is A1 and D1 is —NR6C(═NR7)—, i.e., a compound of formula (IA-11)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IA-11) can be prepared by reacting the above compound of formula (II-1)
- (wherein all symbols have the same meanings as described above.) with the compound of formula (XVI)
- (wherein R34 is C1-4 alkyl and other symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction is known. For example, it may be carried out in an organic solvent (e.g., methanol, ethanol) at 0 to 50° C.
- The removal of the protective group may be carried out by the methods described above.
- (12) Among the compound of the present invention represented by formula (I), a compound in which A is A1 and D3 is —NR9R10 or hetero ring represented by
- (among Cyc2, the hetero ring is a hetero ring having at least one nitrogen atom which binds to D2), i.e., a compound of formula (IA-12)
- (wherein D3-2 is —NR9R10 or hetero ring represented by
- (among Cyc2, the hetero ring is a hetero ring having at least one nitrogen atom which binds to D2 and other symbols have the same meanings as described above.) can be prepared by the following method.
- The compound represented by formula (IA-12) can be prepared by reacting a compound of formula (XVII)
- (wherein all symbols have the same meanings as described above.) with a compound of formula (XVIII)
-
H—NR9R10 (XVIII) - (wherein all symbols have the same meanings as described above.) or a compound of formula (XIX)
- (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction of the compound of formula (XVII) and the compound of formula (XVIII) or (XIX) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- The removal of the protective group may be carried out by the methods described above.
- (13) Among the compounds of the present invention represented formula (I), a compound in which A is A2, and E2 is —C(O)NR24—, i.e., a compound of formula (IB-1)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IB-1) can be prepared by amidation of a compound of formula (XX)
- (wherein all symbols have the same meanings as described above.) and the compound of formula (XXI)
- (wherein E4-1 is E4. With proviso that, hydroxyl, amino or carboxyl in the group represented by E4-1 may be protected, if necessary. Other symbols have the same meanings as defined above.), if necessary, followed by removal of the protecting group.
- The amidation and the removal of the protective group may be carried out by the methods described above.
- (14) Among the compounds of the present invention represented by formula (I), a compound in which A is A2 and E2 is —NR24C(O)—, i.e., a compound of formula (IB-2)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IB-2) can be prepared by amidation of a compound of formula (XXII)
- (wherein all symbols have the same meanings as described above.) and a compound of formula (XXIII)
-
HOOC-E3-E4-1 (XXIII) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The amidation and the removal of the protective group may be carried out by the methods described above.
- (15) Among the compounds of the present invention represented by formula (I), a compound in which A is A2 and E2 is —NR24—, i.e., a compound of formula (IB-3)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IB-3) can be prepared by reacting a compound of formula (XXIV)
- (wherein all symbols have the same meanings as described above.) with the above compound of formula (XXI)
- (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction of the compound of formula (XXIV) and the compound of formula (XXI) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound formula (VIII-2).
- The removal of the protective group may be carried out by the methods described above.
- (16) Among the compound of the present invention represented by formula (I), a compound in which A is A2, and E2 is —C(O)O—, i.e., a compound of formula (IB-4)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IB-4) can be prepared by esterifying the compound of formula (XX)
- (wherein all symbols have the same meanings as described above.) with a compound of formula (XXV)
-
HO-E3-E4-1 (XXV) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The esterifying and the removal of the protective group may be carried out by the methods described above.
- (17) Among the compounds of the present invention represented by formula (I), a compound in which A is A2, and E2 is —S—, i.e., a compound of formula (IB-5)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IB-5) can be prepared by reacting a compound of formula (XXVI)
- (wherein all symbols have the same meanings as described above.) with a compound of formula (XXVII)
-
R32-E3-E4-1 (XXVII) - (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction is known. For example, it may be carried out in an inert organic solvent (e.g., dimethylformamide, dimethylsulfoxide, chloroform, methylene chloride, diethyl ether, tetrahydrofuran, acetonitrile) in the presence or absence of a base (e.g., triethylamine, pyridine) at 0 to 100° C.
- The removal of the protective group may be carried out by the methods described above.
- (18) Among the compounds of the present invention represented by formula (I), a compound in which A is A2, and E4 is —NR25R26 or hetero ring represented by
- (The hetero ring is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to E3.) in Cyc5.), i.e., a compound of formula (IB-6)
- (wherein E4-2 is —NR25R26 or hetero ring represented by
- (The hetero ring is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to E3.) in Cyc5.) and other symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IB-6) can be prepared by reacting a compound of formula (XXVIII)
- (wherein all symbols have the same meanings as described above.) with a compound of formula (XXIX)
-
H—NR25R26 (XXIX) - (wherein all symbols have the same meanings as described above.) or a compound of formula (XXX)
- (wherein all symbols have the same meanings as described above.), if necessary, followed by removal of the protecting group.
- The reaction of the compound of formula (XXVIII) and the compound of formula (XXIX) or (XXX) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- The removal of the protective group may be carried out by the methods described above.
- (19) Among the compounds of the present invention represented by formula (I), a compound in which A is A3, i.e., a compound of formula (IC-1)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (IC-1) can be prepared by reacting a compound of formula (XXXI)
- (wherein G1-1 is bond or C1-7 alkylene, Cyc1′ and G2-1 are Cyc1 and G2 respectively. With proviso that amino in the group represented by Cyc1, and hydroxy and amino in the group represented by G2-1 may be protected, if necessary. Other symbols have the same meanings as described above.) with hydrazine or a salt thereof (e.g., hydride, chloride), if necessary, followed by removal the protecting group.
- The reaction is known. For example, it may be carried out in an organic solvent (e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran) at 50° C. to reflux temperature.
- The removal of the protective group may be carried out by the methods described above.
- Moreover, among the compounds of the present invention represented by formula (IC-1), a compound in which Cyc1 is hetero ring represented by
- (The hetero ring is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to G1.) in Cyc1.), i.e., a compound of formula (IC-1-1)
- is a hetero ring having at least one nitrogen atom (The nitrogen atom binds to G1.) in Cyc1 and other symbols have the same meanings as described above.) can be prepared by following method.
- The compound of formula (IC-1-1) can be prepared by reacting a compound of formula (XXXII)
- (wherein all symbols have the same meanings as described above.) with a compound of formula (XXXIII)
- (wherein all symbols have the same meanings as described above.), if necessary, followed by removal the protecting group.
- The reaction of the compound of formula (XXXII) and the compound of formula (XXXIII) may be carried out by the same method as the above reaction of the compound of formula (IX) and the compound of formula (VIII-2).
- The removal of the protective group may be carried out by the methods described above.
- (20) Among the compounds of the present invention represented by formula (I), a compound in which A is A4 or A5, i.e., a compound of (ID-1)
- (wherein A6 is A4 or A5 and other symbols have the same meanings as described above.) can be prepared by the following a) to b).
a) The compound of formula (ID-1) can be prepared by reacting a compound of formula (XXXIV-1) - (wherein R35 is C1-8 alkyl, and A6-1 is A6. With proviso that hydroxy or amino in the group represented by A6-1 may be protected, if necessary. Other symbols have the same meanings as described above.) or a compound of formula (XXXIV-2)
- (wherein all symbols have the same meanings as described above.) with hydrazine or a salt thereof (e.g., hydride, chloride), if necessary, followed by removal the protecting group.
- The reaction is known. For example, it may be carried out in an organic solvent (e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran) at 50° C. to reflux temperature.
- The removal of the protective group may be carried out by the methods described above.
- b) The compound of formula (ID-1) can be prepared by reacting a compound of formula (XXXV)
- (wherein all symbols have the same meanings as described above.) with hydrazine and a salt thereof (e.g., hydride, chloride), if necessary, followed by removal the protecting group.
- The reaction is known. For example, it may be carried out in an organic solvent (e.g., methanol, ethanol, propanol, isopropanol, butanol, acetic acid, tetrahydrofuran) at 50° C. to reflux temperature.
- The removal of the protective group may be carried out by the methods described above.
-
- is single bond, i.e., a compound of formula (ID-1-1)
- (wherein all symbols have the same meanings as described above.) can be prepared by the following method.
- The compound of formula (ID-1-1) can be prepared by reacting a compound of formula (XXXVI)
- (wherein all symbols have the same meanings as described above.) with a compound of formula (XXXVII)
- (wherein R35 has the same meaning as described above.), if necessary, followed by removal of the protecting group.
- The reaction may be carried out, for example, in an organic solvent (e.g., toluene, tetrahydrofuran, chloroform, methylene chloride) in the presence or absence of catalyst (e.g., p-toluenesulfonic acid, pyridine) at 50° C. to reflux temperature.
- The removal of the protective group may be carried out by the methods described above.
- The compounds represented by formulae (II), (II-1), (III), (IV), (V), (VI-1), (VI-2), (VII-1), (VII-2), (VIII-1), (VIII-2), (VIII-3), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), (XXIII), (XXIV), (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), (XXX), (XXXI), (XXXII), (XXXIII), (XXXIV-1), (XXXIV-2), (XXXV), (XXXVI) and (XXXVII) are known compounds or can be prepared by known methods or methods as described in Examples.
- For example the compounds of formulae (II), (II-1), (V), (VI-1), (VI-2), (IX), (X), (XI), (XX), (XXII), (XXIV), (XXVI), (XXXI), (XXXIV-1), (XXXIV-2), (XXXV) and (XXXVI) can be prepared by the method described in reaction scheme 1, 2, 3 and 4.
- In each reaction scheme, R36 is —NHR6, —CH2—NHR6, —OH, —CH2—OH, —CH2—R33 or halogen atom. With proviso that hydroxy and amino in the group represented by R36 may be protected, if necessary. R37 is the protecting group of amino, R38 is —NHR6, —CH2—NHR6, —OH, —CH2—OH, —CH2—R33 or halogen atom, BOP is benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate, Me is methyl, Et is ethyl, E1-1 is bond or C1-3 alkylene, Ph is phenyl, TBAF is tetrabutylammonium fluoride, TMSN3 is trimethylsilylazide, and R39 is COOH, —NHR24, halogen atom or —SCOCH3. With proviso that amino or carboxy in the group represented by R39 may be protected, if necessary. R40 is COOH, —NHR24, halogen atom or —SCOCH3, and other symbols have the same meanings as described above. The compound represented by formulae (XXXIX) and (XXXXXV) with bromo instead of chloro may be used, which could be readily understood by anyone skilled in the art.
- In Reaction Schemes 1, 2, 3 and 4, the compounds used as the starting materials are known compounds or can be prepared easily by known methods.
- In each reaction described herein, the reaction product can be purified by general purification techniques such as distillation under ordinary pressure or a reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing and recrystallization. Purification may be carried out in each reaction or after completion of several reactions.
- It has been confirmed that the compounds of the present invention of formula (I) have PARP inhibitory activity by the following experimental results.
- The below procedure was carried out with 96 well plate at room temperature. In a final volume of 80 μL, the reaction mixture contained each 10 μL of 500 mM Tris/HCl (pH 8.0, WAKO), 100 mM MgCl2, 50 mM dithiothreitol (sigma), 1 mg/mL activated DNA and 1 mM NAD (containing 3H-NAD). The 10 μL of test compound was added to the reaction mixture and the reaction was started by addition of 10 μL of 0.1 U/μL PARP (TREVIGEN). The reaction was terminated at 10 minutes by addition of 100 μL of 20% trichloroacetic acid. Poly(ADP-ribose), which is the reaction product, was collected on a glass fiber filter (GF/C, PACKARD). The radioactivity was measured by topcount (PACKARD). Inhibitory activity of the compound was represented by 50% inhibitory concentration calculated as 100% of control (distilled water). The results were shown in Table 91.
-
TABLE 91 Example No. IC50(μM) 6 (9) 0.61 11 (4) 0.10 30 (4) 0.29 - Model of cerebral or coronary ischemia-reperfusion was prepared according to procedures described previously (Jpn. J. Stroke, 8, 1 (1986), Stroke, 27, 1624-1628 (1996) and Eur. J. Pharmacol., 270, 45 (1994)). The compounds of the present invention were improvement effective of these diseases.
- The toxicity of the compounds of the present invention represented by formula (I) is very low (For example, as a result of administering the compounds of the present invention to rats, they did not affect circulatory parameters, such as blood pressure, an electrocardiogram, and heart rate.) and therefore the compounds may be considered safe for pharmaceutical use.
- Since the compound of the present invention represented by formula (I) has PARP inhibitory activity, it is useful for prevention and/or treatment of various diseases, for example, ischemic diseases (cerebral infarction, myocardial infarction, reperfusion injury or postoperative injury etc.), inflammatory diseases (inflammatory bowel disease, multiple sclerosis, arthritis or lung injury etc.), neurodegenerative disorders (extrapyramidal disease, Parkinson's disease, Alzheimer's disease, muscular dystrophy or lumbar spinal canal stenosis etc.), glaucoma, diabetes, diabetic complication, shock, head trauma, spinal cord injury, renal failure or hyperalgesia etc. Moreover, it is useful as an antiretroviral drug such as an anti HIV drug, a sensitizer of anticancer therapy or an immunosuppressant.
- The compound represented by formula (I) or pharmaceutically acceptable salt thereof may be administered in combination with other pharmaceutical preparations to accomplish the following purposes:
- 1) To complement for and/or enhance the preventive and/or treatment effect of the compound to be combined;
2) To improve the kinetics/absorption of the compound to be combined and reduce the dose of the compound; and/or
3) To eliminate the side effect of the compound to be combined - The compound represented by formula (I) and other pharmaceutical preparations may be administered in the form of formulation having these components incorporated in one preparation or may be administered in separate preparations. In the case where these pharmaceutical preparations are administered in separate preparations, they may be administered simultaneously or at different times. In the latter case, the compound represented by formula (I) may be administered before the other pharmaceutical preparations. Alternatively, the other pharmaceutical preparations may be administered before the compound represented by formula (I). The method for the administration of these pharmaceutical preparations may be the same or different.
- The diseases on which the preventive and/or treatment effect of the aforementioned combined preparations works are not specifically limited but may be those for which the preventive and/or treatment effect of the compound represented by formula (I) is complemented and/or enhanced.
- Examples of the other pharmaceutical preparations for complementing and/or enhancing the preventive and/or treatment effect of the compound represented by formula (I) on ischemic diseases include radical scavenger, astrocyto modulator, N-methyl-D-aspartate (NMDA) antagonist, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) antagonist, antithrombotic agent, thrombolytic agent, immunosuppressive agent, cell adhesion molecules inhibitor, nitrogen oxide synthase (NOS) inhibitor, neurotrophic factor and interleukin-8 inhibitor etc.
- Examples of the other pharmaceutical preparations for complementing and/or enhancing the preventive and/or treatment effect of the compound represented by formula (I) on lumbar spinal canal stenosis include nitrogen oxide synthase (NOS) inhibitor, aldose reductase (AR) inhibitor, radical scavenger, N-methyl-D-aspartate (NMDA) antagonist, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) antagonist, neurotrophic factor and interleukin-8 inhibitor etc.
- Examples of the radical scavenger include, for example, edaravone and ebselen (DR-3305) etc.
- Examples of the astrocyto modulator include, for example, ONO-2506 etc.
- Examples of the antithrombotic agent include, for example, sodium ozagrel, argatroban and aspirin etc.
- Examples of the thrombolytic agent include, for example, tissue plasminogen activator (t-PA), urokinase and heparin etc.
- Examples of the immunosuppressive agent include, for example, cyclosporin A, cyclophosphamide and tacrolimus etc.
- Examples of the NOS inhibitor include, for example, L-NMMA and ONO-1714 etc.
- Examples of the AR inhibitor include, for example, epalrestat, zenarestat, fidarestat, zopolrestat and AS-3201 etc.
- The weight proportion of the compound represented by formula (I) and the other pharmaceutical preparations is not specifically limited.
- Arbitrary two or more of the other pharmaceutical preparations may be administered in combination.
- Examples of the other pharmaceutical preparations for complementing and/or enhancing the preventive and/or treatment effect of the compound represented by formula (I) include not only those which have so far been found but also those which will be found on the basis of the aforementioned mechanism.
- In order to use the compound of the present invention represented by formula (I) or the pharmaceutically acceptable salt thereof, or the compound represented by formula (I) in combination with the other pharmaceutical preparations, these compounds are normally administered to the entire or local part of human body orally or parenterally.
- The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.
- As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.
- The compound represented by formula (I) or the pharmaceutically acceptable salt thereof, or the concomitant drug combined the compound represented by formula (I) with pharmaceutical preparations may be administered in the form of, for example, solid compositions, liquid compositions or other compositions each for oral administration, or injections, preparations for external use or suppositories, each for parenteral administration.
- Solid compositions for oral administration include compressed tablets, pills, capsules, powders, and granules.
- Capsules include hard capsules and soft capsules.
- In such solid compositions, one or more of the active substance(s) may be admixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium aluminometasilicate. The compositions may comprise, in accordance with the conventional process, additives other than the inert diluent, for example, lubricants such as magnesium stearate, disintegrants such as cellulose calcium glycolate, stabilizer such as lactose, and solubilizing agent such as glutamic acid or aspartic acid. Tablets or pills may be coated with a film of a gastric soluble or enteric substance such as sucrose, gelatin, hydroxypropyl cellulose or hydroxypropyl methylcellulose phthalate, or with two or more layers, if necessary. Furthermore, capsules made of a substance which can be absorbed in the body, for example, gelatin, are included.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups and elixirs etc. Such liquid compositions comprise one or more of the active substance(s) and an ordinarily employed inert diluent(s) (for example, purified water or ethanol) dissolving the substance(s) therein. The compositions may comprise, in addition to the inert diluent, an adjuvant such as humectants or suspending agents, sweetening agents, flavoring agents, aromatic agents and antiseptics.
- The other compositions for oral administration include sprays which comprise one or more active substance(s) and are formulated in a manner known per se in the art. The compositions may comprise, in addition to an inert diluent, a stabilizer such as sodium bisulfite and an isotonization buffer such as sodium chloride, sodium citrate or citric acid. The preparation process of sprays is described in detail in, for example, U.S. Pat. Nos. 2,868,691 and 3,095,355.
- In the present invention, injections for parenteral administration include sterile aqueous and/or non-aqueous solutions, suspensions and emulsions. The aqueous solutions or suspensions include, for example, distilled water for injection and saline. The non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohol such as ethanol and Polysorbate 80 (trade mark). Furthermore, sterile aqueous and non-aqueous solutions, suspensions, and emulsions may be used in combination. Such compositions may additionally comprise adjuvants such as antisaptic, humectant, emulsfier, dispersant, stabilizer (such as lactose) and solubilizing agent (such as glutamic acid and aspartic acid). They are sterilized by filtration through a bacteria retaining filter, the addition of a sterilizer, or irradiation. Also, a sterile solid composition is prepared and then, for example, a freeze-dried product may be dissolved in sterilized or sterile distilled water for injection or another sterile solvent before use.
- The other compositions for parenteral administration include liquids for external use, ointments, endermic liniments, suppositories for intrarectal administration and pessaries for vaginal administration which comprise one or more of the active substance(s) and may be prepared by methods known per se.
- The present invention is explained below in detail based on Reference Examples and Examples, however, the present invention is not limited thereto.
- The solvents in the parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations or TLC. The solvents in the parentheses in NMR show the solvents for measurement.
- To a solution of 3,4,5,6-tetrahydrophthalic acid anhydride (3.04 g) in tetrahydrofuran (40.0 mL) was added a solution of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride in tetrahydrofuran (1M, 20.0 mL) at −78° C. The mixture was stirred for 1.5 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, which was stirred at room temperature for 30 minutes. Anhydrous magnesium sulfate was added to the reaction mixture, which was filtrated. The filtrate was concentrated to give an oily product. Thionyl chloride (5.20 mL) was added dropwise to methanol (20.0 mL) at −10° C. and then the solution was stirred at 0° C. for 15 minutes. To the solution was added the oily product obtained previously and the solution was stirred at room temperature for 18 hours. The reaction mixture was concentrated. The obtained residue was dissolved in methylene chloride (20 mL) and thereto was added triethylamine (2.79 mL) at 0° C. Water was added to the reaction solution, which was extracted with methylene chloride. The extract was washed with water, a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate:hexane=3:7) to give the title compound (2.56 g) having the following physical data.
- NMR (DMSO-d6): δ 7.03 (t, J=7.8 Hz, 1H), 6.60-6.47 (m, 3H), 5.21 (brs, 2H), 3.20 (s, 3H), 2.17-1.60 (m, 8H).
- A solution of the compound prepared in Reference example 1 (2.56 g) and hydrazine monohydrate (503 mg) in ethanol (30.0 mL) was refluxed for 18 hours. After cooling the reaction mixture to room temperature, the deposited crystal was collected by filtration. It was washed with hexane and dried under reduced pressure. 4N hydrogen chloride in dioxane (0.10 mL) was added dropwise to a suspension of the obtained solid (32.0 mg) in methanol (1.00 mL) and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated. The obtained crystal was dried under reduced pressure to give the compound of the present invention (36.2 mg) having the following physical data. Moreover, the compound was converted to methanesulfonate thereof by conventional method.
- TLC: Rf 0.27 (ethyl acetate:hexane=2:1);
- NMR (DMSO-d6): δ 12.95 (s, 1H), 9.40 (brs, 3H), 7.47 (t, J=8.1 Hz, 1H), 7.32-7.26 (m, 3H), 2.43-1.59 (m, 8H).
- TLC: Rf 0.55 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.94 (s, 1H), 8.31 (s, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.26-7.21 (m, 2H), 7.18 (s, 1H), 2.48-2.34 (m, 4H), 2.31 (s, 3H), 1.71-1.60 (m, 4H).
- By the same procedure as described in Reference Example 1→Example 1, if necessary, by converting to corresponding salts by conventional method, using 3,4,5,6-tetrahydrophthalic acid anhydride in tetrahydrofuran or a corresponding derivative, and 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride or a corresponding derivative, the following compounds of the present invention were obtained.
- TLC: Rf 0.50 (methanol:methylene chloride=1:9);
- NMR (CD3OD): δ 7.66-7.58 (m, 2H), 7.51-7.44 (m, 2H), 5.82 (m, 1H), 5.73 (m, 1H), 3.21 (m, 1H), 2.74 (s, 3H), 2.72-2.47 (m, 3H), 2.27 (m, 1H), 1.92 (m, 1H).
- TLC: Rf 0.47 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 13.01 (br-s, 1H), 7.45 (m, 1H), 7.20-7.09 (m, 3H), 2.86-2.80 (m, 2H), 2.58-2.52 (m, 2H), 2.31 (s, 3H), 1.86-1.76 (m, 2H), 1.58-1.46 (m, 4H).
- TLC: Rf 0.24 (ethyl acetate:hexane=1:1);
- NMR (DMSO-d6): δ 13.07 (s, 1H), 8.17 (d, J=1.5 Hz, 1H), 7.86 (d, J=8.4 Hz, 1H), 7.80 (dd, J=8.4, 1.5 Hz, 1H), 2.48-2.38 (m, 4H), 1.71-1.58 (m, 4H).
- To a solution of thiomorpholin-3-ylcarboxylic acid ethyl ester (5.05 g) in methylene chloride (120 mL) were added dimethylaminopyridine (352 mg), triethylamine (4.9 mL) and 3-nitrobenzoyl chloride (5.62 g) in ice bath and then the mixture was stirred at room temperature overnight. 2N hydrochloric acid was added to the reaction mixture, which was extracted with methylene chloride. The extract was wash with a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=2:1) to give the title compound (5.91 g) having the following physical data.
- TLC: Rf 0.23 (hexane:ethyl acetate=2:1);
- NMR (CDCl3): δ 8.32-8.30 (m, 2H), 7.79-7.62 (m, 2H), 5.78 and 4.57 (m, 1H), 4.98-4.93 and 3.84-3.79 (m, 1H), 4.23 (q, J=7.2 Hz, 2H), 3.71-3.63 and 3.28-3.02 and 2.91-2.70 (m, 4H), 2.61-2.57 and 2.43-2.39 (m, 1H), 1.36 (t, J=7.2 Hz, 3H).
- To a solution of the compound prepared in Reference example 2 (5.88 g) in toluene (90 mL) was added Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) (8.62 g) and the mixture was refluxed for 2 hours. After cooling to room temperature, the reaction mixture was filtrated and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=4:1) to give the title compound (6.16 g) having the following physical data.
- TLC: Rf 0.27 (hexane:ethyl acetate=4:1);
- NMR (CDCl3): δ 8.24-8.17 (m, 2H), 7.66-7.55 (m, 2H), 6.96-6.93 and 4.88-4.86 (m, 1H), 5.96-5.90 and 4.13-4.06 (m, 1H), 4.39-4.32 (m, 2H), 3.83-3.73 and 3.59-3.50 (m, 1H), 3.37-3.30 and 3.12-3.07 (m, 1H), 3.20-3.14 and 3.02-2.94 (m, 1H), 2.94-2.88 and 2.80-2.71 (m, 1H), 2.72-2.64 and 2.49-2.41 (m, 1H), 1.40-1.28 (m, 3H).
- To a solution of the compound prepared in Reference example 3 (4.78 g) in ethanol (50 mL) was added hydrazine monohydrate (2.0 mL) and the mixture was refluxed overnight. The reaction mixture was cooled to room temperature and the precipitate was collected by filtration to give the compound of the present invention (2.30 g) having the following physical data.
- TLC: Rf 0.45 (chloroform:methanol=19:1);
- NMR (DMSO-d6): δ 10.65 (s, 1H), 8.30-8.27 (m, 2H), 7.89-7.86 (m, 1H), 7.76-7.70 (m, 1H), 4.24 (dd, J=10.8, 2.7 Hz, 1H), 3.49 (dt, J=13.8, 2.7 Hz, 1H), 3.17-3.08 (m, 1H), 2.97 (dd, J=13.2, 10.8 Hz, 1H), 2.88-2.82 (m, 1H), 2.71 (dt, J=12.6, 2.7 Hz, 1H), 2.32-2.27 (m, 1H).
- By the same procedure as described in Reference example 2→Reference example 3→Example 3, using thiomorpholin-3-ylcarboxylic acid ethyl ester or a corresponding derivative, and 3-nitrobenzoyl chloride or a corresponding derivative, the following compounds of the present invention were obtained.
- TLC: Rf 0.50 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.48 (s, 1H), 8.28 (d, J=8.1 Hz, 1H), 8.22 (s, 1H), 7.86 (d, J=8.1 Hz, 1H), 7.73 (t, J=8.1 Hz, 1H), 3.91 (m, 1H), 3.17 (m, 1H), 2.87 (m, 1H), 2.10 (m, 1H), 1.86 (m, 1H), 1.43 (m, 4H).
- TLC: Rf 0.18 (hexane:ethyl acetate=2:1);
- NMR (DMSO-d6): δ 10.53 (s, 1H), 7.50-7.38 (m, 5H), 4.23 (dd, J=9.6, 3.6 Hz, 1H), 3.52 (m, 1H), 3.08 (m, 1H), 2.94-2.80 (m, 2H), 2.68 (m, 1H), 2.30 (d, J=10.5 Hz, 1H).
- TLC: Rf 0.18 (hexane:ethyl acetate=1:1);
- NMR (CDCl3): δ 8.32 (dd, J=8.1, 1.5 Hz, 1H), 8.27 (s, 1H), 8.14 (br, 1H), 7.72 (d, J=8.1 Hz, 1H), 7.66 (t, J=8.1 Hz, 1H), 4.39 (dd, J=10.8, 2.7 Hz, 1H), 3.72 (dt, J=14.1, 2.7 Hz, 1H), 3.24 (m, 1H), 3.13 (m, 1H), 2.99 (dd, J=14.1, 10.8 Hz, 1H), 2.77 (m, 1H), 2.32 (m, 1H);
- [α]D=−71.9 (c, 0.16, MeOH).
- TLC: Rf 0.28 (ethyl acetate:hexane=1:1);
- NMR (DMSO-d6): δ 10.69 (s, 1H), 8.28 (d, J=8.4 Hz, 2H), 7.73 (d, J=8.4 Hz, 2H), 4.26 (dd, J=10.2, 3.0 Hz, 1H), 3.48 (d, J=14.4 Hz, 1H), 3.17-2.29 (m, 5H).
- TLC: Rf 0.17 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.50 (s, 1H), 7.33 (t, J=8.1 Hz, 1H), 7.00-6.93 (m, 3H), 4.20 (dd, J=10.5, 3.0 Hz, 1H), 3.76 (s, 3H), 3.53 (dt, J=13.8, 3.0 Hz, 1H), 3.10-3.01 (m, 1H), 2.93-2.78 (m, 2H) 2.73-2.63 (m, 1H), 2.32-2.27 (m, 1H).
- TLC: Rf 0.50 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 7.40-7.26 (m, 2H), 7.04-6.92 (m, 2H), 4.20 (dd, J=9.3, 4.2 Hz, 1H), 3.77 (s, 3H), 3.57 (dt, J=14.1, 2.7 Hz, 1H), 3.06 (m, 1H), 2.94-2.78 (m, 2H), 2.68 (m, 1H), 2.30 (m, 1H).
- TLC: Rf 0.50 (methylene chloride:methanol=10:1);
- NMR (CDCl3): δ 8.14 (br, 1H), 7.21 (ddd, J=8.4, 7.5, 2.1 Hz, 1H), 7.09 (t, J=7.5 Hz, 1H), 6.80 (td, J=7.5, 1.2 Hz, 1H), 6.74 (dd, J=8.4, 1.2 Hz, 1H), 4.35 (dd, J=10.5, 3.0 Hz, 1H), 3.72 (dt, J=13.8, 3.0 Hz, 1H), 3.14 (m, 1H), 3.08-2.90 (m, 2H), 2.79 (m, 1H), 2.21 (dd, J=13.8, 1.2 Hz, 1H).
- TLC: Rf 0.27 (methylene chloride:methanol=20:1);
- NMR (DMSO-d6): δ 11.02 (brs, 1H), 8.32 (d, J=8.1 Hz, 1H), 8.28 (s, 1H), 7.92 (d, J=8.1 Hz, 1H), 7.76 (t, J=8.1 Hz, 1H), 6.28 (s, 1H), 3.61 (m, 2H), 3.16 (m, 2H).
- TLC: Rf 0.51 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.89 (s, 1H), 7.45 (m, 5H), 6.24 (s, 1H), 3.60 (m, 2H), 3.14 (m, 2H).
- TLC: Rf 0.53 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.57 (br-s, 1H), 7.50-7.40 (m, 5H), 4.29 (dd, J=6.9, 4.5 Hz, 1H), 3.44-3.36 (m, 1H), 3.16-3.00 (m, 3H), 2.78-2.70 (m, 2H), 1.80-1.64 (m, 1H), 1.55-1.40 (m, 1H).
- TLC: Rf 0.60 (chloroform:methanol=9:1).
- TLC: Rf 0.50 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 7.21 (dd, J=8.1, 7.2 Hz, 1H), 6.75 (m, 1H), 6.72-6.58 (m, 2H), 4.20 (dd, J=10.5, 3.0 Hz, 1H), 3.58 (dt, J=13.8, 2.7 Hz, 1H), 3.04 (m, 1H), 2.98-2.76 (m, 2H), 2.90 (s, 6H), 2.68 (m, 1H), 2.30 (m, 1H).
- TLC: Rf 0.39 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 11.07 (s, 1H), 8.33 (m, 2H), 8.02 (d, J=7.8 Hz, 1H), 7.76 (t, J=7.8 Hz, 1H), 4.53 (m, 2H), 4.28 (m, 1H), 3.46 (m, 2H).
- TLC: Rf 0.44 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 7.41 (dd, J=2.1, 2.1 Hz, 1H), 7.32 (dd, J=2.1, 1.2 Hz, 1H), 6.94 (dd, J=2.1, 1.2 Hz, 1H), 6.52 (brs, 1H), 6.01 (brs, 2H), 4.23 (dd, J=7.5, 3.0 Hz, 1H), 3.57 (m, 1H), 3.10 (m, 1H), 3.00-2.76 (m, 2H), 2.68 (m, 1H), 2.33 (m, 1H).
- TLC: Rf 0.51 (methylene chloride:methanol=10:1).
- TLC: Rf 0.26 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.55 (s, 1H), 7.50-7.24 (m, 10H), 4.53 (d, J=12.3 Hz, 1H), 4.48 (d, J=12.3 Hz, 1H), 4.16 (dd, J=8.7, 7.2 Hz, 1H), 4.09-4.03 (m, 1H), 3.54 (dd, J=10.8, 3.0 Hz, 1H), 3.44 (dd, J=10.8, 4.8 Hz, 1H), 2.39-2.31 (m, 1H), 2.24-2.15 (m, 1H).
- TLC: Rf 0.10 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.73 (s, 1H), 8.31-8.27 (m, 2H), 7.95 (dt, J=7.5, 1.5 Hz, 1H), 7.75-7.69 (m, 1H), 7.34-7.24 (m, 5H), 4.53 (d, J=12.0 Hz, 1H), 4.50 (d, J=12.0 Hz, 1H), 4.24-4.19 (m, 1H), 4.11-4.04 (m, 1H), 3.57 (dd, J=10.5, 3.0 Hz, 1H), 3.50 (dd, J=10.5, 5.1 Hz, 1H), 2.41-2.33 (m, 1H), 2.28-2.19 (m, 1H).
- TLC: Rf 0.51 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.45 (s, 1H), 7.34-7.24 (m, 5H), 7.03 (t, J=7.8 Hz, 1H), 6.72 (t, J=1.8 Hz, 1H), 6.60 (dd, J=7.8, 1.8 Hz, 1H), 5.19 (s, 2H), 4.53 (d, J=12.0 Hz, 1H), 4.48 (d, J=12.0 Hz, 1H), 4.14-4.01 (m, 2H), 3.54 (dd, J=10.8, 2.4 Hz, 1H), 3.46 (dd, J=10.8, 4.8 Hz, 1H), 2.38-2.30 (m, 1H), 2.22-2.13 (m, 1H).
- TLC: Rf 0.55 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.55 (br-s, 1H), 7.53-7.43 (m, 5H), 4.43 (d, J=13.8 Hz, 1H), 4.20 (dd, J=12.0, 2.4 Hz, 1H), 4.06 (dd, J=13.8, 2.4 Hz, 1H), 3.21 (m, 1H), 2.88 (m, 1H), 2.07 (m, 1H), 1.80 (m, 1H).
- TLC: Rf 0.55 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.70 (br-s, 1H), 8.40 (m, 1H), 8.33 (m, 1H), 7.96 (m, 1H), 7.75 (m, 1H), 4.48 (d, J=14.1 Hz, 1H), 4.24 (dd, J=12.0, 2.1 Hz, 1H), 4.14 (dd, J=14.1, 2.1 Hz, 1H), 3.23 (m, 1H), 2.91 (m, 1H), 2.08 (m, 1H), 1.86 (m, 1H).
- TLC: Rf 0.33 (methylene chloride:methanol=20:1);
- NMR (DMSO-d6): δ 10.97 (brs, 1H), 8.04 (d, J=1.8 Hz, 1H), 7.70 (dd, J=7.8, 1.8 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 6.27 (s, 1H), 3.61 (m, 2H), 3.14 (m, 2H), 2.55 (s, 3H).
- TLC: Rf 0.20 (hexane:ethyl acetate=1:1);
- NMR (CDCl3): δ 8.10 (br, 1H), 7.75 (dt, J=6.9, 1.8 Hz, 1H), 7.68 (m, 1H), 7.62-7.55 (m, 2H), 4.36 (dd, J=11.1, 2.7 Hz, 1H), 3.69 (dt, J=11.1, 2.7 Hz, 1H), 3.21 (ddd, J=14.1, 12.0, 2.7 Hz, 1H), 3.12 (dt, J=10.8, 2.4 Hz, 1H), 2.96 (dd, J=14.1, 11.1 Hz, 1H), 2.74 (m, 1H), 2.32 (ddd, J=11.1, 4.5, 2.4 Hz, 1H).
- TLC: Rf 0.59 (chloroform:methanol=9:1).
- TLC: Rf 0.63 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 7.56-7.46 (m, 1H), 7.36-7.24 (m, 3H), 4.20 (dd, J=10.2, 3.6 Hz, 1H), 3.54-3.44 (m, 1H), 3.16-3.02 (m, 1H), 2.96-2.78 (m, 2H), 2.76-2.64 (m, 1H), 2.36-2.24 (m, 1H).
- TLC: Rf 0.66 (chloroform:methanol=9:1).
- TLC: Rf 0.59 (chloroform:methanol=9:1).
- TLC: Rf 0.54 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 11.03 (brs, 1H), 8.32-8.25 (m, 2H), 7.77-7.70 (m, 2H), 6.29 (s, 1H), 3.64-3.54 (m, 2H), 3.20-3.12 (m, 2H).
- TLC: Rf 0.49 (chloroform:methanol=9:1);
- NMR (CDCl3): δ 8.64 (s, 1H), 7.93 (dd, J=7.8, 1.5 Hz, 1H), 7.50-7.40 (m, 2H), 4.34 (dd, J=11.1, 2.4 Hz, 1H), 3.41 (dt, J=11.1, 2.7 Hz, 1H), 3.24-3.00 (m, 2H), 2.91 (dd, J=13.5, 11.1 Hz, 1H), 2.70-2.40 (m, 4H), 2.30-2.26 (m, 1H).
- TLC: Rf 0.46 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.85 (s, 1H), 7.37 (t, J=7.6 Hz, 1H), 7.08-6.96 (m, 3H), 6.23 (s, 1H), 3.77 (s, 3H), 3.64-3.56 (m, 2H), 3.16-3.08 (m, 2H).
- TLC: Rf 0.30 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.92 (s, 1H), 7.95 (d, J=2.1 Hz, 1H), 7.73 (dd, J=8.7, 2.1 Hz, 1H), 7.42 (d, J=8.7 Hz, 1H), 6.25 (s, 1H), 3.96 (s, 3H), 3.65-3.60 (m, 2H), 3.20-3.15 (m, 2H).
- TLC: Rf 0.37 (methylene chloride:methanol=10:1);
- NMR (CDCl3): δ 8.03 (br, 1H), 7.39-7.24 (m, 5H), 4.17 (dd, J=10.8, 2.7 Hz, 1H), 3.93 (dt, J=14.4, 2.7 Hz, 1H), 3.06 (ddd, J=14.4, 12.0, 2.7 Hz, 1H), 2.89 (dt, J=13.5, 2.7 Hz, 1H), 2.78 (dd, J=13.5, 10.8 Hz, 1H), 2.21 (ddd, J=14.4, 12.0, 2.7 Hz, 1H), 2.06 (dq, J=14.4, 2.7 Hz, 1H).
- TLC: Rf 0.60 (chloroform:methanol=9:1);
- NMR (CDCl3): δ 8.61 (s, 1H), 8.20-8.10 (m, 2H), 7.64-7.54 (m, 2H), 6.39 (s, 1H), 3.82 (s, 2H), 3.80-3.74 (m, 2H), 2.76-2.72 (m, 2H).
- TLC: Rf 0.67 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.34 (s, 1H), 7.44-7.34 (m, 5H), 3.86 (dd, J=11.1, 3.0 Hz, 1H), 3.20 (dt, J=13.2, 2.1 Hz, 1H), 2.77 (td, J=13.2, 2.1 Hz, 1H), 2.06 (m, 1H), 1.85 (m, 1H), 1.49-1.26 (m, 4H).
- TLC: Rf 0.30 (ethyl acetate:hexane=1:1);
- NMR (DMSO-d6): δ 10.99 (s, 1H), 7.48 (m, 5H), 5.39 (s, 1H), 3.97 (ddd, J=12.0, 6.3, 1.2 Hz, 1H), 3.35-3.25 (m, 1H), 2.92 (ddd, J=10.0, 6.3, 1.2 Hz, 1H), 2.59-2.48 (m, 1H).
- The compound prepared in Example 4(28) (150 mg) and lithium chloride (59 mg) were dissolved in dimethylformamide (2.0 mL) and the mixture was refluxed for 16 hours. After cooling to room temperature, to the reaction mixture was added 1N hydrochloric acid. The precipitate was collected by filtration. It was dried to give the compound of the present invention (126 mg) having the following physical data.
- TLC: Rf 0.19 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 11.45 (brs, 1H), 10.89 (s, 1H), 7.92 (d, J=2.4 Hz, 1H), 7.58 (dd, J=9.0, 2.4 Hz, 1H), 7.16 (d, J=9.0 Hz, 1H), 6.24 (s, 1H), 3.65-3.60 (m, 2H), 3.20-3.15 (m, 2H).
- To a solution of the compound prepared in Example 3 (537 mg) in ethanol (4 mL) was added tin chloride dihydrate (2.07 g) and the mixture was refluxed for 30 minutes. After cooling to room temperature, a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, which was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. To methanol (2 mL) was added the obtained solid (137 mg) and then 4N hydrogen chloride in dioxane (0.26 mL) was added to the mixture, which was stirred at room temperature for 3 hours. The reaction mixture was concentrated. The residue was recrystallized from a mixture solvent (isopropanol:ethanol=4:1) to give the compound of the present invention (144 mg) having the following physical data. Moreover, the compound was converted to methanesulfonate thereof by conventional method.
- TLC: Rf 0.42 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.90-10.70 (br, 1H), 7.51 (t, J=7.8 Hz, 1H), 7.40-7.36 (m, 3H), 4.25 (dd, J=10.2, 3.0 Hz, 1H), 3.58-3.49 (m, 1H), 3.14-3.06 (m, 1H), 2.96-2.82 (m, 2H), 2.77-2.67 (m, 1H), 2.34-2.30 (m, 1H).
- TLC: Rf 0.36 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.84-10.48 (br, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.25-7.18 (m, 3H), 4.24 (dd, J=9.9, 3.3 Hz, 1H), 3.56-3.49 (m, 1H), 3.15-3.05 (m, 1H), 2.95-2.81 (m, 2H), 2.75-2.65 (m, 1H), 2.33-2.30 (m, 4H).
- By the same procedure as described in Example 6, if necessary, by converting to corresponding salts by conventional method, using the compounds prepared in Example 4, 4(2), 4(3), 4(6), 4(7), 4(10), 4(12), 4(14), 4(13), 4(18), 4(19), 4(21), 4(23)-4(26), 4(28), 4(30) or 5 instead of the compound prepared in Example 3, the following compounds of the present invention were obtained.
- TLC: Rf 0.44 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 10.65 (brs, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.13-7.04 (m, 3H), 3.93 (m, 1H), 3.26 (d, J=13.2 Hz, 1H), 2.82 (m, 1H), 2.31 (s, 3H), 2.07 (m, 1H), 1.86 (m, 1H), 1.46 (m, 4H).
- TLC: Rf 0.27 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 10.44 (s, 1H), 7.04 (t, J=7.5 Hz, 1H), 6.57 (d, J=7.5 Hz, 1H), 6.53 (s, 1H), 6.47 (d, J=7.5 Hz, 1H), 5.23 (s, 2H), 4.19 (t, J=6.6 Hz, 1H), 3.62 (m, 1H), 3.03 (m, 1H), 2.84-2.80 (m, 2H), 2.66 (m, 1H), 2.31 (d, J=13.2 Hz, 1H).
- TLC: Rf 0.39 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.87 (brs, 1H), 7.24 (d, J=8.4 Hz, 2H), 6.86 (d, J=8.4 Hz, 2H), 4.26 (dd, J=10.6, 3.0 Hz, 1H), 3.66 (brd, J=14.1 Hz, 1H), 3.16-2.35 (m, 5H), 2.30 (s, 3H).
- TLC: Rf 0.22 (methylene chloride:methanol=10:1);
- NMR (CDCl3): δ 8.24 (brs, 1H), 7.21 (t, J=7.5 Hz, 1H), 7.09 (d, J=7.5 Hz, 1H), 6.80 (t, J=7.5 Hz, 1H), 6.74 (d, J=7.5 Hz, 1H), 4.34 (dd, J=11.7, 2.7 Hz, 1H), 3.95 (brs, 2H), 3.72 (m, 1H), 3.13 (m, 1H), 3.08-2.92 (m, 2H), 2.80 (m, 1H), 2.21 (m, 1H).
- TLC: Rf 0.31 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.81 (s, 1H), 7.07 (t, J=7.8 Hz, 1H), 6.63 (d, J=7.8 Hz, 1H), 6.56 (s, 1H), 6.50 (d, J=7.8 Hz, 1H), 6.21 (s, 1H), 5.28 (s, 2H), 3.62 (m, 2H), 3.14 (m, 2H).
- TLC: Rf 0.48 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 10.93 (s, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.19 (m, 3H), 6.26 (s, 1H), 3.60 (m, 2H), 3.15 (m, 2H), 2.33 (s, 3H).
- TLC: Rf 0.44 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.47 (br-s, 1H), 7.04 (m, 1H), 6.62-6.52 (m, 3H), 5.21 (br-s, 2H), 4.25 (dd, J=6.9, 4.5 Hz, 1H), 3.52-3.42 (m, 1H), 3.14-2.96 (m, 3H), 2.76-2.60 (m, 2H), 1.82-1.56 (m, 2H).
- TLC: Rf 0.56 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 10.81 (s, 1H), 7.07 (t, J=7.8 Hz, 1H), 6.72 (s, 1H), 6.63 (m, 2H), 5.25 (s, 2H), 4.50 (d, J=9.3 Hz, 1H), 4.41 (d, J=9.3 Hz, 1H), 4.16 (t, J=7.2 Hz, 1H), 3.36 (m, 2H).
- TLC: Rf 0.44 (methylene chloride:methanol=10:1);
- NMR (CDCl3): δ 8.01 (br, 1H), 7.20 (t, J=8.1 Hz, 1H), 6.76-6.69 (m, 2H), 6.64 (t, J=1.8 Hz, 1H), 4.33 (dd, J=10.8, 3.0 Hz, 1H), 3.85 (dt, J=10.8, 3.0 Hz, 1H), 3.78 (br, 2H), 3.11 (m, 1H), 3.05 (m, 1H), 2.94 (dd, J=13.5, 10.8 Hz, 1H), 2.74 (m, 1H), 2.25 (m, 1H).
- TLC: Rf 0.25 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 5.82 (t, J=1.8 Hz, 1H), 5.75 (d, J=1.8 Hz, 2H), 4.86 (brs, 4H), 4.15 (dd, J=9.3, 4.2 Hz, 1H), 3.72 (m, 1H), 3.00 (m, 1H), 2.84-2.50 (m, 3H), 2.32 (m, 1H).
- TLC: Rf 0.40 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.61 (br-s, 1H), 7.42 (m, 1H), 7.29-7.16 (m, 3H), 4.45 (d, J=13.8 Hz, 1H), 4.21 (dd, J=12.0, 2.4 Hz, 1H), 4.11 (dd, J=13.8, 2.4 Hz, 1H), 3.21 (m, 1H), 2.88 (m, 1H), 2.32 (s, 3H), 2.08 (m, 1H), 1.78 (m, 1H).
- TLC: Rf 0.38 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.88 (s, 1H), 8.30 (s, 1H), 7.26 (d, J=7.8 Hz, 1H), 7.09 (s, 1H), 7.04 (d, J=7.8 Hz, 1H), 6.25 (s, 1H), 3.61 (m, 2H), 3.16 (m, 2H), 2.32 (s, 3H), 2.24 (s, 3H).
- TLC: Rf 0.42 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 7.40-7.35 (m, 1H), 7.30-7.25 (m, 2H), 4.25 (dd, J=10.2, 3.6 Hz, 1H), 3.60-3.50 (m, 1H), 3.20-3.05 (m, 1H), 2.95-2.80 (m, 2H), 2.80-2.65 (m, 1H), 2.40-2.25 (m, 7H).
- TLC: Rf 0.37 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.65 (brs, 1H), 6.55-6.40 (m, 3H), 4.21 (dd, J=10.2, 3.3 Hz, 1H), 3.64-3.54 (m, 1H), 3.14-3.02 (m, 1H), 2.94-2.78 (m, 2H), 2.76-2.64 (m, 1H), 2.40-2.30 (m, 4H).
- TLC: Rf 0.40 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.43 (s, 1H), 6.88 (d, J=8.1 Hz, 1H), 6.51 (dd, J=8.1, 2.4 Hz, 1H), 6.45 (brs, 1H), 4.20-4.12 (m, 1H), 3.40-3.26 (m, 1H), 3.06-2.94 (m, 1H), 2.90-2.70 (m, 2H), 2.58-2.46 (m, 1H), 2.34-2.22 (m, 1H), 2.02 (s, 3H).
- TLC: Rf 0.39 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.85 (brs, 1H), 7.40-7.32 (d, J=8.4 Hz, 2H), 7.12-7.05 (d, J=8.4 Hz, 2H), 6.24 (s, 1H), 3.64-3.58 (m, 2H), 3.20-3.12 (m, 2H), 2.34 (s, 3H).
- TLC: Rf 0.41 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 7.35-7.27 (m, 2H), 7.20 (brs, 1H), 4.34-4.21 (m, 1H), 3.26-3.16 (m, 1H), 3.10-2.98 (m, 1H), 2.96-2.78 (m, 2H), 2.58-2.48 (m, 1H), 2.34 (s, 3H), 2.32-2.22 (m, 1H), 2.17 (s, 3H).
- TLC: Rf 0.53 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.86 (s, 1H), 7.24-7.10 (m, 3H), 6.25 (s, 1H), 3.90 (s, 3H), 3.65-3.58 (m, 2H), 3.20-3.13 (m, 2H), 2.32 (s, 3H).
- TLC: Rf 0.14 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.72 (s, 1H), 9.45 (brs, 1H), 6.66 (d, J=7.5 Hz, 1H), 6.60 (d, J=2.1 Hz, 1H), 6.42 (dd, J=7.5, 2.1 Hz, 1H), 6.19 (s, 1H), 4.70 (brs, 2H), 3.70-3.60 (m, 2H), 3.20-3.10 (m, 2H).
- TLC: Rf 0.29 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.69 (s, 1H), 6.95 (dt, J=1.2, 7.2 Hz, 1H), 6.44-6.32 (m, 3H), 6.06 (s, 1H), 5.08 (s, 2H), 3.72-3.64 (m, 2H), 3.58 (s, 2H), 2.76-2.66 (m, 2H).
- To a solution of the compound prepared in Example 4(16a) (76 mg) in methylene chloride (0.5 mL) was added boron tribromide (2 mL; 1.0 M in methylene chloride) at −40° C. and the mixture was stirred for 1.5 hours. To the reaction mixture was added sodium hydrogen carbonate (ca 1 g). The reaction mixture was allowed to return to room temperature slowly and then brine was added to the reaction mixture, which was extracted with methylene chloride. The extract was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=19:1→9:1) to give the compound of the present invention (57 mg) having the following physical data.
- TLC: Rf 0.37 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.69 (s, 1H), 8.30-8.27 (m, 2H), 7.99-7.96 (m, 1H), 7.76-7.71 (m, 1H), 5.21 (d, J=3.6 Hz, 1H), 4.22-4.13 (m, 2H), 3.40 (d, J=3.6 Hz, 2H), 2.17-2.12 (m, 2H).
- To a solution of the compound prepared in Example 4(16b) (188 mg) in methylene chloride (2 mL) was added aluminum trichloride (153 mg) and the mixture was stirred at room temperature overnight. Moreover, aluminum trichloride (151 mg) was added to the reaction mixture, which was stirred at room temperature for 7 hours. Sodium hydrogen carbonate (ca 1 g), small amount of water and methanol were added, sequentially, to the reaction mixture, which was stirred for 30 minutes. The reaction mixture was filtrated through Celite. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=19:1→9:1→4:1). To methanol (1 mL) was added the obtained solid and thereto was added a solution of methanesulfonic acid (42 mg) in methanol (1 mL). The mixture was stirred at room temperature for 10 minutes. The reaction mixture was concentrated to give the compound of the present invention (147 mg) having the following physical data.
- TLC: Rf 0.17 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.90-10.62 (br, 1H), 7.44 (t, J=7.8 Hz, 1H), 7.34-7.21 (m, 3H), 4.24-4.16 (m, 2H), 3.44 (dd, J=10.5, 2.4 Hz, 1H), 3.39 (dd, J=10.5, 4.8 Hz, 1H), 2.32 (s, 3H), 2.16-2.12 (m, 2H).
- To a solution of 4-((3-chloromethylphenyl)carbonothioyl)thiomorpholine-3-carboxylic acid ethyl ester (131 mg; It was prepared by the same procedure as described in Reference example 2→Reference example 3, using 3-chloromethylbenzoyl chloride instead of 3-nitrobenzoyl chloride) in dimethylformamide (1.5 mL) was added phthalimide potassium salt (70 mg) and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, which was extracted with a mixed solvent (hexane:ethyl acetate=1:1). The extract was washed with water and brine sequentially, dried over anhydrous sodium sulfate and concentrated. To a solution of the obtained solid in ethanol (2 mL) was added hydrazine monohydrate (92 μL) and the mixture was refluxed for 1 hour. After cooling the reaction mixture to room temperature, the precipitate was separated by filtration and the filtrate was concentrated. The precipitate and the residue were purified by column chromatography on silica gel (chloroform:methanol:water=8:2:0.2), respectively. To the obtained solid was added a solution of methanesulfonic acid in methanol (1M, 0.11 mL) and the mixture was concentrated. To the obtained residue was added ethyl acetate and the precipitate was separated by filtration. The precipitate was dried under reduced pressure to give the compound of the present invention (40 mg) having the following physical data.
- TLC: Rf 0.11 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 10.59 (s, 1H), 8.14 (br, 3H), 7.60-7.40 (m, 4H), 4.25 (t, J=6.6 Hz, 1H), 4.12-4.02 (m, 2H), 3.52 (m, 1H), 3.12 (m, 1H), 2.88-2.83 (m, 2H), 2.72 (m, 1H), 2.30 (m, 1H), 2.28 (s, 3H).
- By the same procedure as described in Reference example 2→Example 6→Reference example 3 Example 3 using 3,4-dihydro-2H-1,4-thiazine-5-carboxylic acid ethyl ester instead of thiomorpholin-3-ylcarboxylic acid ethyl ester, and 3-nitro-4-fluorobenzoyl chloride instead of 3-nitrobenzoyl chloride, the compound of the present invention having the following physical data.
- TLC: Rf 0.41 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.81 (s, 1H), 7.04 (dd, J=11.4, 7.8 Hz, 1H), 6.79 (d, J=7.8 Hz, 1H), 6.55 (m, 1H), 6.22 (s, 1H), 5.34 (s, 2H), 3.61 (m, 2H), 3.12 (m, 2H).
- Under an atmosphere of hydrogen, a mixture of 8-phenylpyrido[2,3-d]pyridazin-5(6H)-one (100 mg; It was prepared by the same procedure as described in Reference example 1→Example 1 using furo[3,4-b]pyridine-5,7-dione instead of 4,5,6,7-tetrahydro-2-benzofuran-1,3-dione, and phenylmagnesium chloride instead of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride), platinum(IV) oxide (10 mg), 1N hydrochloric acid (0.5 mL) and dimethylformamide (5 mL) was stirred at room temperature for 6 hours. The reaction mixture was filtrated through Celite. The filtrate was concentrated. The residue was diluted with ethyl acetate. The diluted solution was washed with a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous sodium sulfate and concentrated. The residue was recrystallized from ethanol to give the compound of the present invention (42 mg) having the following physical data. Moreover, the compound was converted to a corresponding salt thereof by conventional method.
- TLC: Rf 0.43 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.11 (br-s, 1H), 7.52-7.40 (m, 5H), 5.72 (br-s, 1H), 3.13 (m, 2H), 2.39 (t, J=6.6 Hz, 2H), 1.72 (m, 2H).
- TLC: Rf 0.40 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.41 (brs, 1H), 7.52-7.40 (m, 5H), 5.88 (brs, 2H), 3.16 (t, J=5.4 Hz, 2H), 2.43 (t, J=6.3 Hz, 2H), 1.73 (tt, J=6.3, 5.4 Hz, 2H).
- TLC: Rf 0.39 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.37 (s, 1H), 7.54-7.40 (m, 5H), 4.53 (brs, 2H), 3.22-3.08 (m, 2H), 2.42 (t, J=6.0 Hz, 2H), 2.35 (s, 3H), 1.82-1.64 (m, 2H).
- By the same procedure as described in Example 11, if necessary, by converting to corresponding salts by conventional method, using a corresponding derivative instead of 8-phenylpyrido[2,3-d]pyridazin-5(6H)-one, the following compounds of the present invention were obtained.
- TLC: Rf 0.30 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 13.30 (s, 1H), 8.94 (br-s, 2H), 7.55-7.43 (m, 5H), 4.00 (s, 2H), 3.37 (t, J=6.0 Hz, 2H), 2.74 (t, J=6.0 Hz, 2H), 2.30 (s, 3H).
- TLC: Rf 0.29 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.93 (br-s, 1H), 7.52-7.40 (m, 5H), 3.61 (br-s, 2H), 2.79 (t, J=5.7 Hz, 2H), 2.32 (m, 2H).
- TLC: Rf 0.49 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.51 (br-s, 1H), 7.50-7.36 (m, 5H), 6.69 (br-s, 1H), 3.27 (m, 2H), 2.39 (t, J=5.7 Hz, 2H), 1.67 (m, 2H).
- TLC: Rf 0.40 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 1.73 (m, 2H) 2.41 (t, J=6.04 Hz, 2H) 3.14 (m, 2H) 5.92 (br. s., 1H) 7.37 (m, 3H) 7.52 (m, 1H) 12.23 (br. s., 1H).
- TLC: Rf 0.33 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.60 (brs, 1H), 7.64-7.42 (m, 4H), 6.07 (br, 4H), 3.24-3.08 (m, 2H), 2.44 (t, J=6.0 Hz, 2H), 1.84-1.64 (m, 2H).
- After washing sodium hydride (103 mg; 62.6% in oil) with hexane, the mixture was suspended in dimethylformamide (1.5 mL). A solution of 8-phenylpyrido[2,3-d]pyridazin-5(6H)-one (200 mg; It was prepared by the same procedure as described in Reference example 1→Example 1 using furo[3,4-b]pyridine-5,7-dione instead of 4,5,6,7-tetrahydro-2-benzofuran-1,3-dione, and phenylmagnesium chloride instead of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride) in dimethylformamide (5.7 mL) was added dropwise to the suspension at 0° C. The mixture was stirred at room temperature for 40 minutes. Methoxymethyl chloride (0.27 mL) was added dropwise to the reaction mixture, which was stirred at room temperature overnight. The reaction mixture was concentrated. The obtained residue was diluted in a mixed solvent of water and ethyl acetate. The mixture was poured in a saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated to give the title compound (269 mg) having the following physical data. The obtained compound was used in next reaction without purification.
- TLC: Rf 0.78 (chloroform:methanol=8:1).
- Under an atmosphere of argon, to platinum oxide (70 mg) was added dimethylformamide (1.0 mL). A solution of the compound prepared in Reference example 4 (269 mg) in dimethylformamide (8.0 mL) was added dropwise to the reaction mixture and 1N hydrochloric acid (0.9 mL) was added thereto. Under an atmosphere of hydrogen, the mixture was stirred at room temperature for 4 hours. Under an atmosphere of argon, the reaction mixture was filtrated through Celite. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=40:1→30:1) to give the title compound (224 mg) having the following physical data.
- TLC: Rf 0.16 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 7.56-7.40 (m, 5H), 5.92 (brs, 1H), 5.23 (s, 2H), 3.29 (s, 3H), 3.20-3.06 (m, 2H), 2.43 (t, J=6.0 Hz, 2H), 1.84-1.64 (m, 2H).
- After washing sodium hydride (141 mg; 62.6% in oil) with hexane, the mixture was suspended in dimethylformamide (1.0 mL). A solution of the compound prepared in Reference example 5 (200 mg) in dimethylformamide (6.4 mL) was added dropwise thereto at 0° C. and the mixture was stirred at room temperature for 1 hour. Methyl iodide (0.37 mL) was added dropwise to the reaction mixture, which was stirred at room temperature overnight. After adding water to the reaction mixture, it was poured in ice water and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=100:1→50:1) to give the title compound (116 mg) having the following physical data.
- TLC: Rf 0.23 (hexane:ethyl acetate=1:1).
- 6N hydrochloric acid (2.4 mL) was added dropwise to a solution of the compound prepared in Reference example 6 (110 mg) in methanol (1.2 mL), which was stirred at room temperature overnight. 6N hydrochloric acid (2.4 mL) was added dropwise to the reaction mixture, which was stirred at 110° C. overnight. After cooling the reaction mixture to room temperature, it was poured in cold water. After neutralizing with 5N sodium hydroxide solution, the solution was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was washed with ethyl acetate to give the compound of the present invention (39 mg) having the following physical data.
- TLC: Rf 0.44 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.50 (s, 1H), 7.58-7.34 (m, 5H), 3.12-3.00 (m, 2H), 2.41 (t, J=6.0 Hz, 2H), 2.27 (s, 3H), 1.84-1.66 (m, 2H).
- To a solution of 1-t-butoxycarbonylpiperidine-2-carboxylic acid (2.29 g) in methylene chloride (30 mL) were added N,O-dimethylhydroxyamine hydrochloride (1.17 g), benzotriazol-1-yloxy-tris(dimethylamino)phosphoniumhexafluorophosphate (4.87 g, BOP reagent) and triethylamine (4.88 mL) and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated. The residue was diluted with ethyl acetate. The diluted solution was washed water, 1N hydrochloric acid, water, a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous sodium sulfate and concentrated to give the title compound (2.59 g) having the following physical data.
- TLC: Rf 0.54 (hexane:ethyl acetate=3:1);
- NMR (CDCl3): δ 5.30-4.86 (m, 1H), 4.06-3.84 (m, 1H), 3.77 (br-s, 3H), 3.56-3.36 (m, 1H), 3.19 (s, 3H), 2.04-1.96 (m, 1H), 1.76-1.32 (m, 14H).
- A solution of phenyllithium in cyclohexane-ether (1.06 M, 6.23 mL) was added dropwise to a solution of the compound prepared in Reference example 7 (1.63 g) in tetrahydrofuran (30 mL) at −25° C. and the mixture was stirred at −25° C. for 3 hours. The reaction mixture was poured in 1M sodium dihydrogen phosphate solution and extracted with ethyl acetate. The extract was washed with water and brine sequentially, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=9:1) to give the title compound (850 mg) having the following physical data.
- TLC: Rf 0.56 (hexane:ethyl acetate=4:1);
- NMR (CDCl3): δ 7.96-7.84 (m, 2H), 7.66-7.40 (m, 3H), 5.70-5.44 (m, 1H), 4.04-3.86 (m, 1H), 3.30-3.08 (m, 1H), 2.20-1.98 (m, 1H), 1.92-1.76 (m, 1H), 1.74-1.20 (m, 13H).
- To the compound prepared in Reference example 8 (270 mg) was added 4N hydrogen chloride-ethyl acetate solution (4 mL) and the mixture was stirred at room temperature for 15 minutes. The reaction mixture was concentrated to give the title compound (211 mg) having the following physical data.
- TLC: Rf 0.48 (chloroform:methanol:acetic acid=40:10:1);
- NMR (DMSO-d6): δ 9.02 (br-s, 2H), 8.05 (m, 2H), 7.75 (m, 1H), 7.61 (m, 2H), 5.09 (dd, J=12.0, 3.0 Hz, 1H), 2.97 (m, 1H), 2.09 (m, 1H), 1.82-1.58 (m, 4H), 1.44 (m, 1H).
- The compound prepared in Reference example (199 mg) was separated with ethyl acetate and a saturated aqueous sodium hydrogen carbonate solution and the water layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The obtained powder was dissolved in toluene (10 mL). Thereto were added hydrazine carboxylic acid ethyl ester (184 mg) and p-toluenesulfonic acid monohydrate (8.4 mg) and the mixture was refluxed overnight. After cooling the reaction mixture to room temperature, it was diluted in ethyl acetate. The diluted solution was washed with 1N hydrochloric acid, water and brine sequentially, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=2:1→1:1). The more polar fraction was recrystallized from ethyl acetate to give the compound a (16.3 mg) having the following physical data. The less polar fraction was recrystallized from a mixed solution of ethyl acetate and hexane (1:1) to give the compound b (13.6 mg) having the following physical data.
- TLC: Rf 0.30 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.14 (s, 1H), 7.76-7.66 (m, 2H), 7.46-7.34 (m, 3H), 4.77 (dd, J=11.7, 2.7 Hz, 1H), 4.18 (m, 1H), 2.72 (m, 1H), 1.88-1.34 (m, 6H).
- TLC: Rf 0.46 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.74 (s, 1H), 7.56-7.34 (m, 5H), 4.82 (t, J=4.5 Hz, 1H), 3.64 (m, 2H), 2.10 (m, 2H), 1.71 (m, 2H).
- By the same procedure as described in Reference example 7→Reference example 8→Reference example 9→Example 13 using 3-t-butoxycarbonyl-1,3-thiazinane-4-carboxylic acid instead of 1-t-butoxycarbonylpiperidine-2-carboxylic acid, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.48 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.42 (s, 1H), 7.75-7.70 (m, 2H), 7.46-7.38 (m, 3H), 5.10 (dd, J=11.4, 2.7 Hz, 1H), 4.90 (dd, J=13.2, 2.7 Hz, 1H), 4.34 (d, J=13.2 Hz, 1H), 3.36 (m, 1H), 2.75 (m, 1H), 1.88-1.62 (m, 2H).
- A solution of 3,4,5,6-tetrahydrophthalic acid anhydride (3.04 g) and (triphenylphosphoranylidene)acetic acid methyl ester (6.69 g) in chloroform (50.0 mL) was refluxed for 3 hours. After cooling the reaction mixture to room temperature, it was concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate:hexane=1:9→3:7) to give the title compound (1.93 g) having the following physical data.
- TLC: Rf 0.71 (ethyl acetate:hexane=1:1);
- NMR (CDCl3): δ 5.92 (s, 1H), 3.76 (s, 3H), 2.81 (m, 2H), 2.38 (m, 2H), 1.76 (m, 4H).
- A solution of the compound prepared in Reference example 10 (1.04 g) and hydrazine monohydrate (250 mg) in ethanol (10.0 mL) was refluxed for 18 hours. After cooling the reaction mixture to room temperature, it was concentrated. The obtained crystal was washed with ethanol and ethyl acetate, and dried under reduced pressure to give the compound of the present invention (672 mg) having the following physical data.
- TLC: Rf 0.45 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.66 (brs, 1H), 3.65 (s, 2H), 3.63 (s, 3H), 2.38 (m, 4H), 1.64 (m, 4H).
- By the same procedure as described in Reference example 10→Example 15 using 2-(triphenylphosphoranylidene)propanoic acid ethyl ester instead of (triphenylphosphoranylidene)acetic acid methyl ester, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.56 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.67 (brs, 1H), 4.07 (q, J=6.9 Hz, 2H), 3.91 (q, J=6.9 Hz, 1H), 2.48-2.33 (m, 4H), 1.65 (m, 4H), 1.33 (d, J=6.9 Hz, 3H), 1.13 (t, J=6.9 Hz, 3H).
- 5N sodium hydroxide solution (1.72 mL) was added dropwise to a suspension of the compound prepared in Example 15 (635 mg) in methanol (10.0 mL) in ice bath and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrate. 2N hydrochloric acid was added to the residue, which was adjusted to pH 2. The deposited crystal was collected by filtration. It was washed with hexane and dried under reduced pressure to give the title compound (478 mg) having the following physical data.
- TLC: Rf 0.62 (methanol:methylene chloride:acetic acid=2:8:0.1);
- NMR (DMSO-d6): δ 12.62 (brs, 2H), 3.54 (s, 2H), 2.39 (m, 4H), 1.64 (m, 4H).
- By the same procedure as described in Reference example 11 using the compound prepared in Example 16 instead of the compound prepared in Example 15, the title compound having the following physical data was obtained.
- TLC: Rf 0.28 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.64 (s, 1H), 12.48 (brs, 1H), 3.81 (q, J=7.5 Hz, 1H), 2.48-2.37 (m, 4H), 1.65 (brs, 4H), 1.32 (d, J=7.5 Hz, 3H).
- By the same procedure as described in Reference example 10→Example 15→Example 11, if necessary, by converting to corresponding salts by conventional method, using a corresponding derivative instead of 4,5,6,7-tetrahydro-2-benzofuran-1,3-dione, and (triphenylphosphoranylidene)acetic acid ethyl ester instead of (triphenylphosphoranylidene)acetic acid methyl ester, the following compounds of the present invention were obtained.
- TLC: Rf 0.46 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 11.88 (br-s, 1H), 6.32 (br-s, 1H), 4.07 (q, J=7.2 Hz, 2H), 3.54 (s, 2H), 3.15 (m, 2H), 2.33 (t, J=6.3 Hz, 2H), 1.69 (m, 2H), 1.18 (t, J=7.2 Hz, 3H).
- TLC: Rf 0.48 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.60 (br-s, 1H), 4.10 (q, J=7.2 Hz, 2H), 3.75 (br-s, 2H), 3.28 (m, 2H), 2.45 (m, 2H), 1.77 (m, 2H), 1.18 (t, J=7.2 Hz, 3H).
- The compound prepared in Example 15 (350 mg) was dissolved in tetrahydrofuran (8.0 mL). Under an atmosphere of argon, sodium borohydride (239 mg) was added thereto at 0° C. and the mixture was refluxed for 13 hours. After cooling to 0° C., 1N hydrochloric acid was added to the reaction mixture, which was adjusted to pH 5. The deposited solid was collected by filtration. The filtrate was concentrated and extracted with chloroform. The extract was dried over anhydrous magnesium sulfate and concentrated to give the title compound having the following physical data.
- TLC: Rf 0.32 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 3.87 (t, J=6.6 Hz, 2H), 2.80 (t, J=6.6 Hz, 2H), 2.64-2.58 (m, 2H), 2.54-2.48 (m, 2H), 1.88-1.70 (m, 4H).
- To a solution of the compound prepared in Reference example 12 g (2.47 g) and pyridine (201 mg) in methylene chloride (60 mL) was added thionyl chloride (2.25 g) and the mixture was stirred at room temperature for 20 hours. Chloroform and a saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, which was separated. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution, water and brine sequentially, dried over anhydrous magnesium sulfate and concentrated to give the title compound (2.58 g) having the following physical data.
- TLC: Rf 0.52 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 3.88 (t, J=7.2 Hz, 2H), 3.05 (t, J=7.2 Hz, 2H), 2.60-2.50 (m, 4H), 1.85-1.70 (m, 4H).
- A solution of the compound prepared in Reference example 13 (106 mg), trimethylsilylazide (86.4 mg) and tetrabutylammonium fluoride (237 mg) in tetrahydrofuran (2.00 mL) was refluxed for 24 hours. The reaction mixture was concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate:hexane=1:1) to give the title compound (85.0 mg) having the following physical data.
- TLC: Rf 0.52 (ethyl acetate:hexane=4:1);
- NMR (DMSO-d6): δ 12.62 (brs, 1H), 3.63 (t, J=6.9 Hz, 2H), 2.79 (t, J=6.9 Hz, 2H), 2.48-2.37 (m, 4H), 1.67 (m, 4H).
- Under an atmosphere of hydrogen, a suspension of the compound prepared in Reference example 14 (50.0 mg) and 5% palladium on calcium carbonate (20.0 mg) in ethanol (3.0 mL) was stirred at room temperature for 6 hours. The reaction mixture was filtrated through Celite. The filtrate was concentrated. 4N hydrogen chloride-ethyl acetate solution (0.5 mL) was added dropwise to a solution of the obtained solid (44.0 mg) in methanol (3.0 mL) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated. The residue was recrystallized from a mixed solvent of methanol and ethyl acetate to give the title compound (45.9 mg) having the following physical data.
- TLC: Rf 0.39 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.1);
- NMR (DMSO-d6): δ 12.65 (s, 1H), 8.07 (brs, 3H), 3.07 (m, 2H), 2.83 (t, J=7.2 Hz, 2H), 2.44 (m, 2H), 2.38 (m, 2H), 1.66 (m, 4H).
- To a suspension of the compound prepared in Reference example 13 (500 mg) in tetrahydrofuran (12 mL) were added trimethylsilyl cyanide (0.94 mL) and tetrabutylammonium fluoride (1.84 g) and the mixture was stirred at 80° C. overnight. After cooling to room temperature, the reaction mixture was poured in a cold saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The extracted was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=20:1). The obtained solid was washed with t-butyl methyl ether to give the title compound (249 mg) having the following physical data.
- TLC: Rf 0.52 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 2.94-2.72 (m, 4H), 2.60-2.26 (m, 4H), 1.78-1.54 (m, 4H).
- To a suspension of the compound prepared in Reference example 16 (130 mg) in ethanol (3.2 mL) was added 5N sodium hydroxide solution (0.64 mL) and the mixture was stirred at 90° C. for 1 day. After cooling to 0° C., the reaction mixture was poured in cold water and washed with ethyl acetate. The water layer was neutralized with 2N hydrochloric acid and concentrated. The residue was washed with water. The solid was washed water and ether to give the title compound (131 mg) having the following physical data.
- TLC: Rf 0.36 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.51 (s, 1H), 12.08 (brs, 1H), 2.71 (t, J=6.9 Hz, 2H), 2.56 (t, J=6.9 Hz, 2H), 2.54-2.26 (m, 4H), 1.78-1.54 (m, 4H).
- To a suspension of the compound prepared in Example 1 (100 mg) in methylene chloride (1.5 mL) and dimethylformamide (1.5 mL) was added sulfur trioxide pyridine complex (144 mg) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated. The residue was washed with ethyl acetate to give the compound of the present invention (160 mg) having the following physical data.
- TLC: Rf 0.17 (chloroform:methanol=4:1);
- NMR (CD3OD): δ 8.90-8.78 (m, 2H), 8.59 (dddd, J=7.8, 7.8, 1.5, 1.5 Hz, 1H), 8.12-7.98 (m, 2H), 7.48-7.14 (m, 3H), 6.89 (m, 1H), 2.66-2.52 (m, 2H), 2.52-2.38 (m, 2H), 1.90-1.60 (m, 4H).
- To a solution of the compound prepared in Example 4(20) (127 mg) in dimethylformamide (3 mL) were added sodium hydrosulfide (215 mg) and magnesium chloride hexahydrate (474 mg) and the mixture was stirred at room temperature for 3 hours under an atmosphere of argon. To the reaction mixture was added ethyl acetate and the precipitate was separated by filtration. The filtrate was wash with water and brine sequentially, dried over anhydrous sodium sulfate and concentrated. To a solution of the obtained solid (277 mg) in acetone (2 mL) was added methyl iodide (0.15 mL) and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated. To the residue were added methanol (2 mL) and ammonium acetate (43 mg) and the mixture was refluxed for 2 hours. The reaction mixture was concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol:water=9:1:0.1→8:2:0.2). The obtained solid was washed with a mixed solvent of methanol, ethyl acetate and hexane and converted to methanesulfonate thereof by conventional method to give the compound of the present invention (149 mg) having the following physical data.
- TLC: Rf 0.22 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 10.68 (s, 1H), 9.36 (s, 2H), 9.02 (s, 2H), 7.86 (d, J=7.8 Hz, 1H), 7.84-7.77 (m, 2H), 7.69 (t, J=7.8 Hz, 1H), 4.26 (dd, J=8.7, 4.8 Hz, 1H), 3.50 (m, 1H), 3.16 (m, 1H), 2.95-2.84 (m, 2H), 2.71 (m, 1H), 2.366 and 2.362 (s, 3H), 2.30 (d, J=13.8 Hz, 1H).
- To a solution of the compound prepared in Example 4(4) (175 mg) in methylene chloride (1.3 mL) was added boron tribromide (1.3 mL; 1.0 M in methylene chloride) in ice bath and the mixture was stirred at room temperature for 5 hours. To the reaction mixture was added boron tribromide (1.3 mL; 1.0 M in methylene chloride) and the mixture was stirred at room temperature overnight. Methanol was added to the reaction mixture, which was concentrated. The residue was washed with methylene chloride. Water was added thereto and the mixture was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized from acetonitrile to give the compound of the present invention (73 mg) having the following physical data.
- TLC: Rf 0.43 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.47 (s, 1H), 9.67 (bs, 1H), 7.20 (t, J=7.8 Hz, 1H), 6.81-6.73 (m, 3H), 4.19 (dd, J=9.3, 3.9 Hz, 1H), 3.56 (dt, J=14.1, 3.0 Hz, 1H), 3.09-2.99 (m, 1H), 2.90-2.79 (m, 2H) 2.69-2.60 (m, 1H), 2.33-2.28 (m, 1H).
- By the same procedure as described in Example 20 using the compound prepared in Example 4(5) or 4(27) instead of the compound prepared in Example 4(4), the following compounds of the present invention were obtained.
- TLC: Rf 0.32 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 9.74 (brs, 1H), 7.24-7.14 (m, 2H), 6.84-6.74 (m, 2H), 4.18 (dd, J=8.1, 5.1 Hz, 1H), 3.60 (dt, J=14.1, 2.7 Hz, 1H), 3.05 (m, 1H), 2.92-2.78 (m, 2H), 2.68 (m, 1H), 2.31 (m, 1H).
- TLC: Rf 0.40 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.83 (s, 1H), 9.70 (s, 1H), 7.24 (t, J=7.8 Hz, 1H), 6.88-6.75 (m, 3H), 6.22 (s, 1H), 3.66-3.56 (m, 2H), 3.16-3.06 (m, 2H).
- To a suspension of the compound prepared in Example 1 (60 mg) in ethanol (2.5 mL) was added 2-naphthylmethylethanimidothioate (74 mg) and the mixture was stirred at room temperature for 4 hours. Methanol (1.5 mL) and 2-naphthylmethylethanimidothioate (222 mg) were added to the reaction mixture, which was stirred at 75° C. overnight. After cooling to room temperature, the reaction mixture was concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=20:1→6:1) to give the compound of the present invention (84 mg) having the following physical data.
- TLC: Rf 0.24 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.97 (s, 1H), 7.59 (dd, J=8.1, 8.1 Hz, 1H), 7.50 (m, 1H), 7.44-7.34 (m, 2H), 2.54-2.32 (m, 4H), 2.34 (s, 3H), 1.80-1.50 (m, 4H).
- By the same procedure as described in Example 21 using the compound prepared in Example 6, 6(5) or 11(4) instead of the compound prepared in Example 1, the following compounds of the present invention were obtained.
- TLC: Rf 0.25 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 11.13 (br, 1H), 10.60 (s, 1H), 9.43 (br, 1H), 8.56 (br, 1H), 7.59 (t, J=7.8 Hz, 1H), 7.47 (d, J=7.8 Hz, 1H), 7.38 (d, J=7.8 Hz, 1H), 7.36 (s, 1H), 4.24 (dd, J=9.6, 3.9 Hz, 1H), 3.63 (d, J=13.8 Hz, 1H), 3.10 (d, J=12.0 Hz, 1H), 2.96-2.82 (m, 2H), 2.72 (m, 1H), 2.32 (s, 3H), 2.29 (m, 1H).
- TLC: Rf 0.24 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 10.95 (s, 1H), 9.30 (br, 1H), 8.87 (br, 1H), 8.35 (br, 1H), 7.60 (m, 1H), 7.48 (m, 1H), 7.42-7.36 (m, 2H), 6.28 (s, 1H), 3.72-3.64 (m, 2H), 3.20-3.12 (m, 2H), 2.30 (brs, 3H).
- TLC: Rf 0.14 (chloroform:methanol=4:1).
- To a suspension of the compound prepared in Example 6(5) (100 mg) in methanol (1.1 mL) were added a solution of sodium methylate in methanol (0.5 mL; 28% solution) and paraformaldehyde (32 mg) and the mixture was stirred at room temperature for 3 hours. Methanol (1.1 mL) and sodium borohydride (22 mg) were added to the reaction mixture, which was stirred at 75° C. for 1 hour. After cooling to room temperature, water was added to the reaction mixture, which was poured in cold water. The solution was concentrated. The residue was washed with a mixed solvent of methanol and methylene chloride and filtrated through Celite. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=15:1) to give the compound of the present invention (15 mg) having the following physical data.
- TLC: Rf 0.44 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 10.80 (s, 1H), 7.15 (dd, J=7.5, 7.5 Hz, 1H), 6.66-6.46 (m, 3H), 6.21 (s, 1H), 5.86 (q, J=4.8 Hz, 1H), 3.68-3.56 (m, 2H), 3.20-3.06 (m, 2H), 2.67 (d, J=4.8 Hz, 3H).
- The mixture of the compound prepared in Reference example 11 (183 mg), triethylamine (178 mg), N-(2-aminoethyl)carbamic acid t-butyl ester (160 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (338 mg), 1-hydroxybenzotriazol (238 mg) and dimethylformamide (3.00 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated. To the residue was added water and the deposited crystal was collected by filtration. It was washed with ethyl acetate and dried under reduced pressure to give the compound of the present invention (189 mg) having the following physical data.
- TLC: Rf 0.50 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 8.01 (brs, 1H), 6.77 (brs, 1H), 3.39 (s, 2H), 3.08-2.95 (m, 4H), 2.38 (m, 4H), 2.25 (m, 4H), 1.37 (s, 9H).
- By the same procedure as described in Example 23, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 11 or a corresponding carboxylic acid derivative, and N-(2-aminoethyl)carbamic acid t-butyl ester or a corresponding derivative, the following compounds of the present invention were obtained.
- TLC: Rf 0.37 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.60 (brs, 1H), 11.06 (brs, 1H), 8.45 (t, J=5.7 Hz, 1H), 3.95-3.77 (m, 4H), 3.47 (s, 2H), 3.43 (m, 4H), 3.18-3.02 (m, 4H), 2.37 (m, 4H), 1.64 (brs, 4H).
- TLC: Rf 0.60 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.1);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 7.94 (brt, J=6.2 Hz, 1H), 3.40 (s, 2H), 3.13 (td, J=6.2, 6.2 Hz, 2H), 2.43 (brs, 2H), 2.36 (brs, 2H), 2.26 (t, J=6.2 Hz, 2H), 2.12 (s, 6H), 1.63 (brs, 4H).
- TLC: Rf 0.69 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 10.22 (brs, 1H), 8.39 (t, J=5.7 Hz, 1H), 3.41-2.98 (m, 4H), 2.24 (m, 8H), 2.48-2.36 (m, 4H), 1.64 (brs, 4H).
- NMR (DMSO-d6): δ 12.56 (s, 1H), 7.97 (t, J=5.1 Hz, 1H), 6.75 (m, 1H), 3.39 (s, 2H), 3.02 (q, J=6.6 Hz, 2H), 2.90 (q, J=6.6 Hz, 2H), 2.46-2.33 (m, 4H), 1.68-1.58 (m, 4H), 1.55-1.44 (m, 2H), 1.36 (s, 9H).
- TLC: Rf 0.59 (chloroform:methanol:water=8:2:0.2);
- NMR (CDCl3): δ 10.69 (br, 1H), 6.88 (br, 1H), 3.49 (s, 2H), 3.45-3.32 (m, 4H), 2.86 (s, 3H), 2.60-2.48 (m, 4H), 1.90-1.80 (m, 4H), 1.45 (s, 9H).
- TLC: Rf 0.24 (ethyl acetate:acetic acid:water=3:3:1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 10.46 (br, 1H), 8.39 (m, 1H), 3.61-3.50 (m, 2H), 3.47 (s, 2H), 3.40 (q, J=6.0 Hz, 2H), 3.17 (q, J=6.0 Hz, 2H), 3.04-2.90 (m, 2H), 2.50-2.34 (m, 4H), 2.04-1.90 (m, 2H), 1.90-1.80 (m, 2H), 1.70-1.60 (m, 4H).
- TLC: Rf 0.60 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 4.80 (t, J=5.1 Hz, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.66 (s, 2H), 3.55 (q, J=5.1 Hz, 2H), 2.45-2.34 (m, 4H), 1.70-1.60 (m, 4H).
- TLC: Rf 0.12 (chloroform:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 10.43 (br, 1H), 8.28 (m, 1H), 3.42 (s, 2H), 3.11 (q, J=6.0 Hz, 2H), 3.04-2.96 (m, 2H), 2.71 (s, 3H), 2.69 (s, 3H), 2.46-2.34 (m, 4H), 1.84-1.74 (m, 2H), 1.68-1.48 (m, 4H).
- TLC: Rf 0.82 (chloroform:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 14.64 (br, 1H), 12.60 (s, 1H), 9.17 (m, 1H), 8.39 (m, 1H), 7.81 (d, J=1.5 Hz, 1H), 7.68 (d, J=1.5 Hz, 1H), 4.22 (t, J=6.6 Hz, 2H), 3.44 (s, 2H), 3.03 (q, J=6.6 Hz, 2H), 2.46-2.32 (m, 4H), 1.93 (quin, J=6.6 Hz, 2H), 1.68-1.46 (m, 4H).
- TLC: Rf 0.44 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 7.93 (t, J=5.1 Hz, 1H), 6.74 (brs, 1H), 3.66 (q, J=7.2 Hz, 1H), 3.05 (m, 2H), 2.96 (m, 2H), 2.48-2.30 (m, 4H), 1.63 (m, 4H), 1.36 (s, 9H), 1.30 (d, J=7.2 Hz, 3H).
- TLC: Rf 0.59 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 10.42 (brs, 1H), 8.56 (m, 1H), 3.58-2.96 (m, 9H), 2.42-2.36 (m, 4H), 2.08-1.64 (m, 8H), 1.24 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.48 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.00 (brt, 1H), 3.64-3.48 (m, 4H), 3.46-3.18 (m, 6H), 3.14-2.96 (m, 2H), 2.50-2.14 (m, 6H), 1.74-1.44 (m, 6H).
- TLC: Rf 0.25 (chloroform:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 10.59 (br, 1H), 8.25 (br, 1H), 3.52-3.38 (m, 4H), 3.17-3.00 (m, 4H), 2.98-2.84 (m, 2H), 2.46-2.32 (m, 4H), 2.00-1.75 (m, 6H), 1.69-1.58 (m, 4H).
- TLC: Rf 0.47 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.67 (s, 1H), 11.31 (s, 1H), 9.12 (d, J=2.1 Hz, 1H), 8.55 (d, J=4.8 Hz, 1H), 8.43 (d, J=8.7 Hz, 1H), 7.86 (dd, J=8.7, 4.8 Hz, 1H), 3.78 (s, 2H), 2.48-2.39 (m, 4H), 1.65 (brs, 4H).
- TLC: Rf 0.53 (chloroform:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 10.30 (br, 1H), 8.44 (br, 1H), 3.50-3.34 (m, 2H), 3.31 (s, 2H), 3.10-2.96 (br, 2H), 2.90-2.72 (br, 2H), 2.48-2.32 (m, 4H), 1.80-1.68 (br, 4H), 1.68-1.56 (br, 6H), 1.50-1.40 (br, 2H).
- TLC: Rf 0.26 (chloroform:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 10.40 (br, 1H), 8.32 (br, 1H), 3.48 (s, 2H), 3.42-3.12 (m, 3H), 2.58 (s, 6H), 2.46-2.32 (m, 4H), 1.68-1.58 (m, 4H), 1.12 (d, J=6.0 Hz, 3H).
- NMR (CD3OD): δ 8.12 (br, 1H), 6.59 (br, 1H), 3.54 (s, 2H), 3.23-3.15 (m, 2H), 3.08-2.98 (m, 2H), 2.56-2.47 (m, 4H), 1.82-1.74 (m, 4H), 1.56-1.46 (m, 4H), 1.42 (s, 9H).
- TLC: Rf 0.51 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.64 (s, 1H), 11.08 (s, 1H), 8.33 (m, 1H), 7.97 (d, J=8.4 Hz, 1H), 7.87 (m, 1H), 7.18 (m, 1H), 3.77 (s, 2H), 2.45-2.38 (m, 4H), 1.65 (brs, 4H).
- TLC: Rf 0.51 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 4.13 (t, J=5.7 Hz, 2H), 3.64 (s, 2H), 2.44 (t, J=5.7 Hz, 2H), 2.44-2.35 (m, 4H), 2.12 (s, 6H), 1.72-1.58 (m, 4H).
- TLC: Rf 0.51 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.70 (s, 1H), 10.72 (br, 1H), 4.44-4.36 (m, 2H), 3.74 (s, 2H), 3.40-3.32 (m, 2H), 2.75 (s, 6H), 2.46-2.32 (m, 4H), 1.72-1.60 (m, 4H).
- TLC: Rf 0.60 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.11 (m, 1H), 6.69 (d, J=1.2 Hz, 2H), 5.96 (d, J=1.2 Hz, 2H), 3.92 (t, J=6.0 Hz, 2H), 3.38 (s, 2H), 3.35 (t, J=6.0 Hz, 2H), 2.40-2.24 (m, 4H), 1.68-1.58 (m, 4H).
- TLC: Rf 0.56 (chloroform:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 8.10 (m, 1H), 7.73 (br, 1H), 6.86 (s, 1H), 3.39 (s, 2H), 3.34-3.23 (m, 2H), 2.74-2.62 (m, 2H), 2.40-2.30 (m, 4H), 1.66-1.56 (m, 4H).
- TLC: Rf 0.38 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 7.93 (t, J=5.7 Hz, 1H), 6.77 (m, 1H), 3.66 (q, J=7.0 Hz, 1H), 3.01 (m, 2H), 2.88 (m, 2H), 2.48-2.26 (m, 4H), 1.63 (brs, 4H), 1.42-1.28 (m, 16H).
- TLC: Rf 0.85 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 8.62 (t, J=6.0 Hz, 1H), 8.49 (m, 1H), 7.75 (dt, J=7.5, 1.8 Hz, 1H), 7.29 (m, 1H), 7.25 (m, 1H), 4.35 (d, J=6.0 Hz, 2H), 3.51 (s, 2H), 2.48-2.34 (m, 4H), 1.70-1.58 (m, 4H).
- TLC: Rf 0.64 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.32 (m, 1H) 3.52-3.44 (m, 2H), 3.43 (s, 2H), 3.42-3.33 (m, 2H), 2.48-2.33 (m, 4H), 2.70-1.60 (m, 4H).
- TLC: Rf 0.60 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 8.10 (t, J=6.0 Hz, 1H), 3.51 (t, J=6.0 Hz, 2H), 3.40 (s, 2H), 3.15 (q, J=6.0 Hz, 2H), 2.45-2.33 (m, 4H), 1.93 (quin, J=6.0 Hz, 2H), 1.68-1.59 (m, 4H).
- NMR (DMSO-d6): δ 12.56 (s, 1H), 7.99 (t, J=6.0 Hz, 1H), 6.75 (t, J=6.0 Hz, 1H), 3.38 (s, 2H), 3.10 (q, J=6.0 Hz, 2H), 2.86 (q, J=6.0 Hz, 2H), 2.45-2.33 (m, 4H), 1.69-1.62 (m, 4H), 1.44-1.29 (m, 4H), 1.36 (s, 9H), 1.28-1.18 (m, 2H).
- TLC: Rf 0.57 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.65 (brs, 1H), 12.12 (brs, 1H), 7.12 (s, 1H), 3.73 (s, 2H), 2.39 (m, 4H), 2.32 (s, 3H), 1.65 (brs, 4H).
- TLC: Rf 0.11 (methylene chloride:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 10.92 and 10.51 (br, 1H), 3.68 and 3.66 (s, 2H), 3.43 and 3.36 (t, J=6.6 Hz, 2H), 3.80-2.90 (m, 2H), 3.01 and 2.82 (s, 3H), 2.73 and 2.71 and 2.69 (s, 6H), 2.42-2.32 (m, 4H), 2.02-1.82 (m, 2H), 1.67-1.58 (m, 4H).
- TLC: Rf 0.21 (methylene chloride:methanol:water=7:3:0.3);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 10.69 and 9.93 (br, 1H), 3.75 and 3.68 (s, 2H), 3.64 (t, J=6.0 Hz, 2H), 3.20 (q, J=6.0 Hz, 2H), 3.04 and 2.84 (s, 3H), 2.79 and 2.77 and 2.76 (s, 6H), 2.42-2.33 (m, 4H), 1.68-1.60 (m, 4H).
- TLC: Rf 0.65 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 8.02 (t, J=6.3 Hz, 1H), 3.52 (t, J=6.3 Hz, 2H), 3.39 (s, 2H), 3.06 (q, J=6.3 Hz, 2H), 2.45-2.33 (m, 4H), 1.82-1.73 (m, 2H), 1.67-1.58 (m, 4H), 1.58-1.48 (m, 2H).
- NMR (CD3OD): δ 4.15 (t, J=5.7 Hz, 1H), 3.71 (m, 2H), 3.54 (t, J=5.7 Hz, 2H), 3.29 (t, J=5.7 Hz, 1H), 3.14 (t, J=5.7 Hz, 1H), 2.56-2.47 (m, 4H), 1.91-1.84 (m, 4H), 1.43 (s, 9H).
- NMR (DMSO-d6): δ 12.73 (brs, 1H), 12.67 (s, 1H), 3.88 (s, 2H), 3.80 (s, 2H), 2.38 (brs, 4H), 1.65 (brs, 4H).
- TLC: Rf 0.49 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.52 (brs, 1H), 11.03 (brs, 1H), 4.00 (s, 2H), 3.58 (s, 2H), 2.90 (s, 3H), 2.41 (m, 4H), 1.63 (brs, 4H).
- TLC: Rf 0.66 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.50 (s, 1H), 7.87 (brt, 1H), 6.78 (brt, 1H), 3.12-2.84 (m, 4H), 2.78-2.62 (m, 2H), 2.56-2.26 (m, 6H), 1.76-1.54 (m, 4H), 1.36 (s, 9H).
- TLC: Rf 0.79 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.39 (t, J=5.7 Hz, 1H), 3.43 (s, 2H), 3.32-3.23 (m, 2H), 2.64 (t, J=6.3 Hz, 2H), 2.45-2.33 (m, 4H), 1.68-1.60 (m, 4H).
- TLC: Rf 0.75 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s 1H), 8.03 (m, 1H), 7.60 (s, 1H), 7.13 (s, 1H), 6.87 (s, 1H), 3.94 (t, J=6.6 Hz, 2H), 3.38 (s, 2H), 3.05 (q, J=6.6 Hz, 2H), 2.46-2.33 (m, 4H), 1.74-1.60 (m, 6H), 1.31 (quin, J=6.6 Hz, 2H).
- TLC: Rf 0.83 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s 1H), 8.13 (m, 1H), 3.58 (s, 3H), 3.38 (s, 2H), 3.32-3.24 (m, 2H), 2.50-2.43 (m, 2H), 2.42-2.32 (m, 4H), 1.68-1.60 (m, 4H).
- TLC: Rf 0.81 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 3.68 and 3.60 (m, 2H), 3.63 and 3.31 (s, 2H), 3.45 and 3.41 (t, J=6.3 Hz, 2H), 3.02 and 2.81 (s, 3H), 2.41-2.33 (m, 4H), 2.01 and 1.90 (m, 2H), 1.70-1.60 (m, 4H).
- A mixture of the compound prepared in Example 15 (222 mg) and 2-aminoethanol (305 mg) was stirred at 100° C. for 1 hour. After cooling the reaction mixture to room temperature, the deposited crystal was washed with ethyl acetate. The obtained crystal was recrystallized from a mixed solvent methanol and ethyl acetate to give the compound of the present invention (190 mg) having the following physical data.
- TLC: Rf 0.23 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.55 (brs, 1H), 8.03 (t, J=5.4 Hz, 1H), 4.66 (t, J=5.4 Hz, 1H), 3.41 (s, 2H), 3.38 (m, 2H), 3.11 (m, 2H), 2.42 (brs, 2H), 2.36 (brs, 2H), 1.63 (brs, 4H).
- By the same procedure as described in Example 24, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 15 or a corresponding ester derivative, and a corresponding derivative instead of 2-aminoethanol, the following compounds of the present invention were obtained.
- TLC: Rf 0.36 (chloroform:methanol:28% ammonia water=15:5:1);
- NMR (DMSO-d6): δ 12.32 (br-s, 1H), 8.41 (t, J=5.4 Hz, 1H), 8.06 (br-s, 3H), 3.49 (s, 2H), 3.30 (m, 2H), 3.20 (m, 2H), 2.86 (m, 2H), 2.38 (t, J=6.0 Hz, 2H), 1.70 (m, 2H).
- TLC: Rf 0.53 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.11 (t, J=5.4 Hz, 1H), 3.41 (s, 2H), 3.32 (m, 2H), 3.23 (s, 3H), 3.19 (m, 2H), 2.41-2.36 (m, 4H), 1.63 (brs, 4H).
- TLC: Rf 0.35 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 7.85 (t, J=5.4 Hz, 1H), 3.39 (s, 2H), 3.09 (q, J=6.6 Hz, 2H), 2.48-2.32 (m, 10H), 1.67-1.58 (m, 4H), 0.91 (t, J=7.2 Hz, 6H).
- TLC: Rf 0.60 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 8.00 (t, J=6.9 Hz, 1H), 3.39 (s, 2H), 2.99 (q, J=6.9 Hz, 2H), 2.46-2.32 (m, 4H), 1.68-1.58 (m, 4H), 1.39 (sextet, J=6.9 Hz, 2H), 0.83 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.68 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.54 (brs, 1H), 8.00 (t, J=5.6 Hz, 1H), 4.37 (t, J=5.1 Hz, 1H), 3.38 (s, 2H), 3.36 (m, 2H), 3.02 (m, 2H), 2.42-2.36 (m, 4H), 1.63 (brs, 4H), 1.38 (m, 4H).
- TLC: Rf 0.37 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.51 (t, J=5.4 Hz, 1H), 7.56 (m, 1H), 6.38 (m, 1H), 6.22 (m, 1H), 4.25 (d, J=5.4 Hz, 2H), 3.44 (s, 2H), 2.37 (m, 4H), 1.62 (brs, 4H).
- TLC: Rf 0.21 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.2);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.92 (m, 1H), 8.63 (m, 1H), 8.19 (t, J=5.4 Hz, 1H), 3.42 (s, 2H), 3.21 (m, 2H), 2.97-2.72 (m, 4H), 2.38 (m, 4H), 1.76-1.26 (m, 9H).
- TLC: Rf 0.45 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.10 (t, J=5.7 Hz, 1H), 3.85-3.56 (m, 3H), 3.42 (s, 2H), 3.18-3.04 (m, 2H), 2.41-2.36 (m, 4H), 1.90-1.42 (m, 8H).
- TLC: Rf 0.20 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.60 (brs, 1H), 7.80 (t, J=5.7 Hz, 1H), 3.69 (q, J=6.9 Hz, 1H), 3.20-3.05 (m, 2H), 2.48-2.25 (m, 10H), 1.65-1.34 (m, 10H), 1.30 (d, J=6.9 Hz, 3H).
- TLC: Rf 0.37 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.53 (brs, 1H), 8.44 (d, J=6.3 Hz, 2H), 8.10 (t, J=5.7 Hz, 1H), 7.22 (d, J=6.3 Hz, 2H), 3.35 (m, 4H), 2.84-2.63 (m, 2H), 2.34-2.27 (m, 4H), 1.59 (brs, 4H).
- TLC: Rf 0.36 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.48 (d, J=3.9 Hz, 1H), 8.09 (t, J=5.4 Hz, 1H), 7.70 (m, 1H), 7.23 (m, 2H), 3.42 (td, J=6.9, 5.4 Hz, 2H), 3.36 (s, 2H), 2.87 (t, J=6.9 Hz, 2H), 2.33 (m, 4H), 1.60 (brs, 4H).
- TLC: Rf 0.24 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 7.89 (t, J=6.0 Hz, 1H), 3.44 (s, 2H), 2.95 (d, J=6.0 Hz, 2H), 2.43 (m, 2H), 2.36 (m, 2H), 2.15 (s, 6H), 2.05 (s, 2H), 1.63 (brs, 4H), 0.78 (s, 6H).
- TLC: Rf 0.27 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.57 (br, 1H), 7.96 (m, 1H), 3.40 (s, 2H), 3.09 (q, J=6.0 Hz, 2H), 2.66 (m, 1H), 2.58-2.48 (m, 2H), 2.45-2.32 (m, 4H), 1.68-1.59 (m, 4H), 0.93 (d, J=6.0 Hz, 6H).
- TLC: Rf 0.22 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.53 (br, 1H), 7.96 (m, 1H), 3.40 (s, 2H), 3.10 (q, J=6.0 Hz, 2H), 2.57-2.45 (m, 4H), 2.45-2.34 (m, 4H), 1.68-1.58 (m, 4H), 0.97 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.20 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 8.01 (t, J=6.9 Hz, 1H), 3.38 (s, 2H), 3.07 (q, J=6.9 Hz, 2H), 2.41 (t, J=6.9 Hz, 2H), 2.45-2.33 (m, 4H), 2.21 (s, 3H), 1.70-1.60 (m, 4H), 1.52 (quin, J=6.9 Hz, 2H).
- TLC: Rf 0.47 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.40 (m, 2H), 8.10 (t, J=5.7 Hz, 1H), 7.61 (m, 1H), 7.30 (m, 1H), 3.36 (s, 2H), 3.31 (m, 2H), 2.73 (t, J=6.9 Hz, 2H), 2.31 (m, 4H), 1.60 (brs, 4H).
- TLC: Rf 0.38 (methanol:methylene chloride=1:10);
- NMR (CD3OD): δ 7.36 (m, 5H), 3.76 (m, 1H), 3.69 (s, 2H), 3.59 (s, 2H), 3.01 (m, 2H), 2.56 (brs, 4H), 2.33 (m, 2H), 1.97-1.61 (m, 8H).
- TLC: Rf 0.49 (methanol:methylene chloride:saturated aqueous ammonia=1:9:0.1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 10.63 (brs, 1H), 8.33 (d, J=7.2 Hz, 1H), 7.58 (m, 2H), 7.44 (m, 3H), 4.29-2.92 (m, 9H), 2.38 (m, 4H), 1.94-1.70 (m, 4H), 1.62 (brs, 4H).
- TLC: Rf 0.47 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.12 (t, J=5.7 Hz, 1H), 7.05 (dd, J=8.4, 7.2 Hz, 2H), 6.52 (m, 3H), 5.55 (t, J=5.7 Hz, 1H), 3.42 (s, 2H), 3.22 (m, 2H), 3.06 (m, 2H), 2.38 (m, 4H), 1.60 (brs, 4H).
- TLC: Rf 0.57 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 8.31 (m, 1H), 7.35-7.04 (m, 5H), 3.44 (s, 2H), 3.33-3.23 (m, 4H), 2.38 (m, 4H), 1.62 (brs, 4H).
- TLC: Rf 0.47 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.13 (t, J=5.7 Hz, 1H), 6.58 (t, J=2.4 Hz, 1H), 5.84 (t, J=2.4 Hz, 1H), 5.76 (brs, 1H), 3.49 (s, 3H), 3.39 (s, 2H), 3.24 (m, 2H), 2.64 (t, J=7.2 Hz, 2H), 2.37 (m, 4H), 1.63 (brs, 4H).
- TLC: Rf 0.29 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 7.99 (t, J=5.4 Hz, 1H), 4.33 (t, J=5.4 Hz, 1H), 3.38 (s, 2H), 3.35 (m, 2H), 3.02 (td, J=6.3, 5.4 Hz, 2H), 2.39 (m, 4H), 1.63 (brs, 4H), 1.41-1.22 (m, 6H).
- TLC: Rf 0.15 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.55 (brs, 1H), 7.97 (t, J=6.0 Hz, 1H), 7.30-7.17 (m, 5H), 3.67 (s, 2H), 3.40 (s, 2H), 3.15 (q, J=6.0 Hz, 2H), 2.56-2.35 (m, 6H), 1.61 (brs, 4H).
- TLC: Rf 0.38 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.16 (t, J=5.7 Hz, 1H), 7.56 (t, J=1.5 Hz, 1H), 6.37 (dd, J=3.0, 1.5 Hz, 1H), 6.26 (d, J=3.0 Hz, 1H), 3.77 (s, 2H), 3.40 (s, 2H), 3.22 (m, 2H), 2.53-2.36 (m, 6H), 1.63 (brs, 4H).
- TLC: Rf 0.43 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.00 (t, J=5.7 Hz, 1H), 3.38 (s, 2H), 3.03 (m, 2H), 2.73-1.96 (m, 11H), 1.63-1.13 (m, 10H), 0.94 (d, J=6.3 Hz, 3H).
- TLC: Rf 0.41 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.01 (t, J=5.1 Hz, 1H), 3.38 (s, 2H), 3.08 (m, 2H), 2.51-2.25 (m, 7H), 1.77-0.92 (m, 16H).
- TLC: Rf 0.66 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 7.95 (t, J=5.4 Hz, 1H), 3.40 (s, 2H), 3.11 (m, 2H), 2.55-2.36 (m, 8H), 1.63 (brs, 4H), 1.31 (m, 4H), 0.85 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.51 (methanol:methylene chloride:saturated aqueous ammonia=1:10:0.1);
- NMR (DMSO-d6): δ 7.99 (t, J=5.1 Hz, 1H), 4.44 (brs, 1H), 3.62 (m, 1H), 3.40 (s, 2H), 3.11 (m, 2H), 2.57-2.37 (m, 8H), 1.63 (brs, 4H), 1.01 (d, J=6.3 Hz, 3H).
- TLC: Rf 0.58 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.07 (t, J=5.4 Hz, 1H), 7.14 (t, J=7.5 Hz, 2H), 6.61 (m, 3H), 3.41 (s, 2H), 3.29 (m, 2H), 3.08 (m, 2H), 2.83 (s, 3H), 2.39 (m, 4H), 1.62 (m, 6H).
- TLC: Rf 0.26 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.54 (brs, 1H), 7.99 (t, J=5.4 Hz, 1H), 4.41 (t, J=5.4 Hz, 1H), 3.40 (m, 2H), 3.39 (s, 2H), 3.09 (m, 2H), 2.39 (m, 4H), 1.63 (brs, 4H), 1.58-1.49 (m, 2H).
- TLC: Rf 0.48 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.16 (t, J=5.7 Hz, 1H), 7.32 (d, J=5.1 Hz, 1H), 6.94 (dd, J=5.1, 3.3 Hz, 1H), 6.67 (d, J=3.3 Hz, 1H), 3.39 (s, 2H), 3.30 (m, 2H), 2.92 (t, J=6.9 Hz, 2H), 2.35 (brs, 4H), 1.62 (brs, 4H).
- TLC: Rf 0.30 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.01 (t, J=5.4 Hz, 1H), 3.38 (s, 2H), 3.07 (m, 2H), 2.88 (m, 1H), 2.38 (m, 4H), 2.15 (s, 3H), 2.03-1.24 (m, 12H).
- TLC: Rf 0.44 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 7.96 (t, J=5.4 Hz, 1H), 7.32-7.19 (m, 5H), 3.40 (s, 2H), 3.37 (s, 2H), 3.06 (m, 2H), 2.75 (m, 2H), 2.31 (m, 4H), 1.87-1.03 (m, 13H).
- TLC: Rf 0.48 (methanol:methylene chloride:saturated aqueous ammonia=1:9:0.1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 10.21 (brs, 1H), 8.05 (t, J=5.4 Hz, 1H), 7.56 (m, 2H), 7.45 (m, 3H), 4.24 (m, 2H), 3.38-2.78 (m, 8H), 2.37 (m, 4H), 1.83-1.31 (m, 11H).
- TLC: Rf 0.18 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.55 (br, 1H), 7.99 (t, J=6.0 Hz, 1H), 4.43 (m, 1H), 3.44-3.37 (m, 2H), 3.40 (s, 2H), 3.11 (q, J=6.0 Hz, 2H), 2.59-2.52 (m, 4H), 2.45-2.33 (m, 4H), 1.68-1.60 (m, 4H).
- TLC: Rf 0.60 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.05 (t, J=5.4 Hz, 1H), 3.39 (s, 2H), 3.11 (m, 2H), 2.44-2.36 (m, 6H), 2.02 (s, 3H), 1.66 (m, 6H).
- TLC: Rf 0.63 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.59 (brs, 1H), 8.12 (t, J=5.4 Hz, 1H), 7.00 (dd, J=7.2, 7.2 Hz, 1H), 6.50 (m, 2H), 6.37 (d, J=7.2 Hz, 1H), 3.40 (s, 2H), 3.33-3.18 (m, 6H), 2.38 (m, 4H), 2.20 (s, 3H), 1.62 (brs, 4H), 1.04 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.34 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.01 (t, J=5.4 Hz, 1H), 4.31 (t, J=5.4 Hz, 1H), 3.39 (s, 2H), 3.19 (s, 6H), 3.01 (m, 2H), 2.39 (m, 4H), 1.63 (brs, 4H), 1.52-1.34 (m, 4H).
- TLC: Rf 0.34 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 7.99 (t, J=5.7 Hz, 1H), 3.38 (s, 2H), 3.05 (q, J=5.7 Hz, 2H), 2.44-2.29 (m, 10H), 1.66-1.59 (m, 4H), 1.49 (quin, J=5.7 Hz, 2H), 0.91 (t, J=6.9 Hz, 6H).
- TLC: Rf 0.18 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.52 (br, 1H), 8.00 (m, 1H), 3.38 (s, 2H), 3.08 (q, J=6.0 Hz, 2H), 2.62 (sep, J=6.0 Hz, 1H), 2.48-2.32 (m, 6H), 1.68-1.60 (m, 4H), 1.49 (quin, J=6.0 Hz, 2H), 0.92 (d, J=6.0 Hz, 6H).
- TLC: Rf 0.41 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.01 (t, J=5.7 Hz, 1H), 4.79 (t, J=4.8 Hz, 1H), 3.89-3.71 (m, 4H), 3.38 (s, 2H), 3.13 (m, 2H), 2.38 (m, 4H), 1.70 (m, 2H), 1.63 (brs, 4H).
- TLC: Rf 0.14 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.60 (br, 1H), 8.00 (m, 1H), 3.38 (s, 2H), 3.08 (q, J=6.6 Hz, 2H), 2.47-2.34 (m, 8H), 1.70-1.60 (m, 4H), 1.50 (quin, J=6.6 Hz, 2H), 1.38 (sex, J=6.6 Hz, 2H), 0.83 (t, J=6.6 Hz, 3H).
- TLC: Rf 0.31 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.59 (br, 1H), 7.96 (m, 1H), 3.40 (s, 2H), 3.11 (q, J=6.3 Hz, 2H), 2.57-2.47 (m, 2H), 2.45-2.33 (m, 6H), 1.70-1.60 (m, 4H), 1.37 (sex, J=7.2 Hz, 2H), 0.84 (t, J=7.2 Hz, 3H).
- TLC: Rf 0.47 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.04 (t, J=5.7 Hz, 1H), 7.10 (d, J=8.7 Hz, 2H), 6.83 (d, J=8.7 Hz, 2H), 3.70 (s, 3H), 3.36 (s, 2H), 3.24 (m, 2H), 2.63 (t, J=7.2 Hz, 2H), 2.33 (m, 4H), 1.60 (brs, 4H).
- TLC: Rf 0.39 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 10.38 (brs, 3H), 8.19 (t, J=5.4 Hz, 1H), 7.31 (m, 4H), 3.37 (s, 2H), 3.29 (q, J=6.9 Hz, 2H), 2.73 (t, J=6.9 Hz, 2H), 2.35 (brs, 4H), 1.61 (brs, 4H).
- TLC: Rf 0.40 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.27 (brs, 1H), 8.36 (m, 1H), 7.31 (t, J=7.8 Hz, 2H), 7.10-6.00 (m, 7H), 3.46 (s, 2H), 3.24 (m, 6H), 2.38 (t, J=6.3 Hz, 2H), 1.70 (m, 2H).
- TLC: Rf 0.36 (methanol:methylene chloride:saturated aqueous ammonia=1:10:0.1);
- NMR (DMSO-d6): δ 11.87 (s, 1H), 9.20 (brs, 1H), 8.05 (t, J=5.1 Hz, 1H), 7.48 (m, 5H), 6.38 (brs, 1H), 4.27 (m, 2H), 3.33-3.06 (m, 8H), 2.83 (m, 2H), 2.33 (m, 2H), 2.30 (s, 3H), 1.87-1.22 (m, 9H).
- TLC: Rf 0.31 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 11.85 (s, 1H), 8.05 (t, J=5.4 Hz, 1H), 6.41 (s, 1H), 3.54 (m, 4H), 3.29 (m, 2H), 3.17 (brs, 2H), 3.06 (q, J=6.6 Hz, 2H), 2.28 (m, 8H), 1.69 (m, 2H), 1.53 (m, 2H).
- TLC: Rf 0.14 (methanol:methylene chloride:acetic acid=1:4:0.2);
- NMR (DMSO-d6): δ 11.91 (s, 1H), 8.94 (brs, 1H), 8.29 (t, J=5.4 Hz, 1H), 6.30 (brs, 1H), 3.50-3.38 (m, 6H), 3.12 (m, 4H), 2.90 (m, 2H), 2.35 (m, 2H), 2.32 (s, 3H), 1.98-1.33 (m, 8H).
- TLC: Rf 0.29 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 11.85 (s, 1H), 7.99 (t, J=5.4 Hz, 1H), 6.40 (s, 1H), 3.53 (m, 4H), 3.34 (s, 2H), 3.16 (m, 4H), 2.30 (m, 8H), 1.70 (m, 2H).
- TLC: Rf 0.35 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 11.84 (s, 1H), 8.02 (t, J=5.4 Hz, 1H), 6.76 (t, J=5.4 Hz, 1H), 6.38 (s, 1H), 3.31 (m, 2H), 3.18 (brs, 2H), 2.98 (td, J=6.6, 5.4 Hz, 2H), 2.90 (td, J=6.6, 5.4 Hz, 2H), 2.32 (t, J=6.3 Hz, 2H), 1.69 (m, 2H), 1.47 (m, 2H), 1.36 (s, 9H).
- 5-chloropentanoyl chloride (171 mg) was added dropwise to a mixed solution of the compound prepared in Example 1 (241 mg) and potassium carbonate (89.8 mg) in tetrahydrofuran (3.00 mL) and water (1.00 mL) in ice bath and the mixture was stirred for 30 minutes. Moreover, potassium carbonate (45.0 mg) and 5-chloropentanoyl chloride (85.5 mg) was added the reaction mixture, which was stirred for 30 minutes. 1N hydrochloric acid was added to the reaction mixture, which was adjusted to pH 2. Water was added thereto and the deposited crystal was collected by filtration. It was washed with water and hexane sequentially and dried under reduced pressure to give the compound of the present invention (347 mg) having the following physical data.
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.00 (s, 1H), 7.69 (s, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 3.65 (t, J=6.0 Hz, 2H), 2.56-2.32 (m, 6H), 1.75-1.59 (m, 8H).
- By the same procedure as described in Example 25 using a corresponding derivative instead of the compound prepared in Example 1, and a corresponding derivative instead of 5-chloropentanoyl chloride, the following compounds of the present invention were obtained.
- TLC: Rf 0.28 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.00 (s, 1H), 7.69 (t, J=1.2 Hz, 1H), 7.59 (dd, J=7.8, 1.2 Hz, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.09 (dd, J=7.8, 1.2 Hz, 1H), 3.55 (t, J=6.6 Hz, 2H), 2.48-2.32 (m, 6H), 1.86-1.59 (m, 8H).
- TLC: Rf 0.50 (chloroform:methanol=9:1);
- NMR (CDCl3): δ 8.47-8.28 (br, 1H), 7.69 (bs, 1H), 7.62 (bs, 1H), 7.53 (d, J=7.8 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 4.35 (dd, J=10.5, 2.7 Hz, 1H), 3.85 (dt, J=13.5, 2.7 Hz, 1H), 3.67 (t, J=6.3 Hz, 2H), 3.21-3.11 (m, 1H), 3.08-3.02 (m, 1H), 2.94 (dd, J=13.5, 10.5 Hz, 1H), 2.86-2.76 (m, 1H), 2.56 (t, J=7.2 Hz, 2H), 2.32-2.16 (m, 3H).
- TLC: Rf 0.40 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 10.52 (s, 1H), 10.05 (s, 1H), 7.67 (s, 1H), 7.56 (d, J=8.1 Hz, 1H), 7.34 (t, J=8.1 Hz, 1H), 7.06 (d, J=8.1 Hz, 1H), 4.23 (dd, J=8.7, 4.8 Hz, 1H), 3.56 (m, 1H), 3.08 (m, 1H), 2.89-2.83 (m, 2H), 2.70 (m, 1H), 2.32 (m, 1H), 2.04 (s, 3H).
- TLC: Rf 0.51 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.88 (s, 1H), 10.08 (s, 1H), 7.70 (s, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 6.26 (s, 1H), 3.61 (m, 2H), 3.15 (m, 2H), 2.05 (s, 3H).
- TLC: Rf 0.45 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.87 (s, 1H), 10.02 (s, 1H), 7.67 (s, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 2.39 (m, 4H), 2.04 (s, 3H), 1.64 (m, 4H).
- NMR (DMSO-d6): δ 10.89 (s, 1H), 10.12 (s, 1H), 7.71 (t, J=1.5 Hz, 1H), 7.62 (m, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.10 (dt, J=7.8, 1.5 Hz, 1H), 6.26 (s, 1H), 3.70 (t, J=6.9 Hz, 2H), 3.64-3.58 (m, 2H), 3.18-3.13 (m, 2H), 2.35 (t, J=6.9 Hz, 2H), 2.03 (quin, J=6.9 Hz, 2H).
- TLC: Rf 0.27 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.90 (s, 1H), 10.40 (s, 1H), 7.68 (s, 1H), 7.60 (d, J=7.8 Hz, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.15 (d, J=7.8 Hz, 1H), 4.25 (s, 2H), 2.39 (m, 4H), 1.68 (m, 2H), 1.59 (m, 2H).
- TLC: Rf 0.20 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.15 (s, 1H), 7.70 (s, 1H), 7.60 (d, J=7.8 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.12 (d, J=7.8 Hz, 1H), 3.72 (t, J=6.3 Hz, 2H), 2.95 (t, J=6.3 Hz, 2H), 2.48-2.34 (m, 4H), 1.70 (m, 2H), 1.60 (m, 2H).
- TLC: Rf 0.31 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.11 (s, 1H), 10.06 (s, 1H), 7.70 (m, 1H), 7.61 (m, 1H), 7.37 (dd, J=7.8, 7.8 Hz, 1H), 7.09 (m, 1H), 5.37 (s, 1H), 3.20-3.06 (m, 2H), 2.39 (t, J=6.3 Hz, 2H), 2.04 (s, 3H), 1.82-1.60 (m, 2H).
- TLC: Rf 0.31 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.31 (s, 1H), 10.06 (s, 1H), 7.70 (m, 1H), 7.62 (m, 1H), 7.38 (t, J=7.9 Hz, 1H), 7.09 (m, 1H), 3.14 (m, 2H), 2.41 (t, J=6.2 Hz, 2H), 2.33 (s, 3H), 2.04 (s, 3H), 1.73 (m, 2H).
- TLC: Rf 0.56 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 9.86 (brs, 1H), 7.39 (t, J=7.8 Hz, 1H), 7.25 (d, J=7.8 Hz, 1H), 7.23 (s, 1H), 7.16 (d, J=7.8 Hz, 1H), 3.00 (s, 3H), 2.48-2.34 (m, 4H), 1.69 (m, 2H), 1.59 (m, 2H).
- TLC: Rf 0.41 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.11 (s, 1H), 10.09 (s, 1H), 7.72 (m, 1H), 7.63 (s, 1H), 7.38 (dd, J=7.8, 7.8 Hz, 1H), 7.09 (m, 1H), 5.74 (s, 1H), 3.69 (t, J=6.3 Hz, 2H), 3.22-3.04 (m, 2H), 2.60-2.32 (m, 4H), 2.12-1.94 (m, 2H), 1.82-1.64 (m, 2H).
- TLC: Rf 0.68 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 8.33 (brt, J=5.1 Hz, 1H), 3.82 (s, 2H), 3.44-3.26 (m, 2H), 2.64 (t, J=6.9 Hz, 2H), 2.54-2.28 (m, 4H), 1.78-1.52 (m, 4H).
- TLC: Rf 0.71 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.55 (brs, 1H), 8.07 (brt, J=6.0 Hz, 1H), 3.61 (t, J=6.0 Hz, 2H), 3.44-3.24 (m, 2H), 2.72-2.28 (m, 8H), 1.78-1.54 (m, 4H).
- A mixture of the compound prepared in Example 1 (277 mg), triethylamine (223 mg), 5-(N-methyl-N-t-butoxycarbonylamino)pentanoic acid (277 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (230 mg), 1-hydroxybenzotriazole (184 mg) and dimethylformamide (3.00 mL) was stirred at room temperature for 18 hours. The reaction mixture was concentrated. Water was added to the residue, which was extracted with ethyl acetate. The extract was washed with 1N hydrochloric acid, water, a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized from a mixed solvent of ethyl acetate and hexane to give the compound of the present invention (298 mg) having the following physical data.
- TLC: Rf 0.49 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 9.97 (s, 1H), 7.69 (s, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.35 (t, J=8.1 Hz, 1H), 7.08 (d, J=8.1 Hz, 1H), 3.15 (t, J=6.8 Hz, 2H), 2.74 (s, 3H), 2.48-2.30 (m, 6H), 1.70-1.50 (m, 8H), 1.36 (s, 9H).
- By the same procedure as described in Example 26, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 1 or a corresponding derivative, and (N-methyl-N-t-butoxycarbonylamino)pentanoic acid or a corresponding derivative, the following compounds of the present invention were obtained.
- TLC: Rf 0.29 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 9.98 (s, 1H), 7.70 (s, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.32 (m, 6H), 7.08 (d, J=7.8 Hz, 1H), 5.04 (s, 2H), 3.28-2.33 (m, 11H), 1.69-1.51 (m, 8H).
- TLC: Rf 0.48 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.07 (s, 1H), 7.69 (s, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 3.69 (t, J=6.3 Hz, 2H), 2.46-1.59 (m, 12H).
- TLC: Rf 0.30 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (CD3OD): δ 7.75 (t, J=1.8 Hz, 1H), 7.63 (brd, J=8.1 Hz, 1H), 7.45 (t, J=8.1 Hz, 1H), 7.20 (brd, J=8.1 Hz, 1H), 3.16 (m, 2H), 2.89 (s, 6H), 2.74 (s, 3H), 2.66-2.50 (m, 6H), 1.81 (m, 8H).
- TLC: Rf 0.79 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 9.97 (s, 1H), 7.69 (s, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.37-7.26 (m, 6H), 7.08 (d, J=7.8 Hz, 1H), 4.99 (s, 2H), 3.00 (m, 2H), 2.48-2.28 (m, 6H), 1.69-1.42 (m, 8H).
- TLC: Rf 0.41 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 9.81 (s, 1H), 7.73 (s, 1H), 7.67 (d, J=7.8 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.13 (d, J=7.8 Hz, 1H), 4.14 (s, 2H), 3.81 (s, 4H), 2.48-2.34 (m, 4H), 1.70-1.59 (m, 4H).
- TLC: Rf 0.28 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 10.34 (s, 1H), 9.98 (s, 1H), 7.68 (s, 1H), 7.56 (d, J=9.0 Hz, 1H), 7.33 (m, 6H), 7.01 (d, J=7.8 Hz, 1H), 5.04 (s, 2H), 3.86 (m, 1H), 3.25-1.42 (m, 19H).
- TLC: Rf 0.24 (methanol:chloroform=1:10);
- NMR (DMSO-d6): δ 10.53 (s, 1H), 10.01 (s, 1H), 7.67 (t, J=1.5 Hz, 1H), 7.58 (m, 1H), 7.34 (m, 6H), 7.06 (m, 1H), 5.04 (s, 2H), 4.23 (dd, J=8.6, 4.8 Hz, 1H), 3.57 (brd, J=13.8 Hz, 1H), 3.28 (m, 3H), 3.07 (t, J=12.0 Hz, 1H), 2.88-2.65 (m, 5H), 2.33 (m, 3H), 1.52 (m, 4H).
- TLC: Rf 0.54 (chloroform:methanol=9:1);
- NMR (CDCl3): δ 10.58 (br-s, 1H), 8.21 (br-s, 1H), 7.69 (br-s, 1H), 7.60 (m, 1H), 7.40-7.28 (m, 6H), 7.04 (m, 1H), 5.13 (s, 2H), 3.42-3.28 (m, 2H), 3.00-2.86 (m, 5H), 2.70-2.64 (m, 2H), 2.46-2.30 (m, 2H), 1.94-1.84 (m, 2H), 1.80-1.60 (m, 8H).
- TLC: Rf 0.35 (methylene chloride:methanol=10:1).
- TLC: Rf 0.35 (methylene chloride:methanol=10:1).
- TLC: Rf 0.31 (hexane:ethyl acetate=1:3);
- NMR (DMSO-d6): δ 12.87 (s, 1H), 9.95 (s, 1H), 7.68 (m, 1H), 7.58 (m, 1H), 7.34 (dd, J=7.8, 7.8 Hz, 1H), 7.07 (m, 1H), 5.10 (m, 1H), 3.72 (d, J=6.6 Hz, 2H), 3.16-3.00 (m, 2H), 2.62-2.40 (m, 2H), 2.40-2.22 (m, 4H), 1.78-1.30 (m, 8H), 1.64 (s, 3H), 1.60 (s, 3H), 1.36 (s, 9H).
- TLC: Rf 0.63 (chloroform:methanol:water=8:2:0.2);
- NMR (CD3OD): δ 7.74 (s, 1H), 7.57 (d, J=7.8 Hz, 1H), 7.41 (t, J=7.8 Hz, 1H), 7.35-7.20 (m, 5H), 7.14 (d, J=7.8 Hz, 1H), 6.39 (s, 1H), 5.08 (s, 2H), 3.73-3.68 (m, 2H), 3.38-3.28 (m, 2H), 3.16-3.10 (m, 2H), 2.91 (brs, 3H), 2.44-2.25 (m, 2H), 1.78-1.50 (m, 4H).
- TLC: Rf 0.27 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.92 (s, 1H), 10.97 (s, 1H), 9.96 (brs, 1H), 7.72 (m, 1H), 7.65 (m, 1H), 7.43 (dd, J=7.8, 7.8 Hz, 1H), 7.20 (m, 1H), 4.16 (s, 2H), 2.87 (s, 6H), 2.60-2.24 (m, 4H), 1.80-1.50 (m, 4H).
- TLC: Rf 0.27 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.13 (s, 1H), 7.71 (m, 1H), 7.60 (m, 1H), 7.37 (dd, J=7.5, 7.5 Hz, 1H), 7.12 (m, 1H), 4.08-3.84 (m, 4H), 3.46 (m, 1H), 2.54-2.28 (m, 4H), 1.78-1.52 (m, 4H), 1.38 (s, 9H).
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.07 (s, 1H), 7.71 (s, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 4.17 (m, 1H), 3.38-2.34 (m, 8H), 1.98-1.60 (m, 6H), 1.38 (s, 9H×⅓), 1.26 (s, 9H×⅔).
- TLC: Rf 0.31 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.54 (s, 1H), 7.82 (brt, 1H), 6.91 (brt, 1H), 3.47 (d, J=6.3 Hz, 2H), 3.40-3.26 (m, 2H), 2.61 (t, J=7.2 Hz, 2H), 2.56-2.30 (m, 4H), 1.76-1.54 (m, 4H), 1.36 (s, 9H).
- TLC: Rf 0.44 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.54 (s, 1H), 7.92 (t, J=6.0 Hz, 1H), 6.72 (brt, 1H), 3.42-3.18 (m, 2H), 3.16-3.02 (m, 2H), 2.68-2.28 (m, 6H), 2.18 (t, J=7.2 Hz, 2H), 1.78-1.52 (m, 4H), 1.36 (s, 9H).
- TLC: Rf 0.62 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.54 (brs, 1H), 7.80 (t, J=5.7 Hz, 1H), 3.44-3.24 (m, 2H), 2.80 (s, 2H), 2.64 (t, J=7.2 Hz, 2H), 2.54-2.26 (m, 4H), 2.16 (s, 6H), 1.76-1.52 (m, 4H).
- TLC: Rf 0.67 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.53 (s, 1H), 7.85 (t, J=5.4 Hz, 1H), 6.78 (t, J=5.7 Hz, 1H), 3.40-3.20 (m, 2H), 2.94-2.80 (m, 2H), 2.60 (t, J=7.2 Hz, 2H), 2.56-2.28 (m, 4H), 2.01 (t, J=7.2 Hz, 2H), 1.78-1.46 (m, 6H), 1.36 (s, 9H).
- The compound prepared in Reference example 13 (40 mg), sodium iodide (8.4 mg) and benzylamine (0.21 mL) were stirred at room temperature for 10 hours. Methylene chloride and a saturated aqueous sodium hydrogen carbonate solution were added to the reaction mixture, which was separated. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=50:1) to give the compound of the present invention (18 mg) having the following physical data.
- TLC: Rf 0.29 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.46 (s, 1H), 7.40-7.15 (m, 5H), 3.69 (s, 2H), 2.80-2.60 (m, 4H), 2.50-2.30 (m, 4H), 1.63 (brs, 4H).
- By the same procedure as described in Example 27, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Reference example 13 or a corresponding derivative, and a corresponding derivative instead of benzylamine, the following compounds of the present invention were obtained.
- TLC: Rf 0.38 (chloroform:methanol:acetic acid=90:10:1);
- NMR (CD3OD): δ 3.74-3.66 (m, 4H), 2.84-2.77 (m, 2H), 2.75-2.66 (m, 2H), 2.64-2.48 (m, 8H), 1.88-1.72 (m, 4H).
- TLC: Rf 0.24 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.68 (s, 1H), 10.85 (brs, 1H), 4.02-3.92 (m, 2H), 3.82-3.70 (m, 2H), 3.54-3.44 (m, 2H), 3.44-3.32 (m, 2H), 3.15-3.05 (m, 2H), 3.05-2.96 (m, 2H), 2.53-2.33 (m, 4H), 1.76-1.58 (m, 4H).
- TLC: Rf 0.12 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 3.78-3.66 (m, 2H), 3.63 (t, J=8.1 Hz, 2H), 3.26-3.10 (m, 2H), 3.06 (t, J=8.1 Hz, 2H), 2.62-2.48 (m, 4H), 2.26-1.96 (m, 4H), 1.90-1.72 (m, 4H).
- TLC: Rf 0.32 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.68 (s, 1H), 11.80 (brs, 2H), 4.00-3.20 (m, 10H), 3.10-2.95 (m, 2H), 2.80 (s, 3H), 2.50-2.30 (m, 4H), 1.75-1.55 (m, 4H).
- TLC: Rf 0.34 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 10.45 (brs, 1H), 3.52-3.42 (m, 2H), 3.34-3.22 (m, 2H), 3.06-2.96 (m, 2H), 2.96-2.80 (m, 2H), 2.54-2.32 (m, 4H), 1.84-1.56 (m, 9H), 1.46-1.26 (m, 1H).
- TLC: Rf 0.34 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.65 (s, 1H), 8.85 (brs, 2H), 3.26-3.10 (m, 2H), 3.10-2.96 (m, 1H), 2.90 (t, J=7.2 Hz, 2H), 2.50-2.36 (m, 4H), 2.06-1.98 (m, 2H), 1.80-1.54 (m, 7H), 1.40-1.00 (m, 5H).
- TLC: Rf 0.28 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 10.55 (s, 1H), 3.46-3.28 (m, 4H), 3.20-3.06 (m, 2H), 3.06-2.98 (m, 2H), 2.56-2.46 (m, 2H), 2.44-2.34 (m, 2H), 1.90-1.50 (m, 12H).
- TLC: Rf 0.29 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.51 (s, 1H), 3.32-3.24 (m, 6H), 2.70-2.60 (m, 2H), 2.60-2.50 (m, 2H), 2.40-2.30 (m, 6H), 1.72-1.56 (m, 4H), 1.37 (s, 9H).
- TLC: Rf 0.40 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.67 (s, 1H), 10.90 (brs, 1H), 3.84-3.70 (m, 2H), 3.44-3.30 (m, 2H), 3.24-3.10 (m, 4H), 3.08-2.98 (m, 2H), 2.90-2.76 (m, 2H), 2.52-2.44 (m, 2H), 2.42-2.34 (m, 2H), 1.76-1.58 (m, 4H).
- TLC: Rf 0.28 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 9.70-9.45 (m, 2H), 3.98-3.88 (m, 2H), 3.70 (t, J=2.4 Hz, 1H), 3.30-3.18 (m, 2H), 2.91 (t, J=7.8 Hz, 2H), 2.48-2.32 (m, 4H), 1.76-1.58 (m, 4H).
- TLC: Rf 0.19 (chloroform:methanol=5:1);
- NMR (CD3OD): δ 2.84-2.76 (m, 2H), 2.75-2.67 (m, 2H), 2.67-2.47 (m, 12H), 2.44 (q, J=7.5H, 2H), 1.79 (m, 4H), 1.10 (t, J=7.5 Hz, 3H).
- TLC: Rf 0.49 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 8.86 (brs, 2H), 3.26-3.08 (m, 2H), 3.02-2.88 (m, 2H), 2.86-2.70 (m, 2H), 2.58-2.30 (m, 4H), 1.88-1.50 (m, 10H), 1.32-0.82 (m, 5H).
- TLC: Rf 0.41 (chloroform:methanol=5:1);
- NMR (CD3OD): δ 3.61 (t, J=6.6 Hz, 2H), 3.58-3.30 (m, 4H), 3.08 (t, J=6.6 Hz, 2H), 2.62-2.50 (m, 4H), 2.12-1.60 (m, 14H).
- TLC: Rf 0.29 (chloroform:methanol:saturated aqueous ammonia=5:1:0.1);
- NMR (CD3OD): δ 3.26 (m, 4H), 3.08-3.01 (m, 4H), 2.96 (t, J=6.0 Hz, 2H), 2.84 (m, 2H), 2.81 (s, 3H), 2.60 (m, 2H), 2.52 (m, 2H), 2.03 (m, 2H), 1.80 (m, 4H).
- TLC: Rf 0.47 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.52 (brs, 1H), 6.73 (brt, 1H), 3.34 (br, 1H), 3.06-2.94 (m, 2H), 2.80 (t, J=7.2 Hz, 2H), 2.70-2.54 (m, 4H), 2.54-2.28 (m, 4H), 1.76-1.54 (m, 4H), 1.36 (s, 9H).
- TLC: Rf 0.50 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.23 (dd, J=7.5, 7.5 Hz, 2H), 6.97 (d, J=7.5 Hz, 2H), 6.83 (dd, J=7.5, 7.5 Hz, 1H), 3.20 (m, 4H), 2.90-2.70 (m, 8H), 2.62 (m, 2H), 2.52 (m, 2H), 1.80 (m, 4H).
- TLC: Rf 0.44 (chloroform:methanol=9:1);
- NMR (CDCl3): δ 10.61 (s, 1H), 7.36 (d, J=7.8 Hz, 1H), 7.22 (dd, J=7.8, 7.8 Hz, 1H), 7.05 (d, J=7.8 Hz, 1H), 6.98 (dd, J=7.8, 7.8 Hz, 1H), 3.11 (m, 4H), 2.78 (s, 4H), 2.74 (m, 4H), 2.59 (m, 2H), 2.53 (m, 2H), 1.78 (m, 4H).
- TLC: Rf 0.43 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.36-7.22 (m, 5H), 3.54 (s, 2H), 2.84-2.64 (m, 4H), 2.64-2.45 (m, 12H), 1.86-1.72 (m, 4H).
- TLC: Rf 0.33 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.63 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 3.90 (s, 2H), 2.96 (t, J=6.9 Hz, 2H), 2.80 (t, J=6.9 Hz, 2H), 2.52 (m, 4H), 1.77 (m, 4H).
- TLC: Rf 0.32 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.28 (m, 5H), 3.56 (s, 2H), 2.83-2.65 (m, 4H), 2.49 (m, 4H), 2.31 (s, 3H), 1.73 (m, 4H).
- TLC: Rf 0.44 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.69 (s, 1H), 9.42 (m, 1H), 7.49 (m, 5H), 4.48 (m, 1H), 4.31 (m, 1H), 3.50-3.25 (m, 2H), 2.98 (m, 2H), 2.75 (m, 3H), 2.38 (m, 4H), 2.29 (s, 3H), 1.68 (m, 4H).
- TLC: Rf 0.41 (methanol:methylene chloride=1:10);
- NMR (CD3OD): δ 7.37 (m, 5H), 3.52 (t, J=6.8 Hz, 2H), 3.38 (m, 2H), 3.07 (m, 4H), 2.60 (m, 4H), 1.85 (m, 4H).
- TLC: Rf 0.37 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.44 (d, J=7.5 Hz, 2H), 7.23 (d, J=7.5 Hz, 2H), 3.82 (s, 2H), 2.93 (t, J=6.9 Hz, 2H), 2.79 (t, J=6.9 Hz, 2H), 2.59-2.49 (m, 4H), 1.77 (m, 4H).
- TLC: Rf 0.55 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 8.08 (m, 1H), 7.56 (m, 1H), 6.82 (d, J=8.4 Hz, 1H), 6.68 (dd, J=6.3, 4.8 Hz, 1H), 3.54 (t, J=5.1 Hz, 4H), 2.90-2.74 (m, 4H), 2.68 (t, J=5.1 Hz, 4H), 2.62 (m, 2H), 2.52 (m, 2H), 1.79 (m, 4H).
- TLC: Rf 0.26 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.18-7.08 (m, 2H), 6.74-6.64 (m, 3H), 3.48-3.36 (m, 4H), 3.22 (t, J=6.0 Hz, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.51 (m, 4H), 1.78 (m, 4H).
- TLC: Rf 0.21 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 3.62-3.52 (m, 4H), 2.85-2.70 (m, 4H), 2.64-2.48 (m, 8H), 2.09 (s, 3H), 1.79 (m, 4H).
- TLC: Rf 0.45 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.49 (brs, 1H), 8.15 (m, 1H), 7.89 (m, 1H), 7.79 (d, J=7.2 Hz, 1H), 7.53-7.40 (m, 4H), 4.15 (s, 2H), 2.87 (t, J=7.2 Hz, 2H), 2.69 (t, J=7.2 Hz, 2H), 2.35 (m, 4H), 1.62 (brs, 4H).
- TLC: Rf 0.41 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 7.30-7.20 (m, 5H), 3.60 (s, 2H), 2.72 (s, 4H), 2.62 (q, J=7.2 Hz, 2H), 2.48 (m, 2H), 2.40 (m, 2H), 1.70 (m, 4H), 1.10 (t, J=7.2 Hz, 3H).
- TLC: Rf 0.17 (methylene chloride:methanol:water=9:1:0.1);
- NMR (CD3OD): δ 7.43-7.23 (m, 5H), 3.60 (s, 2H), 3.41 (t, J=6.6 Hz, 2H), 3.14 (m, 1H), 3.06-2.98 (m, 2H), 2.95 (t, J=6.6 Hz, 2H), 2.60-2.50 (m, 4H), 2.22-2.06 (m, 4H), 1.86-1.60 (m, 6H).
- TLC: Rf 0.44 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.19 (m, 5H), 3.65 (t, J=8.7 Hz, 2H), 3.61 (s, 2H), 2.78-2.67 (m, 6H), 2.43 (m, 2H), 2.30 (m, 2H), 1.64 (m, 4H).
- TLC: Rf 0.55 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 3.30-2.70 (m, 13H), 2.59 (m, 2H), 2.51 (m, 2H), 2.05 (m, 2H), 1.91 (m, 2H), 1.86-1.65 (m, 6H), 1.44-1.20 (m, 4H).
- TLC: Rf 0.50 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 7.41 (m, 2H), 7.10 (dd, J=8.7, 8.7 Hz, 2H), 3.94 (s, 2H), 3.10 (t, J=6.9 Hz, 2H), 2.85 (t, J=6.9 Hz, 2H), 2.52 (m, 4H), 1.78 (m, 4H).
- TLC: Rf 0.43 (methylene chloride:methanol=4:1);
- NMR (DMSO-d6): δ 12.68 (s, 1H), 9.00 (s, 2H), 7.57 (m, 2H), 7.29 (m, 2H), 4.20 (m, 2H), 3.21 (m, 2H), 2.90 (m, 2H), 2.58-2.38 (m, 4H), 1.67 (m, 4H).
- TLC: Rf 0.39 (methylene chloride:methanol:saturated aqueous ammonia=4:1:0.3);
- NMR (CD3OD): δ 7.40 (d, J=8.7 Hz, 2H), 6.99 (d, J=8.7 Hz, 2H), 4.15 (s, 2H), 3.81 (s, 3H), 3.37 (t, J=6.9 Hz, 2H), 2.95 (t, J=6.9 Hz, 2H), 2.53 (m, 4H), 1.78 (m, 4H).
- TLC: Rf 0.38 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.50 (m, 5H), 4.48 (q, J=6.9 Hz, 1H), 3.29 (m, 2H), 2.92 (t, J=6.6 Hz, 2H), 2.51 (m, 4H), 1.78 (m, 4H), 1.70 (d, J=6.9 Hz, 3H).
- TLC: Rf 0.39 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.48-7.06 (m, 4H), 4.06 (s, 2H), 3.20 (t, J=6.9 Hz, 2H), 2.90 (t, J=6.9 Hz, 2H), 2.53 (m, 4H), 1.77 (m, 4H).
- TLC: Rf 0.48 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.48-7.40 (m, 4H), 7.32-7.13 (m, 6H), 4.25 (s, 1H), 3.16 (t, J=5.1 Hz, 2H), 2.81-2.40 (m, 14H), 1.78 (m, 4H).
- TLC: Rf 0.44 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.32 (dd, J=8.1, 8.1 Hz, 1H), 7.02-6.90 (m, 3H), 4.05 (s, 2H), 3.81 (s, 3H), 3.24 (t, J=6.9 Hz, 2H), 2.90 (t, J=6.9 Hz, 2H), 2.51 (m, 4H), 1.77 (m, 4H).
- TLC: Rf 0.26 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 11.94 (s, 1H), 9.31 (brs, 1H), 6.39 (brs, 1H), 3.60-3.10 (m, 6H), 3.06-2.74 (m, 4H), 2.34 (t, J=6.6 Hz, 2H), 1.94-1.50 (m, 7H), 1.38 (m, 1H).
- TLC: Rf 0.62 (methylene chloride:methanol:water=4:1:0.2);
- NMR (CD3OD): δ 7.26 (dd, J=8.1, 8.1 Hz, 2H), 6.98-6.88 (m, 3H), 4.11 (t, J=5.1 Hz, 2H), 3.14-3.05 (m, 4H), 2.84 (t, J=6.6 Hz, 2H), 2.60-2.50 (m, 4H), 1.78 (m, 4H).
- TLC: Rf 0.67 (methylene chloride:methanol:saturated aqueous ammonia=4:1:0.3);
- NMR (CD3OD): δ 7.34 (m, 5H), 5.11 (s, 2H), 3.54 (m, 4H), 2.82-2.70 (m, 8H), 2.60 (m, 2H), 2.52 (m, 2H), 1.90-1.72 (m, 6H).
- TLC: Rf 0.64 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.7 (s, 1H), 9.35 (s, 1H), 7.40-7.30 (m, 5H), 5.11 (s, 2H), 3.89 (m, 1H), 3.72-3.40 (m, 7H), 3.35-3.16 (m, 2H), 2.95 (t, J=7.2 Hz, 2H), 2.65-2.50 (m, 4H), 2.30 (s, 3H), 1.85 (m, 2H), 1.67 (m, 4H).
- TLC: Rf 0.14 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 4.00-3.40 (m, 11H), 3.12 (t, J=7.5 Hz, 2H), 2.62-2.50 (m, 4H), 2.22-2.15 (m, 2H), 1.92-1.68 (m, 10H).
- TLC: Rf 0.16 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 4.10-3.45 (m, 8H), 3.74 (t, J=7.2 Hz, 2H), 3.30 (m, 2H), 3.16 (t, J=7.2 Hz, 2H), 2.60 (m, 2H), 2.53 (m, 2H), 1.90-1.75 (m, 6H), 1.45 (m, 2H), 1.01 (t, J=7.2 Hz, 3H).
- TLC: Rf 0.36 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.17 (s, 1H), 11.85 (brs, 1H), 5.09 (br, 3H), 3.98-3.08 (m, 11H), 2.96 (m, 2H), 2.36 (t, J=6.0 Hz, 2H), 2.10 (m, 2H), 1.94-0.98 (m, 12H).
- TLC: Rf 0.75 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 9.39 (brs, 2H), 7.59 (d, J=8.4 Hz, 2H), 7.51 (d, J=8.4 Hz, 2H), 4.19 (m, 2H), 3.18 (m, 2H), 2.94 (t, J=7.5 Hz, 2H), 2.40 (m, 4H), 1.66 (m, 4H).
- TLC: Rf 0.68 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 4.04-3.45 (m, 8H), 3.71 (t, J=7.2 Hz, 2H), 3.26 (m, 2H), 3.15 (t, J=7.2 Hz, 2H), 2.59 (m, 2H), 2.53 (m, 2H), 1.80 (m, 6H), 1.39 (m, 6H), 0.93 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.25 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 4.12-3.58 (m, 11H), 3.18 (t, J=6.9 Hz, 2H), 2.60 (m, 2H), 2.53 (m, 2H), 1.80 (m, 4H), 1.44 (d, J=6.9 Hz, 6H).
- TLC: Rf 0.65 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 7.61-7.50 (m, 2H), 7.32-7.20 (m, 2H), 4.39 (s, 2H), 3.51 (t, J=6.9 Hz, 2H), 3.02 (t, J=6.9 Hz, 2H), 2.52 (m, 4H), 1.79 (m, 4H).
- TLC: Rf 0.42 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 3.55 (t, J=6.6 Hz, 2H), 3.45 (t, J=6.9 Hz, 2H), 3.35 (s, 3H), 3.21 (t, J=6.9 Hz, 2H), 2.99 (t, J=6.6 Hz, 2H), 2.54 (m, 4H), 1.97 (m, 2H), 1.79 (m, 4H).
- TLC: Rf 0.30 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.41 (brs, 1H), 9.60 (brs, 2H), 7.65 (dd, J=8.4, 5.7 Hz, 2H), 7.27 (dd, J=8.4, 8.4 Hz, 2H), 6.00 (brs, 2H), 4.16 (m, 2H), 3.34-3.06 (m, 4H), 2.95 (t, J=7.2 Hz, 2H), 2.39 (t, J=6.0 Hz, 2H), 1.71 (m, 2H).
- TLC: Rf 0.32 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 9.33 (brs, 2H), 7.78 (d, J=1.5 Hz, 1H), 6.65 (d, J=3.3 Hz, 1H), 6.53 (dd, J=3.3, 1.5 Hz, 1H), 4.27 (m, 2H), 3.18 (m, 2H), 2.90 (t, J=7.6 Hz, 2H), 2.40 (m, 4H), 1.66 (m, 4H).
- TLC: Rf 0.16 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.66 (s, 1H), 9.23 (brs, 2H), 7.43 (d, J=7.8 Hz, 2H), 7.24 (d, J=7.8 Hz, 2H), 4.13 (m, 2H), 3.16 (m, 2H), 2.92 (t, J=7.2 Hz, 2H), 2.40 (m, 4H), 2.31 (s, 3H), 1.66 (m, 4H).
- TLC: Rf 0.34 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 7.50-7.42 (m, 2H), 7.15-7.00 (m, 2H), 4.29 (s, 2H), 3.92 (s, 3H), 3.48 (t, J=6.6 Hz, 2H), 3.00 (t, J=6.6 Hz, 2H), 2.53 (m, 4H), 1.78 (m, 4H).
- TLC: Rf 0.069 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 3.47 (t, J=6.6 Hz, 2H), 3.20 (t, J=7.2 Hz, 2H), 3.00 (t, J=6.6 Hz, 2H), 2.62 (t, J=7.2 Hz, 2H), 2.63-2.50 (m, 4H), 2.12 (s, 3H), 2.01 (m, 2H), 1.90-1.75 (m, 4H).
- TLC: Rf 0.39 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 8.53 (d, J=6.0 Hz, 2H), 7.48 (d, J=6.0 Hz, 2H), 4.06 (s, 2H), 3.15 (t, J=6.9 Hz, 2H), 2.89 (t, J=6.9 Hz, 2H), 2.60-2.45 (m, 4H), 1.88-1.72 (m, 4H).
- TLC: Rf 0.26 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.24 (s, 1H), 11.73 (brs, 1H), 5.59 (br, 3H), 4.00-3.06 (m, 14H), 2.97 (t, J=8.1 Hz, 2H), 2.37 (t, J=6.0 Hz, 2H), 1.73 (m, 2H), 1.26 (t, J=6.9 Hz, 3H).
- TLC: Rf 0.60 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.10-7.00 (m, 4H), 3.82-3.72 (m, 4H), 3.67 (t, J=7.2 Hz, 2H), 3.42-3.30 (m, 4H), 3.15 (t, J=7.2 Hz, 2H), 2.65-2.50 (m, 4H), 1.82 (m, 4H).
- TLC: Rf 0.14 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 8.28 (d, J=8.1 Hz, 2H), 7.33 (d, J=8.1 Hz, 2H), 4.50 (m, 2H), 3.95-3.30 (m, 6H), 3.71 (t, J=6.9 Hz, 2H), 3.18 (t, J=6.9 Hz, 2H), 2.62 (m, 2H), 2.53 (m, 2H), 1.81 (m, 4H).
- TLC: Rf 0.45 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.23 (s, 1H), 12.22 (brs, 1H), 4.66 (br, 3H), 4.00-3.30 (m, 11H), 3.23 (m, 2H), 2.98 (m, 2H), 2.37 (t, J=6.0 Hz, 2H), 2.00 (m, 2H), 1.92-1.40 (m, 8H).
- TLC: Rf 0.26 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.18 (s, 1H), 11.86 (brs, 1H), 4.55 (br, 3H), 3.98-3.30 (m, 11H), 3.22 (m, 2H), 2.97 (m, 2H), 2.37 (t, J=6.3 Hz, 2H), 1.72 (m, 2H), 1.30 (d, J=6.3 Hz, 6H).
- TLC: Rf 0.32 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.65 (s, 1H), 9.59 (brs, 2H), 7.62 (d, J=5.1 Hz, 1H), 7.37 (d, J=2.7 Hz, 1H), 7.09 (dd, J=5.1, 2.7 Hz, 1H), 4.41 (s, 2H), 3.18 (m, 2H), 2.96 (t, J=7.8 Hz, 2H), 2.40 (m, 4H), 1.66 (m, 4H).
- TLC: Rf 0.72 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.15-6.90 (m, 4H), 3.87 (s, 3H), 3.82-3.05 (m, 8H), 3.67 (t, J=6.9 Hz, 2H), 3.13 (t, J=6.9 Hz, 2H), 2.62-2.50 (m, 4H), 1.80 (m, 4H).
- TLC: Rf 0.13 (methylene chloride:methanol:saturated aqueous ammonia=4:1:0.5);
- NMR (CD3OD): δ 3.16 (t, J=6.3 Hz, 2H), 3.00 (t, J=6.9 Hz, 2H), 2.94-2.83 (m, 4H), 2.78 (s, 6H) 2.61 (m, 2H), 2.52 (m, 2H), 2.48 (s, 3H), 1.80 (m, 4H).
- TLC: Rf 0.54 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.20 (dd, J=8.4, 8.4 Hz, 1H), 6.66-6.52 (m, 3H), 3.90-3.08 (m, 8H), 3.77 (s, 3H), 3.67 (t, J=7.2 Hz, 2H), 3.14 (t, J=7.2 Hz, 2H), 2.61 (m, 2H), 2.54 (m, 2H), 1.81 (m, 4H).
- TLC: Rf 0.53 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.52 (m, 2H), 7.42-7.32 (m, 3H), 6.96 (d, J=16.2 Hz, 1H), 6.36 (dt, J=16.2, 7.2 Hz, 1H), 4.04 (d, J=7.2 Hz, 2H), 3.90-3.45 (m, 10H), 3.13 (t, J=7.2 Hz, 2H), 2.59 (m, 2H), 2.53 (m, 2H), 1.79 (m, 4H).
- TLC: Rf 0.13 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 4.15-3.40 (m, 11H), 3.15 (t, J=6.9 Hz, 2H), 2.60 (m, 2H), 2.53 (m, 2H), 2.02-1.58 (m, 6H), 1.41 (d, J=6.6 Hz, 3H), 1.06 (t, J=7.5 Hz, 3H).
- TLC: Rf 0.42 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.73 (dd, J=1.8, 0.9 Hz, 1H), 7.17 (dd, J=2.4, 0.9 Hz, 1H), 6.63 (dd, J=2.4, 1.8 Hz, 1H), 4.80-4.65 (m, 2H), 3.90-3.25 (m, 6H), 3.66 (t, J=7.2 Hz, 2H), 3.13 (t, J=7.2 Hz, 2H), 2.60 (m, 2H), 2.53 (m, 2H), 1.80 (m, 4H).
- TLC: Rf 0.38 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.60 (s, 1H), 7.47 (s, 3H), 4.31 (s, 2H), 3.49 (t, J=6.9 Hz, 2H), 3.02 (t, J=6.9 Hz, 2H), 2.72 (s, 3H), 2.54 (m, 4H), 1.79 (m, 4H).
- TLC: Rf 0.42 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 7.58-7.45 (m, 5H), 4.28 (s, 2H), 3.47 (t, J=6.6 Hz, 2H), 3.34 (m, 2H), 2.89 (t, J=6.6 Hz, 2H), 2.52 (t, J=6.6 Hz, 2H), 1.86 (m, 2H).
- TLC: Rf 0.23 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 7.15 (m, 2H), 6.69 (m, 3H), 3.50 (m, 4H), 3.32 (m, 4H), 2.89 (t, J=6.6 Hz, 2H), 2.51 (t, J=6.6 Hz, 2H), 1.84 (m, 2H).
- TLC: Rf 0.51 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 4.10-3.55 (m, 10H), 3.47 (t, J=5.7 Hz, 2H), 3.30 (m, 2H), 3.18 (t, J=7.2 Hz, 2H), 2.63 (t, J=6.3 Hz, 2H), 1.92 (m, 2H), 1.81 (m, 2H), 1.39 (m, 6H), 0.93 (m, 3H).
- TLC: Rf 0.15 (methanol:methylene chloride=1:10).
- TLC: Rf 0.63 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 4.05-3.50 (m, 8H), 3.78 (t, J=7.2 Hz, 2H), 3.24-3.15 (m, 4H), 2.60 (m, 2H), 2.53 (m, 2H), 2.20 (m, 1H), 1.80 (m, 4H), 1.10 (d, J=6.6 Hz, 6H).
- TLC: Rf 0.69 (methylene chloride:methanol=9:1);
- NMR (CD3OD): δ 7.12-7.00 (m, 4H), 3.85-3.70 (m, 6H), 3.51 (t, J=5.7 Hz, 2H), 3.50-3.18 (m, 6H), 2.67 (t, J=6.3 Hz, 2H), 1.95 (m, 2H).
- TLC: Rf 0.12 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 8.15 (d, J=7.8 Hz, 2H), 7.20 (d, J=7.8 Hz, 2H), 3.90-3.75 (m, 4H), 3.35 (m, 2H), 3.05-2.78 (m, 8H), 2.69 (s, 3H), 2.52 (t, J=6.3 Hz, 2H), 1.86 (m, 2H).
- TLC: Rf 0.65 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.0 (s, 1H), 9.53 (brs, 1H), 6.97 (d, J=9.0 Hz, 2H), 6.85 (d, J=9.0 Hz, 2H), 6.42 (s, 1H), 3.80-3.60 (m, 4H), 3.69 (s, 3H), 3.50 (m, 2H), 3.30-3.18 (m, 4H), 2.98-2.80 (m, 4H), 2.35 (m, 2H), 2.32 (s, 3H), 1.73 (m, 2H).
- TLC: Rf 0.10 (methylene chloride:methanol:saturated aqueous ammonia=4:1:0.5%);
- NMR (CD3OD): δ 2.77 (m, 4H), 2.64-2.45 (m, 6H), 2.36 (m, 2H), 2.33 (s, 3H), 2.26 (s, 6H), 1.85-1.65 (m, 6H).
- TLC: Rf 0.13 (methylene chloride:methanol:saturated aqueous ammonia=4:1:0.5%);
- NMR (CD3OD): δ 3.38 (t, J=6.6H, 2H), 3.24 (m, 2H), 3.10 (m, 2H), 3.05-2.92 (m, 6H), 2.62-2.48 (m, 4H), 1.80 (m, 4H), 1.21 (t, J=7.2H, 6H).
- TLC: Rf 0.60 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 11.73 (s, 1H), 6.58 (s, 1H), 3.58-3.55 (m, 4H), 3.17 (m, 2H), 2.58 (m, 4H), 2.41 (m, 4H), 2.32 (t, J=6.0 Hz, 2H), 1.71-1.67 (m, 2H).
- TLC: Rf 0.52 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 11.96 (s, 1H), 9.65 (brs, 1H), 6.36 (s, 1H), 4.01 (m, 2H), 3.65 (t, J=11.7 Hz, 2H), 3.45 (m, 4H), 3.16 (m, 4H), 2.83 (t, J=7.8 Hz, 2H), 2.35 (m, 2H), 2.31 (s, 3H), 1.72 (m, 2H).
- TLC: Rf 0.41 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.1);
- NMR (DMSO-d6): δ 11.85 (s, 1H), 10.28 (brs, 1H), 6.41 (s, 1H), 3.32-2.78 (m, 16H), 2.42-2.20 (m, 6H), 2.12 (m, 2H), 1.71 (m, 2H).
- TLC: Rf 0.52 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 4.10-3.50 (m, 8H), 3.76 (t, J=6.9H, 2H), 3.20-3.12 (m, 4H), 2.65-2.48 (m, 4H), 1.98-1.65 (m, 12H), 1.48-1.00 (m, 3H).
- TLC: Rf 0.28 (methylene chloride:methanol=4:1);
- NMR (CD3OD): δ 4.15-3.60 (m, 8H), 3.80 (t, J=7.2 Hz, 2H), 3.48 (t, J=5.7 Hz, 2H), 3.28 (m, 2H), 3.19 (t, J=7.2 Hz, 2H), 2.65 (t, J=6.6 Hz, 2H), 1.94 (m, 2H), 1.80 (m, 2H), 1.45 (m, 2H), 1.01 (t, J=7.2 Hz, 3H).
- TLC: Rf 0.43 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.48 (s, 1H), 3.54 (t, J=7.5 Hz, 4H), 2.54-2.43 (m, 4H), 2.40-2.28 (m, 6H), 2.22 (t, J=7.5 Hz, 2H), 1.74-1.60 (m, 4H), 1.64-1.48 (m, 2H), 1.50-1.37 (m, 2H), 1.40-1.26 (m, 2H).
- A mixture of the compound prepared in Example 25(1) (115 mg) and morpholine (0.5 mL) was refluxed for 3 hours. The reaction mixture was concentrated. Water was added to the residue, which was extracted with ethyl acetate. The extract was washed with a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous magnesium sulfate and concentrated. The residue was recrystallized from a mixed solvent of isopropanol and hexane. A solution of the obtained solid (56.2 mg) and methanesulfonic acid (13.2 mg) in methanol (3.0 mL) was stirred at room temperature for 1 hour. The reaction mixture was concentrated to give the compound of the present invention (67.9 mg) having the following physical data.
- TLC: Rf 0.41 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.90 (s, 1H), 10.04 (s, 1H), 9.42 (brs, 1H), 7.70 (s, 1H), 7.60 (d, J=8.1 Hz, 1H), 7.36 (t, J=8.1 Hz, 1H), 7.10 (d, J=8.1 Hz, 1H), 3.96 (m, 2H), 3.61 (t, J=11.4 Hz, 2H), 3.43-2.30 (m, 12H), 2.29 (s, 3H), 1.63 (m, 8H).
- By the same procedure as described in Example 28, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 25(1) or the compound prepared in Example 23(23), 23(24), 23(29), 23(37), 25, 25(2), 25(6) to 25(8), 25(11) to 25(13), 26(2) or 26(5), and morpholine or a corresponding derivative, the following compounds of the present invention were obtained.
- TLC: Rf 0.22 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.90 (s, 1H), 10.12 (s, 1H), 9.54 (brs, 1H), 7.70 (s, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.11 (d, J=7.8 Hz, 1H), 3.98 (m, 2H), 3.63 (t, J=11.6 Hz, 2H), 3.43-2.32 (m, 12H), 2.30 (s, 3H), 1.95 (m, 2H), 1.64 (m, 4H).
- TLC: Rf 0.29 (methanol:methylene chloride=2:3);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 10.04 (s, 1H), 8.95 (brs, 1H), 7.70 (s, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.36 (t, J=7.8 Hz, 1H), 7.10 (d, J=7.8 Hz, 1H), 3.52-2.33 (m, 13H), 3.24 (s, 3H), 2.29 (s, 3H), 2.15-1.46 (m, 12H).
- TLC: Rf 0.50 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.91 (s, 1H), 10.00 (s, 1H), 9.78 (brs, 1H), 7.70 (s, 1H), 7.64 (d, J=7.8 Hz, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.15 (d, J=7.8 Hz, 1H), 4.20 (s, 2H), 4.05-3.40 (m, 10H), 3.16 (m, 2H), 2.56-2.33 (m, 4H), 2.31 (s, 3H), 1.70-1.59 (m, 4H).
- TLC: Rf 0.16 (chloroform:methanol=9:1);
- NMR (DMSO-d6): δ 10.53 (s, 1H), 10.15 (s, 1H), 9.59 (bs, 1H), 7.70 (s, 1H), 7.58-7.55 (m, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.07 (d, J=7.8 Hz, 1H), 4.28-4.18 (m, 1H), 3.99-3.94 (m, 2H), 3.68-3.42 (m, 5H), 3.17-3.00 (m, 5H), 2.90-2.80 (m, 2H), 2.74-2.64 (m, 1H), 2.43 (t, J=6.9 Hz, 2H), 2.33-2.26 (m, 4H), 2.00-1.90 (m, 2H).
- TLC: Rf 0.30 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.03 (s, 1H), 8.93 (brs, 2H), 7.70 (s, 1H), 7.60 (d, J=7.8 Hz, 1H), 7.36 (t, J=7.8 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 3.92 (m, 2H), 3.72 (t, J=2.4 Hz, 1H), 2.96 (m, 2H), 2.48-2.32 (m, 6H), 2.31 (s, 3H), 1.65 (m, 8H).
- TLC: Rf 0.36 (methanol:methylene chloride:saturated aqueous ammonia=1:9:0.1);
- NMR (DMSO-d6): δ 12.88 (brs, 1H), 10.07 (s, 1H), 8.54 (brs, 2H), 7.71 (s, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.35 (t, J=7.8 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 5.08 (s, 1H), 5.07 (s, 1H), 3.51 (t, J=6.0 Hz, 2H), 2.89 (m, 2H), 2.48-2.34 (m, 9H), 1.77 (s, 3H), 1.69-1.59 (m, 8H).
- TLC: Rf 0.48 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.05 (s, 1H), 9.43 (brs, 1H), 7.70 (s, 1H), 7.60 (m, 1H), 7.36 (dd, J=7.8, 7.8 Hz, 1H), 7.09 (d, J=7.8 Hz, 1H), 5.90 (m, 1H), 5.70 (m, 1H), 3.80 (m, 1H), 3.54 (m, 1H), 3.22-2.98 (m, 4H), 2.60-2.18 (m, 8H), 2.50 (s, 3H), 1.82-1.50 (m, 8H).
- TLC: Rf 0.35 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.06 (s, 1H), 8.56 (brs, 2H), 7.70 (s, 1H), 7.60 (m, 1H), 7.36 (dd, J=7.8, 7.8 Hz, 1H), 7.09 (m, 1H), 3.08-2.90 (m, 2H), 2.69 (m, 1H), 2.56-2.20 (m, 6H), 2.34 (s, 3H), 1.80-1.46 (m, 8H), 0.84-0.64 (m, 4H).
- TLC: Rf 0.69 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 10.89 (s, 1H), 10.16 (s, 1H), 9.52 (br, 1H), 7.74 (s, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.12 (d, J=7.8 Hz, 1H), 6.27 (s, 1H), 4.02-3.94 (m, 2H), 3.69-3.58 (m, 4H), 3.50-3.42 (m, 2H), 3.20-3.01 (m, 6H), 2.48-2.42 (m, 2H), 2.02-1.92 (m, 2H).
- TLC: Rf 0.30 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 10.19 (s, 2H), 7.83 (s, 1H), 7.79 (d, J=8.1 Hz, 1H), 7.38 (t, J=8.1 Hz, 1H), 7.13 (d, J=8.1 Hz, 1H), 4.16 (s, 2H), 3.85 (t, J=5.1 Hz, 2H), 3.28 (m, 2H), 2.58 (m, 2H), 2.48-2.35 (m, 6H), 1.82-1.59 (m, 10H).
- TLC: Rf 0.55 (methanol:methylene chloride:saturated aqueous ammonia=1:9:0.1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.66 (brs, 1H), 10.17 (s, 1H), 7.86 (s, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.37 (t, J=7.8 Hz, 1H), 7.12 (d, J=7.8 Hz, 1H), 4.16 (s, 2H), 3.82-3.55 (m, 4H), 3.38 (m, 2H), 3.03 (m, 2H), 2.48-2.36 (m, 4H), 1.99-1.59 (m, 8H).
- TLC: Rf 0.45 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.51 (brs, ½H), 10.24 (s, ½H), 10.20 (s, ½H), 9.11 (brs, ½H), 7.73 (s, 1H), 7.64 (m, 1H), 7.35 (dd, J=7.8, 7.8 Hz, 1H), 7.09 (m, 1H), 3.74-3.20 (m, 8H), 3.14-2.94 (m, 2H), 2.80-2.24 (m, 8H), 2.16-1.10 (m, 10H).
- TLC: Rf 0.44 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.92 (s, 1H), 10.92 (brs, 1H), 10.52 (brs, 1H), 7.71 (s, 1H), 7.64 (d, J=7.8 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H), 7.20 (d, J=7.8 Hz, 1H), 4.20-2.27 (m, 14H), 1.69 (m, 2H), 1.60 (m, 2H).
- TLC: Rf 0.43 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.92 (s, 1H), 10.88 (s, 1H), 9.64 (brs, 2H), 7.69 (s, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H), 7.18 (d, J=7.8 Hz, 1H), 4.02 (s, 2H), 3.97 (s, 2H), 3.76 (t, J=2.1 Hz, 1H), 2.48-2.35 (m, 4H), 1.69 (m, 2H), 1.60 (m, 2H).
- TLC: Rf 0.40 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.92 (s, 1H), 10.81 (s, 1H), 9.29 (m, 2H), 7.69 (s, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H), 7.18 (d, J=7.8 Hz, 1H), 3.85-3.71 (m, 3H), 2.45-2.13 (m, 8H), 1.80-1.61 (m, 6H).
- TLC: Rf 0.41 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 10.57 (brs, 1H), 10.42 (s, 1H), 7.70 (s, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.12 (d, J=7.8 Hz, 1H), 3.96 (m, 2H), 3.74 (t, J=11.5 Hz, 2H), 3.42-3.33 (m, 4H), 3.09 (m, 2H), 2.92 (t, J=7.5 Hz, 2H), 2.48-2.34 (m, 4H), 1.69 (m, 2H), 1.60 (m, 2H).
- TLC: Rf 0.40 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 10.43 (s, 1H), 9.37 (brs, 2H), 7.72 (s, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.12 (d, J=7.8 Hz, 1H), 3.93-3.71 (m, 3H), 3.25 (m, 2H), 2.83 (t, J=6.9 Hz, 2H), 2.48-2.34 (m, 4H), 1.69 (m, 2H), 1.59 (m, 2H).
- TLC: Rf 0.25 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.89 (s, 1H), 10.24 (s, 1H), 9.35 (brs, 2H), 7.70 (s, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.36 (t, J=8.1 Hz, 1H), 7.10 (d, J=8.1 Hz, 1H), 3.91 (d, J=2.7 Hz, 2H), 3.70 (t, J=2.7 Hz, 1H), 3.00 (m, 2H), 2.44 (m, 4H), 2.34 (m, 2H), 1.92 (m, 2H), 1.69 (m, 2H), 1.60 (m, 2H).
- TLC: Rf 0.54 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.34 (brs, 1H), 11.04 (brs, 1H), 10.31 (s, 1H), 7.78-7.64 (m, 2H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.11 (m, 1H), 4.02-3.70 (m, 4H), 3.50-3.32 (m, 2H), 3.24-2.90 (m, 6H), 2.60-2.34 (m, 4H), 2.12-1.90 (m, 2H), 1.82-1.62 (m, 2H).
- TLC: Rf 0.43 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 7.77 (t, J=5.7 Hz, 1H), 3.42-3.26 (m, 2H), 2.97 (s, 2H), 2.63 (t, J=6.9 Hz, 2H), 2.54-2.28 (m, 8H), 1.76-1.52 (m, 8H).
- TLC: Rf 0.21 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (br, 1H), 7.97 (t, J=6.0 Hz, 1H), 3.40 (s, 2H), 3.18-3.03 (m, 3H), 2.52-2.45 (m, 2H), 2.44-2.32 (m, 4H), 2.12-2.02 (m, 2H), 1.78-1.56 (m, 8H).
- TLC: Rf 0.29 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.58 (br, 1H), 7.82 (t, J=6.0 Hz, 1H), 3.39 (s, 2H), 3.10 (q, J=6.0 Hz, 2H), 2.60-2.52 (m, 4H), 2.52-2.45 (m, 2H), 2.44-2.33 (m, 4H), 1.68-1.60 (m, 4H), 1.58-1.46 (m, 8H).
- TLC: Rf 0.34 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 10.44 (br, 1H), 8.49 (m, 1H), 3.51-3.42 (m, 2H), 3.47 (s, 2H), 3.42-3.31 (m, 2H), 3.18-3.03 (m, 4H), 2.46-2.34 (m, 4H), 1.88-1.76 (m, 4H), 1.72-1.50 (m, 8H).
- TLC: Rf 0.17 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.55 (brs, 1H), 7.99 (t, J=5.4 Hz, 1H), 4.08 (br, 1H), 3.46-3.20 (m, 2H), 3.09 (m, 1H), 2.68-2.28 (m, 8H), 2.13 (t, J=6.9 Hz, 2H), 2.04 (m, 2H), 1.80-1.40 (m, 8H).
- TLC: Rf 0.26 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.55 (s, 1H), 8.05 (t, J=5.4 Hz, 1H), 3.42-3.24 (m, 4H), 2.60 (t, J=7.2 Hz, 2H), 2.56-2.22 (m, 8H), 2.18 (t, J=7.2 Hz, 2H), 1.76-1.54 (m, 4H), 1.52-1.24 (m, 6H).
- TLC: Rf 0.25 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 7.84 (m, 1H), 3.39 (s, 2H), 3.09 (q, J=6.0 Hz, 2H), 2.72 (m, 1H), 2.46-2.30 (m, 6H), 2.10 (s, 3H), 1.66-1.60 (m, 4H), 0.89 (d, J=6.6 Hz, 6H).
- TLC: Rf 0.43 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 7.93 (m, 1H), 3.40 (s, 2H), 3.12 (q, J=6.0 Hz, 2H), 2.61 (t, J=6.0 Hz, 2H), 2.44-2.32 (m, 2H), 2.04 (m, 1H), 1.68-1.60 (m, 4H), 0.37-0.30 (m, 2H), 0.20-0.14 (m, 2H).
- TLC: Rf 0.20 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.70 (s, 1H), 8.00 (m, 1H), 3.38 (s, 2H), 3.04 (q, J=6.3 Hz, 2H), 2.46-2.33 (m, 4H), 2.32-2.16 (m, 6H), 1.68-1.60 (m, 4H), 1.59-1.42 (m, 6H), 1.41-1.30 (m, 2H).
- TLC: Rf 0.35 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.62 (s, 1H), 8.44 (m, 2H), 8.21 (t, J=6.0 Hz, 1H), 3.46 (m, 1H), 3.46 (s, 2H), 3.38-3.26 (m, 2H), 300-2.92 (m, 2H), 2.45-2.34 (m, 4H), 2.00-1.86 (m, 2H), 1.74-1.60 (m, 6H), 1.60-1.48 (m, 4H).
- TLC: Rf 0.30 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 8.53 (m, 2H), 8.19 (t, J=6.0 Hz, 1H), 3.65 (quin, J=7.8 Hz, 1H), 3.42 (s, 2H), 3.12 (q, J=6.0 Hz, 2H), 2.80-2.70 (m, 2H), 2.45-2.36 (m, 4H), 2.20-2.00 (m, 4H), 1.84-1.60 (m, 8H).
- TLC: Rf 0.26 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 8.53 (br, 2H), 8.09 (t, J=6.0 Hz, 1H), 3.64 (quin, J=6.0 Hz, 1H), 3.40 (s, 2H), 3.06, (q, J=6.0 Hz, 2H), 2.82-2.70 (m, 2H), 2.46-2.33 (m, 4H), 2.22-2.02 (m, 4H), 1.84-1.72 (m, 2H), 1.70-1.60 (m, 4H), 1.60-1.38 (m, 4H).
- TLC: Rf 0.18 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.62 (br, 1H), 8.40-8.20 (m, 2H), 8.22 (m, 1H), 3.45 (s, 2H), 3.30 (m, 1H), 3.03-2.90 (m, 2H), 2.43-2.32 (m, 4H), 2.00-1.90 (m, 2H), 1.78-1.54 (m, 8H), 1.28-1.00 (m, 6H).
- TLC: Rf 0.063 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.28-8.00 (br, 2H), 8.10 (m, 1H), 3.40 (s, 2H), 3.05 (q, J=6.0 Hz, 2H), 2.86 (t, J=7.2 Hz, 2H), 2.52 (s, 3H), 2.48-2.32 (m, 4H), 1.70-1.60 (m, 4H), 1.60-1.36 (m, 4H).
- TLC: Rf 0.28 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.58 (s 1H), 8.37 (br, 2H), 8.11 (m, 1H), 3.43 (m, 1H), 3.41 (s, 2H), 3.07 (q, J=6.0 Hz, 2H), 2.92-2.83 (m, 2H), 2.46-2.33 (m, 4H), 2.00-1.88 (m, 2H), 1.74-1.40 (m, 14H).
- TLC: Rf 0.56 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.61 (s 1H), 8.30-8.00 (br, 2H), 8.22 (m, 1H), 3.43 (s, 2H), 3.43 (m, 1H), 3.14 (q, J=6.6 Hz, 2H), 2.86 (t, J=7.5 Hz, 2H), 2.46-2.34 (m, 4H), 1.96-1.84 (m, 2H), 1.80-1.46 (m, 12H).
- TLC: Rf 0.56 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.58 (s 1H), 8.24 (br, 2H), 8.10 (m, 1H), 3.40 (s, 2H), 3.07 (q, J=6.3 Hz, 2H), 3.00-2.84 (m, 3H), 2.46-2.34 (m, 4H), 2.04-1.95 (m, 2H), 1.80-1.40 (m, 11H), 1.28-1.10 (m, 5H).
- TLC: Rf 0.44 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.59 (s 1H), 8.09 (t, J=6.0 Hz, 1H), 3.40 (s, 2H), 3.09 (q, J=6.0 Hz, 2H), 2.74 (t, J=5.2 Hz, 2H), 2.46-2.25 (m, 5H), 1.70-1.55 (m, 6H), 0.58-0.50 (m, 2H), 0.50-0.40 (m, 2H).
- TLC: Rf 0.44 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.56 (brs 1H), 8.01 (t, J=6.0 Hz, 1H), 3.38 (s, 2H), 3.18-2.98 (m, 2H), 2.60-2.52 (m, 2H), 2.46-2.32 (m, 4H), 2.06 (m, 1H), 1.70-1.60 (m, 4H), 1.44-1.35 (m, 4H), 0.40-0.34 (m, 2H), 0.26-0.18 (m, 2H).
- TLC: Rf 0.20 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 8.62 and 8.42 (br, 2H), 3.68 (s, 2H), 3.43-3.34 (m, 2H), 3.02 and 2.82 (s, 3H), 3.00-2.78 (m, 3H), 2.42-2.32 (m, 4H), 2.02-1.54 (m, 12H), 1.32-1.17 (m, 4H).
- TLC: Rf 0.20 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 8.73 and 8.49 (br, 2H), 3.68 and 3.67 (s, 2H), 3.46-3.36 (m, 3H), 3.01 and 2.82 (s, 3H), 2.98-2.78 (m, 2H), 2.42-2.34 (m, 4H), 1.98-1.76 (m, 4H), 1.70-1.44 (m, 10H).
- TLC: Rf 0.24 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.63 (br, 2H), 3.67 and 3.65 (s, 2H), 3.62 (m, 1H), 3.44-3.30 (m, 2H), 3.00 and 2.81 (s, 3H), 2.82-2.67 (m, 2H), 2.41-2.32 (m, 4H), 2.20-2.04 (m, 4H), 1.90-1.70 (m, 4H), 1.70-1.60 (m, 4H).
- TLC: Rf 0.24 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.59 and 12.57 (s, 1H), 8.57 (br, 2H), 3.67 (s, 2H), 3.46-3.30 (m, 2H), 3.01 and 2.81 (s, 3H), 2.95-2.82 (m, 2H), 2.57 (m, 1H), 2.41-2.33 (m, 4H), 1.95-1.75 (m, 2H), 1.70-1.58 (m, 4H), 0.81-0.72 (m, 2H), 0.72-0.64 (m, 2H).
- TLC: Rf 0.38 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.00 (t, J=5.4 Hz, 1H), 3.55 (m, 4H), 3.39 (s, 2H), 3.29-2.20 (m, 12H), 1.63 (brs, 4H), 1.40 (brs, 4H).
- TLC: Rf 0.37 (methanol:methylene chloride:saturated aqueous ammonia=1:9:0.1);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 10.34 (brs, 1H), 8.13 (t, J=5.4 Hz, 1H), 3.94 (m, 2H), 3.72 (t, J=11.4 Hz, 2H), 3.41 (s, 2H), 3.38 (m, 2H), 3.07 (m, 6H), 2.39 (m, 4H), 1.63-1.40 (m, 8H).
- TLC: Rf 0.34 (methanol:methylene chloride:28% ammonia water=1:9:0.1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 9.54 (brs, 1H), 8.10 (t, J=5.4 Hz, 1H), 4.00-3.94 (m, 2H), 3.69-3.61 (m, 2H), 3.41 (s, 2H), 3.36 (m, 2H), 3.11-2.97 (m, 6H), 2.42-2.33 (m, 4H), 2.34 (s, 3H), 1.63 (m, 6H), 1.48-1.38 (m, 2H).
- Under an atmosphere of hydrogen, a mixture of the compound prepared in Example 26(4) (430 mg) and 10% palladium on carbon (86.0 mg) in methanol (5.0 mL) was stirred at room temperature for 10 hours. The reaction mixture was filtrated through Celite. The filtrate was concentrated. The obtained powder was recrystallized from ethyl acetate to give a free form of the title compound (268 mg). A suspension of the obtained free form (264 mg) and methanesulfonate (74.6 mg) in methanol (3.0 mL) was stirred at room temperature for 1 hour. The reaction mixture was concentrated to give the compound of the present invention (307 mg) having the following physical data.
- TLC: Rf 0.28 (methanol:methylene chloride:saturated aqueous ammonia=4:8:0.1);
- NMR (CD3OD): δ 7.80 (s, 1H), 7.66 (m, 1H), 7.47 (t, J=7.8 Hz, 1H), 7.22 (m, 1H), 3.01 (brt, J=6.8 Hz, 2H), 2.75 (s, 3H), 2.68 (brt, J=6.0 Hz, 2H), 2.53 (m, 4H), 1.90-1.74 (m, 8H).
- By the same procedure as described in Example 29, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 26(6) to 26(8), 26(12), 24(31) or 27(38) instead of the compound prepared in Example 26(4), the following compounds of the present invention were obtained.
- TLC: Rf 0.34 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.2);
- NMR (CD3OD): δ 10.02 (brs, 1H), 7.78 (s, 1H), 7.65 (d, J=7.8 Hz, 1H), 7.45 (t, J=7.8 Hz, 1H), 7.17 (d, J=7.8 Hz, 1H), 4.07 (m, 1H), 3.47 (m, 1H), 3.07 (t, J=6.9 Hz, 2H), 2.91 (m, 1H), 2.75 (s, 6H), 2.53 (t, J=6.6 Hz, 2H), 2.29-1.52 (m, 10H).
- TLC: Rf 0.26 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.2);
- NMR (CD3OD): δ 8.14 (t, J=1.8 Hz, 1H), 7.78 (m, 1H), 7.64 (t, J=7.8 Hz, 1H), 7.39 (m, 1H), 4.68 (dd, J=11.1, 2.4 Hz, 1H), 4.00 (dt, J=14.1, 3.0 Hz, 1H), 3.53-3.34 (m, 2H), 3.10 (m, 4H), 2.76 (s, 6H), 2.57 (m, 3H), 1.84 (m, 4H).
- TLC: Rf 0.29 (chloroform:methanol:28% ammonia water=40:10:1);
- NMR (DMSO-d6): δ 12.96 (br-s, 1H), 10.05 (s, 1H), 8.22 (br-s, 2H), 7.69 (m, 1H), 7.57 (m, 1H), 7.37 (m, 1H), 7.00 (m, 1H), 2.92-2.78 (m, 4H), 2.58-2.52 (m, 5H), 2.40-2.32 (m, 2H), 2.30 (s, 3H), 1.86-1.76 (m, 2H), 1.66-1.46 (m, 8H).
- TLC: Rf 0.34 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 10.89 (s, 1H), 10.37 (br, 1H), 8.83 (br, 2H), 7.76 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 6.26 (s, 1H), 3.64-3.58 (m, 2H), 3.20-3.14 (m, 2H), 2.94-2.84 (m, 2H), 2.54-2.30 (m, 5H), 1.70-1.60 (m, 4H).
- TLC: Rf 0.14 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.1);
- NMR (DMSO-d6): δ 12.54 (brs, 1H), 8.44 (s, 1H), 8.01 (t, J=5.4 Hz, 1H), 3.38 (s, 2H), 3.08-2.26 (m, 12H), 1.63 (brs, 4H), 1.34-1.00 (m, 5H).
- TLC: Rf 0.43 (methylene chloride:methanol:28% ammonia water=6:3:1);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.18 (brs, 2H), 8.02 (t, J=5.4 Hz, 1H), 3.38 (s, 2H), 3.22 (m, 2H), 3.08 (m, 2H), 2.76 (m, 2H), 2.46-2.34 (m, 4H), 2.30 (s, 3H), 1.77 (m, 2H), 1.63 (m, 4H), 1.50 (m, 1H), 1.40-1.24 (m, 4H).
- TLC: Rf 0.083 (methylene chloride:methanol=4:1);
- NMR (DMSO-d6): δ 12.5 (brs, 1H), 2.80-2.55 (m, 12H), 2.49 (m, 2H), 2.35 (m, 2H), 1.75-1.68 (m, 6H).
- 4N hydrogen chloride in dioxane (2.50 mL) was added dropwise to a solution of the compound prepared in Example 26 (290 mg) in methanol (3.0 mL) in ice bath, the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated. The residue was purified by column chromatography on silica gel (methanol:methylene chloride=1:9→methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1). 1N sodium hydroxide solution (0.34 mL) was added dropwise to a suspension of the obtained solid (134 mg) in methanol (1.0 mL) and the mixture was stirred at room temperature for 30 minutes. A saturated aqueous ammonium chloride solution was added to the reaction mixture, which was extracted with methylene chloride. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. A solution of the obtained solid (64.8 mg) and methanesulfonate (17.6 mg) in methanol (3.0 mL) was stirred at room temperature for 30 minutes. The reaction mixture was concentrated to give the compound of the present invention (82.4 mg) having the following physical data.
- TLC: Rf 0.27 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.5);
- NMR (CD3OD): δ 10.00 (brs, 1H), 7.75 (d, J=1.2 Hz, 1H), 7.63 (dd, J=8.1, 1.2 Hz, 1H), 7.45 (t, J=8.1 Hz, 1H), 7.21 (d, J=8.1 Hz, 1H), 3.07 (brt, J=7.2 Hz, 2H), 2.74 (s, 6H), 2.65 (brt, J=6.3 Hz, 2H), 2.52 (m, 4H), 1.82 (m, 8H).
- By the same procedure as described in Example 30, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 26(9), 26(10), 26(11), 23, 26(14), 26(15), 23(3), 23(4), 23(9), 23(16), 26(16), 27(7), 23(21), 26(17), 27(14), 26(19), 23(25), 23(33) or 24(48) instead of the compound prepared in Example 26, the following compounds of the present invention were obtained.
- TLC: Rf 0.20 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 10.56 (s, 1H), 10.17 (s, 1H), 8.45 (br, 2H), 7.71 (s, 1H), 7.58 (d, J=7.8 Hz, 1H), 7.36 (t, J=7.8 Hz, 1H), 7.08 (d, J=7.8 Hz, 1H), 4.24 (dd, J=8.4, 4.5 Hz, 1H), 3.56 (m, 1H), 3.09 (m, 1H), 2.98-2.90 (m, 2H), 2.88-2.84 (m, 2H), 2.71 (m, 1H), 2.56 (t, J=6.0 Hz, 3H), 2.44 (t, J=6.0 Hz, 2H), 2.31 (s, 3H), 2.31 (m, 1H), 1.94-1.86 (m, 2H).
- TLC: Rf 0.17 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 10.54 (s, 1H), 10.05 (s, 3H), 8.36 (br, 2H), 7.71 (s, 1H), 7.58 (d, J=7.5 Hz, 1H), 7.35 (t, J=7.5 Hz, 1H), 7.06 (d, J=7.5 Hz, 1H), 4.24 (m, 1H), 3.59 (m, 1H), 3.08 (m, 1H), 2.92-2.82 (m, 2H), 2.71 (m, 1H), 2.60-2.40 (m, 3H), 2.31 (m, 1H), 2.293 (s, 3H), 2.289 (s, 3H), 1.68-1.55 (m, 4H), 1.40-1.30 (m, 2H).
- TLC: Rf 0.34 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.88 (s, 1H), 10.24 (s, 1H), 8.84 (s, 2H), 7.73 (s, 1H), 7.64 (m, 1H), 7.35 (dd, J=7.8, 7.8 Hz, 1H), 7.08 (m, 1H), 5.25 (t, J=7.2 Hz, 1H), 3.56-3.40 (m, 2H), 2.98-2.72 (m, 2H), 2.60-2.24 (m, 6H), 1.80-1.50 (m, 14H).
- TLC: Rf 0.19 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 7.98 (m, 1H), 3.41 (s, 2H), 3.03 (q, J=6.6 Hz, 2H), 2.55 (t, J=6.6 Hz, 2H), 2.46-2.33 (m, 4H), 1.70-1.60 (m, 4H).
- TLC: Rf 0.44 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.2);
- NMR (DMSO-d6): δ 12.60 (brs, 1H), 8.42 (t, J=6.0 Hz, 1H), 8.11 (brs, 3H), 3.46 (s, 2H), 3.31 (q, J=6.0 Hz, 2H), 2.84 (q, J=6.0 Hz, 2H), 2.39 (m, 4H), 1.63 (m, 4H).
- TLC: Rf 0.18 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 10.43 (s, 1H), 9.10 (brs, 1H), 8.82 (brs, 1H), 7.73 (m, 1H), 7.64 (m, 1H), 7.39 (dd, J=7.8, 7.8 Hz, 1H), 7.14 (m, 1H), 4.20-3.92 (m, 4H), 3.79 (m, 1H), 2.62-2.20 (m, 4H), 1.78-1.50 (m, 4H).
- TLC: Rf 0.53 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 12.91 (s, 1H), 10.86 (s, 1H), 9.65 (brs, 1H), 8.67 (brs, 1H), 7.71 (s, 1H), 7.64 (d, J=7.8 Hz, 1H), 7.43 (t, J=7.8 Hz, 1H), 7.19 (d, J=7.8 Hz, 1H), 4.37 (m, 1H), 3.27-2.26 (m, 6H), 1.94 (m, 4H), 1.70-1.59 (m, 4H).
- TLC: Rf 0.41 (ethyl acetate:acetic acid:water=3:3:1);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.23 (br, 1H), 7.88 (br, 3H), 3.42 (s, 2H), 3.11 (q, J=6.6 Hz, 2H), 2.76 (q, J=6.6 Hz, 2H), 2.50-2.32 (m, 4H), 1.76-1.60 (m, 6H).
- TLC: Rf 0.29 (ethyl acetate:acetic acid:water=3:3:1);
- NMR (DMSO-d6): δ 12.60 (brs, 1H), 8.86 (br, 2H), 8.38 (br, 1H), 3.47 (s, 2H), 3.35 (q, J=6.0 Hz, 2H), 2.94 (quin, J=6.0 Hz, 2H), 2.53 (t, J=5.4 Hz, 3H), 2.50-2.34 (m, 4H), 1.70-1.60 (m, 4H).
- TLC: Rf 0.62 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.2);
- NMR (DMSO-d6): δ 12.62 (s, 1H), 8.25 (t, J=5.4 Hz, 1H), 8.00 (brs, 3H), 3.73 (q, J=6.9 Hz, 1H), 3.26 (m, 2H), 2.83 (m, 2H), 2.48-2.30 (m, 4H), 1.64 (m, 4H), 1.31 (d, J=6.9 Hz, 3H).
- TLC: Rf 0.15 (ethyl acetate:acetic acid:water=3:1:1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 8.17 (t, J=6.3 Hz, 1H), 7.95 (br, 3H), 3.41 (s, 2H), 3.05 (q, J=6.3 Hz, 2H), 2.75 (m, 2H), 2.46-2.33 (m, 4H), 1.68-1.60 (m, 4H), 1.60-1.40 (m, 4H).
- TLC: Rf 0.11 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.58 (brs, 1H), 8.59 (t, J=5.7 Hz, 1H), 8.19 (brs, 3H), 3.56-3.28 (m, 4H), 2.65 (t, J=7.2 Hz, 2H), 2.54-2.28 (m, 4H), 1.76-1.54 (m, 4H).
- TLC: Rf 0.15 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 3.80-3.50 (m, 10H), 3.14 (t, J=7.5 Hz, 2H), 2.64-2.50 (m, 4H), 1.90-1.74 (m, 4H).
- TLC: Rf 0.19 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 8.04 (t, J=5.4 Hz, 1H), 7.83 (brs, 3H), 3.69 (q, J=7.2 Hz, 1H), 3.09 (m, 2H), 2.74 (m, 2H), 2.48-2.25 (m, 4H), 1.64-1.42 (m, 8H), 1.31 (d, J=7.2 Hz, 3H).
- TLC: Rf 0.11 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.24 (t, J=5.7 Hz, 1H), 7.94 (brs, 3H), 3.42-3.24 (m, 2H), 3.04-2.84 (m, 2H), 2.63 (t, J=7.2 Hz, 2H), 2.56-2.28 (m, 6H), 1.76-1.52 (m, 4H).
- TLC: Rf 0.10 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.1);
- NMR (DMSO-d6): δ 12.69 (s, 1H), 9.63 (brs, 2H), 8.41 (brs, 3H), 3.78-3.06 (m, 6H), 2.94 (t, J=7.5 Hz, 2H), 2.58-2.30 (m, 4H), 1.78-1.54 (m, 4H).
- TLC: Rf 0.10 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 8.09 (m, 4H), 3.36-3.20 (m, 2H), 2.82-2.66 (m, 2H), 2.61 (t, J=7.2 Hz, 2H), 2.54-2.28 (m, 4H), 2.15 (t, J=7.2 Hz, 2H), 1.84-1.52 (m, 6H).
- TLC: Rf 0.34 (chloroform:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (br, 1H), 8.09 (m, 1H), 7.87 (br, 2H), 3.40 (s, 2H), 3.03 (q, J=6.0 Hz, 2H), 2.80-2.66 (m, 2H), 2.46-2.33 (m, 4H), 1.70-1.60 (m, 4H), 1.60-1.49 (m, 2H), 1.48-1.36 (m, 2H), 1.36-1.26 (m, 2H).
- TLC: Rf 0.18 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.52 (s, 1H), 8.20 (t, J=5.4 Hz, 1H), 8.02 (brs, 3H), 3.36-3.20 (m, 2H), 2.92-2.76 (m, 2H), 2.73 (t, J=7.5 Hz, 2H), 2.54-2.28 (m, 6H), 1.76-1.54 (m, 4H).
- TLC: Rf 0.25 (methanol:acetic acid=5:1);
- NMR (DMSO-d6): δ 12.24 (s, 1H), 8.41 (t, J=5.4 Hz, 1H), 7.94 (brs, 5H), 3.42 (s, 2H), 3.20 (t, J=5.4 Hz, 2H), 3.12 (m, 2H), 2.78 (m, 2H), 2.37 (t, J=6.0 Hz, 2H), 1.69 (m, 4H).
- To a solution of the compound prepared in Reference example 13 (650 mg) in dimethylformamide (15 mL) were added potassium thioacetate (698 mg) and potassium carbonate (422 mg) and the mixture was stirred at 50° C. for 2 hours. After cooling to room temperature, the reaction mixture was poured in cold water and extracted with ethyl acetate. The extract was washed with water and brine sequentially, dried over anhydrous magnesium sulfate and concentrated to give the compound of the present invention (688 mg) having the following physical data.
- TLC: Rf 0.40 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 3.11 (t, J=7.2 Hz, 2H), 2.75 (t, J=7.2 Hz, 2H), 2.56-2.28 (m, 4H), 2.31 (s, 3H), 1.76-1.54 (m, 4H).
- By the same procedure as described in Example 31 using a corresponding derivative instead of the compound prepared in Reference example 13, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.43 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 11.82 (s, 1H), 6.32 (s, 1H), 3.16 (m, 2H), 3.09 (t, J=7.2 Hz, 2H), 2.66 (t, J=7.2 Hz, 2H), 2.32 (t, J=6.3 Hz, 2H), 2.31 (s, 3H), 1.69 (m, 2H).
- To a suspension of the compound prepared in Example 31 (100 mg) in methanol (4.0 mL) were added benzyl bromide (0.06 mL) and potassium carbonate (82 mg) and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured in cold 0.5N hydrochloric acid and extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=70:1→30:1) to give the compound of the present invention (47 mg) having the following physical data.
- TLC: Rf 0.42 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.54 (s, 1H), 7.38-7.16 (m, 5H), 3.77 (s, 2H), 2.80-2.58 (m, 4H), 2.50-2.26 (m, 4H), 1.76-1.52 (m, 4H).
- By the same procedure as described in Example 32, if necessary, by converting to corresponding salts by conventional method, using a corresponding derivative instead of benzyl bromide, the following compounds of the present invention were obtained.
- TLC: Rf 0.57 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 2.78-2.70 (m, 4H), 2.58-2.20 (m, 12H), 1.76-1.56 (m, 6H), 1.54-1.26 (m, 6H).
- TLC: Rf 0.28 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 2.82-2.70 (m, 4H), 2.68-2.56 (m, 2H), 2.54-2.22 (m, 10H), 1.76-1.55 (m, 4H), 1.54-1.26 (m, 6H).
- TLC: Rf 0.28 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 10.22 (brs, 1H), 3.44 (m, 2H), 3.19 (m, 2H), 3.04-2.68 (m, 8H), 2.62-2.28 (m, 4H), 1.90-1.54 (m, 9H), 1.35 (m, 1H).
- To a solution of 4-(2-(2-t-butyldimethylsilyloxyethylthio)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one (300 mg; It was prepared by the same procedure as described in Example 32 using 1-t-butyldimethylsilyloxy-2-iodoethane instead of benzyl bromide.) in tetrahydrofuran (4.0 mL) was added tetrabutylammonium fluoride (638 mg) and the mixture was stirred at room temperature overnight. The reaction mixture was poured in a cold saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and concentrated. The residue was washed with t-butyl methyl ether to give the compound of the present invention (191 mg) having the following physical data.
- TLC: Rf 0.36 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 4.77 (t, J=5.4 Hz, 1H), 3.53 (dt, J=5.4, 6.6 Hz, 2H), 2.84-2.72 (m, 4H), 2.59 (t, J=6.6 Hz, 2H), 2.56-2.28 (m, 4H), 1.76-1.54 (m, 4H).
- By the same procedure as described in Example 33 using 4-(2-(3-t-butyldimethylsilyloxypropylthio)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one, 8-(2-(2-t-butyldimethylsilyloxyethylthio)ethyl)-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one or 8-(2-(3-t-butyldimethylsilyloxypropylthio)ethyl)-2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one instead of 4-(2-(2-t-butyldimethylsilyloxyethylthio)ethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one, the following compounds of the present invention were obtained.
- TLC: Rf 0.37 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 4.46 (t, J=5.1 Hz, 1H), 3.44 (dt, J=5.1, 6.9 Hz, 2H), 2.80-2.68 (m, 4H), 2.56 (t, J=7.2 Hz, 2H), 2.54-2.30 (m, 4H), 1.76-1.54 (m, 6H).
- TLC: Rf 0.31 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 11.78 (s, 1H), 6.33 (s, 1H), 4.78 (t, J=5.4 Hz, 1H), 3.53 (dt, J=5.4, 6.6 Hz, 2H), 3.17 (m, 2H), 2.84-2.60 (m, 4H), 2.59 (t, J=6.6 Hz, 2H), 2.32 (t, J=6.3 Hz, 2H), 1.69 (m, 2H).
- TLC: Rf 0.32 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 11.77 (s, 1H), 6.33 (s, 1H), 4.46 (t, J=5.1 Hz, 1H), 3.44 (dt, J=5.1, 5.7 Hz, 2H), 3.16 (m, 2H), 2.80-2.60 (m, 4H), 2.55 (t, J=7.2 Hz, 2H), 2.32 (t, J=6.3 Hz, 2H), 1.78-1.50 (m, 4H).
- To a solution of the compound prepared in Example 33 (160 mg) in chloroform (5.0 mL) were added triphenylphosphine (248 mg) and carbon tetrabromide (313 mg), and the mixture was stirred at room temperature for 2 hours. Methanol (1.0 mL) was added dropwise to the reaction mixture, which was stirred for 5 minutes and concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=80:1→50:1) to give a crude compound of the present invention (598 mg) having the following physical data. The obtained compound was used in next reaction without purifying.
- TLC: Rf 0.49 (chloroform:methanol=8:1);
- NMR (CD3OD): δ 3.55 (t, J=6.3 Hz, 2H), 2.96-2.82 (m, 4H), 2.72 (t, J=6.3 Hz, 2H), 2.64-2.44 (m, 4H), 1.86-1.70 (m, 4H).
- To a suspension of the compound prepared in Example 33(1) (110 mg) in methylene chloride (2.1 mL) were added thionyl chloride (0.08 mL) and pyridine (0.01 mL), and the mixture was stirred at room temperature for 1 day. The reaction mixture was poured in cold water and extracted with methylene chloride. The extract was washed with a saturated aqueous sodium hydrogen carbonate solution and brine sequentially, dried over anhydrous magnesium sulfate and concentrated to give the compound of the present invention (109 mg) having the following physical data.
- TLC: Rf 0.49 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 3.70 (t, J=6.3 Hz, 2H), 2.82-2.72 (m, 4H), 2.64 (t, J=6.9 Hz, 2H), 2.54-2.30 (m, 4H), 1.95 (tt, J=6.9, 6.3 Hz, 2H), 1.76-1.54 (m, 4H).
- By the same procedure as described in Example 28, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 34 or 35 instead of the compound prepared in Example 25(1) and cyclopentylamine instead of morpholine, the following compounds of the present invention were obtained.
- TLC: Rf 0.36 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.56 (brs, 1H), 3.00 (quint, J=6.3 Hz, 1H), 2.82-2.72 (m, 4H), 2.71-2.28 (m, 8H), 1.80-1.16 (m, 12H).
- TLC: Rf 0.38 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.99 (brs, 2H), 3.41 (m, 1H), 2.92 (m, 2H), 2.84-2.70 (m, 4H), 2.63 (t, J=7.2 Hz, 2H), 2.58-2.28 (m, 4H), 2.06-1.38 (m, 14H).
- By the same procedure as described in Reference example 1→Example 1→Example 26→Example 29 using furo[3,4-d]pyrazine-5,7-dione instead of 4,5,6,7-tetrahydro-2-benzofuran-1,3-dione, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.17 (methanol:methylene chloride:saturated aqueous ammonia=1:4:0.2);
- NMR (CD3OD): δ 7.81 (s, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.49 (t, J=7.8 Hz, 1H), 7.32 (d, J=7.8 Hz, 1H), 3.50 (m, 2H), 3.39 (m, 2H), 3.08 (m, 2H), 2.75 (s, 3H), 2.74 (s, 3H), 2.53 (m, 2H), 1.81 (m, 4H).
- A mixture of the compound prepared in Example 23(34) (180 mg), trimethyltin azide (285 mg) and toluene (1.5 mL) was refluxed overnight. The reaction mixture was concentrated. The residue was washed with ethyl acetate and hot methanol sequentially to give the compound of the present invention (113 mg) having the following physical data.
- TLC: Rf 0.14 (methylene chloride:methanol:saturated aqueous ammonia=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.19 (t, J=6.0 Hz, 1H), 3.44 (q, J=6.0 Hz, 2H), 3.37 (s, 2H), 3.02 (t, J=6.0 Hz, 2H), 2.40-2.24 (m, 4H), 1.67-1.58 (m, 4H).
- To a suspension of the compound prepared in Example 11(1) (150 mg) in tetrahydrofuran (2.9 mL) was added an aqueous solution (1.1 mL) of potassium carbonate (157 mg) and then thereto was added acetyl chloride (0.05 mL) at 0° C., and the mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with water and 1N hydrochloric acid was added thereto. The mixture was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was washed with ether to give the compound of the present invention (131 mg) having the following physical data.
- TLC: Rf 0.36 (chloroform:methanol=8:1);
- NMR (DMSO-d6): δ 13.08 (s, 1H), 7.60-7.40 (m, 5H), 4.28 (s, 2H), 3.66 (t, J=5.7 Hz, 2H), 2.63 (t, J=5.7 Hz, 2H), 2.04 (s, 3H).
- By the same procedure as described in Example 39 and then by converting to a corresponding salt by conventional method, using 2-dimethylaminoacetyl chloride instead of acetyl chloride, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.57 (chloroform:methanol=4:1);
- NMR (DMSO-d6): δ 13.17 (s, 1H), 9.75 (brs, 1H), 7.64-7.36 (m, 5H), 4.48-4.30 (m, 3H), 4.21 (m, 1H), 3.96-3.52 (m, 8H), 2.86-2.64 (m, 2H).
- By the same procedure as described in Reference example 11 using the compound prepared in Example 23(36) instead of the compound prepared in Example 15, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.26 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.15 (m, 1H), 4.11 (m, 1H), 3.39 (s, 2H), 3.23 (q, J=6.0 Hz, 2H), 2.58-2.35 (m, 2H), 2.42-2.32 (m, 4H), 1.66-1.58 (m, 4H).
- By the same procedure as described in Example 20 using the compound prepared in Example 24(41) instead of the compound prepared in Example 4(4), the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.35 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 9.15 (s, 1H), 8.04 (t, J=5.7 Hz, 1H), 6.96 (d, J=8.4 Hz, 2H), 6.65 (d, J=8.4 Hz, 2H), 3.36 (s, 2H), 3.22 (m, 2H), 2.58 (t, J=7.5 Hz, 2H), 2.33 (m, 4H), 1.61 (brs, 4H).
- To a solution of 3,4,5,6-tetrahydrophthalic acid anhydride (10.0 g) in tetrahydrofuran (50.0 mL) was added sodium borohydride (600 mg) in ice bath. The mixture was stirred at room temperature for 30 minutes and refluxed for 5 hours. After cooling to room temperature, 1N hydrochloric acid (10.0 mL) was added to the reaction mixture, which was concentrated. Water was added to the residue, which was extracted with ethyl acetate. The extract was washed with water and brine sequentially, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate:hexane=1:4) to give the title compound (5.40 g) having the following physical data.
- TLC: Rf 0.64 (ethyl acetate:hexane=1:1);
- NMR (CDCl3): δ 5.98 (brs, 1H), 4.90-4.50 (m, 1H), 2.52-2.40 (m, 1H), 2.32-2.16 (m, 3H), 1.86-1.60 (m, 4H).
- A mixed solution of the compound prepared in Reference example 18 (1.54 g), tri-n-butylphosphine (2.02 g) and hydrogen bromide acetic acid solution (47%, 1.20 mL) in acetic acid (0.700 mL) was refluxed for 21 hours. After cooling to room temperature, the reaction mixture was concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=20:1) to give the title compound (3.56 g) having the following physical data.
- TLC: Rf 0.51 (methanol:methylene chloride=1:10).
- To a solution of the compound prepared in Reference example 19 (419 mg) and benzaldehyde (106 mg) in methylene chloride (4.00 mL) was added triethylamine (0.130 mL) and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture, which was extracted with ethyl acetate. The extract was washed with water and brine sequentially, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate:hexane=1:8) to give the title compound (206 mg) having the following physical data.
- TLC: Rf 0.83 (hexane:ethyl acetate=2:1).
- A solution of the compound prepared in Reference example 20 (206 mg) and hydrazine monohydrate (49.0 μL) in ethanol (4.00 mL) was refluxed for 1 hour. Hydrazine monohydrate (49.0 μL) was added to the reaction mixture, which was refluxed for 1 hour. After cooling the reaction mixture to room temperature, the deposited crystal was collected by filtration. It was washed with ethanol and hexane, and dried under reduced pressure to give the compound of the present invention (152 mg) having the following physical data.
- TLC: Rf 0.63 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 7.32-7.24 (m, 2H), 7.23-7.13 (m, 3H), 3.88 (s, 2H), 2.44-2.25 (m, 4H), 1.65-1.54 (m, 4H).
- By the same procedure as described in Reference example 20→Example 42 using a corresponding derivative instead of benzaldehyde, the following compounds of the present invention were obtained.
- TLC: Rf 0.51 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.54 (s, 1H), 7.35-7.15 (m, 5H), 2.90-2.82 (m, 2H), 2.81-2.72 (m, 2H), 2.52-2.42 (m, 2H), 2.41-2.32 (m, 2H), 1.70-1.58 (m, 4H).
- TLC: Rf 0.42 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.59 (s, 1H), 8.45-8.39 (m, 2H), 7.56 (m, 1H), 7.31 (dd, J=7.5, 4.8 Hz, 1H), 3.92 (s, 2H), 2.46-2.33 (m, 4H), 1.72-1.56 (m, 4H).
- TLC: Rf 0.59 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 8.45 (d, J=4.5 Hz, 1H), 7.71 (t, J=7.8 Hz, 1H), 7.28-7.18 (m, 2H), 4.04 (s, 2H), 2.44-2.32 (m, 4H), 1.68-1.56 (m, 4H).
- TLC: Rf 0.68 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 5.95 (m, 2H), 3.84 (s, 2H), 2.50-2.35 (m, 4H), 2.18 (s, 3H), 1.70-1.58 (m, 4H).
- TLC: Rf 0.59 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.40 (s, 1H), 8.03 (dd, J=7.8, 1.2 Hz, 1H), 7.68 (dt, J=1.2, 7.8 Hz, 1H), 7.53 (m, 1H), 7.46 (d, J=7.8 Hz, 1H), 4.24 (s, 2H), 2.56-2.46 (m, 2H), 2.44-2.35 (m, 2H), 1.78-1.62 (m, 4H).
- NMR (DMSO-d6): δ 12.61 (s, 1H), 8.15-8.06 (m, 2H), 7.68-7.57 (m, 2H), 4.06 (s, 2H), 2.47-2.34 (m, 4H), 1.70-1.56 (m, 4H).
- TLC: Rf 0.60 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.65 (s, 1H), 8.16 (dt, J=6.9, 1.8 Hz, 2H), 7.46 (dt, J=6.9, 1.8 Hz, 2H), 4.05 (s, 2H), 2.42-2.33 (m, 4H), 1.70-1.55 (m, 4H).
- Under an atmosphere of hydrogen, a mixed solution of the compound prepared in Example 43(4) (145 mg) and 10% palladium on carbon (30.0 mg) in methanol (15.0 mL) was stirred at room temperature for 30 minutes. The reaction mixture was filtrated through Celite. The filtrate was concentrated to give the compound of the present invention (129 mg) having the following physical data.
- TLC: Rf 0.42 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 6.91 (dt, J=1.2, 7.8 Hz, 1H), 6.72 (dd, J=7.8, 1.2 Hz, 1H), 6.61 (dd, J=7.8, 1.2 Hz, 1H), 6.46 (dt, J=1.2, 7.8 Hz, 1H), 4.97 (s, 2H), 3.66 (s, 2H), 2.50-2.30 (m, 4H), 1.70-1.57 (m, 4H).
- By the same procedure as described in Example 44 using the compound prepared in Example 43(5) or 43(6) instead of the compound prepared in Example 43(4), the following compounds of the present invention were obtained.
- TLC: Rf 0.38 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 6.91 (t, J=8.1 Hz, 1H), 6.37 (d, J=8.1 Hz, 1H), 6.31 (s, 1H), 6.29 (d, J=8.1 Hz, 1H), 5.00 (s, 2H), 3.71 (s, 2H), 2.45-2.30 (m, 4H), 1.70-1.50 (m, 4H).
- TLC: Rf 0.53 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.67 (s, 1H), 9.60 (br, 3H), 7.41 (t, J=7.8 Hz, 1H), 7.22 (d, J=7.8 Hz, 1H), 7.16 (d, J=7.8 Hz, 1H), 7.06 (s, 1H), 3.93 (s, 2H), 2.43-2.28 (m, 4H), 2.33 (s, 3H), 1.67-1.54 (m, 4H).
- TLC: Rf 0.44 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.55 (s, 1H), 6.78 (d, J=8.1 Hz, 2H), 6.47 (d, J=8.1 Hz, 2H), 4.90 (s, 2H), 3.68 (s, 2H), 2.42-2.25 (m, 4H), 1.70-1.50 (m, 4H).
- A solution of (4aS,7aR)-4-phenyl-2,4a,5,6,7,7a-hexahydro-1H-cyclopenta[d]pyridazin-1-one (210 mg; It was prepared by the same procedure as described in Example 1 using (1R,2S)-2-benzoylcyclopentanecarboxylic acid instead of the compound prepared in Reference example 1.) and thionyl chloride (0.500 mL) in benzene (3.00 mL) was refluxed for 18 hours. After cooling to room temperature, the reaction mixture was concentrated. The residue was recrystallized from ethyl acetate to give the compound of the present invention (154 mg) having the following physical data.
- TLC: Rf 0.21 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 13.02 (s, 1H), 7.62-7.58 (m, 2H), 7.50-7.42 (m, 3H), 2.99 (t, J=7.5 Hz, 2H), 2.76 (t, J=7.5 Hz, 2H), 2.06-1.96 (m, 2H).
- To a solution of 2,3-pyridinedicarboxylic acid anhydride (19.4 g) in tetrahydrofuran (260 mL) was added aniline (11.8 mL) and the mixture was refluxed 2 hours. The reaction mixture was concentrated. Acetic anhydride (65 mL) was added to the reaction mixture, which was refluxed for 1.5 hours. After cooling in ice bath, the reaction mixture was poured in ice water (200 mL) and stirred for 1 hours. The precipitate was collected by filtration. It was washed with water and then washed with ethanol on heating to give the title compound (20.9 g) having the following physical data.
- TLC: Rf 0.31 (hexane:ethyl acetate=1:1);
- NMR (CDCl3): δ 7.48 (m, 5H) 7.70 (dd, J=7.69, 4.94 Hz, 1H) 8.28 (dd, J=7.69, 1.65 Hz, 1H) 9.06 (dd, J=4.94, 1.65 Hz, 1H).
- A solution of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride in tetrahydrofuran (5.50 mL, 1.0M) was added dropwise to a suspension of the compound prepared in Reference example 21 (1.12 g) in tetrahydrofuran (20 mL) in ice bath and the mixture was stirred for 1 hour. 1N hydrochloric acid (10 mL) was added dropwise to the reaction mixture, which was stirred for 30 minutes. A saturated aqueous sodium hydrogen carbonate solution (10 mL) was added to the reaction mixture, which was extracted with ethyl acetate. The extract was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was washed with ethyl acetate on heating to give the title compound (1.35 g) having the following physical data.
- TLC: Rf 0.52 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 5.02 (s, 2H) 6.36 (m, 1H) 6.47 (m, 1H) 6.62 (t, J=1.92 Hz, 1H) 6.86 (t, J=7.83 Hz, 1H) 7.14 (m, 1H) 7.28 (m, 2H) 7.54 (m, 4H) 8.20 (dd, J=7.69, 1.65 Hz, 1H) 8.70 (dd, J=4.94, 1.65 Hz, 1H).
- To the compound prepared in Reference example 22 (3.17 g) was added 6N hydrochloric acid (20 mL) and the mixture was refluxed overnight. The reaction mixture was cooled in ice bath, adjusted to pH 5 with 5N sodium hydroxide solution (24 mL) and concentrated. The residue was azeotroped with ethanol and suspended in ethanol (50 mL) with refluxing. Unnecessary sodium chloride was separated by filtration. The filtrate was concentrated. The residue was washed with isopropanol (15 mL) on heating to give the title compound (2.13 g) having the following physical data.
- TLC: Rf 0.49 (methylene chloride:methanol:acetic acid=8:1:1);
- NMR (DMSO-d6): δ 6.74 (m, 2H) 6.85 (t, J=2.00 Hz, 1H) 7.09 (t, J=7.87 Hz, 1H) 7.63 (dd, J=7.97, 4.76 Hz, 1H) 8.33 (dd, J=7.97, 1.55 Hz, 1H) 8.77 (dd, J=4.76, 1.55 Hz, 1H).
- To a suspension of the compound prepared in Reference example 23 (1.94 g) in ethanol (40 mL) was added hydrazine monohydrate (400 mg) and the mixture was refluxed overnight. After cooling the reaction mixture to room temperature, the precipitate was collected by filtration. It was washed with ethanol to give the title compound (1.70 g) having the following physical data.
- TLC: Rf 0.54 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 5.14 (s, 2H) 6.64 (m, 1H) 6.94 (m, 1H) 6.99 (m, 1H) 7.09 (t, J=7.69 Hz, 1H) 7.84 (dd, J=8.06, 4.39 Hz, 1H) 8.63 (dd, J=8.06, 1.83 Hz, 1H) 9.12 (dd, J=4.39, 1.83 Hz, 1H) 13.00 (s, 1H).
- To a suspension of the compound prepared in Reference example 24 (1.67 g) and platinum oxide (83 mg) in dimethylformamide (35 mL) was added 6N hydrochloric acid (2.5 mL) and the mixture was stirred 8 hours under an atmosphere of hydrogen. The reaction mixture was filtrated through Celite. The filtrate was concentrated. A saturated aqueous sodium hydrogen carbonate solution was added to the residue, which was extracted with tetrahydrofuran three times. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was dissolved in methanol (35 mL) on heating. Activated carbon (340 mg) was added to the mixture, which was stirred for 15 minutes. Activated carbon was filtrated through Celite. The filtrate was concentrated. The residue was washed with isopropanol on heating to give the compound of the present invention (1.25 g; free form) having the following physical data. The obtained compound (242 mg) was suspended in methanol (4 mL). A solution of methanesulfonic acid (96 mg) in methanol (1 mL) was added to the mixture, which was stirred. The deposited crystal was collected by filtration. It was washed with methanol to give the compound of the present invention (258 mg; methanesulfonate) having the following physical data.
- TLC: Rf 0.40 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.00 (s, 1H), 7.07 (m, 1H), 6.64-6.60 (m, 2H), 6.53 (d, J=7.3 Hz, 1H), 5.60 (s, 1H), 5.21 (s, 2H), 3.15 (m, 2H), 2.38 (t, J=6.2 Hz, 2H), 1.71 (m, 2H).
- TLC: Rf 0.40 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.28 (s, 1H), 7.53 (m, 1H), 7.40-7.30 (m, 3H) 3.13 (m, 2H), 2.40 (t, J=6.0 Hz, 2H), 2.35 (s, 3H), 1.73 (m, 2H).
- By the same procedure as described in Reference example 21→Reference example 22→Reference example 23→Reference example 24→Example 46, if necessary, by converting to corresponding salts by conventional method, using furo[3,4-b]pyridine-5,7-dione or a corresponding derivative, and a corresponding derivative instead of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride, the following compounds of the present invention were obtained.
- TLC: Rf 0.56 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.29 (s, 1H), 7.39 (t, J=8.1 Hz, 1H), 7.22-6.78 (m, 3H), 3.15 (m, 2H), 3.01 (s, 6H), 2.41 (t, J=6.0 Hz, 2H), 2.33 (s, 3H), 1.73 (m, 2H).
- TLC: Rf 0.51 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.13 (s, 1H), 7.31-7.16 (m, 5H), 6.22 (brs, 2H), 3.83 (s, 2H), 3.19 (t, J=6.0 Hz, 2H), 2.36 (t, J=6.0 Hz, 2H), 2.32 (s, 3H), 1.73-1.65 (m, 2H).
- TLC: Rf 0.50 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.27 (s, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.03-6.96 (m, 3H), 6.21 (m, 2H), 3.78 (s, 3H), 3.16-3.13 (m, 2H), 2.41 (t, J=6.0 Hz, 2H), 2.32 (s, 3H), 1.76-1.71 (m, 2H).
- TLC: Rf 0.25 (methylene chloride:methanol=19:1);
- NMR (DMSO-d6): δ 12.2 (brs, 1H), 7.42 (d, J=8.1 Hz, 2H), 7.16 (d, J=8.1 Hz, 2H), 3.14 (m, 2H), 2.40 (t, J=6.3 Hz, 2H), 2.33 (s, 3H), 1.73 (m, 2H).
- TLC: Rf 0.49 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.21 (s, 1H), 9.79 (br-s, 1H), 7.80-7.37 (m, 4H), 5.83 (s, 1H), 4.40 (d, J=4.0 Hz, 2H), 3.96 (d, J=12.1 Hz, 2H), 3.62 (t, J=11.7 Hz, 2H), 3.30 (d, J=12.1 Hz, 2H), 3.20-3.06 (m, 4H), 2.40 (t, J=6.0 Hz, 2H), 2.30 (s, 3H), 1.73 (m, 2H).
- TLC: Rf 0.50 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.38 (s, 1H), 7.34 (d, J=8.1 Hz, 2H), 6.95 (m, 2H), 3.15 (m, 2H), 2.99 (s, 6H), 2.42 (m, 2H), 2.34 (s, 3H), 1.73 (m, 2H).
- TLC: Rf 0.51 (methylene chloride:methanol=10:1);
- NMR (CD3OD): δ 7.72 (d, J=8.1 Hz, 2H), 7.66 (d, J=8.1 Hz, 2H), 4.46 (s, 2H), 4.11-4.02 (m, 2H), 3.80 (t, J=12.6 Hz, 2H), 3.42 (d, J=12.6 Hz, 2H), 3.40-3.18 (m, 4H), 2.69 (s, 6H), 2.72-2.64 (m, 2H), 2.00-1.89 (m, 2H).
- TLC: Rf 0.54 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.32 (s, 1H), 9.45 (br, 1H), 7.76 (m, 1H), 7.64-7.53 (m, 2H), 7.43 (m, 1H), 5.64 (br, 1H), 4.25 (s, 2H), 3.87 (d, J=12.0 Hz, 2H), 3.67 (t, J=12.0 Hz, 2H), 3.25 (d, J=12.0 Hz, 2H), 3.16-3.00 (m, 4H), 2.42 (t, J=6.0 Hz, 2H), 2.33 (s, 3H), 1.79-1.66 (m, 2H).
- TLC: Rf 0.42 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.40 (br, 1H), 11.99 (br, 1H), 7.77-7.69 (m, 2H), 7.62-7.48 (m, 2H), 6.30-5.30 (br, 3H), 4.45 (s, 2H), 3.80-3.50 (m, 4H), 3.70-3.40 (m, 4H), 3.30-3.00 (m, 4H), 2.42 (t, J=6.3 Hz, 2H), 1.80-1.66 (m, 2H), 1.24 (t, J=7.2 Hz, 3H).
- TLC: Rf 0.27 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.21 (s, 1H), 9.59 (br, 1H), 7.62-7.52 (m, 4H), 5.82 (s, 1H), 4.35-4.31 (m, 2H), 3.20-3.12 (m, 2H), 2.76 (s, 3H), 2.75 (s, 3H), 2.41 (t, J=6.3 Hz, 2H), 2.30 (s, 3H), 1.81-1.68 (m, 2H).
- TLC: Rf 0.82 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.19 (s, 1H), 9.68 (br, 1H), 7.57 (d, J=8.4 Hz, 2H), 7.53 (d, J=8.4 Hz, 2H), 5.76 (s, 1H), 4.34 (s, 2H), 3.18-3.10 (m, 2H), 2.76 (s, 6H), 2.40 (t, J=6.0 Hz, 2H), 2.31 (s, 3H), 1.80-1.68 (m, 2H).
- TLC: Rf 0.38 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.20 (s, 1H), 9.34 (br, 1H), 7.60 (d, J=8.4 Hz, 2H), 7.54 (d, J=8.4 Hz, 2H), 5.77 (s, 1H), 4.36 (d, J=4.8 Hz, 2H), 3.12-3.02 (m, 6H), 2.40 (t, J=6.0 Hz, 2H), 2.30 (s, 3H), 1.80-1.68 (m, 2H), 1.24 (t, J=7.2 Hz, 6H).
- TLC: Rf 0.49 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.95 (s, 1H), 9.64 (br, 1H), 7.60-7.52 (m, 4H), 4.33 (s, 2H), 2.76 (s, 6H), 2.50-2.40 (m, 2H), 2.40-2.32 (m, 2H), 2.30 (s, 3H), 1.76-1.66 (m, 2H), 1.66-1.55 (m, 2H).
- TLC: Rf 0.50 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.12 (s, 1H), 9.41 (br, 1H), 7.42 (d, J=8.1 Hz, 2H), 7.37 (d, J=8.1 Hz, 2H), 5.70 (s, 1H), 3.35-3.25 (m, 2H), 3.18-3.09 (m, 2H), 3.05-2.96 (m, 2H), 2.83 (s, 6H), 2.39 (t, J=6.3 Hz, 2H), 2.30 (s, 3H), 1.80-1.68 (m, 2H).
- After cooling methanol (5 mL) to −15° C., thionyl chloride (1.3 mL) was added dropwise thereto and the solution was stirred for 15 minutes. To the solution was added the compound prepared in Reference example 23 (1.21 g). The solution was allowed to return to room temperature and then refluxed overnight. The reaction mixture was concentrated. To the residue were added a saturated aqueous sodium hydrogen carbonate solution and ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was recrystallized from isopropanol (5 mL) to give the title compound (815 mg) having the following physical data.
- TLC: Rf 0.37 (hexane:ethyl acetate=1:3);
- NMR (DMSO-d6): δ 3.69 (s, 3H) 5.36 (s, 2H) 6.79 (m, 2H) 6.89 (m, 1H) 7.12 (t, J=7.83 Hz, 1H) 7.70 (dd, J=8.04, 4.81 Hz, 1H) 8.39 (dd, J=8.04, 1.65 Hz, 1H) 8.83 (dd, J=4.74, 1.65 Hz, 1H).
- To a solution of the compound prepared in Reference example 25 (800 mg) in methylene chloride (15 mL) were added pyridine (505 μL) and trifluoroacetic acid anhydride (529 μL) sequentially in ice bath, and the mixture was stirred for 30 minutes. The reaction mixture was diluted with methylene chloride and washed with 1N hydrochloric acid and water sequentially. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane:ethyl acetate=1:1) to give the title compound (1.10 g) having the following physical data.
- TLC: Rf 0.48 (hexane:ethyl acetate=1:1);
- NMR (CDCl3): δ 3.79 (s, 3H) 7.49 (t, J=7.97 Hz, 1H) 7.56 (dd, J=8.11, 4.81 Hz, 1H) 7.63 (m, 1H) 7.99 (m, 2H) 8.28 (s, 1H) 8.39 (dd, J=8.11, 1.65 Hz, 1H) 8.82 (dd, J=4.81, 1.65 Hz, 1H).
- To a solution of the compound prepared in Reference example 26 (1.06 g) in dimethylformamide (12 mL) was added sodium hydride (127 mg) in ice bath and the mixture was stirred for 30 minutes. Methyl iodide (224 μL) was added to the reaction mixture, which was stirred at 0° C. for 1 hour and subsequently at room temperature for 6 hours. The reaction mixture was poured in ice water and extracted with a mixed solvent (ethyl acetate:hexane=1:1) twice. The combined organic layer was washed with water and brine sequentially, dried over anhydrous sodium sulfate and concentrated. The residue was recrystallized from a mixed solvent (isopropanol:hexane=1:1) to give the title compound (892 mg) having the following physical data.
- TLC: Rf 0.31 (hexane:ethyl acetate=1:1);
- NMR (CDCl3): δ 3.37 (s, 3H) 3.76 (s, 3H) 7.55 (m, 3H) 7.71 (s, 1H) 7.87 (d, J=7.69 Hz, 1H) 8.40 (dd, J=7.97, 1.65 Hz, 1H) 8.83 (dd, J=4.94, 1.65 Hz, 1H).
- To a solution of the compound prepared in Reference example 27 (880 mg) in ethanol (12 mL) was added a solution of hydrazine monohydrate (240 mg) in ethanol (3 mL) and the mixture was refluxed overnight. 1N sodium hydroxide solution (5 mL) was added to the reaction mixture, which was refluxed for 1 hour. The reaction mixture was cooled in ice bath and 1N hydrochloric acid (5 mL) was added thereto. The precipitate was collected by filtration. It was washed with water and then washed with ethanol on heating to give the title compound (581 mg) having the following physical data.
- TLC: Rf 0.39 (methylene chloride:methanol=19:1);
- NMR (DMSO-d6): δ 2.69 (d, J=5.13 Hz, 3H) 5.73 (q, J=5.13 Hz, 1H) 6.62 (m, 1H) 6.97 (m, 2H) 7.18 (t, J=7.69 Hz, 1H) 7.85 (dd, J=8.06, 4.39 Hz, 1H) 8.64 (dd, J=8.06, 1.83 Hz, 1H) 9.13 (dd, J=4.39, 1.83 Hz, 1H) 13.02 (s, 1H).
- By the same procedure as described in Example 46 using the compound prepared in Reference example 28 instead of the compound prepared in Reference example 24, the compounds of the present invention having the following physical data was obtained.
- TLC: Rf 0.49 (methylene chloride:methanol=9:1);
- NMR (DMSO-d6): δ 12.31 (s, 1H), 7.36 (t, J=7.9 Hz, 1H), 7.18-6.85 (m, 3H), 3.16 (m, 2H), 2.83 (s, 3H), 2.41 (t, J=6.0 Hz, 2H), 2.34 (s, 3H), 1.73 (m, 2H).
- By the same procedure as described in Reference example 25→Reference example 26→Reference example 27→Reference example 28→Example 46 using a corresponding derivative instead of the compound prepared in Reference example 23, the compounds of the present invention having the following physical data was obtained.
- TLC: Rf 0.39 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.26 (brs, 1H), 7.27 (d, J=7.8 Hz, 2H), 6.79 (d, J=7.8 Hz, 2H), 5.96 (brs, 3H), 3.16 (m, 2H), 2.76 (s, 3H), 2.41 (m, 2H), 2.32 (s, 3H), 1.72 (m, 2H).
- By the same procedure as described in Reference example 20→Example 42 using a corresponding derivative instead of benzaldehyde, the compounds of the present invention having the following physical data was obtained.
- TLC: Rf 0.41 (methylene chloride:methanol=19:1);
- NMR (DMSO-d6): δ 12.6 (s, 1H), 7.30-7.22 (m, 2H), 6.95-6.90 (m, 3H), 4.26 (t, J=6.9 Hz, 2H), 2.97 (t, J=6.9 Hz, 2H), 2.60-2.35 (m, 4H), 1.66 (m, 4H).
- TLC: Rf 0.40 (methylene chloride:methanol=19:1);
- NMR (DMSO-d6): δ 12.52 (s, 1H), 7.26 (m, 2H), 6.90 (m, 3H), 4.01 (t, J=6.3 Hz, 2H), 2.65 (t, J=7.5 Hz, 2H), 2.55-2.30 (m, 4H), 2.01 (m, 2H), 1.64 (m, 4H).
- TLC: Rf 0.37 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 9.32 (brs, 1H), 7.08 (d, J=8.4 Hz, 2H), 6.86 (d, J=8.4 Hz, 2H), 3.99 (t, J=6.0 Hz, 2H), 3.81 (s, 2H), 3.24-3.16 (m, 2H), 2.79 (s, 6H), 2.40-2.28 (m, 4H), 2.14-2.02 (m, 2H), 1.64-1.54 (m, 4H).
- TLC: Rf 0.54 (methylene chloride:methanol=19:1);
- NMR (DMSO-d6): δ 12.5 (s, 1H), 7.35-7.22 (m, 5H), 4.47 (s, 2H), 3.69 (t, J=7.2 Hz, 2H), 2.78 (t, J=7.2 Hz, 2H), 2.50-2.36 (m, 4H), 1.63 (m, 4H).
- TLC: Rf 0.53 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.60 (s, 1H), 8.79 (d, J=1.8 Hz, 1H), 8.08 (d, J=1.8 Hz, 1H), 7.98 (d, J=8.1 Hz, 1H), 7.92 (dd, J=8.1, 1.5 Hz, 1H), 7.70 (ddd, J=8.1, 6.9, 1.5 Hz, 1H), 7.57 (ddd, J=8.1, 6.9, 1.5 Hz, 1H), 4.12 (s, 2H), 2.54-2.40 (m, 2H), 2.46-2.30 (m, 2H), 1.70-1.55 (m, 4H).
- By the same procedure as described in Example 27, if necessary, by converting to corresponding salts by conventional method, using a corresponding derivative instead of the compound prepared in Reference example 13 and a corresponding derivative instead of benzylamine, the following compounds of the present invention were obtained.
- TLC: Rf 0.83 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.51 (s, 1H), 9.96 (br, 1H), 3.46-3.28 (m, 2H), 3.02-2.84 (m, 2H), 2.95-2.65 (m, 2H), 2.54-2.44 (m, 2H), 2.42-2.32 (m, 2H), 1.84-1.54 (m, 14H), 1.44-1.26 (m, 4H).
- TLC: Rf 0.15 (methylene chloride:methanol:saturated aqueous ammonia=4:1:0.5%);
- NMR (CD3OD): δ 3.69 (m, 4H), 3.33 (m, 2H), 2.78-2.42 (m, 22H), 1.85 (m, 2H).
- TLC: Rf 0.19 (methylene chloride:methanol=19:1);
- NMR (DMSO-d6): δ 11.97 (s, 1H), 9.39 (s, 1H), 7.41-7.30 (m, 5H), 6.38 (brs, 1H), 5.11 (s, 2H), 4.32 (brs, 2H), 3.87 (m, 1H), 3.70-3.40 (m, 7H), 3.30-3.15 (m, 2H), 2.84 (t, J=7.5 Hz, 2H), 2.35 (t, J=6.3 Hz, 2H), 2.31 (s, 3H), 2.07 (m, 2H), 1.72 (m, 2H).
- TLC: Rf 0.29 (methylene chloride:methanol=10:1);
- NMR (300 MHz, CD3OD) 3.10-3.00 (m, 4H), 2.37-2.26 (m, 4H), 2.25-2.16 (m, 2H), 1.85 (t, J=6.9 Hz, 2H), 1.83-1.75 (m, 2H), 1.75-1.67 (m, 2H), 1.08-0.88 (m, 8H).
- TLC: Rf 0.25 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.55 (s, 1H), 9.52 (br, 1H), 4.01-3.92 (m, 2H), 3.64 (t, J=11.4 Hz, 2H), 3.45-3.36 (m, 2H), 3.17-2.95 (m, 4H), 2.58-2.43 (m, 4H), 2.43-2.34 (m, 2H), 2.31 (s, 3H), 1.77-1.54 (m, 8H).
- By the same procedure as described in Example 24, if necessary, by converting to corresponding salts by conventional method, using a corresponding ester derivative instead of the compound prepared in Example 15 and a corresponding derivative instead of 2-aminoethanol, the following compounds of the present invention were obtained.
- TLC: Rf 0.54 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 11.84 (s, 1H), 8.06 (t, J=5.7 Hz, 1H), 6.42 (s, 1H), 4.37 (t, J=4.8 Hz, 1H), 3.35 (m, 4H), 3.18 (m, 2H), 3.03 (td, J=6.6, 5.7 Hz, 2H), 2.32 (t, J=6.3 Hz, 2H), 1.69 (m, 2H), 1.41 (m, 4H).
- TLC: Rf 0.22 (methanol:methylene chloride=1:4);
- NMR (DMSO-d6): δ 11.84 (s, 1H), 8.06 (t, J=5.4 Hz, 1H), 6.43 (s, 1H), 3.55-3.52 (m, 4H), 3.32-3.31 (m, 2H), 3.18 (brs, 2H), 3.04 (m, 2H), 2.34-2.19 (m, 8H), 1.71-1.68 (m, 2H), 1.40-1.36 (m, 4H).
- TLC: Rf 0.39 (methanol:methylene chloride:saturated aqueous ammonia=2:8:0.1);
- NMR (DMSO-d6): δ 11.90 (s, 1H), 9.13 (brs, 1H), 8.30 (t, J=5.4 Hz, 1H), 6.30 (brs, 1H), 3.45-3.35 (m, 6H), 3.19-3.08 (m, 6H), 2.40-2.29 (m, 2H), 2.33 (s, 3H), 1.80-1.52 (m, 10H).
- TLC: Rf 0.23 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.56 (s, 1H), 7.99 (t, J=5.7 Hz, 1H), 4.32 (t, J=5.1 Hz, 1H), 3.38 (s, 2H), 3.37-3.33 (m, 2H), 3.05-2.99 (m, 2H), 2.41-2.36 (m, 4H), 1.63 (m, 4H), 1.40-1.23 (m, 8H).
- By the same procedure as described in Example 34 using a corresponding derivative instead of the compound prepared in Example 33, the following compounds of the present invention were obtained.
- TLC: Rf 0.53 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 8.02 (t, J=5.1 Hz, 1H), 3.51 (t, J=6.3 Hz, 2H), 3.39 (s, 2H), 3.04 (q, J=6.3 Hz, 2H), 2.46-2.33 (m, 4H), 1.78 (quin, J=6.3 Hz, 2H), 1.70-1.58 (m, 4H), 1.48-1.30 (m, 4H).
- TLC: Rf 0.37 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 7.99 (t, J=5.4 Hz, 1H), 3.51 (t, J=6.6 Hz, 2H), 3.38 (s, 2H), 3.06-3.00 (m, 2H), 2.41-2.36 (m, 4H), 1.82-1.75 (m, 2H), 1.64 (m, 4H), 1.41-1.16 (m, 6H).
- By the same procedure as described in Example 28, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 53, 23(23) or 53(1) instead of the compound prepared in Example 25(1), the following compounds of the present invention were obtained.
- TLC: Rf 0.57 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.57 (s, 1H), 7.99 (t, J=5.7 Hz, 1H), 3.54 (t, J=4.8 Hz, 4H), 3.38 (s, 2H), 3.02 (q, J=6.9 Hz, 2H), 2.46-2.33 (m, 4H), 2.33-2.25 (m, 4H), 2.21 (t, J=6.9 Hz, 2H), 1.68-1.58 (m, 4H), 1.39 (quin, J=6.9 Hz, 4H), 1.31-1.19 (m, 2H).
- TLC: Rf 0.67 (methanol:methylene chloride:28% ammonia water=2:8:0.1);
- NMR (DMSO-d6): δ 12.63 (s, 1H), 9.37 (brs, 1H), 8.36 (t, J=5.7 Hz, 1H), 3.46 (s, 2H), 3.43-3.34 (m, 4H), 3.16-3.12 (m, 4H), 2.42-2.37 (m, 4H), 2.29 (s, 3H), 1.84-1.49 (m, 14H).
- TLC: Rf 0.22 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 12.58 (s, 1H), 9.48 (brs, 1H), 8.03 (t, J=5.4 Hz, 1H), 3.98-3.94 (m, 2H), 3.67-3.39 (m, 6H), 3.07-3.01 (m, 6H), 2.48-2.36 (m, 7H), 1.63-1.27 (m, 12H).
- By the same procedure as described in Reference example 22→Reference example 24→Example 20→Example 46, if necessary, by converting to corresponding salts by conventional method, using a corresponding derivative instead of 4-(bis(trimethylsilyl)amino)phenylmagnesium bromide, the following compounds of the present invention were obtained.
- TLC: Rf 0.59 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 11.94 (s, 1H), 9.14 (br, 2H), 6.80 (s, 1H), 6.79 (d, J=7.8 Hz, 1H), 6.68 (m, 1H), 5.65 (s, 1H), 3.16-3.08 (m, 2H), 2.37 (t, J=6.0 Hz, 2H), 1.77-1.65 (m, 2H).
- TLC: Rf 0.29 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 12.40 (brs, 1H), 9.20 (brs, 1H), 7.26 (d, J=8.7 Hz, 2H), 6.84 (d, J=8.7 Hz, 2H), 3.16 (t, J=5.1 Hz, 2H), 2.42 (t, J=6.0 Hz, 2H), 2.34 (s, 3H), 1.71 (m, 2H).
- TLC: Rf 0.4 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.58 (br, 1H), 9.58 (br, 1H), 7.29 (t, J=7.5 Hz, 1H), 7.12 (d, J=7.5 Hz, 1H), 6.93 (d, J=7.5 Hz, 1H), 6.88 (t, J=7.5 Hz, 1H), 5.96 (br, 1H), 3.23-3.12 (m, 2H), 2.54-2.4- (m, 2H), 1.82-1.64 (m, 2H).
- By the same procedure as described in Example 46, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 43(1), Example 43(2), 23(17), 23(22), 24(11) or 24(16), or 4-(pyridin-4-ylmethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one instead of the compound prepared in Reference example 24 and, the following compounds of the present invention were obtained.
- TLC: Rf 0.21 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.49 (br, 1H), 2.97-2.84 (m, 2H), 2.53-2.42 (m, 5H), 2.41-2.31 (m, 4H), 2.26 (m, 1H), 1.84 (m, 1H), 1.82 (s, 3H), 1.77-1.53 (m, 6H), 1.40 (m, 1H), 1.09 (m, 1H).
- TLC: Rf 0.16 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d): δ 12.51 (br, 1H), 2.90 (m, 1H), 2.78 (m, 1H), 2.58-2.40 (m, 7H), 2.40-2.32 (m, 2H), 1.86 (s, 3H), 1.74-1.45 (m, 7H), 1.38-1.20 (m, 2H), 1.10 (m, 1H).
- TLC: Rf 0.58 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 12.47 (br, 1H), 3.01-2.91 (m, 2H), 2.56-2.42 (m, 6H), 2.41-2.32 (m, 4H), 1.81 (s, 3H), 1.80 (m, 1H), 1.70-1.55 (m, 6H), 1.22-1.07 (m, 2H).
- TLC: Rf 0.27 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.64 (s, 1H), 9.22 (d, J=7.5 Hz, 1H), 8.77 (br, 2H), 4.83 (m, 1H), 3.55 (s, 2H), 3.10 (m, 1H), 2.97 (m, 1H), 2.55-2.35 (m, 4H), 2.34 (s, 3H), 1.94-1.50 (m, 10H).
- TLC: Rf 0.55 (methylene chloride:methanol:28% ammonia water=15:5:1);
- NMR (DMSO-d6): δ 12.62 (s, 1H), 8.50 (m, 1H), 8.30-8.10 (m, 2H), 3.48 (s, 2H), 3.40-3.00 (m, 4H), 2.84 (m, 1H), 2.46-2.34 (m, 4H), 2.32 (s, 3H), 1.82-1.20 (m, 10H).
- TLC: Rf 0.40 (methylene chloride:methanol:28% ammonia water=15:5:1);
- NMR (DMSO-d6): δ 12.61 (s, 1H), 8.41 (m, 1H), 8.30-8.16 (m, 2H), 3.42 (s, 2H), 3.30-2.70 (m, 5H), 2.46-2.32 (m, 4H), 2.31 (s, 3H), 1.92-1.20 (m, 12H).
- TLC: Rf 0.28 (methylene chloride:methanol:28% ammonia water=15:5:1);
- NMR (DMSO-d6): δ 12.57 (brs, 1H), 8.26 (brs, 2H), 8.06 (t, J=5.5 Hz, 1H), 3.39 (s, 2H), 3.24-3.02 (m, 4H), 2.73 (m, 1H), 2.46-2.32 (m, 4H), 2.30 (s, 3H), 1.80-1.04 (m, 12H).
- By the same procedure as described in Example 20, if necessary, by converting to corresponding salts by conventional method, using the compound prepared in Example 47(2) instead of the compound prepared in Example 4(4), the compounds of the present invention having the following data were obtained.
- TLC: Rf 0.33 (methanol:methylene chloride=1:20);
- NMR (DMSO-d6): δ 12.06 (s, 1H), 9.60 (s, 1H), 7.25 (t, J=8.1 Hz, 1H), 6.81 (m, 3H), 5.71 (s, 1H), 3.13 (m, 2H), 2.36 (m, 2H), 1.71 (m, 2H).
- TLC: Rf 0.43 (methanol:methylene chloride=1:9);
- NMR (DMSO-d6): δ 11.85 (brs, 1H), 6.92 (t, J=7.8 Hz, 1H), 6.36 (brs, 2H), 6.17 (brs, 1H), 5.40 (s, 1H), 3.13 (m, 2H), 2.36 (m, 2H), 1.68 (m, 2H).
- A mixed solution of the compound prepared in Example 24(44) (307 mg), 10% palladium on carbon (307 mg) and ammonium formate (236 mg) in methanol (3.00 mL) was refluxed for 30 minutes. After cooling to room temperature, the reaction mixture was filtrated through Celite. The filtrate was concentrated. The residue was washed with a mixed solution of methanol and ethyl acetate and dried under reduced pressure to give the compound of the present invention (187 mg) having the following physical data.
- TLC: Rf 0.13 (methanol:methylene chloride:acetic acid=1:4:1);
- NMR (DMSO-d6): δ 11.83 (brs, 1H), 8.06 (t, J=5.1 Hz, 1H), 6.44 (s, 1H), 3.18-2.09 (m, 13H), 1.69 (m, 2H), 1.52 (m, 2H), 1.29 (m, 3H), 0.94 (m, 2H).
- Under an atmosphere of argon, to 8-(pyridin-2-yl)pyrido[2,3-d]pyridazin-5(6H)-one (118 mg; It was prepared by the same procedure as described in Reference example 22→Reference example 23→Reference example 24 using pyridin-2-ylmagnesium bromide instead of 3-(bis(trimethylsilyl)amino)phenylmagnesium chloride.) were added methanol (6 mL), methanesulfonate (51 mg) and platinum oxide (12 mg) sequentially. Under an atmosphere of hydrogen, the reaction mixture was stirred at room temperature for 5.5 hours. The reaction mixture was filtrated through Celite. The filtrate was concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=20:1 methylene chloride:methanol:water=8:2:0.2) to give free form of the compound A (14 mg) and methanesulfonate of the compound B (77 mg) having the following physical data. The obtained compound A and B were converted to corresponding salts or free form by conventional method to give the compound of the present invention having the following physical data.
- TLC: Rf 0.51 (methylene chloride:methanol=10:1).
- NMR (DMSO-d6): δ 12.39 (br, 1H), 8.88 (br, 1H), 8.59 (m, 1H), 8.04 (d, J=8.4 Hz, 1H), 7.93 (m, 1H), 7.44 (m, 1H), 3.40-3.25 (m, 2H), 2.43 (t, J=6.3 Hz, 2H), 1.85-1.74 (m, 2H).
- TLC: Rf 0.15 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 12.36 (s, 1H), 8.76 (br, 2H), 6.63 (s, 1H), 4.21 (d, J=9.9 Hz, 1H), 3.30 (m, 1H), 3.28-3.16 (m, 2H), 2.89 (m, 1H), 2.36 (t, J=6.0 Hz, 2H), 2.29 (s, 3H), 2.03 (d, J=12.3 Hz, 1H), 1.84-1.60 (m, 6H), 1.43 (m, 1H).
- TLC: Rf 0.14 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 11.74 (s, 1H), 7.36 (s, 1H), 3.54 (dd, J=9.6, 3.9 Hz, 1H), 3.26-3.16 (m, 2H), 2.94 (d, J=12.0 Hz, 1H), 2.65-2.50 (m, 1H), 2.32 (t, J=6.3 Hz, 2H), 1.79 (m, 1H), 1.76-1.26 (m, 7H).
- TLC: Rf 0.50 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.63 (br, 1H), 9.45 (br, 2H), 8.60 (d, J=4.5 Hz, 1H), 8.06 (d, J=8.4 Hz, 1H), 7.97 (t, J=8.4 Hz, 1H), 7.48 (m, 1H), 3.40-3.33 (m, 2H), 2.52-2.42 (m, 2H), 2.36 (s, 3H), 1.84-1.73 (m, 2H).
- TLC: Rf 0.66 (methylene chloride:methanol:ammonia water=8:2:0.2);
- NMR (DMSO-d6): δ 1.45 (m, 1H) 1.72 (m, 6H) 2.04 (d, J=12.82 Hz, 1H) 2.37 (m, 8H) 2.94 (s, 1H) 3.25 (m, 3H) 4.26 (t, J=10.44 Hz, 1H) 7.21 (m, 1H) 8.71 (m, 1H) 8.89 (m, 1H) 12.48 (s, 1H).
- By the same procedure as described in Example 59, if necessary, by converting to corresponding salts by conventional method, using 8-(pyridin-3-yl)pyrido[2,3-d]pyridazin-5(6H)-one, 8-(pyridin-4-yl)pyrido[2,3-d]pyridazin-5(6H)-one or 8-(1-benzylpyridin-4-yl)pyrido[2,3-d]pyridazin-5(6H)-one instead of 8-(pyridin-2-yl)pyrido[2,3-d]pyridazin-5(6H)-one, the following compounds of the present invention were obtained.
- TLC: Rf 0.66 (methylene chloride:methanol=4:1);
- NMR (DMSO-d6): δ 12.46 (s, 1H), 8.92 (s, 1H), 8.86 (d, J=5.1 Hz, 1H), 8.37 (d, J=7.5 Hz, 1H), 7.91 (dd, J=7.5, 5.1 Hz, 1H), 6.20 (brs, 1H), 3.13 (m, 2H), 2.41 (m, 2H), 2.31 (s, 3H), 1.75 (m, 2H).
- TLC: Rf 0.12 (methylene chloride:methanol:acetic acid=4:1:2%);
- NMR (DMSO-d6): δ 11.75 (s, 1H), 6.48 (s, 1H), 3.18 (m, 2H), 2.98 (m, 2H), 2.71 (m, 1H), 2.44 (m, 2H), 2.32 (m, 2H), 1.86 (s, 3H), 1.83 (m, 1H), 1.74-1.43 (m, 5H).
- TLC: Rf 0.28 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 12.63 (br, 1H), 8.90 (d, J=6.0 Hz, 2H), 8.00 (d, J=6.0 Hz, 2H), 6.23 (br, 1H), 3.18-3.10 (m, 2H), 2.42 (t, J=6.0 Hz, 2H), 2.31 (s, 3H), 1.82-1.70 (m, 2H).
- TLC: Rf 0.053 (methylene chloride:methanol:acetic acid=4:1:2%);
- NMR (DMSO-d6): δ 11.71 (s, 1H), 6.33 (s, 1H), 3.16 (m, 2H), 2.94 (m, 2H), 2.74-2.38 (m, 3H), 2.32 (m, 2H), 1.75-1.32 (m, 6H).
- TLC: Rf 0.86 (methylene chloride:methanol:water=8:2:0.2);
- NMR (DMSO-d6): δ 11.79 (br, 1H), 8.13 (br, 3H), 6.40 (s, 1H), 3.23-3.15 (m, 2H), 3.15-3.04 (m, 2H), 2.81-2.64 (m, 3H), 2.33 (t, J=6.3 Hz, 2H), 1.82 (s, 6H), 1.80-1.65 (m, 4H), 1.64-1.46 (m, 2H).
- TLC: Rf 0.41 (methylene chloride:methanol:acetic acid=4:1:2%).
- By the same procedure as described in Reference example 2→Reference example 3→Example 3 using thiomorpholin-3-ylcarboxylic acid ethyl ester or a corresponding derivative, and a corresponding derivative instead of 3-nitrobenzoyl chloride, the following compounds of the present invention were obtained.
- TLC: Rf 0.18 (hexane:ethyl acetate=2:1);
- NMR (DMSO-d6): δ 10.27 (s, 1H), 5.79 (m, 1H), 4.03 (dd, J=10.3, 3.0 Hz, 1H), 3.82 (dt, J=13.8, 3.0 Hz, 1H), 3.06 (ddd, J=13.8, 11.7, 2.1 Hz, 1H), 2.77 (m, 1H), 2.74-2.58 (m, 2H), 2.42 (m, 1H), 2.10-2.00 (m, 4H), 1.68-1.50 (m, 4H).
- TLC: Rf 0.37 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.66 (s, 1H) 7.80 (m, 1H), 6.72 (d, J=3.3 Hz, 1H), 6.58 (m, 1H), 4.22 (dd, J=10.2, 3.0 Hz, 1H), 3.73 (dt, J=14.1, 3.0 Hz, 1H), 3.22 (m, 1H), 2.94-2.72 (m, 3H), 2.49 (m, 1H).
- TLC: Rf 0.37 (hexane:ethyl acetate=1:1);
- NMR (DMSO-d6): δ 10.62 (s, 1H), 7.65 (dd, J=5.1, 1.2 Hz, 1H), 7.30 (dd, J=3.6, 1.2 Hz, 1H), 7.11 (dd, J=5.1, 3.6 Hz, 1H), 4.24 (dd, J=8.1, 3.3 Hz, 1H), 3.96 (dt, J=13.8, 3.3 z, 1H), 3.20 (m, 1H), 2.92-2.76 (m, 3H), 2.49 (m, 1H).
- TLC: Rf 0.53 (hexane:ethyl acetate=1:1);
- NMR (CDCl3): δ 8.24 (br, 1H), 7.85 (d, J=3.3 Hz, 1H), 7.42 (d, J=3.3 Hz, 1H), 5.15 (m, 1H), 4.20 (dd, J=11.1, 3.0 Hz, 1H), 3.36-3.20 (m, 2H), 3.03-2.83 (m, 2H), 2.41 (m, 1H).
- TLC: Rf 0.32 (methylene chloride:methanol=10:1);
- NMR (CDCl3): δ 8.70 (dd, J=4.8, 1.8 Hz, 1H), 8.66 (d, J=1.8 Hz, 1H), 8.13 (br, 1H), 7.71 (dt, J=8.1, 1.8 Hz, 1H), 7.39 (dd, J=8.1, 4.8 Hz, 1H), 4.38 (dd, J=11.1, 2.7 Hz, 1H), 3.75 (dt, J=14.1, 2.7 Hz, 1H), 3.21 (ddd, J=14.1, 12.0, 2.7 Hz, 1H), 3.11 (m, 1H), 2.98 (dd, J=14.1, 10.8 Hz, 1H), 2.76 (m, 1H), 2.31 (m, 1H).
- TLC: Rf 0.30 (chloroform:methanol=9:1);
- NMR (CD3OD): δ 8.10-8.00 (brs, 1H), 6.85-6.83 (m, 2H), 6.82-6.80 (m, 1H), 6.01 (s, 2H), 4.33 (dd, J=10.8, 2.4 Hz, 1H), 3.83 (dt, J=13.5, 2.7 Hz, 1H), 3.20-3.02 (m, 2H), 3.00-2.88 (m, 1H), 2.80-2.68 (m, 1H), 2.32-2.22 (m, 1H).
- TLC: Rf 0.36 (methanol:methylene chloride=1:10);
- NMR (DMSO-d6): δ 10.99 (s, 1H), 8.66 (m, 2H), 7.90 (dt, J=7.8, 2.1 Hz, 1H), 7.50 (dd, J=7.8, 4.8 Hz, 1H), 6.27 (s, 1H), 3.62 (m, 2H), 3.16 (m, 2H).
- TLC: Rf 0.54 (methylene chloride:methanol=10:1);
- NMR (DMSO-d6): δ 10.96 (s, 1H), 8.04-7.95 (m, 4H), 7.62-7.53 (m, 3H), 6.28 (s, 1H), 3.69-3.64 (m, 2H), 3.24-3.16 (m, 2H).
- To a suspension of 4-chloro-5,6,7,8-tetrahydrophthalazin-1(2H)-one (150 mg; CAS Registry No. 89981-21-5; the compound described in Yakugaku Zassi., 82, 302-303 (1962)) in ethylene glycol (1.6 mL) was added piperazine (420 mg) and the mixture was stirred at 200° C. for 7 hours. After cooling to room temperature, the reaction mixture was poured in a cold saturated aqueous sodium hydrogen carbonate solution and extracted with chloroform. The extract was washed brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (methylene chloride:methanol=20:1→10:1) to give free form of the title compound (64 mg). To a solution of the obtained free form in methanol (2.0 mL) was added 4N hydrogen chloride-ethyl acetate solution (1 mL). The mixture was stirred at room temperature and concentrated. The residue was recrystallized from a mixed solution of methanol and ethyl acetate to give the compound of the present invention (21 mg) having the following physical data.
- TLC: Rf 0.46 (methylene chloride:methanol:acetic acid=20:5:2);
- NMR (DMSO-d6): δ 12.31 (s, 1H), 8.98 (brs, 2H), 3.24-3.02 (m, 8H), 2.58-2.30 (m, 4H), 1.78-1.50 (m, 4H).
- By the same procedure as described in Example 60→Example 59 using 8-chloropyrido[2,3-d]pyridazin-5(6H)-one (the compound described in Chem. Pharm. Bull., 13(5), 586-593 (1965)) instead of 4-chloro-5,6,7,8-tetrahydrophthalazin-1(2H)-one, the compound of the present invention having the following physical data was obtained.
- TLC: Rf 0.18 (methylene chloride:methanol:acetic acid=20:5:2);
- NMR (DMSO-d6): δ 11.51 (s, 1H), 6.12 (s, 1H), 3.26-3.04 (m, 8H), 3.02-2.88 (m, 3H), 2.31 (t, J=6.0 Hz, 2H), 1.71 (m, 2H).
- The following components were admixed in conventional method and punched out to obtain 100 tablets each containing 50 mg of active ingredient.
-
4-(N-(2-aminoethyl)carbamoylmethyl)-5,6,7,8- 5.0 g tetrahydrophthalazin-1(2H)-one carboxymethyl cellulose calcium (disintegrating agent) 0.2 g magnesium stearate (lubricating agent) 0.1 g microcrystalline cellulose 4.7 g - After mixing the following components by a conventional method, the resulting solution was sterilized by a conventional method and 5 ml portions thereof were filled in amples, respectively, and freeze-dried by a conventional method to obtain 100 amples of injection containing each 20 mg of the active ingredient.
-
4-(N-(2-aminoethyl)carbamoylmethyl)-5,6,7,8- 2.0 g tetrahydrophthalazin-1(2H)-one mannitol 20 g distilled water 1000 mL
Claims (17)
1. A fused pyridazine derivative compound represented by formula (I)
wherein R1 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) halogen atom, (6) nitro, (7) NR2R3, (8) C2-8 acyl, (9) C1-8 alkoxy substituted by phenyl or (10) C2-8 acyl substituted by NR2R3,
R2 and R3 are each independently
(1) a hydrogen atom or (2) C1-8 alkyl,
X and Y are each independently
(1) a single bond or (2) a double bond,
(1) partially or fully saturated C3-10 mono-carbocyclic aryl or (2) partially or fully saturated 3-10 membered mono-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms,
A is (1) A1, (2) A2, (3) A3, (4) A4 or (5) A5,
A1 is
D1 is
(1) —NR6C(O)—, (2) —NR6C(S)—, (3) —NR6SO2—, (4) —CH2—NR6—, (5) —CH2—O—, (6) —OC(O)—, (7) —CH2—NR6C(O)—, (8) —NR6C(O)NR7—, (9) —NR6C(O)O—, (10) —NR6C(S)NR7—, (11) —NR6— or (12) —NR6C(═NR7)—,
R6 and R7 are each independently
(1) a hydrogen atom, (2) C1-8 alkyl, (3) phenyl or (4) C1-8 alkyl substituted by phenyl,
D2 is
(1) C1-8 alkylene, (2) C2-8 alkenylene, (3) Cyc2, (4) —(C1-4 alkylene)-O—(C1-4 alkylene)-, (5) —(C1-4 alkylene)-S—(C1-4 alkylene)-, (6) —(C1-4 alkylene)-NR8—(C1-4 alkylene)-, (7)-(Cyc2)-(C1-8 alkylene)-, (8) —(C1-8 alkylene)-(Cyc2)- or (9) —(C1-4 alkylene)-(Cyc2)-(C1-4 alkylene)-,
R8 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) phenyl or (5) C1-8 alkyl substituted by phenyl,
D3 is
(1) a hydrogen atom, (2) —NR9R10, (3) Cyc3, (4) —OR11, (5) COOR12, (6) CONR13R14, (7) cyano, (8) a halogen atom, (9) —C(═CR15)NR16R17 or (10) —NR18C(═NR19)NR20R21,
R9 and R13 are each independently
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) Cyc3, (6) C1-8 alkoxy, (7) C2-8 alkenyloxy, (8) C2-8 alkynyloxy or (9) C1-8 alkyl substituted by Cyc3, C1-8 alkoxy, C1-8 alkylthio, cyano, hydroxy or 1 to 3 halogen atom(s),
R10 and R14 are each independently
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) C1-8 alkoxycarbonyl, (6) C2-8 acyl, (7) C3-8 cycloalkyl, (8) C1-8 alkoxycarbonyl substituted by Cyc4 or 1 to 3 halogen atom(s), or (9) C1-8 alkyl substituted by C1-8 alkoxy,
R11 and R12 are each independently
(1) a hydrogen atom or (2) C1-8 alkyl,
R15, R16, R17, R18, R19, R20 and R21 are each independently
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) phenyl or (5) C1-8 alkyl substituted by phenyl,
R4 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) halogen atom, (6) nitro or (7) NR22R23,
R22 and R23 are each independently
(1) a hydrogen atom or (2) C1-8 alkyl,
E1 is C1-4 alkylene,
E2 is
(1) —C(O)NR24—, (2) —NR24C(O)—, (3) —NR24—, (4) —C(O)O— or (5) —S—,
R24 is
(1) a hydrogen atom, (2) C1-8 alkyl or (3) C1-8 alkyl substituted by phenyl,
E3 is
(1) a bond or (2) C1-8 alkylene,
E4 is
(1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C2-8 alkynyl, (4) Cyc5, (5) NR25R26, (6) OR27, (7) SR27, (8) COOR27, (9) C1-8 alkyl substituted by two of OR25, (10) C1-8 alkyl substituted by 1 to 3 halogen atom(s), (11) cyano or (12) C2-8 acyl,
R25 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, (5) Cyc5 or (6) C1-8 alkyl substituted by Cyc5 or OR28,
R26 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) phenyl or (5) C1-8 alkyl substituted by phenyl,
R27 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) Cyc5 or (4) C1-8 alkyl substituted by Cyc5,
R28 is
(1) a hydrogen atom or (2) C1-8 alkyl,
G1 is C1-8 alkylene,
Cyc1 is
(1) partially or fully saturated C3-10 mono- or bi-carbocyclic aryl, or (2) partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms,
G2 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxycarbonyl, (4) C2-8 acyl, (5) Cyc6, (6) C1-8 alkyl or C2-8 alkenyl substituted by 1 to 2 substituent(s) selected from Cyc6, hydroxy and C1-8 alkoxy, (7) C1-8 alkoxycarbonyl substituted by Cyc6, (8) —C(O)-Cyc6, (9) nitro, (10) NR41R42, (11) C1-8 alkoxy or (12) C1-8 alkyl substituted by NR41R42,
R41 and R42 are each dependently
(1) a hydrogen atom or (2) C1-8 alkyl,
R5 is
(1) a hydrogen atom, (2) C1-8 alkyl, (3) C1-8 alkoxy, (4) hydroxy, (5) nitro, (6) NR29R30, (7) C1-8 alkyl substituted by NR29R30, (8) NHSO2OH, (9) amidino, (10) cyano, (11) a halogen atom, (12) Cyc8 or (13) C1-8 alkyl substituted by Cyc8,
R29 and R30 are each independently
(1) a hydrogen atom or (2) C1-8 alkyl,
Cyc2, Cyc3, Cyc4, Cyc5, Cyc6 and Cyc8 are each independently
(1) partially or fully saturated C3-10 mono- or bi-carbocyclic aryl, or (2) partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms,
Cyc7 is
(1) partially or fully saturated C3-10 mono- or bi-carbocyclic aryl, or (2) partially or fully saturated 3-10 membered mono- or bi-hetero aryl containing 1 to 4 hetero atom(s) selected from oxygen, nitrogen and sulfur atoms, with proviso that Cyc7 is not benzene,
Cyc2, Cyc3, Cyc4, Cyc5, Cyc6 and Cyc8 are optionally substituted by 1 to 3 substituent(s) selected from (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C1-8 alkoxy, (4) halogen atom, (5) trihalomethyl, (6) trihalomethoxy, (7) C1-8 alkoxycarbonyl, (8) oxo, (9) C1-8 alkyl substituted by C1-8 alkoxy or phenyl, (10) hydroxy and (11) NR29R30;
m and n are each independently 1 or 2,
wherein
(i) when A is A1 or A2, then
(1) 4-(3-chloro-4-methoxyphenyl)-4a,5,8,8a-tetrahydrophthalazin-1(2H)-one,
(2) 4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(3) 4-phenyl-6,7,8,8a-tetrahydropyrrolo[1,2-d][1,2,4]triazin-1(2H)-one,
(4) 4-phenyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(5) 4-(4-methylphenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(6) 4-(4-fluorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(7) 4-(4-chlorophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(8) 4-(4-bromophenyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(9) 7-hydroxy-4-phenyl-6,7,8,8a-tetrahydropyrrolo[1,2-d][1,2,4]triazin-1(2H)-one,
(10) 4-phenyl-8,8a-dihydro[1,3]thiazolo[3,4-d][1,2,4]triazin-1(2H)-one,
(11) 4-(pyridin-4-ylmethyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(12) 4-t-butoxycarbonylmethyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one,
(13) 4-ethoxycarbonylmethyl-5,6,7,8-tetrahydrophthalazin-1(2H)-one, or
a pharmaceutically acceptable salt thereof.
11. A poly(ADP-ribose)polymerase inhibitor comprising, as an active ingredient, the compound represented by formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
12. A preventive and/or treatment agent for ischemic diseases, inflammatory diseases, neurodegenerative diseases, glaucoma, diabetes, diabetic complication, shock, head trauma, spinal cord injury, renal failure or hyperalgesia comprising, as an active ingredient, the compound represented by formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
13. An antiretroviral drug comprising, as an active ingredient, the compound represented by formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
14. A sensitizer of anticancer therapy comprising, as an active ingredient, the compound represented by formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
15. An immunosuppressant comprising, as an active ingredient, the compound represented by formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
16. The preventive and/or treatment agent according to claim 12 , wherein the ischemic disease is cerebral infarction.
17. The compound or the pharmaceutically acceptable salt according to claim 1 , which is described in any one of Example 1 to 62.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/137,267 US20080261947A1 (en) | 2002-02-19 | 2008-06-11 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002042259 | 2002-02-19 | ||
JPP.2002-42259 | 2002-02-19 | ||
JPP.2002-199673 | 2002-07-09 | ||
JP2002199673 | 2002-07-09 | ||
US10/505,012 US7402580B2 (en) | 2002-02-19 | 2003-02-18 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
PCT/JP2003/001694 WO2003070707A1 (en) | 2002-02-19 | 2003-02-18 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
US12/137,267 US20080261947A1 (en) | 2002-02-19 | 2008-06-11 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001694 Division WO2003070707A1 (en) | 2002-02-19 | 2003-02-18 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
US10/505,012 Division US7402580B2 (en) | 2002-02-19 | 2003-02-18 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080261947A1 true US20080261947A1 (en) | 2008-10-23 |
Family
ID=27759644
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/505,012 Expired - Fee Related US7402580B2 (en) | 2002-02-19 | 2003-02-18 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
US12/137,267 Abandoned US20080261947A1 (en) | 2002-02-19 | 2008-06-11 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/505,012 Expired - Fee Related US7402580B2 (en) | 2002-02-19 | 2003-02-18 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient |
Country Status (18)
Country | Link |
---|---|
US (2) | US7402580B2 (en) |
EP (2) | EP1477175B1 (en) |
JP (2) | JP3843454B2 (en) |
KR (1) | KR100663147B1 (en) |
CN (1) | CN100348587C (en) |
AT (1) | ATE507207T1 (en) |
AU (1) | AU2003211381B9 (en) |
BR (1) | BR0307780A (en) |
CA (1) | CA2476406A1 (en) |
DE (1) | DE60336890D1 (en) |
IL (1) | IL163562A0 (en) |
MX (1) | MXPA04008014A (en) |
NO (1) | NO328053B1 (en) |
NZ (1) | NZ534712A (en) |
PL (1) | PL372171A1 (en) |
RU (1) | RU2292337C2 (en) |
TW (1) | TW200306836A (en) |
WO (1) | WO2003070707A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
EP1501822B1 (en) | 2002-04-30 | 2010-12-15 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP5545690B2 (en) | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | DNA damage repair inhibitors for cancer treatment |
PE20060285A1 (en) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS |
AU2005276229A1 (en) * | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
DE102005011822A1 (en) * | 2005-03-15 | 2006-09-21 | Merck Patent Gmbh | phthalazinones |
US20090226412A1 (en) | 2005-06-24 | 2009-09-10 | Ono Pharmaceutical Co., Ltd., | Agent for reduction of bleeding in cerebrovascular disorder |
WO2007026771A1 (en) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | Injection for intravenous drip |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP2032140A1 (en) * | 2006-05-31 | 2009-03-11 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
TWI404716B (en) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | Phthalazinone derivative |
PL2120579T3 (en) * | 2006-12-28 | 2014-04-30 | Abbvie Inc | Inhibitors of poly(adp-ribose)polymerase |
US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
CL2008000119A1 (en) * | 2007-01-16 | 2008-05-16 | Wyeth Corp | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. |
US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
RU2010108008A (en) | 2007-09-14 | 2011-10-20 | Астразенека Аб (Se) | Phthalazinone derivatives |
MX2010003056A (en) | 2007-09-21 | 2010-04-07 | Epiphany Biosciences Inc | Valomaciclovir polymorphs. |
CA2702429A1 (en) | 2007-10-17 | 2009-04-23 | Kudos Pharmaceuticals Limited | Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one |
UY31603A1 (en) | 2008-01-23 | 2009-08-31 | DERIVATIVES OF FTALAZINONA | |
KR101671535B1 (en) | 2008-06-06 | 2016-11-01 | 가부시키가이샤 프리즘 파마 | Alpha helix mimetics and methods relating thereto |
CN102065863A (en) * | 2008-06-23 | 2011-05-18 | 日本新药株式会社 | Therapeutic agent for spinal canal stenosis |
US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
NZ591166A (en) | 2008-08-06 | 2012-11-30 | Biomarin Pharm Inc | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
BRPI0920604B1 (en) | 2008-10-07 | 2021-11-23 | Kudos Pharmaceuticals Limited | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION IN THE FORM OF A SOLID DISPERSION COMPRISING AS ACTIVE THE COMPOUND 4-[3-(4-CYCLOPROPANCARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORINE-BENZYL]-2H-PHTALAZIN-1-ONE (OLAPARIB) |
DE102009007075B4 (en) * | 2009-02-02 | 2011-05-26 | Siemens Aktiengesellschaft | Workflow-dependent creation of a patient CD |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
CN102108078B (en) * | 2009-12-24 | 2013-10-30 | 沈阳药科大学 | 1,4-substituted phthalazine compound and preparation method and applications thereof |
CN106943406A (en) | 2010-02-03 | 2017-07-14 | 麦迪韦逊科技有限公司 | Dihydro pyrido phthalazines ketone inhibitors for poly- (ADP ribose) polymerase (PARP) of the treatment of PTEN gene delection relevant diseases |
KR101826652B1 (en) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | Processes of synthesizing dihydropyridophthalazinone derivatives |
CN102372716A (en) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | Phthalazone derivative, its preparation method and application in medicine thereof |
MX2013003139A (en) * | 2010-09-24 | 2013-06-18 | Shionogi & Co | Substituted polycyclic carbamoyl pyridone derivative prodrug. |
KR20140009181A (en) | 2010-10-21 | 2014-01-22 | 바이오마린 파머수티컬 인크. | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
EP3925962A1 (en) | 2011-05-31 | 2021-12-22 | Rakovina Therapeutics Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerase |
US9163003B2 (en) | 2011-07-13 | 2015-10-20 | Novartis Ag | 4-piperidinyl compounds for use as tankyrase inhibitors |
EP2731951B1 (en) | 2011-07-13 | 2015-08-19 | Novartis AG | 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors |
JP2014520858A (en) | 2011-07-13 | 2014-08-25 | ノバルティス アーゲー | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
DK2975030T3 (en) * | 2013-03-13 | 2020-08-31 | Chugai Pharmaceutical Co Ltd | DIHYDROPYRIDAZINE-3,5-DION-DERIVATIVE |
WO2015034785A1 (en) * | 2013-09-05 | 2015-03-12 | Warner Babcock Institute For Green Chemistry, Llc | Rilyazine derivatives and compositions for the treatment of cancer |
RU2550346C2 (en) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | New chemical compounds (versions) and using them for treating oncological diseases |
DK3428170T3 (en) * | 2015-04-28 | 2021-03-01 | Shionogi & Co | ANTI-INFLUENZA POLYCYCLIC PYRIDON DERIVATIVE AND PRODUCT THEREOF |
CN105646497B (en) * | 2016-02-01 | 2019-06-04 | 南京格亚医药科技有限公司 | Pyrrolo-triazine ketone derivatives |
AU2018260094A1 (en) | 2017-04-28 | 2019-11-07 | Akribes Biomedical Gmbh | A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
US20230017948A1 (en) | 2019-11-25 | 2023-01-19 | The Research Foundation For The State University Of New York | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (en) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
DE3302021A1 (en) | 1983-01-22 | 1984-07-26 | Basf Ag, 6700 Ludwigshafen | 6-ARYL-4,5-DIHYDRO-3 (2H) -PYRIDAZINONE, THEIR PRODUCTION AND USE |
FR2647676A1 (en) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors |
WO1998031674A1 (en) | 1997-01-15 | 1998-07-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinones |
US6677333B1 (en) * | 1999-01-26 | 2004-01-13 | Ono Pharmaceutical Co., Ltd. | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient |
AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
-
2003
- 2003-02-18 DE DE60336890T patent/DE60336890D1/en not_active Expired - Lifetime
- 2003-02-18 IL IL16356203A patent/IL163562A0/en unknown
- 2003-02-18 EP EP03705265A patent/EP1477175B1/en not_active Expired - Lifetime
- 2003-02-18 NZ NZ534712A patent/NZ534712A/en not_active IP Right Cessation
- 2003-02-18 WO PCT/JP2003/001694 patent/WO2003070707A1/en active Application Filing
- 2003-02-18 AU AU2003211381A patent/AU2003211381B9/en not_active Ceased
- 2003-02-18 CN CNB038084597A patent/CN100348587C/en not_active Expired - Fee Related
- 2003-02-18 KR KR1020047012806A patent/KR100663147B1/en not_active IP Right Cessation
- 2003-02-18 JP JP2003569614A patent/JP3843454B2/en not_active Expired - Fee Related
- 2003-02-18 BR BR0307780-2A patent/BR0307780A/en not_active IP Right Cessation
- 2003-02-18 RU RU2004127932/04A patent/RU2292337C2/en not_active IP Right Cessation
- 2003-02-18 PL PL03372171A patent/PL372171A1/en not_active Application Discontinuation
- 2003-02-18 US US10/505,012 patent/US7402580B2/en not_active Expired - Fee Related
- 2003-02-18 MX MXPA04008014A patent/MXPA04008014A/en active IP Right Grant
- 2003-02-18 CA CA002476406A patent/CA2476406A1/en not_active Abandoned
- 2003-02-18 AT AT03705265T patent/ATE507207T1/en not_active IP Right Cessation
- 2003-02-18 EP EP10178316A patent/EP2281818A1/en not_active Withdrawn
- 2003-02-19 TW TW092103373A patent/TW200306836A/en unknown
-
2004
- 2004-08-17 NO NO20043429A patent/NO328053B1/en not_active IP Right Cessation
-
2008
- 2008-06-11 US US12/137,267 patent/US20080261947A1/en not_active Abandoned
-
2010
- 2010-05-20 JP JP2010115956A patent/JP2010209106A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
BR0307780A (en) | 2004-12-28 |
EP1477175A1 (en) | 2004-11-17 |
AU2003211381B9 (en) | 2009-07-30 |
TW200306836A (en) | 2003-12-01 |
NO20043429L (en) | 2004-11-19 |
WO2003070707A1 (en) | 2003-08-28 |
RU2004127932A (en) | 2005-05-27 |
DE60336890D1 (en) | 2011-06-09 |
JP3843454B2 (en) | 2006-11-08 |
AU2003211381A1 (en) | 2003-09-09 |
CN1646499A (en) | 2005-07-27 |
AU2003211381B2 (en) | 2009-03-05 |
US20050085476A1 (en) | 2005-04-21 |
ATE507207T1 (en) | 2011-05-15 |
US7402580B2 (en) | 2008-07-22 |
CA2476406A1 (en) | 2003-08-28 |
EP1477175A4 (en) | 2006-03-22 |
KR20040085199A (en) | 2004-10-07 |
KR100663147B1 (en) | 2007-02-28 |
IL163562A0 (en) | 2005-12-18 |
RU2292337C2 (en) | 2007-01-27 |
CN100348587C (en) | 2007-11-14 |
PL372171A1 (en) | 2005-07-11 |
NO328053B1 (en) | 2009-11-16 |
EP2281818A1 (en) | 2011-02-09 |
JP2010209106A (en) | 2010-09-24 |
JPWO2003070707A1 (en) | 2005-06-09 |
EP1477175B1 (en) | 2011-04-27 |
NZ534712A (en) | 2006-11-30 |
MXPA04008014A (en) | 2004-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7402580B2 (en) | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | |
US6677333B1 (en) | 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient | |
JP4500161B2 (en) | Phthalazinone derivatives | |
US8476430B2 (en) | Fused heterocyclic compounds useful as kinase modulators | |
US9174969B2 (en) | Indoline scaffold SHP-2 inhibitors and cancer treatment method | |
US7407957B2 (en) | Phthalazinone derivatives | |
US20050267114A1 (en) | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient | |
WO2007049771A1 (en) | Compound containing basic group and use thereof | |
JP2010522241A (en) | Condensed heterocyclic compounds useful as proliferative diseases, allergic diseases, autoimmune diseases or inflammatory diseases | |
JP2008510783A (en) | 4-heteroarylmethyl-substituted phthalazinone derivatives | |
JP2002020386A (en) | Pyrazolopyridine derivative | |
JP2013506638A (en) | Pyrazole derivatives that modulate stearoyl-CoA desaturase | |
JP4561698B2 (en) | Fused pyridazine derivative compound and drug containing the compound as an active ingredient | |
AU2004255930B2 (en) | Tacrine derivatives as inhibitors of acetylcholinesterase | |
WO2013151877A1 (en) | Pyrimidinedione carboxamide inhibitors of endothelial lipase | |
WO2010059555A1 (en) | Prolyl hydroxylase inhibitors | |
CN101284819A (en) | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | |
WO2002014272A1 (en) | (thio)urea derivatives, process for their production and medicines containing the derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |